WO2020208139A1 - Inhibitors of notch signalling pathway and use thereof in treatment of cancers - Google Patents

Inhibitors of notch signalling pathway and use thereof in treatment of cancers Download PDF

Info

Publication number
WO2020208139A1
WO2020208139A1 PCT/EP2020/060153 EP2020060153W WO2020208139A1 WO 2020208139 A1 WO2020208139 A1 WO 2020208139A1 EP 2020060153 W EP2020060153 W EP 2020060153W WO 2020208139 A1 WO2020208139 A1 WO 2020208139A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
halogen
heteroalkyl
cycloalkyl
heteroaryl
Prior art date
Application number
PCT/EP2020/060153
Other languages
French (fr)
Inventor
Rajwinder Lehal
Guido Bold
Charlotte URECH
Vincent Zoete
Original Assignee
Cellestia Biotech Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2021559902A priority Critical patent/JP2022529324A/en
Priority to SG11202110545TA priority patent/SG11202110545TA/en
Priority to AU2020271268A priority patent/AU2020271268A1/en
Priority to US17/602,959 priority patent/US20220169642A1/en
Priority to MX2021012359A priority patent/MX2021012359A/en
Priority to BR112021020226A priority patent/BR112021020226A2/en
Priority to CN202080043231.4A priority patent/CN113966324A/en
Priority to EP20717868.2A priority patent/EP3953335A1/en
Application filed by Cellestia Biotech Ag filed Critical Cellestia Biotech Ag
Priority to KR1020217036445A priority patent/KR20220021462A/en
Priority to CA3134791A priority patent/CA3134791A1/en
Priority to EA202192394A priority patent/EA202192394A1/en
Publication of WO2020208139A1 publication Critical patent/WO2020208139A1/en
Priority to IL287043A priority patent/IL287043A/en
Priority to ZA2021/08579A priority patent/ZA202108579B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
    • C07C211/45—Monoamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
    • C07C217/90—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to a carbon atom of a six-membered aromatic ring, e.g. amino-diphenylethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/22—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to new inhibitors of Notch signalling pathway and its use in the treatment and/or prevention of cancers.
  • the Notch signalling pathway represents a critical component in the molecular circuits that control cell fate during development, cell survival and cell proliferation (Shih IeM, Wang TL in Cancer Res 2007;67(5):1879–82). Aberrant activation of this pathway contributes to tumorigenesis.
  • the Notch family members are being revealed as oncogenes in an ever- increasing number of cancers.
  • the role of Notch in human cancer has been highlighted recently by the presence of activating mutations and amplification of Notch genes in human cancer and by the demonstration that genes/proteins in the Notch signalling pathway could be potential therapeutic targets.
  • Notch receptors in which g-secretase inhibitors prevent the generation of the oncogenic (intracellular) domain of Notch molecules and suppress the Notch activity.
  • Notch inhibitors are already in clinical trials for few cancer types, such as g-secretase inhibitors AL101 from Ayala Pharma (formerly BMS 906024), LY3039478 from Eli Lilly and Nirogacestat from Springworks Therapeutics, a synthetic small molecule, inhibits the Notch signalling pathway, which may result in induction of growth arrest in tumor cells in which the Notch signalling pathway is
  • g-secretase inhibitors to block Notch signaling, as currently under investigation, is their wide range of additional targets such as amyloid precursor protein. Due to their ability to block Notch signalling via all four receptors g-secretase inhibitors are known to cause goblet cell metaplasia in the intestine. In addition, some of the hematological malignancies and solid tumors harbor mutations in the Notch receptors (such as chromosomal translocations) resulting in constitutive expression of dominant active form of NICD independent of cleavage by g-secretase complex. Therefore these tumors will fail to respond to g-secretase inhibitors treatment.
  • WO2013/093885 discloses several Notch inhibiting compounds among them 6-(4-tert- butylphenoxy)pyridin-3-amine as particular preferred compound. Notch inhibition measured varies significantly among the disclosed compounds. Therefore, there is still a need to identify and develop further specific and selective inhibitors of Notch signaling pathway with improved properties useful for treating and/or preventing cancers.
  • the present invention provides compounds of formula (I)
  • X is selected from CH 2 , CF 2 , CHF, CO, CHOH, CHO(C 1 -C 3 ) alkyl, NH, N(C 1 -C 3 alkyl), S, SO and O;
  • Y 1 , Y 2 , and Y 3 are each independently selected from N and C;
  • Z is NR 10 R 11 , wherein R 10 and R 11 are each independently selected from H and C 1 -C 6 alkyl;
  • R 1 is selected from H, halogen, C 1 -C 6 alkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C 1 -C 6 alkoxy, C 1 -C 6 heteroalkyl, C 0 -C 3 alkylOC 0 -C 3 alkyl aryl wherein the aryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl; C 0 -C 3 alkylOC 0 -C 3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 - C 3
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 - C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C(O)R 12 , C 1 -C 6 alkyl C(O)R 12 ;
  • R 3 is selected from H, halogen, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 3 -C 12 cycloalkyl, C 3 - C 12 heterocyclyl and C 1 -C 6 alkoxy;
  • R 4 , R 5 and R 6 are each independently selected from H, halogen, CN, C 1 -C 6 alkoxy, C 1 -C 6 -S-alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 3 -C 12 cycloalkyl and C 3 -C 12 heterocyclyl; wherein R 7 is absent when Y 1 is N or is selected from H, halogen, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl and C1-C6 alkoxy when Y 1 is C;
  • R 8 is absent when Y 3 is N or is selected from H, halogen, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl and C 1 -C 6 alkoxy when Y 3 is C;
  • R 9 is absent when Y 2 is N or is selected from H, halogen, C 1 -C 6 alkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C 1 -C 6 alkoxy, C 1 -C 6 heteroalkyl, C 0 -C 3 alkylOC 0 -C 3 alkyl aryl wherein the aryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl; C 0 -C 3 alkylOC 0 -C 3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen,
  • R 12 is selected from H, NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 12 cycloalkyl and C 3 -C 12 heterocyclyl;
  • the compound of formula (I) is not 6-([1,1’-Biphenyl]-4-yloxy)- pyridine-3-amine, 4-([1,1’-Biphenyl]-4-yloxy)-aniline, 6-([1,1’-Biphenyl]-4-yloxy)-2- methylpyridin-3-amine and 6-([1,1’-Biphenyl]-4-yloxy)-4-methylpyridin-3-amine.
  • the present invention also provides compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof,
  • X is selected from CH 2 , CF 2 , CHF, CO, CHOH, CHO(C 1 -C 3 ) alkyl, NH, N(C 1 -C 3 alkyl), S, SO and O;
  • Y 1 , Y 2 , and Y 3 are each independently selected from N and C;
  • Z is NR 10 R 11 , wherein R 10 and R 11 are each independently selected from H and C 1 -C 6 alkyl;
  • R 1 is selected from H, halogen, C 1 -C 6 alkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C 1 -C 6 alkoxy, C 1 -C 6 heteroalkyl, C 0 -C 3 alkylOC 0 -C 3 alkyl aryl wherein the aryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl; C 0 -C 3 alkylOC 0 -C 3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 - C 3
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 - C 1 cycloalkyl, C -C heterocyclyl, C(O)R 12 , C -C alkyl C(O)R 12
  • R 3 is selected from H, halogen, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 3 -C 12 cycloalkyl, C 3 - C 12 heterocyclyl and C 1 -C 6 alkoxy;
  • R 4 , R 5 and R 6 are each independently selected from H, halogen, CN, C 1 -C 6 alkoxy, C 1 -C 6 -S-alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 3 -C 12 cycloalkyl and C 3 -C 12 heterocyclyl; wherein R 7 is absent when Y 1 is N or is selected from H, halogen, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl and C 1 -C 6 alkoxy when Y 1 is C;
  • R 8 is absent when Y 3 is N or is selected from H, halogen, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl and C 1 -C 6 alkoxy when Y 3 is C; wherein R 9 is absent when Y 2 is N or is selected from H, halogen, C 1 -C 6 alkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C 1 -C 6 alkoxy, C 1 -C 6 heteroalkyl, C 0 -C 3 alkylOC 0 -C 3 alkyl aryl wherein the aryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -
  • R 12 is selected from H, NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 12 cycloalkyl and C 3 -C 12 heterocyclyl, for use in a method for the prevention or treatment of cancer, preferably for use in a method for the prevention or treatment of a Notch dependent cancer.
  • the present invention also provides a pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically acceptable carrier, and a kit comprising a compound of formula (I), optionally with reagents and/or instructions.
  • the present invention also provides the use of compounds of formula (I), for inhibiting in vitro or in vitro the Notch signalling pathway in cells. It has been surprisingly found by the inventors of the present application that compounds which differ with respect to their chemical structure substantially from the compounds specifically disclosed in WO2013/093885 show unrivalled biological properties in Notch inhibition like high potency against NOTCH driven human cancers and high potency in downregulating NOTCH target genes.
  • Figure 1 shows anti-proliferative effect of compounds on NOTCH positive and NOTCH dependent human leukemic cell lines (RPMI8402). Cells were treated with compounds for 72 hours and effect on proliferation was quantified using Alamar blue readout.
  • Figure 2 shows effect of 6-([1,1'-Biphenyl]-4-yloxy)-N-methylpyridin-3-amine on N1-ICD and cMYC (NOTCH target gene) in human leukemic cells.
  • NOTCH positive human leukemic RPMI8402 cells were treated with 1 ⁇ M of 6-(4-tert-butylphenoxy)pyridin-3-amine and 6- ([1,1'-Biphenyl]-4-yloxy)-N-methylpyridin-3-amine for 24 hours. Following treatment, total protein lysates were extracted and protein expression analysed by western blot.
  • Figure 3 shows effect of 6-((4'-Fluoro-[1,1'-biphenyl]-4-yl)oxy)pyridin-3-amine, 6-([1,1'- Biphenyl]-4-yloxy)-4-methylpyridin-3-amine, 6-([1,1'-Biphenyl]-4-yloxy)-2-methylpyridin-3- amine and N-Methyl-6-((6-phenylpyridin-3-yl)oxy)pyridin-3-amine on N1-ICD and cMYC (NOTCH target gene) in human leukemic cells.
  • NOTCH positive human leukemic RPMI8402 cells were treated with 1 ⁇ M of 6-(4-tert-butylphenoxy)pyridin-3-amine and 6-((4'-Fluoro- [1,1'-biphenyl]-4-yl)oxy)pyridin-3-amine, 6-([1,1'-Biphenyl]-4-yloxy)-4-methylpyridin-3- amine, 6-([1,1'-Biphenyl]-4-yloxy)-2-methylpyridin-3-amine and N-Methyl-6-((6- phenylpyridin-3-yl)oxy)pyridin-3-amine for 24 hours.
  • the terms“comprise” and“comprising” also encompass the more restricted terms“consist” and“consisting”.
  • the singular form“a”,“an” and“the” include plural references unless the context clearly dictates otherwise.
  • the terms“subject” is well-recognized in the art, and, refers to a mammal, including dog, cat, rat, mouse, monkey, cow, horse, goat, sheep, pig, camel, and, most preferably, a human.
  • the subject is a subject in need of treatment or a subject with a disease or disorder, such as cancer.
  • the subject can be a normal subject or a subject who has already undergone a treatment against cancer.
  • cancer refers preferably to solid tumors, such as salivary, liver, brain, breast, prostate, colorectum, kidney, lung, sarcoma, or melanoma and liquid tumors, affecting the blood, such as leukemia. More preferably according to the present invention, cancers are Notch dependent cancers selected from the group comprising adenoid cystic carcinoma (ACC), T cell-Acute
  • T-ALL lymphoblastic leukemia
  • CML chronic myeloid leukemia
  • CLL chronic lymphocytic leukemia
  • Mantle cell lymphoma breast cancer, pancreatic cancer, prostate cancer, melanoma, brain tumors, tumor angiogenesis, liver cancer and colorectal cancer.
  • the Notch dependent cancer is resistant to g–secretase inhibitor treatment.
  • Examples of g–secretase inhibitor treatment comprise 1) Gamma secretase inhibitor
  • NCT01131234 2) Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia (NCT01088763), 3) Study of MK-0752 in combination with Tamoxifen or Letrozole to treat early stage breast cancer (NCT00756717), 4) GDC-0449 and RO4929097 in treating patients with Advances or metastatic sarcoma (NCT01154452) 5) RO4929097 and Erlotinib
  • alkyl refers to a saturated straight or branched chain group of carbon atoms derived from an alkane by the removal of one hydrogen atom.
  • C 1 -C 3 alkyl comprises for example methyl, ethyl, n-propyl, i-propyl and comprises preferably non- branched C 1 -C 3 alkyl.
  • C 1 -C 4 alkyl comprises for example methyl, ethyl, n-propyl, i-propyl, n- butyl, i-butyl, tert-butyl and comprises preferably non-branched C 1 -C 4 alkyl.
  • C 1 -C 6 alkyl comprises for example methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl, and n-hexyl and comprises preferably non-branched C 1 -C 6 alkyl.
  • C 1 -C 10 alkyl comprises for example methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl, n-hexyl, n- heptyl, n- octyl, n-nonyl or n-decyl and comprises preferably non-branched C1-C10 alkyl.
  • the term“C 0 alkyl“as used herein refers to a covalent bond.
  • the term“C 0 alkylOC 0 alkyl aryl” refers to Oaryl.
  • C 0 -C 3 alkylOC 0 -C 3 alkyl aryl refers to Oaryl as defined herein when both C 0 -C 3 alkyl groups are C 0 alkyl.
  • the term refers to OC 0 -C 3 alkyl aryl when the first C 0 -C 3 alkyl group is C 0 alkyl.
  • the term refers to C 0 -C 3 alkylOaryl when the second C 0 -C 3 alkyl group is C0 alkyl.
  • C 0 -C 3 alkylOC 0 -C 3 alkyl aryl is C 0 -C 3 alkylOaryl, more preferably Oaryl or C 1 -C 3 alkylOaryl.
  • the term“C 0 -C 3 alkylOC 0 -C 3 alkyl heteroaryl” as used herein refers to Oheteroaryl as defined herein when both C 0 -C 3 alkyl groups are C 0 alkyl.
  • the term refers to OC 0 -C 3 alkyl heteroaryl when the first C 0 -C 3 alkyl group is C 0 alkyl.
  • C 0 -C 3 alkylOheteroaryl when the second C 0 -C 3 alkyl group is C 0 alkyl.
  • C 0 -C 3 alkylOC 0 -C 3 alkyl heteroaryl is C 0 -C 3 alkylOheteroaryl, more preferably Oheteroaryl or C 1 -C 3 alkylOheteroaryl, most preferably Oheteroaryl.
  • the aryl and the heteroaryl of C 0 -C 3 alkylOC 0 -C 3 alkyl aryl and C 0 -C 3 alkylOC 0 -C 3 alkyl heteroaryl are optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, preferably are optionally substituted by NH 2 .
  • heteroalkyl refers to an alkyl radical as defined herein wherein one, two, three or four hydrogen atoms have been replaced with a substituent independently selected from the group consisting of ORa, C(O)ORa, NRbRc, C(O)NRbRc, S(O)nRd (where n is an integer from 0 to 2) and halogen, with the understanding that the point of attachment of the heteroalkyl radical is through a carbon atom, wherein Ra is H, C 1 -C 3 alkylcarbonyl, C 1 -C 3 alkyl, or C 3-7 cycloalkyl; Rb and Rc are each independently H, C 1 -C 3 alkylcarbonyl, C 1 -C 3 alkyl, C 3-7 cycloalkyl or NRbRc is guanidinyl; and when n is 0, R d is H, C 1 -C 3 alkyl or C 3-7 cycloalkyl,
  • heteroalkyl or“heteroalkanediyl” as used herein refers to an alkyl radical or an alkanediyl radical as defined herein wherein one, two, three or four hydrogen atoms have been replaced with a substituent independently selected from the group consisting of OH, NH 2 , guanidinyl and halogen, more preferably wherein one or two hydrogen atoms have been replaced with a substituent independently selected from the group consisting of OH, NH 2 and halogen.
  • Representative examples include, but are not limited to, 2-hydroxyethyl, 2-hydroxypropyl, 3- hydroxypropyl, 2-hydroxy-1-hydroxymethylethyl, 2-hydroxy-1-methylethyl, 2,3- dihydroxypropyl, 1-hydroxymethylethyl, 3-hydroxybutyl, 2,3-dihydroxybutyl, 1-hydroxy-2- methylpropyl, 3-hydroxy-1-(2-hydroxyethyl)-propyl, 2-hydroxy-1-methylpropyl, 1,1,1- trifluoroethyl, 1,1,1-trifluoromethyl, 2,2,3,3-tetrafluoropropyl.
  • C 3-12 cycloalkyl “ and“C 3-7 cycloalkyl” as used herein refers to a monovalent saturated monocyclic or bicyclic hydrocarbon group, preferably a monovalent saturated monocyclic goup of 3-12 or 3-7 carbons, respectively derived from a cycloalkane by the removal of a single hydrogen atom.
  • “C 3-7 cycloalkyl” includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • C3-12 cycloalkyl “ and“C 3-7 cycloalkyl” as used herein also includes cycloalkyl groups that comprise a C 1-3 alkyl radical. Examples of such "C 3-7 cycloalkyl” groups comprise cyclopropylmethyl, 2-cyclopropylethyl,
  • aryloxy or“Oaryl” which are used interchangeably herein refers to a radical -OR where R is an aryl as defined herein, e. g. phenoxy.
  • C 1 -C 6 alkoxy or“OC 1 -C 6 alkyl” which are used interchangeably herein refers to a radical -OR where R is a C 1 -C 6 alkyl as defined herein. Examples are methoxy, ethoxy, propoxy, butoxy.
  • aryl refers to a mono- or bicyclic carbocyclic ring system having one or two aromatic rings, and is preferably a monocyclic carbocyclic ring system.
  • the aryl group can also be fused to a cyclohexane, cyclohexene, cyclopentane, or cyclopentene ring or to a cyclohexane, cyclohexene, cyclopentane, or cyclopentene ring comprising a carbonyl group.
  • the aryl groups of this invention can be optionally substituted as further described below.
  • a preferred aryl group and optionally substituted aryl group, respectively of this invention is a phenyl group or substituted phenyl group.
  • Substituents can be e.g. NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C(O)R 12 , C 1 -C 6 alkyl C(O)R 12 .
  • heteroaryl refers to substituted and unsubstituted aromatic 5-, or 6- membered monocyclic groups and 9- or 10-membered bicyclic groups, preferably a substituted and unsubstituted aromatic 5-, or 6- membered monocyclic group, which have at least one heteroatom (O, S or N) in at least one of the ring(s).
  • Each ring of the heteroaryl group containing a heteroatom can contain one or two oxygen or sulfur atoms and/or from one to four nitrogen atoms provided that the total number of heteroatoms in each ring is four or less and each ring has at least one carbon atom.
  • the fused rings completing the bicyclic group may contain only carbon atoms and may be saturated, partially saturated, or unsaturated.
  • Heteroaryl groups must include at least one fully aromatic ring but the other fused ring or rings may be aromatic or non-aromatic.
  • the heteroaryl group may be attached at any available nitrogen or carbon atom of any ring.
  • Heteroaryl groups of this invention can be optionally substituted as further described below.
  • a heteroaryl group and optionally substituted heteroaryl group, respectively of this invention is selected from the group consisting of substituted and/or unsubstituted aromatic 5-, or 6- membered monocyclic groups, which have at least one heteroatom (O, S or N), preferably one or two heteroatoms selected from S and N in the ring, more preferably one S and one N in the ring, or one or two N in the ring.
  • a preferred heteroaryl group is an optionally substituted heteroaryl group, selected from the group consisting of an optionally substituted pyridinyl group, an optionally substituted pyrimidinyl group, an optionally substituted di- or triazine group, an optionally substituted thiazole group, an optionally substituted oxazole group, and an optionally substituted imidazole group.
  • An even more preferred heteroaryl group is an optionally substituted pyridinyl group, an optionally substituted pyrimidinyl group, an optionally substituted imidazole group or an optionally substituted thiazole group.
  • an optionally substituted pyridinyl group, an optionally substituted imidazole group or an optionally substituted thiazole group is used as heteroaryl group in the present invention.
  • Optional substituents can be e.g. NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 - C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C(O)R 12 , C 1 -C 6 alkyl C(O)R 12 , or NH 2 , OC 1 -C 6 alkyl, C 1 - C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl.
  • heterocyclyl as used herein means a saturated, monocyclic ring with 3 to 12, preferably with 3 to 7, more preferably 5 to 6 ring atoms which contains up to 3, preferably 1 or 2 heteroatoms selected independently from nitrogen, oxygen or sulfur, and wherein the remaining ring atoms being carbon atoms.
  • saturated heterocycles include [1,3]dioxanyl, [1,3]dioxolanyl, pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl, oxazolidinyl, thiazolidinyl, azepanyl and the like.
  • heterocyclyl groups are unsubstituted.
  • halo or “halogen” as used herein refers to F, Cl, Br, or I and is preferably F, Cl, or Br, more preferably F.
  • optionally substituted or“substituted” means that the referenced group is substituted with one or more additional group(s), preferably with one additional group, individually and independently selected from the listed groups.
  • the compound 6-([1,1’-Biphenyl]-4-yloxy)-pyridine-3-amine which is excluded from the compounds of formula (I) in some aspects or embodiments of the present invention has the following chemical structure:
  • the compound 4-([1,1’-Biphenyl]-4-yloxy)-aniline which is excluded from the compounds of formula (I) in some aspects or embodiments of the present invention has the following chemical structure:
  • the compound 6-([1,1’-Biphenyl]-4-yloxy)-2-methylpyridin-3-amine which is excluded from the compounds of formula (I) in some aspects or embodiments of the present invention has the following chemical structure:
  • the compound 6-([1,1’-Biphenyl]-4-yloxy)-4-methylpyridin-3-amine which is excluded from the compounds of formula (I) in some aspects or embodiments of the present invention has the following chemical structure:
  • the compound 4-(4’-Methoxy-biphenyl-4-yloxy)phenylamine which is excluded from the compounds of formula (I) in some aspects or embodiments of the present invention has the following chemical structure:
  • the compound 4-(4’-Chloro-biphenyl-4-yloxy)phenylamine which is excluded from the compounds of formula (I) in some aspects or embodiments of the present invention has the following chemical structure:
  • the compound 4-(4’-tert-Butyl-biphenyl-4-yloxy)phenylamine which is excluded from the compounds of formula (I) in some aspects or embodiments of the present invention has the following chemical structure:
  • the compound 4-(4-(thiazol-2-yl)phenoxy)aniline which is excluded from the compounds of formula (I) in some aspects or embodiments of the present invention has the following chemical structure:
  • the compound 4-(4-(1H-imidazol-2-yl)phenoxy)aniline which is excluded from the compounds of formula (I) in some aspects or embodiments of the present invention has the following chemical structure:
  • the compound 4-(4-(oxazol-2-yl)phenoxy)aniline which is excluded from the compounds of formula (I) in some aspects or embodiments of the present invention has the following chemical structure:
  • the compound 4-(4-(1H-pyrrol-1-yl)phenoxy)aniline which is excluded from the compounds of formula (I) in some aspects or embodiments of the present invention has the following chemical structure:
  • the present invention provides a compound of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof,
  • X is selected from CH 2 , CF 2 , CHF, CO, CHOH, CHO(C 1 -C 3 ) alkyl, NH, N(C 1 -C 3 alkyl), S, SO and O;
  • Y 1 , Y 2 , and Y 3 are each independently selected from N and C;
  • Z is NR 10 R 11 , wherein R 10 and R 11 are each independently selected from H and C 1 -C 6 alkyl;
  • R 1 is selected from H, halogen, C 1 -C 6 alkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C 1 -C 6 alkoxy, C 1 -C 6 heteroalkyl, C 0 -C 3 alkylOC 0 -C 3 alkyl aryl wherein the aryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl; C 0 -C 3 alkylOC 0 -C 3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 - C 3
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 - C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C(O)R 12 , C 1 -C 6 alkyl C(O)R 12 ;
  • R 3 is selected from H, halogen, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 3 -C 12 cycloalkyl, C 3 - C 12 heterocyclyl and C 1 -C 6 alkoxy;
  • R 4 , R 5 and R 6 are each independently selected from H, halogen, CN, C 1 -C 6 alkoxy, C 1 -C 6 -S-alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 3 -C 12 cycloalkyl and C 3 -C 12 heterocyclyl; wherein R 7 is absent when Y 1 is N or is selected from H, halogen, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl and C 1 -C 6 alkoxy when Y 1 is C;
  • R 8 is absent when Y 3 is N or is selected from H, halogen, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl and C 1 -C 6 alkoxy when Y 3 is C; wherein R 9 is absent when Y 2 is N or is selected from H, halogen, C 1 -C 6 alkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C 1 -C 6 alkoxy, C 1 -C 6 heteroalkyl, C 0 -C 3 alkylOC 0 -C 3 alkyl aryl wherein the arylis optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -
  • R 12 is selected from H, NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 12 cycloalkyl and C 3 -C 12 heterocyclyl;
  • Notch signalling pathway is evolutionarily conserved and the basic molecular players in this pathway are ligands (Delta and Jagged), Notch receptors, and the transcription factors (Shih IeM, Wang TL in Cancer Res 2007;67(5):1879–82).
  • Notch is a transmembrane heterodimeric receptor and there are four distinct members (Notch1, Notch2, Notch3 and Notch4) in humans and rodents.
  • Notch-ICD Notch receptor
  • Notch signalling The physiologic functions of Notch signalling are multifaceted, including maintenance of stem cells, specification of cell fate, and regulation of differentiation in development as well as in oncogenesis.
  • molecular genetic alterations such as chromosomal translocation, point mutations, and chromosomal amplification at the Notch receptor loci, are the known mechanisms for constitutive activation of Notch pathway. Despite the different mechanisms, they all result in increased levels of intracellular Notch-IC.
  • T-ALL T-cell acute lymphoblastic leukemia
  • ACC adenoid cystic carcinoma
  • CLL chronic lymphocytic leukemia
  • Notch1 signalling is essential for normal development of T-cell progenitors
  • constitutive activation of Notch1 signalling due to molecular genetic alterations is associated with T-ALL.
  • interstitial deletions of the extracellular portion of human Notch1 due to chromosomal translocation are associated with ⁇ 1% of T-ALL cases and activating point mutations of Notch1 are present in about 50% of T-ALL cases.
  • Formation of T-cell leukemia/lymphoma was observed in a Notch-ICD transgenic mouse model, which indicates a causal role of Notch activation in T-ALL development.
  • chromosomal translocation has been identified in a subset of tumors, and the translocation is thought to elevate Notch3 transcription in tumors.
  • Notch3 gene amplification was found to occur in about 19% of tumors, and overexpression of Notch3 was found in more than half of the ovarian serous carcinomas.
  • Notch signalling activation has been shown in the development of breast cancer.
  • constitutively active Notch4 expression causes mammary tumors in mice and Notch1-activating mutations contribute to the development of T-ALL.
  • overexpression of activated Notch1 and Notch3 in transgenic mice blocks mammary gland development and induces mouse breast tumors.
  • Notch signalling activation has also been implicated in lung and bone metastasis of breast cancer cells.
  • Notch3 is sufficient to induce choroid plexus tumor formation in a mouse model, suggesting a role of Notch3 in the development of certain types of brain tumors.
  • the present invention also encompasses chemical modifications of the compounds of the present invention to prolong their circulating lifetimes.
  • Non-limiting examples of methods for transiently, or reversibly, pegylating drugs, including polypeptide-based drugs, are provided in U.S. Pat. Nos.4,935,465 (issued in Jun.19, 1990) and 6,342,244 (issued Jan.29, 2002); and in U.S. published applications number US2006/0074024.
  • the invention also relates to salts, hydrates or solvates of the compounds of formula (I).
  • these salts, hydrates and/or solvates are pharmaceutically acceptable.
  • pharmaceutically acceptable salts are produced from acidic inorganic or organic compounds, or alkaline inorganic or organic compounds.
  • pharmaceutically acceptable salt refers to a salt that retains the biological effectiveness of the free acids and bases of a specified compound and that is not biologically or otherwise undesirable.
  • the invention also relates to stereoisomers of the compounds of formula (I).“Stereoisomer” or“stereoisomers” refer to compounds that differ in the chirality of one or more stereocentres. Stereoisomers include enantiomers and diastereomers.
  • a compound of formula (I) may exist in stereoisomeric form if they possess one or more asymmetric centres or a double bond with asymmetric substitution and, therefore, can be produced as individual stereoisomers or as mixtures. Unless otherwise indicated, the description is intended to include individual stereoisomers as well as mixtures.
  • the methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art (see discussion in Chapter 4 of Advanced Organic Chemistry, 4th ed., J. March, John Wiley and Sons, New York, 1992). A skilled person will know that, if the compounds of the present invention contain charged group, a suitable counterion will be derived from an organic or inorganic acid.
  • Such counterions include halide (such as chloride, bromide, fluoride, iodide), sulfate, phosphate, acetate, succinate, citrate, lactate, maleate, fumarate, palmitate, cholate, glutamate, glutarate, tartrate, stearate, salicylate, methanesulfonate, benzenesulfonate, sorbate, picrate, benzoate, cinnamate, and the like.
  • a suitable counterion will be selected from sodium, ammonium, barium, calcium, copper, iron, lithium, potassium and zinc, and the like.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising the compounds of the present invention, pharmaceutically acceptable salts, hydrates, or stereoisomers thereof, and a pharmaceutically acceptable carrier.
  • a pharmaceutical composition comprising a compound of formula (I)
  • X is selected from CH 2 , CF 2 , CHF, CO, CHOH, CHO(C 1 -C 3 ) alkyl, NH, N(C 1 -C 3 alkyl), S, SO and O;
  • Y 1 , Y 2 , and Y 3 are each independently selected from N and C;
  • Z is NR 10 R 11 , wherein R 10 and R 11 are each independently selected from H and C 1 -C 6 alkyl;
  • R 1 is selected from H, halogen, C 1 -C 6 alkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C 1 -C 6 alkoxy, C 1 -C 6 heteroalkyl, C 0 -C 3 alkylOC 0 -C 3 alkyl aryl wherein the aryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl; C 0 -C 3 alkylOC 0 -C 3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 - C 3
  • R 3 is selected from H, halogen, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 3 -C 12 cycloalkyl, C 3 - C 12 heterocyclyl and C 1 -C 6 alkoxy;
  • R 4 , R 5 and R 6 are each independently selected from H, halogen, CN, C 1 -C 6 alkoxy, C 1 -C 6 -S-alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 3 -C 12 cycloalkyl and C 3 -C 12 heterocyclyl; wherein R 7 is absent when Y 1 is N or is selected from H, halogen, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl and C 1 -C 6 alkoxy when Y 1 is C;
  • R 8 is absent when Y 3 is N or is selected from H, halogen, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl and C 1 -C 6 alkoxy when Y 3 is C;
  • R 9 is absent when Y 2 is N or is selected from H, halogen, C 1 -C 6 alkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C 1 -C 6 alkoxy, C 1 -C 6 heteroalkyl, C 0 -C 3 alkylOC 0 -C 3 alkyl aryl wherein the arylis optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl; C 0 -C 3 alkylOC 0 -C 3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen,
  • R 12 is selected from H, NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 12 cycloalkyl and C 3 -C 12 heterocyclyl; and a pharmaceutically acceptable carrier.
  • the compound of formula (I) comprised by the pharmaceutical composition is not 4-([1,1’-Biphenyl]-4-yloxy)-aniline, more preferably is not 6-([1,1’- Biphenyl]-4-yloxy)-pyridine-3-amine, 4-([1,1’-Biphenyl]-4-yloxy)-aniline, 6-([1,1’- Biphenyl]-4-yloxy)-2-methylpyridin-3-amine and 6-([1,1’-Biphenyl]-4-yloxy)-4- methylpyridin-3-amine.
  • the compound of formula (I) comprised by the pharmaceutical composition is not 6-([1,1’-Biphenyl]-4-yloxy)-pyridine-3-amine, 4-([1,1’- Biphenyl]-4-yloxy)-aniline, 6-([1,1’-Biphenyl]-4-yloxy)-2-methylpyridin-3-amine, 6-([1,1’- Biphenyl]-4-yloxy)-4-methylpyridin-3-amine, 4-(4’-Methoxy-biphenyl-4-yloxy)phenylamine, 4-(4’-Chloro-biphenyl-4-yloxy)phenylamine, and 4-(4’-tert-Butyl-biphenyl-4- yloxy)phenylamine.
  • composition is not 6-([1,1’-Biphenyl]-4-yloxy)-pyridine-3-amine, 4-([1,1’- Biphenyl]-4-yloxy)-aniline, 6-([1,1’-Biphenyl]-4-yloxy)-2-methylpyridin-3-amine, 6-([1,1’- Biphenyl]-4-yloxy)-4-methylpyridin-3-amine, 4-(4’-Methoxy-biphenyl-4-yloxy)phenylamine, 4-(4’-Chloro-biphenyl-4-yloxy)phenylamine, 4-(4’-tert-Butyl-biphenyl-4-yloxy)phenylamine, 4-(4-(thiazol-2-yl)phenoxy)aniline, 4-(4-(1H-imidazol-2-yl)phenoxy)aniline, 4-(4-(oxazol-2- yl)phenoxy)aniline and 4-(4-(
  • X is selected from CH 2 , CF 2 , CHF, CO, CHOH, CHO(C 1 -C 3 ) alkyl, NH, N(C 1 -C 3 alkyl), S, SO and O;
  • Y 1 , Y 2 , and Y 3 are each independently selected from N and C;
  • Z is NR 10 R 11 , wherein R 10 and R 11 are each independently selected from H and C 1 -C 6 alkyl;
  • R 1 is selected from H, halogen, C 1 -C 6 alkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C 1 -C 6 alkoxy, C 1 -C 6 heteroalkyl, C 0 -C 3 alkylOC 0 -C 3 alkyl aryl wherein the aryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl; C 0 -C 3 alkylOC 0 -C 3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 - C 3
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 - C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C(O)R 12 , C 1 -C 6 alkyl C(O)R 12 ; wherein R 3 is selected from H, halogen, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 3 -C 12 cycloalkyl, C 3 - C 12 heterocyclyl and C 1 -C 6 alkoxy;
  • R 4 , R 5 and R 6 are each independently selected from H, halogen, CN, C 1 -C 6 alkoxy, C 1 -C 6 -S-alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 3 -C 12 cycloalkyl and C 3 -C 12 heterocyclyl; wherein R 7 is absent when Y 1 is N or is selected from H, halogen, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl and C 1 -C 6 alkoxy when Y 1 is C;
  • R 8 is absent when Y 3 is N or is selected from H, halogen, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl and C 1 -C 6 alkoxy when Y 3 is C;
  • R 9 is absent when Y 2 is N or is selected from H, halogen, C 1 -C 6 alkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C 1 -C 6 alkoxy, C 1 -C 6 heteroalkyl, C 0 -C 3 alkylOC 0 -C 3 alkyl aryl wherein the arylis optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl; C 0 -C 3 alkylOC 0 -C 3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen,
  • R 12 is selected from H, NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 12 cycloalkyl and C 3 -C 12 heterocyclyl, for use in a method for the prevention or treatment of cancer.
  • the compound of formula (I) for use in a method for the prevention or treatment of cancer is not 4-([1,1’-Biphenyl]-4-yloxy)-aniline, more preferably is not 6-([1,1’-Biphenyl]-4-yloxy)-pyridine-3-amine, 4-([1,1’-Biphenyl]-4-yloxy)- aniline, 6-([1,1’-Biphenyl]-4-yloxy)-2-methylpyridin-3-amine and 6-([1,1’-Biphenyl]-4- yloxy)-4-methylpyridin-3-amine.
  • the compound of formula (I) for use in a method for the prevention or treatment of cancer is not 6-([1,1’-Biphenyl]-4-yloxy)- pyridine-3-amine, 4-([1,1’-Biphenyl]-4-yloxy)-aniline, 6-([1,1’-Biphenyl]-4-yloxy)-2- methylpyridin-3-amine, 6-([1,1’-Biphenyl]-4-yloxy)-4-methylpyridin-3-amine, 4-(4’- Methoxy-biphenyl-4-yloxy)phenylamine, 4-(4’-Chloro-biphenyl-4-yloxy)phenylamine, and 4- (4’-tert-Butyl-biphenyl-4-yloxy)phenylamine.
  • the compound of formula (I) for use in a method for the prevention or treatment of cancer is not 6-([1,1’-Biphenyl]-4-yloxy)- pyridine-3-amine, 4-([1,1’-Biphenyl]-4-yloxy)-aniline, 6-([1,1’-Biphenyl]-4-yloxy)-2- methylpyridin-3-amine, 6-([1,1’-Biphenyl]-4-yloxy)-4-methylpyridin-3-amine, 4-(4’- Methoxy-biphenyl-4-yloxy)phenylamine, 4-(4’-Chloro-biphenyl-4-yloxy)phenylamine, 4-(4’- tert-Butyl-biphenyl-4-yloxy)phenylamine, 4-(4-(thiazol-2-yl)phenoxy)aniline, 4-(4-(1H- imidazol-2-yl)phenoxy)aniline, 4-(
  • R 1 is C 0 -C 3 alkylOC 0 -C 3 alkyl aryl or C 0 -C 3 alkylOC 0 -C 3 alkyl heteroaryl
  • the optional substitutions of the aryl and the heteroaryl group are preferably in para position.
  • R 2 is aryl or heteroaryl
  • the optional substitutions are preferably in ortho or meta position, provided that the substitutents are not halogen, OC 1 -C 6 alkyl or methyl and are in para position when the substituents are halogen, OC 1 -C 6 alkyl or methyl.
  • R 9 is C 0 -C 3 alkylOC 0 -C 3 alkyl aryl or C 0 -C 3 alkylOC 0 -C 3 alkyl heteroaryl
  • the optional substitutions of the aryl and the heteroaryl group are preferably in para position.
  • X is selected from CH2, CF2, CHF, NH, N(C1-C3 alkyl), S, SO and O.
  • X is selected from CO, CHOH, CHO(C 1 -C 3 ) alkyl, S, SO and O.
  • X is selected from CH 2 , NH, and O.
  • X is selected from CH 2 , CO, CHOH, CHO(C 1 -C 3 ) alkyl, NH, and O. In an even more preferred embodiment X is selected from CH 2 , CO, CHOH, CHO(C 1 -C 3 ) alkyl, and O. In a particular preferred embodiment X is selected from CH 2 , CO, CHOH, CHOCH 3 , and O. In a more particular preferred embodiment X is selected from CH 2 and O. In an even more particular preferred embodiment X is O.
  • R 1 is selected from H, halogen, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 0 -C 3 alkylOC 0 -C 3 alkyl aryl wherein the aryl is optionally substituted by NH 2 , C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, preferably is optionally substituted by NH 2 ; and C 0 -C 3 alkylOC 0 -C 3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, preferably is optionally substituted by NH 2 .
  • R 1 is selected from H, halogen, C 1 -C 6 alkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C 1 -C 6 alkoxy and C 1 -C 6 heteroalkyl.
  • R 1 is selected from H, halogen and C 1 -C 4 alkyl, C 0 -C 3 alkylOC 0 -C 3 alkyl aryl wherein the aryl is optionally substituted by NH 2 , C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, preferably is optionally substituted by NH 2 ; and C 0 -C 3 alkylOC 0 -C 3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, preferably is optionally substituted by NH 2 .
  • R 1 is selected from H, halogen, C 1 -C 6 alkyl and C 1 -C 6 heteroalkyl.
  • R 1 is selected from H, C 1 -C 6 alkyl, C 0 -C 3 alkylOC 0 -C 3 alkyl aryl wherein the aryl is optionally substituted by NH 2 , C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, preferably is optionally substituted NH 2 ; C 0 -C 3 alkylOC 0 -C 3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH 2 , C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, preferably is optionally substituted by NH 2.
  • R 1 is selected from H, C 1 -C 4 alkyl and C 0 -C 3 alkylOC 0 -C 3 alkyl aryl wherein the aryl is optionally substituted by NH 2 , C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, preferably is optionally substituted by NH 2 ; C 0 -C 3 alkylOC 0 -C 3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, preferably is optionally substituted by NH 2 .
  • R 1 is selected from H, halogen and C 1 -C 4 alkyl.
  • R 1 is selected from H, methyl, C 0 -C 3 alkylOC 0 -C 3 alkyl aryl wherein the aryl is optionally substituted by NH2, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, preferably is optionally substituted by NH 2 ; and C 0 -C 3 alkylOC 0 -C 3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, preferably is optionally substituted by NH 2 .
  • R 1 is selected from C 0 -C 3 alkylOC 0 -C 3 alkyl aryl wherein the aryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, preferably is optionally substituted by NH2; C 0 -C 3 alkylOC 0 -C 3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, preferably is optionally substituted by NH 2 ; and C 1 -C 6 alkyl substitute
  • R 1 is selected from C 0 -C 3 alkylOC 0 -C 3 alkyl aryl wherein the aryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, preferably is optionally substituted by NH 2 ; and C 0 -C 3 alkylOC 0 -C 3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 - C 12 cycloalkyl, C 3 -C 12 heterocyclyl, preferably is optionally substituted by NH 2 .
  • R 1 is selected from H and methyl.
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl is substituted by a substituent selected from NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C(O)R 12 and C 1 -C 6 alkyl C(O)R 12 .
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6
  • heteroalkyl halogen, CN, C(O)R 12 , C 1 -C 6 alkyl C(O)R 12 .
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH 2 , C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 - C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C(O)R 12 and C 1 -C 6 alkyl C(O)R 12 .
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH 2 , C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C(O)R 12 , C 1 -C 6 alkyl C(O)R 12 .
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH 2 , C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl.
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by C 1 -C 6 alkyl, halogen, C 1 -C 6 heteroalkyl, C(O)R 12 , C 1 -C 6 alkyl C(O)R 12 .
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by C 1 -C 6 alkyl, halogen.
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH 2 , halogen, CN.
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by C(O)R 12 , C 1 -C 6 alkyl C(O)R 12 .
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by C 1 -C 6 alkyl, halogen, C 1 -C 6 heteroalkyl, C(O)R 12 , C 1 -C 6 alkyl C(O)R 12 is preferred.
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, C 1 -C 6 alkyl C(O)R 12 .
  • R 2 is selected from phenyl, pyridyl, imidazole and thiazole each optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C(O)R 12 , C 1 -C 6 alkyl C(O)R 12 .
  • R 2 is selected from phenyl, thiazole, pyridyl, imidazole and thiazole each optionally substituted by NH 2 , C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C(O)R 12 , C 1 -C 6 alkyl C(O)R 12 .
  • R 2 is selected from phenyl, pyridyl, imidazole and thiazole each optionally substituted by NH 2 , C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C(O)R 12 , C 1 -C 6 alkyl C(O)R 12 .
  • R 2 is selected from phenyl, pyridyl, imidazole and thiazole each optionally substituted by C 1 -C 6 alkyl, halogen, C 1 -C 6 heteroalkyl, C(O)R 12 , C 1 -C 6 alkyl C(O)R 12 .
  • R 2 is selected from phenyl, pyridyl, imidazole and thiazole each optionally substituted by C 1 -C 6 alkyl, halogen. In a further even more particular preferred embodiment R 2 is selected from phenyl, pyridyl, imidazole and thiazole each optionally substituted by NH 2 , halogen, CN. In a further even more particular preferred embodiment R 2 is selected from phenyl, pyridyl, imidazole and thiazole each optionally substituted by C(O)R 12 , C 1 -C 6 alkyl C(O)R 12 .
  • R 2 is selected from phenyl, pyridyl, imidazole and thiazole each optionally substituted by C 1 -C 6 alkyl, halogen, C 1 -C 6 heteroalkyl, C(O)R 12 , C 1 -C 6 alkyl C(O)R 12 is preferred.
  • R 2 is selected from phenyl, pyridyl, imidazole and thiazole each optionally substituted by C 1 -C 6 alkyl, halogen.
  • R 2 is selected from phenyl, pyridyl, imidazole and thiazole each optionally substituted by C(O)R 12 , C 1 -C 6 alkyl C(O)R 12 .
  • R 2 is selected from phenyl, pyridyl, imidazole and thiazole each optionally substituted by OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, C 1 -C 6 alkyl C(O)R 12 .
  • R 2 is selected from aryl and heteroaryl wherein the heteroaryl is an optionally substituted aromatic 5-, or 6- membered monocyclic group.
  • R 2 is selected from aryl and heteroaryl, with the proviso that the heteroaryl is not unsubstituted thiazole, oxazole, imidazole and pyrrole.
  • R 2 is selected from aryl and heteroaryl, with the proviso that the heteroaryl is not thiazole, oxazole, imidazole and pyrrole.
  • R 3 is selected from H, halogen, C 1 -C 6 alkyl, and C 3 -C 12 cycloalkyl.
  • R 3 is selected from H, halogen, C 1 -C 4 alkyl, and C 3 -C 7 cycloalkyl.
  • R 3 is selected from H, halogen and C 1 -C 4 alkyl.
  • R 3 is H.
  • R 4 , R 5 and R 6 are each independently selected from H, halogen, CN, C 1 - C6 alkyl and C 1 -C 6 heteroalkyl.
  • R 4 , R 5 and R 6 are each independently selected from H, halogen, CN, C 1 - C6 alkyl and C 1 -C 6 heteroalkyl.
  • R 4 , R 5 and R 6 are
  • R 4 , R 5 and R 6 are each independently selected from H, halogen, and C 1 -C 4 alkyl.
  • R 4 , R 5 and R 6 are each independently selected from H, halogen, and methyl.
  • R 4 is selected from H and halogen and/or R 5 and/or R 6 are selected from H and C 1 -C 6 alkyl, in particular from H and C 1 -C 4 alkyl, more particular from H and methyl.
  • R 7 is absent when Y 1 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 1 is C. In a preferred embodiment R 7 is absent when Y 1 is N or is selected from H, halogen, C 1 -C 4 alkyl and C 3 -C 7 cycloalkyl when Y 1 is C. In a more preferred embodiment R 7 is absent when Y 1 is N or is selected from H, halogen and C 1 -C 4 alkyl, preferably selected from H, halogen, and methyl when Y 1 is C.
  • R 7 is absent when Y 1 is N or is selected from H, halogen, and methyl when Y 1 is C. In a particular preferred embodiment R 7 is absent when Y 1 is N or is selected from H and halogen when Y 1 is C. In a more particular preferred embodiment R 7 is absent.
  • R 8 is absent when Y 3 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 3 is C. In a preferred embodiment R 8 is absent when Y 3 is N or is selected from H, halogen, C 1 -C 4 alkyl and C 3 -C 7 cycloalkyl when Y 3 is C. In a more preferred embodiment R 8 is absent when Y 3 is N or is selected from H, halogen and C 1 -C 4 alkyl preferably selected from H, halogen, and methyl when Y 3 is C.
  • R 8 is absent when Y 3 is N or is selected from H, halogen, and methyl when Y 3 is C. In a particular preferred embodiment R 8 is absent when Y 3 is N or is selected from H and halogen when Y 3 is C. In a particular preferred embodiment R 8 is H.
  • R 9 is absent when Y 2 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 2 is C. In a preferred embodiment R 9 is absent when Y 2 is N or is selected from H, halogen, C 1 -C 4 alkyl and C 3 -C 7 cycloalkyl when Y 2 is C. In a more preferred embodiment R 9 is absent when Y 2 is N or is selected from H and C 1 -C 4 alkyl preferably selected from H, halogen, and methyl when Y 2 is C.
  • R 9 is absent when Y 2 is N or is selected from H, halogen, and methyl when Y 2 is C. In a particular preferred embodiment R 9 is absent when Y 2 is N or is selected from H and halogen, preferably H, when Y 2 is C.
  • R 7 is absent when Y 1 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 1 is C, preferably selected from H, halogen, and methyl when Y 1 is C
  • R 8 is absent when Y 3 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl, preferably selected from H, halogen, and methyl when Y 3 is C
  • R 9 is absent when Y 2 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl, preferably selected from H, halogen, and methyl when Y 2 is C.
  • R 7 is absent when Y 1 is N or is selected from H and halogen when Y 1 is C
  • R 8 is absent when Y 3 is N or is H when Y 3 is C
  • R 9 is absent when Y 2 is N or is selected from H and methyl when Y 2 is C.
  • at least one of R 10 and R 11 is C 1 -C 6 alkyl, preferably C 1 -C 4 alkyl, more preferably methyl.
  • R 10 and R 11 are independently selected from H and methyl.
  • R 10 is H and R 11 is selected from H and C 1 -C 4 alkyl.
  • R 10 is H and R 11 is H or methyl.
  • R 10 is H and R 11 is C 1 -C 6 alkyl. In a more particular preferred embodiment R 10 is H and R 11 is C 1 -C 4 alkyl. In an even more particular preferred embodiment R 10 is H and R 11 is methyl.
  • R 12 is selected from NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl. In a preferred embodiment R 12 is selected from NH 2 , C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl. In a more preferred embodiment R 12 is NH 2 . In one embodiment Y 1 is N.
  • Y 1 and Y 2 are each independently selected from N and C and Y 3 is C. In a more preferred embodiment Y 1 is selected from N and C and Y 2 and Y 3 are selected from N and C with the proviso that one of Y 2 and Y 3 is C. In a particular preferred embodiment Y 1 is N and R 7 is absent, Y 2 is selected from N and C and Y 3 is C. In a more particular preferred embodiment Y 1 is N and R 7 is absent. In one embodiment at least one of the substituents selected from R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 is not H.
  • At least one of the substituents selected from R 1 , R 3 , R 8 , and R 9 is not H.
  • Preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
  • X is selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, NH, and O, preferably selected from CH 2 , CO, CHOH, CHO(C 1 -C 3 ) alkyl, and O; wherein Y 1 , Y 2 , and Y 3 are each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 is C, more preferably Y 1 is N and R 7 is absent, Y 2 is selected from N and C and Y 3 is C;
  • Z is NR 10 R 11 , wherein R 10 and R 11 are each independently selected from H and C 1 -C 6 alkyl;
  • R 1 is selected from H, halogen, C 1 -C 6 alkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C 1 -C 6 alkoxy; C 1 -C 6 heteroalkyl, C 0 -C 3 alkylOC 0 -C 3 alkyl aryl wherein the aryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl; C 0 -C 3 alkylOC 0 -C 3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 - C 3
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 - C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C(O)R 12 , C 1 -C 6 alkyl C(O)R 12 ;
  • R 3 is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl;
  • R 4 , R 5 and R 6 are each independently selected from H, halogen, CN, C 1 -C 6 alkyl and C 1 -C 6 heteroalkyl;
  • R 7 is absent when Y 1 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 1 is C;
  • R 8 is absent when Y 3 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 3 is C;
  • R 9 is absent when Y 2 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 2 is C;
  • R 12 is selected from NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl.
  • R 12 is selected from NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl.
  • Further preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
  • X is selected from CH 2 , CO, CHOH, CHO(C 1 -C 3 ) alkyl, NH, and O, preferably selected from CH 2 , CO, CHOH, CHO(C 1 -C 3 ) alkyl, and O;
  • Y 1 , Y 2 , and Y 3 are each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 is C, more preferably Y 1 is N and R 7 is absent, Y 2 is selected from N and C and Y 3 is C; wherein Z is NR 10 R 11 , wherein R 10 and R 11 are each independently selected from H and C 1 -C 6 alkyl;
  • R 1 is selected from H, halogen, C 1 -C 6 alkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C 1 -C 6 alkoxy; C 1 -C 6 heteroalkyl, C 0 -C 3 alkylOC 0 -C 3 alkyl aryl wherein the aryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl; C 0 -C 3 alkylOC 0 -C 3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 - C 3
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C3- C 12 cycloalkyl C 3 -C 12 heterocyclyl, C(O)R 12 , C 1 -C 6 alkyl C(O)R 12 ;
  • R 3 is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl;
  • R 4 , R 5 and R 6 are each independently selected from H, halogen, CN, C 1 -C 6 alkyl and C 1 -C 6 heteroalkyl;
  • R 7 is absent when Y 1 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 1 is C;
  • R 8 is absent when Y 3 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 3 is C;
  • R 9 is absent when Y 2 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 2 is C;
  • R 12 is selected from NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl; with the proviso that when R 1 is selected from C 0 -C 3 alkylOC 0 -C 3 alkyl aryl wherein the aryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl; C 0 -C 3 alkylOC 0 -C 3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -
  • X is selected from CH 2 , CO, CHOH, CHO(C 1 -C 3 ) alkyl, NH, and O, preferably selected from CH 2 , CO, CHOH, CHO(C 1 -C 3 ) alkyl, and O;
  • Y 1 , Y 2 , and Y 3 are each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 is C, more preferably Y 1 is N and R 7 is absent, Y 2 is selected from N and C and Y 3 is C;
  • Z is NR 10 R 11 , wherein R 10 and R 11 are each independently selected from H and C 1 -C 6 alkyl;
  • R 1 is selected from H, halogen, C 1 -C 6 alkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C 1 -C 6 alkoxy and C 1 -C 6 heteroalkyl;
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 - C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C(O)R 12 , C 1 -C 6 alkyl C(O)R 12 ;
  • R 3 is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl;
  • R 4 , R 5 and R 6 are each independently selected from H, halogen, CN, C 1 -C 6 alkyl and C 1 -C 6 heteroalkyl;
  • R 7 is absent when Y 1 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 1 is C;
  • R 8 is absent when Y 3 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 3 is C;
  • R 9 is absent when Y 2 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 2 is C;
  • R 12 is selected from NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl.
  • R 12 is selected from NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl.
  • pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
  • X is selected from CH 2 , CO, CHOH, CHO(C 1 -C 3 ) alkyl, NH, and O, preferably selected from CH 2 , CO, CHOH, CHO(C 1 -C 3 ) alkyl, and O;
  • Y 1 , Y 2 , and Y 3 are each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 is C, more preferably Y 1 is N and R 7 is absent, Y 2 is selected from N and C and Y 3 is C;
  • Z is NR 10 R 11 , wherein R 10 and R 11 are each independently selected from H and C 1 -C 6 alkyl; wherein R 1 is selected from H, halogen, C 1 -C 6 alkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C 1 -C 6 alkoxy and C 1 -C 6 heteroalkyl;
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 - C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C(O)R 12 , C 1 -C 6 alkyl C(O)R 12 ;
  • R 3 is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl;
  • R 4 , R 5 and R 6 are each independently selected from H, halogen, CN, C 1 -C 6 alkyl and C 1 -C 6 heteroalkyl;
  • R 7 is absent when Y 1 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 1 is C;
  • R 8 is absent when Y 3 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 3 is C;
  • R 9 is absent when Y 2 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 2 is C;
  • R 12 is selected from NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl, with the proviso that when R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are substituted by C 1 -C 6 alkyl, halogen, C 1 -C 6 heteroalkyl, C(O)R 12 , C 1 -C 6 alkyl C(O)R 12 , R 1 is selected from H, halogen, C 1 -C 6 alkyl and C 1 -C 6 heteroalkyl, preferably is H or methyl.
  • pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
  • X is selected from CH 2 , CO, CHOH, CHO(C 1 -C 3 ) alkyl, NH, and O, preferably selected from CH 2 , CO, CHOH, CHO(C 1 -C 3 ) alkyl, and O;
  • Y 1 , Y 2 , and Y 3 are each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 is C, more preferably Y 1 is N and R 7 is absent, Y 2 is selected from N and C and Y 3 is C;
  • Z is NR 10 R 11 , wherein R 10 and R 11 are each independently selected from H and C 1 -C 6 alkyl;
  • R 1 is selected from H, halogen, C 1 -C 6 alkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C 1 -C 6 alkoxy and C 1 -C 6 heteroalkyl;
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH 2 , C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C(O)R 12 , C 1 -C 6 alkyl C(O)R 12 ; wherein R 3 is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl;
  • R 4 , R 5 and R 6 are each independently selected from H, halogen, CN, C 1 -C 6 alkyl and C 1 -C 6 heteroalkyl;
  • R 7 is absent when Y 1 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 1 is C;
  • R 8 is absent when Y 3 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 3 is C;
  • R 9 is absent when Y 2 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 2 is C;
  • R 12 is selected from NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl.
  • R 12 is selected from NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl.
  • pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those ,
  • X is selected from CH 2 , CO, CHOH, CHO(C 1 -C 3 ) alkyl, NH, and O, preferably selected from CH 2 , CO, CHOH, CHO(C 1 -C 3 ) alkyl, and O;
  • Y 1 , Y 2 , and Y 3 are each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 is C, more preferably Y 1 is N and R 7 is absent, Y 2 is selected from N and C and Y 3 is C;
  • Z is NR 10 R 11 , wherein R 10 and R 11 are each independently selected from H and C 1 -C 6 alkyl;
  • R 1 is selected from H, halogen, C 1 -C 6 alkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C 1 -C 6 alkoxy; C 1 -C 6 heteroalkyl, C 0 -C 3 alkylOC 0 -C 3 alkyl aryl wherein the aryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl; C 0 -C 3 alkylOC 0 -C 3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 - C 3
  • R 3 is selected from H, halogen and C 1 -C 4 alkyl
  • R 4 , R 5 and R 6 are each independently selected from H, halogen, and C 1 -C 4 alkyl; wherein R 7 is absent when Y 1 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 1 is C;
  • R 8 is absent when Y 3 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 3 is C;
  • R 9 is absent when Y 2 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 2 is C.
  • R 9 is absent when Y 2 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 2 is C.
  • pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
  • X is selected from CH 2 , CO, CHOH, CHO(C 1 -C 3 ) alkyl, NH, and O, preferably selected from CH 2 , CO, CHOH, CHO(C 1 -C 3 ) alkyl, and O;
  • Y 1 , Y 2 , and Y 3 are each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 is C, more preferably Y 1 is N and R 7 is absent, Y 2 is selected from N and C and Y 3 is C;
  • Z is NR 10 R 11 , wherein R 10 and R 11 are each independently selected from H and C 1 -C 6 alkyl;
  • R 1 is selected from H, halogen, C 1 -C 4 alkyl and C 1 -C 4 heteroalkyl;
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH 2 , C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C(O)R 12 , C 1 -C 6 alkyl C(O)R 12 ;
  • R 3 is selected from H, halogen, C 1 -C 4 alkyl and C 3 -C 7 cycloalkyl;
  • R 4 , R 5 and R 6 are each independently selected from H, halogen, CN, C 1 -C 4 alkyl and C 1 -C 4 heteroalkyl;
  • R 7 is absent when Y 1 is N or is selected from H, halogen, C 1 -C 4 alkyl and C 3 -C 7 cycloalkyl when Y 1 is C;
  • R 8 is absent when Y 3 is N or is selected from H, halogen, C 1 -C 4 alkyl and C 3 -C 7 cycloalkyl when Y 3 is C;
  • R 9 is absent when Y 2 is N or is selected from H, halogen, C1-C4 alkyl and C3-C7 cycloalkyl when Y 2 is C; and wherein R 12 is selected from NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl.
  • Particular preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
  • X is selected from CH 2 , CO, CHOH, CHO(C 1 -C 3 ) alkyl, NH, and O, preferably selected from CH 2 , CO, CHOH, CHO(C 1 -C 3 ) alkyl, and O;
  • Y 1 , Y 2 , and Y 3 are each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 is C, more preferably Y 1 is N and R 7 is absent, Y 2 is selected from N and C and Y 3 is C;
  • Z is NR 10 R 11 , wherein R 10 and R 11 are each independently selected from H and C 1 -C 6 alkyl, preferably independently selected from H and methyl, more preferably R 10 is H and R 11 is H or methyl;
  • R 1 is selected from H, halogen and C 1 -C 4 alkyl
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, C(O)R 12 , C 1 -C 6 alkyl C(O)R 12 ;
  • R 3 is selected from H, halogen and C 1 -C 4 alkyl
  • R 4 , R 5 and R 6 are each independently selected from H, halogen and C 1 -C 4 alkyl; wherein R 7 is absent when Y 1 is N or is selected from H, halogen and C1-C4 alkyl when Y 1 is C;
  • R 8 is absent when Y 3 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 3 is C;
  • R 9 is absent when Y 2 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 2 is C;
  • R 12 is selected from NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl.
  • R 12 is selected from NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl.
  • pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
  • X is selected from CH 2 , CO, CHOH, CHO(C 1 -C 3 ) alkyl, NH, and O, preferably selected from CH 2 , CO, CHOH, CHO(C 1 -C 3 ) alkyl, and O;
  • Y 1 , Y 2 , and Y 3 are each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 is C, more preferably Y 1 is N and R 7 is absent, Y 2 is selected from N and C and Y 3 is C; wherein Z is NR 10 R 11 , wherein R 10 and R 11 are each independently selected from H and C 1 -C 6 alkyl, preferably independently selected from H and methyl, preferably R 10 is H and R 11 is H or methyl;
  • R 1 is selected from H, halogen and C 1 -C 4 alkyl
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by C 1 -C 6 heteroalkyl;
  • R 3 is selected from H, halogen and C 1 -C 4 alkyl
  • R 4 , R 5 and R 6 are each independently selected from H, halogen and C 1 -C 4 alkyl; wherein R 7 is absent when Y 1 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 1 is C;
  • R 8 is absent when Y 3 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 3 is C;
  • R 9 is absent when Y 2 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 2 is C;
  • R 12 is selected from NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl.
  • R 12 is selected from NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl.
  • pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
  • X is selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, NH, and O, preferably selected from CH 2 , CO, CHOH, CHO(C 1 -C 3 ) alkyl, and O;
  • Y 1 , Y 2 , and Y 3 are each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 is C, more preferably Y 1 is N and R 7 is absent, Y 2 is selected from N and C and Y 3 is C;
  • Z is NR 10 R 11 , wherein R 10 and R 11 are each independently selected from H and C 1 -C 6 alkyl, preferably independently selected from H and methyl, preferably R 10 is H and R 11 is H or methyl;
  • R 1 is selected from H, halogen and C 1 -C 4 alkyl
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by C 1 -C 6 alkyl, halogen;
  • R 3 is selected from H, halogen and C 1 -C 4 alkyl
  • R 4 , R 5 and R 6 are each independently selected from H, halogen and C 1 -C 4 alkyl; wherein R 7 is absent when Y 1 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 1 is C; wherein R 8 is absent when Y 3 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 3 is C;
  • R 9 is absent when Y 2 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 2 is C;
  • R 12 is selected from NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl.
  • R 12 is selected from NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl.
  • pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
  • X is selected from CH 2 , CO, CHOH, CHO(C 1 -C 3 ) alkyl, NH, and O, preferably selected from CH 2 , CO, CHOH, CHO(C 1 -C 3 ) alkyl, and O;
  • Y 1 , Y 2 , and Y 3 are each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 is C, more preferably Y 1 is N and R 7 is absent, Y 2 is selected from N and C and Y 3 is C;
  • Z is NR 10 R 11 , wherein R 10 and R 11 are each independently selected from H and C 1 -C 6 alkyl, preferably independently selected from H and methyl, preferably R 10 is H and R 11 is H or methyl;
  • R 1 is selected from H, halogen and C 1 -C 4 alkyl
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by C(O)R 12 , C 1 -C 6 alkyl C(O)R 12 ;
  • R 3 is selected from H, halogen and C 1 -C 4 alkyl
  • R 4 , R 5 and R 6 are each independently selected from H, halogen and C 1 -C 4 alkyl; wherein R 7 is absent when Y 1 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 1 is C;
  • R 8 is absent when Y 3 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 3 is C;
  • R 9 is absent when Y 2 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 2 is C;
  • R 12 is selected from NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl.
  • R 12 is selected from NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl.
  • pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
  • X is selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, NH, and O, preferably selected from CH 2 , CO, CHOH, CHO(C 1 -C 3 ) alkyl, and O; wherein Y 1 , Y 2 , and Y 3 are each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 is C, more preferably Y 1 is N and R 7 is absent, Y 2 is selected from N and C and Y 3 is C;
  • Z is NR 10 R 11 , wherein R 10 and R 11 are each independently selected from H and C 1 -C 6 alkyl, preferably independently selected from H and methyl, preferably R 10 is H and R 11 is H or methyl;
  • R 1 is selected from C 0 -C 3 alkylOC 0 -C 3 alkyl aryl wherein the aryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, preferably is optionally substituted by NH 2 ; C 0 -C 3 alkylOC 0 - C 3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 - C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, preferably is optionally substituted by NH2; and C 1 -C 6 alkyl substituted by aryl or
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH 2 , halogen, C 1 -C 6 alkyl, CN, preferably optionally substituted by halogen, C 1 -C 6 alkyl;
  • R 3 is selected from H, halogen and C 1 -C 4 alkyl
  • R 4 , R 5 and R 6 are each independently selected from H, halogen, and C 1 -C 4 alkyl; wherein R 7 is absent when Y 1 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 1 is C;
  • R 8 is absent when Y 3 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 3 is C;
  • R 9 is absent when Y 2 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 2 is C.
  • Preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those, wherein X is selected from CH 2 , NH and O;
  • Y 1 , Y 2 , and Y 3 are each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 is C, more preferably Y 1 is N and R 7 is absent, Y 2 is selected from N and C and Y 3 is C;
  • Z is NR 10 R 11 , wherein R 10 and R 11 are each independently selected from H and C 1 -C 6 alkyl;
  • R 1 is selected from H, halogen, C 1 -C 6 alkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C 1 -C 6 alkoxy; C 1 -C 6 heteroalkyl, C 0 -C 3 alkylOC 0 -C 3 alkyl aryl wherein the aryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl; C 0 -C 3 alkylOC 0 -C 3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 - C 3
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 - C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C(O)R 12 , C 1 -C 6 alkyl C(O)R 12 ;
  • R 3 is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl;
  • R 4 , R 5 and R 6 are each independently selected from H, halogen, CN, C 1 -C 6 alkyl and C 1 -C 6 heteroalkyl;
  • R 7 is absent when Y 1 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 1 is C;
  • R 8 is absent when Y 3 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 3 is C;
  • R 9 is absent when Y 2 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 2 is C;
  • R 12 is selected from NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl.
  • R 12 is selected from NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl.
  • Further preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
  • X is selected from CH 2 , NH and O;
  • Y 1 , Y 2 , and Y 3 are each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 is C, more preferably Y 1 is N and R 7 is absent, Y 2 is selected from N and C and Y 3 is C; wherein Z is NR 10 R 11 , wherein R 10 and R 11 are each independently selected from H and C 1 -C 6 alkyl;
  • R 1 is selected from H, halogen, C 1 -C 6 alkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C 1 -C 6 alkoxy; C 1 -C 6 heteroalkyl, C 0 -C 3 alkylOC 0 -C 3 alkyl aryl wherein the aryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl; C 0 -C 3 alkylOC 0 -C 3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 - C 3
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C3- C 12 cycloalkyl C 3 -C 12 heterocyclyl, C(O)R 12 , C 1 -C 6 alkyl C(O)R 12 ;
  • R 3 is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl;
  • R 4 , R 5 and R 6 are each independently selected from H, halogen, CN, C 1 -C 6 alkyl and C 1 -C 6 heteroalkyl;
  • R 7 is absent when Y 1 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 1 is C;
  • R 8 is absent when Y 3 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 3 is C;
  • R 9 is absent when Y 2 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 2 is C;
  • R 12 is selected from NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl; with the proviso that when R 1 is selected from C 0 -C 3 alkylOC 0 -C 3 alkyl aryl wherein the aryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl; C 0 -C 3 alkylOC 0 -C 3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -
  • X is selected from CH 2 , NH and O;
  • Y 1 , Y 2 , and Y 3 are each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 is C, more preferably Y 1 is N and R 7 is absent, Y 2 is selected from N and C and Y 3 is C;
  • Z is NR 10 R 11 , wherein R 10 and R 11 are each independently selected from H and C 1 -C 6 alkyl;
  • R 1 is selected from H, halogen, C 1 -C 6 alkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C 1 -C 6 alkoxy and C 1 -C 6 heteroalkyl;
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C3- C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C(O)R 12 , C 1 -C 6 alkyl C(O)R 12 ;
  • R 3 is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl;
  • R 4 , R 5 and R 6 are each independently selected from H, halogen, CN, C 1 -C 6 alkyl and C 1 -C 6 heteroalkyl;
  • R 7 is absent when Y 1 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 1 is C;
  • R 8 is absent when Y 3 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 3 is C;
  • R 9 is absent when Y 2 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 2 is C;
  • R 12 is selected from NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl.
  • R 12 is selected from NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl.
  • pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
  • X is selected from CH 2 , NH and O;
  • Y 1 , Y 2 , and Y 3 are each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 is C, more preferably Y 1 is N and R 7 is absent, Y 2 is selected from N and C and Y 3 is C;
  • Z is NR 10 R 11 , wherein R 10 and R 11 are each independently selected from H and C 1 -C 6 alkyl;
  • R 1 is selected from H, halogen, C 1 -C 6 alkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C 1 -C 6 alkoxy and C 1 -C 6 heteroalkyl;
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 - C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C(O)R 12 , C 1 -C 6 alkyl C(O)R 12 ;
  • R 3 is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl;
  • R 4 , R 5 and R 6 are each independently selected from H, halogen, CN, C 1 -C 6 alkyl and C 1 -C 6 heteroalkyl;
  • R 7 is absent when Y 1 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 1 is C;
  • R 8 is absent when Y 3 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 3 is C;
  • R 9 is absent when Y 2 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 2 is C;
  • R 12 is selected from NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl, with the proviso that when R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are substituted by C 1 -C 6 alkyl, halogen, C 1 -C 6 heteroalkyl, C(O)R 12 , C 1 -C 6 alkyl C(O)R 12 , R 1 is selected from H, halogen, C 1 -C 6 alkyl and C 1 -C 6 heteroalkyl, preferably is H or methyl.
  • pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
  • X is selected from CH 2 , NH and O;
  • Y 1 , Y 2 , and Y 3 are each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 is C, more preferably Y 1 is N and R 7 is absent, Y 2 is selected from N and C and Y 3 is C;
  • Z is NR 10 R 11 , wherein R 10 and R 11 are each independently selected from H and C 1 -C 6 alkyl;
  • R 1 is selected from H, halogen, C 1 -C 6 alkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C 1 -C 6 alkoxy and C 1 -C 6 heteroalkyl;
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH 2 , C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C(O)R 12 , C 1 -C 6 alkyl C(O)R 12 ;
  • R 3 is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl;
  • R 4 , R 5 and R 6 are each independently selected from H, halogen, CN, C 1 -C 6 alkyl and C 1 -C 6 heteroalkyl; wherein R 7 is absent when Y 1 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 1 is C;
  • R 8 is absent when Y 3 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 3 is C;
  • R 9 is absent when Y 2 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 2 is C;
  • R 12 is selected from NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl.
  • R 12 is selected from NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl.
  • pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those ,
  • X is selected from CH 2 , NH and O;
  • Y 1 , Y 2 , and Y 3 are each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 is C, more preferably Y 1 is N and R 7 is absent, Y 2 is selected from N and C and Y 3 is C;
  • Z is NR 10 R 11 , wherein R 10 and R 11 are each independently selected from H and C 1 -C 6 alkyl;
  • R 1 is selected from H, halogen, C 1 -C 6 alkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C 1 -C 6 alkoxy; C 1 -C 6 heteroalkyl, C 0 -C 3 alkylOC 0 -C 3 alkyl aryl wherein the aryl is optionally substituted by NH2, OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl; C 0 -C 3 alkylOC 0 -C 3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 - C 12 -
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, halogen, CN;
  • R 3 is selected from H, halogen and C 1 -C 4 alkyl
  • R 4 , R 5 and R 6 are each independently selected from H, halogen, and C 1 -C 4 alkyl; wherein R 7 is absent when Y 1 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 1 is C;
  • R 8 is absent when Y 3 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 3 is C;
  • R 9 is absent when Y 2 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 2 is C.
  • R 9 is absent when Y 2 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 2 is C.
  • pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
  • X is selected from CH 2 , NH and O, and is preferably O;
  • Y 1 , Y 2 , and Y 3 are each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 is C, more preferably Y 1 is N and R 7 is absent, Y 2 is selected from N and C and Y 3 is C;
  • Z is NR 10 R 11 , wherein R 10 and R 11 are each independently selected from H and C 1 -C 6 alkyl;
  • R 1 is selected from H, halogen, C 1 -C 4 alkyl and C 1 -C 4 heteroalkyl;
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH 2 , C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C(O)R 12 , C 1 -C 6 alkyl C(O)R 12 ;
  • R 3 is selected from H, halogen, C 1 -C 4 alkyl and C 3 -C 7 cycloalkyl;
  • R 4 , R 5 and R 6 are each independently selected from H, halogen, CN, C 1 -C 4 alkyl and C 1 -C 4 heteroalkyl;
  • R 7 is absent when Y 1 is N or is selected from H, halogen, C 1 -C 4 alkyl and C 3 -C 7 cycloalkyl when Y 1 is C;
  • R 8 is absent when Y 3 is N or is selected from H, halogen, C 1 -C 4 alkyl and C 3 -C 7 cycloalkyl when Y 3 is C;
  • R 9 is absent when Y 2 is N or is selected from H, halogen, C 1 -C 4 alkyl and C 3 -C 7 cycloalkyl when Y 2 is C;
  • R 12 is selected from NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl.
  • Particular preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
  • X is selected from CH 2 , NH and O, and is preferably O; wherein Y 1 , Y 2 , and Y 3 are each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 is C, more preferably Y 1 is N and R 7 is absent, Y 2 is selected from N and C and Y 3 is C;
  • Z is NR 10 R 11 , wherein R 10 and R 11 are each independently selected from H and C 1 -C 6 alkyl, preferably independently selected from H and methyl, more preferably R 10 is H and R 11 is H or methyl;
  • R 1 is selected from H, halogen and C 1 -C 4 alkyl
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, C(O)R 12 , C 1 -C 6 alkyl C(O)R 12 ;
  • R 3 is selected from H, halogen and C 1 -C 4 alkyl
  • R 4 , R 5 and R 6 are each independently selected from H, halogen and C1-C4 alkyl; wherein R 7 is absent when Y 1 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 1 is C;
  • R 8 is absent when Y 3 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 3 is C;
  • R 9 is absent when Y 2 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 2 is C;
  • R 12 is selected from NH2, NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl.
  • R 12 is selected from NH2, NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl.
  • pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
  • X is selected from CH 2 , NH and O, and is preferably O;
  • Y 1 , Y 2 , and Y 3 are each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 is C, more preferably Y 1 is N and R 7 is absent, Y 2 is selected from N and C and Y 3 is C;
  • Z is NR 10 R 11 , wherein R 10 and R 11 are each independently selected from H and C 1 -C 6 alkyl, preferably independently selected from H and methyl, preferably R 10 is H and R 11 is H or methyl;
  • R 1 is selected from H, halogen and C 1 -C 4 alkyl
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by C 1 -C 6 heteroalkyl;
  • R 3 is selected from H, halogen and C 1 -C 4 alkyl
  • R 4 , R 5 and R 6 are each independently selected from H, halogen and C 1 -C 4 alkyl; wherein R 7 is absent when Y 1 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 1 is C;
  • R 8 is absent when Y 3 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 3 is C;
  • R 9 is absent when Y 2 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 2 is C;
  • R 12 is selected from NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl.
  • R 12 is selected from NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl.
  • pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
  • X is selected from CH 2 , NH and O, and is preferably O;
  • Y 1 , Y 2 , and Y 3 are each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 is C, more preferably Y 1 is N and R 7 is absent, Y 2 is selected from N and C and Y 3 is C;
  • Z is NR 10 R 11 , wherein R 10 and R 11 are each independently selected from H and C 1 -C 6 alkyl, preferably independently selected from H and methyl, preferably R 10 is H and R 11 is H or methyl;
  • R 1 is selected from H, halogen and C 1 -C 4 alkyl
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by C 1 -C 6 alkyl, halogen;
  • R 3 is selected from H, halogen and C 1 -C 4 alkyl
  • R 4 , R 5 and R 6 are each independently selected from H, halogen and C 1 -C 4 alkyl; wherein R 7 is absent when Y 1 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 1 is C;
  • R 8 is absent when Y 3 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 3 is C;
  • R 9 is absent when Y 2 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 2 is C;
  • R 12 is selected from NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl.
  • R 12 is selected from NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl.
  • pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
  • X is selected from CH 2 , NH and O, and is preferably O; wherein Y 1 , Y 2 , and Y 3 are each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 is C, more preferably Y 1 is N and R 7 is absent, Y 2 is selected from N and C and Y 3 is C;
  • Z is NR 10 R 11 , wherein R 10 and R 11 are each independently selected from H and C 1 -C 6 alkyl, preferably independently selected from H and methyl, preferably R 10 is H and R 11 is H or methyl;
  • R 1 is selected from H, halogen and C 1 -C 4 alkyl
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by C(O)R 12 , C 1 -C 6 alkyl C(O)R 12 ;
  • R 3 is selected from H, halogen and C 1 -C 4 alkyl
  • R 4 , R 5 and R 6 are each independently selected from H, halogen and C 1 -C 4 alkyl; wherein R 7 is absent when Y 1 is N or is selected from H, halogen and C1-C4 alkyl when Y 1 is C;
  • R 8 is absent when Y 3 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 3 is C;
  • R 9 is absent when Y 2 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 2 is C;
  • R 12 is selected from NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl.
  • R 12 is selected from NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl.
  • pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
  • X is selected from CH 2 , NH and O, and is preferably O;
  • Y 1 , Y 2 , and Y 3 are each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 is C, more preferably Y 1 is N and R 7 is absent, Y 2 is selected from N and C and Y 3 is C;
  • Z is NR 10 R 11 , wherein R 10 and R 11 are each independently selected from H and C 1 -C 6 alkyl, preferably independently selected from H and methyl, preferably R 10 is H and R 11 is H or methyl;
  • R 1 is selected from C 0 -C 3 alkylOC 0 -C 3 alkyl aryl wherein the aryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, preferably is optionally substituted by NH 2 ; C 0 -C 3 alkylOC 0 - C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC 1 -C 6 alkyl, C1- C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, preferably is optionally substituted by NH 2 ; and C 1 -C 6 alkyl substituted by aryl or heteroary
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH 2 , halogen, C 1 -C 6 alkyl, CN, preferably optionally substituted by halogen, C 1 -C 6 alkyl;
  • R 3 is selected from H, halogen and C1-C4 alkyl
  • R 4 , R 5 and R 6 are each independently selected from H, halogen, and C 1 -C 4 alkyl; wherein R 7 is absent when Y 1 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 1 is C;
  • R 8 is absent when Y 3 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 3 is C;
  • R 9 is absent when Y 2 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 2 is C.
  • R 9 is absent when Y 2 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 2 is C.
  • pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
  • X is selected from CH 2 , CO, CHOH, CHO(C 1 -C 3 ) alkyl, NH, and O;
  • Y 1 , Y 2 , and Y 3 are each independently selected from N and C;
  • Z is NR 10 R 11 , wherein R 10 and R 11 are each independently selected from H and C 1 -C 6 alkyl;
  • R 1 is selected from H, halogen, C 1 -C 6 alkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C 1 -C 6 alkoxy and C 1 -C 6 heteroalkyl;
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 - C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C(O)R 12 , C 1 -C 6 alkyl C(O)R 12 ;
  • R 3 is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl;
  • R 4 , R 5 and R 6 are each independently selected from H, halogen, CN, C 1 -C 6 alkyl and C 1 -C 6 heteroalkyl; wherein R 7 is absent when Y 1 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 1 is C;
  • R 8 is absent when Y 3 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 3 is C;
  • R 9 is absent when Y 2 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 2 is C;
  • R 12 is selected from NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl. More particular preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
  • X is selected from CH 2 , CO, CHOH, CHO(C 1 -C 3 ) alkyl, NH, and O;
  • Y 1 , Y 2 , and Y 3 are each independently selected from N and C;
  • Z is NR 10 R 11 , wherein R 10 and R 11 are each independently selected from H and C 1 -C 6 alkyl;
  • R 1 is selected from H, halogen, C 1 -C 6 alkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C 1 -C 6 alkoxy, C 1 -C 6 heteroalkyl, C 0 -C 3 alkylOC 0 -C 3 alkyl aryl wherein the aryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl; C 0 -C 3 alkylOC 0 -C 3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C3- C 12 cycly
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 - C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C(O)R 12 , C 1 -C 6 alkyl C(O)R 12 ;
  • R 3 is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl;
  • R 4 , R 5 and R 6 are each independently selected from H, halogen, CN, C 1 -C 6 alkyl and C 1 -C 6 heteroalkyl;
  • R 7 is absent when Y 1 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 1 is C;
  • R 8 is absent when Y 3 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 3 is C;
  • R 9 is absent when Y 2 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 2 is C; and wherein R 12 is selected from NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl.
  • R 12 is selected from NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl.
  • X is selected from CH 2 , CO, CHOH, CHO(C 1 -C 3 ) alkyl, NH, and O;
  • Y 1 is N and R 7 is absent, Y 2 is selected from N and C and Y 3 is C;
  • Z is NR 10 R 11 , wherein R 10 and R 11 are each independently selected from H and C 1 -C 6 alkyl;
  • R 1 is selected from H, halogen, C 1 -C 6 alkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl, C 1 -C 6 alkoxy, C 1 -C 6 heteroalkyl, C 0 -C 3 alkylOC 0 -C 3 alkyl aryl wherein the aryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl; C 0 -C 3 alkylOC 0 -C 3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 - C 3
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 - C12 cycloalkyl, C 3 -C 12 heterocyclyl, C(O)R 12 , C 1 -C 6 alkyl C(O)R 12 ;
  • R 3 is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl;
  • R 4 , R 5 and R 6 are each independently selected from H, halogen, CN, C 1 -C 6 alkyl and C 1 -C 6 heteroalkyl;
  • R 8 is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl;
  • R 9 is absent when Y 2 is N or is selected from H, halogen, C 1 -C 6 alkyl and C 3 -C 12 cycloalkyl when Y 2 is C;
  • R 12 is selected from NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl.
  • R 12 is selected from NH 2 , NHC 1 -C 6 alkyl, C 1 -C 6 alkyl, and C 1 -C 6 heteroalkyl.
  • pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
  • X is selected from CH 2 , CO, CHOH, CHO(C 1 -C 3 ) alkyl, NH, and O;
  • Y 1 , Y 2 , and Y 3 are each independently selected from N and C;
  • Z is NR 10 R 11 , wherein R 10 and R 11 are each independently selected from H and C 1 -C 6 alkyl; wherein R 1 is selected from H, C 1 -C 6 alkyl, C 0 -C 3 alkylOC 0 -C 3 alkyl aryl wherein the aryl is optionally substituted by NH 2 ; C 0 -C 3 alkylOC 0 -C 3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH 2 ;
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, C 1 -C 6 alkyl C(O)R 12 ;
  • R 3 is H
  • R 4 is selected from H and halogen
  • R 5 and R 6 are each independently selected from H and C 1 -C 6 alkyl
  • R 7 is absent when Y 1 is N or is H when Y 1 is C;
  • R 8 is absent when Y 3 is N or is H when Y 3 is C;
  • R 9 is absent when Y 2 is N or is H when Y 2 is C;
  • X is selected from CH 2 , CO, CHOH, CHO(C 1 -C 3 ) alkyl, NH, and O;
  • Y 1 is N and R 7 is absent, Y 2 is selected from N and C and Y 3 is C;
  • Z is NR 10 R 11 , wherein R 10 and R 11 are each independently selected from H and C 1 -C 6 alkyl;
  • R 1 is selected from H, C 1 -C 6 alkyl, C 0 -C 3 alkylOC 0 -C 3 alkyl aryl wherein the aryl is optionally substituted by NH 2 ; C 0 -C 3 alkylOC 0 -C 3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH 2 ;
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, C 1 -C 6 alkyl C(O)R 12 ;
  • R 3 is H
  • R 4 is selected from H and halogen
  • R 5 and R 6 are each independently selected from H and C 1 -C 6 alkyl
  • R 8 is H
  • R 9 is absent when Y 2 is N or is H when Y 2 is C;
  • R 12 is NH2.
  • pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
  • X is selected from CH 2 , CO, CHOH, CHO(C 1 -C 3 ) alkyl, NH, and O;
  • Y 1 , Y 2 , and Y 3 are each independently selected from N and C;
  • Z is NR 10 R 11 , wherein R 10 and R 11 are each independently selected from H and C 1 -C 6 alkyl;
  • R 1 is selected from H and C 1 -C 6 alkyl
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, C 1 -C 6 alkyl C(O)R 12 ;
  • R 3 is H
  • R 4 is selected from H and halogen
  • R 5 and R 6 are each independently selected from H and C 1 -C 6 alkyl
  • R 7 is absent when Y 1 is N or is H when Y 1 is C;
  • R 8 is absent when Y 3 is N or is H when Y 3 is C;
  • R 9 is absent when Y 2 is N or is H when Y 2 is C;
  • X is selected from CH 2 , CO, CHOH, CHO(C 1 -C 3 ) alkyl, NH, and O;
  • Y 1 is N and R 7 is absent, Y 2 is selected from N and C and Y 3 is C;
  • Z is NR 10 R 11 , wherein R 10 and R 11 are each independently selected from H and C 1 -C 6 alkyl;
  • R 1 is selected from H and C 1 -C 6 alkyl
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, C 1 -C 6 alkyl C(O)R 12 ;
  • R 3 is H
  • R 4 is selected from H and halogen
  • R 5 and R 6 are each independently selected from H and C 1 -C 6 alkyl
  • R 8 is H
  • R 9 is absent when Y 2 is N or is H when Y 2 is C; and wherein R 12 is NH 2 .
  • pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
  • X is selected from CH 2 , CO, CHOH, CHO(C 1 -C 3 ) alkyl, NH, and O;
  • Y 1 , Y 2 , and Y 3 are each independently selected from N and C;
  • Z is NR 10 R 11 , wherein R 10 and R 11 are each independently selected from H and C 1 -C 6 alkyl;
  • R 1 is selected from C 0 -C 3 alkylOC 0 -C 3 alkyl aryl wherein the aryl is optionally substituted by NH 2 , OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl; and C 0 -C 3 alkylOC 0 -C 3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, halogen, CN, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocyclyl;
  • R 2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH 2 , halogen, C 1 -C 6 alkyl, CN;
  • R 3 is selected from H, halogen and C 1 -C 4 alkyl
  • R 4 , R 5 and R 6 are each independently selected from H, halogen, and C 1 -C 4 alkyl; wherein R 7 is absent when Y 1 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 1 is C;
  • R 8 is absent when Y 3 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 3 is C;
  • R 9 is absent when Y 2 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 2 is C.
  • R 9 is absent when Y 2 is N or is selected from H, halogen and C 1 -C 4 alkyl when Y 2 is C.
  • the compounds of the invention may be prepared by the exemplary processes described in the following reaction schemes or by the processes described in the examples. Exemplary reagents and procedures for these reactions appear hereinafter. Starting materials can be purchased or readily prepared by one of ordinary skilled in the art.
  • Scheme 1: X NH, N(C1-C3-alkyl), S and O
  • a polar solvent in presence of a base at elevated temperatures.
  • the solvent is a mixture of DMSO and an alcohol like tBuOH.
  • an alcoholate like tBuOK can be used as a base.
  • Reaction temperatures are between room temperature and 150 °C, preferably between 60 and 110 °C.
  • a preferred reaction condition is carbonate as base in DMF at room temperature.
  • nitro function of formula (IV) can be reduced to the respective amine of formula (V) under Béchamp conditions or via catalytic hydrogenation.
  • Preferred Béchamp conditions are Fe powder in a mixture of EtOH, H 2 O and AcOH under sonication.
  • Catalytic hydrogenation can be performed in presence of Pd/C in a polar solvent like an alcohol.
  • Preferred conditions are phosphate as a base in an unpolar aromatic solvent at 100 to 150 °C under ferrocenyl catalysis [see: Advanced Synthesis & Catalysis 353 (2011), 3403].
  • Scheme 2 depicts the reductive alkylation of amino-derivatives of formula (V):
  • a preferred method is stirring the amine of formula (V) and the respective aldehyde in a polar solvent like an alcohol in presence of a weak acid like acetic acid. Then a reducing reagent like NaBH 3 CN is added. Basic work-up finally yields compounds of formula (IX).
  • the amine of formula (V) and the aldehyde are mixed in an unpolar solvent like dichloromethane in presence of a base like triethylamine. Then a reducing reagent like NaBH(OAc) 3 is added. Aqueous work-up finally yields compounds of formula (IX).
  • the halogen-aryl moiety of formula (X) is decarboxylatively coupled to the aryl-acetate of formula (XI), catalyzed by a transition metal complex, yielding the nitro derivative of formula (XII).
  • Preferred conditions are XPhos/Pd 2 (allyl) 2 Cl 2 as the catalyst in a unpolar solvent at elevated temperatures.
  • Preferred conditions are oxygen as the reagent in a mixture of acetic acid and DMSO at elevated temperature, catalyzed by FeCl .
  • benzylic alcohol of formula (XVII) Reduction of the carbonyl group of formula (XIV) leads to the benzylic alcohol of formula (XVII).
  • a preferred reducing reagent could be sodium borohydride.
  • the benzylic alcohol of formula (XVII) can be obtained via cross coupling of a boronate of formula (XV) with an aryl-aldehyde of formula (XVI). Alkylation of the compound of formula (XVII) with an alkyl-iodide in presence of a strong base (e.g. NaH) in an aprotic polar solvent yields the alkoxy-derivative of formula (XVIII) [analogously to: Example 2 in US 5965740].
  • a strong base e.g. NaH
  • the mono-fluoro derivative of formula (XIX) can be obtained either by oxidative fluorination of the compound of formula (XII) or hydroxy-substitution in a compound of formula (XVII).
  • the oxidative fluorination can be done under conditions as Jacobsen salene complex, iodosylbenzene, base, tris(hydrogen fluoride) in a polar solvent at elevated temperatures [J. Am. Chem.Soc.136 (2014), 6842].
  • Substitution of the benzylic hydroxy group by fluoride can be achieved by applying conditions like activation with trichloroacetimidate, 1,8-diazabicyclo[5.4.0]undec-7-ene in dichloromethane in presence of bis(1,5-cyclooctadiene)rhodium(I) tetrafluoroborate followed by triethylamine tris(hydrogen fluoride) in a mixture of F 3 C-C 6 H 5 and tetrahydrofurane at slightly elevated temperatures [Tetrahedron 71 (2015), 5932].
  • Stereoisomers include enantiomers and diastereomers, and mixtures of enantiomers or diastereomers.
  • Individual stereoisomers of compounds of the present invention can be prepared synthetically from commercially available starting materials which contain asymmetric or chiral centers or by preparation of racemic mixtures followed by resolution well-known to those of ordinary skill in the art.
  • Geometric isomers can also exist in the compounds of the present invention.
  • the present invention contemplates the various geometric isomers and mixtures thereof resulting from the arrangement of substituents around a carbon-carbon double bond or arrangement of substituents around a carbocyclic ring.
  • racemates can also exist as racemates which is given the descriptor “rac”.
  • racemate as used herein, means an equimolar mixture of a pair of enantiomers. A racemate is usually formed when synthesis results in the generation of a stereocenter.
  • racemic mixture means racemate.
  • Compounds of the present invention can also exist as diastereomeric meso forms which is given the descriptor “rel”.
  • diastereomeric meso form as used herein means achiral forms with a pseudostereogenic C-atom, which is given the descriptor“r”or“s”, respectively. Salts
  • the compounds of the present invention may be used in the form of pharmaceutically- acceptable salts derived from inorganic or organic acids.
  • pharmaceutically-acceptable salt is meant those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
  • Pharmaceutically-acceptable salts are well-known in the art. The salts may be prepared in situ during the final isolation and purification of the compounds of the invention or separately by reacting a free base function with a suitable acid.
  • Representative acid addition salts include, but are not limited to trifluoroacetic acid (TFA), acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate (isethionate), lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, phosphate, glutamate, bicarbonate, p-toluen
  • the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl and diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides ; arylalkyl halides like benzyl and phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained.
  • lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides
  • dialkyl sulfates like dimethyl, diethyl, dibutyl and diamyl sulfates
  • long chain halides such as decy
  • acids which may be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, hydrobromic acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, succinic acid and citric acid.
  • Basic addition salts can be prepared in situ during the final isolation and purification of compounds of this invention by reacting a carboxylic acid-containing moiety with a suitable base such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation or with ammonia or an organic primary, secondary or tertiary amine.
  • Pharmaceutically- acceptable basic addition salts include, but are not limited to, cations based on alkali metals or alkaline earth metals such as lithium, sodium, potassium, calcium, magnesium and aluminum salts and the like and nontoxic quaternary ammonia and amine cations including ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine and the like.
  • Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, piperazine and the like. Solvates/hydrates
  • solvates and hydrates of the compound according to formula (I) are also within the scope of the present application. Methods of solvation are generally known in the art.
  • a further embodiment of the present invention may also include compounds, which are identical to the compounds of formula (I) except that one or more atoms are replaced by an atom having an atomic mass number or mass different from the atomic mass number or mass usually found in nature, e.g. compounds enriched in 2H (D), 3H, 13C, etc.
  • isotopic analogs and their pharmaceutical salts and formulations are considered useful agents in therapy and/or diagnosis, for example, but not limited to, where a fine-tuning of in vivo half-life time could lead to an optimized dosage regimen.
  • the present invention provides a pharmaceutical composition comprising a compound of formula (I) according to the invention and a pharmaceutically acceptable diluent, excipient or carrier.
  • the pharmaceutical composition further comprises another pharmaceutical active agent.
  • the invention provides a pharmaceutical composition comprising a compound of formula (I) according to the invention and a pharmaceutically acceptable diluent, excipient or carrier, wherein said compound of formula (I) is present in a
  • the compounds of the present invention may, in accordance with the invention, be administered in single or divided doses by oral, parenteral, inhalatory, rectal or topical administration including cutaneous, ophthalmic, mucosal scalp, sublingual, buccal and intranasal routes of administration; further, the compounds provided by the invention may be formulated to be used for the treatment of leukocyte populations ex vivo and in vitro.
  • the compounds of the present invention When the compounds of the present invention are to be administered e.g. by the oral route, they may be administered as medicaments in the form of pharmaceutical compositions which contain them in association with a pharmaceutically acceptable diluent, excipient or carrier material.
  • a pharmaceutical composition comprising the compounds according to the invention as described supra and one or more
  • compositions can be prepared in a conventional manner and finished dosage forms can be solid dosage forms, for example, tablets, dragees, capsules, and the like, or liquid dosage forms, for example solutions, suspensions, emulsions and the like.
  • Pharmaceutically acceptable diluent, excipient or carrier include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. The use of such media and agents for pharmaceutically active substances is known in the art.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I) according to the invention and at least one pharmaceutically acceptable diluent, excipient or carrier, wherein the composition is a tablet or a capsule, preferably a tablet.
  • An exemplary treatment regime entails administration once daily, twice daily, three times daily, every second day, twice per week, once per week.
  • the composition of the invention is usually administered on multiple occasions. Intervals between single dosages can be, for example, less than a day, daily, every second day, twice per week, or weekly.
  • composition of the invention may be given as a continous uninterrupted treatment.
  • the compound of formula (I) according to the invention can be administered from 0.1– 100 mg per day.
  • the present invention provides the use of the compounds as described herein and the use of the pharmaceutical composition described herein for preventive and/or therapeutic purposes.
  • the compounds according to the invention as described herein or the pharmaceutical composition as described herein may be used as a medicament, preferably for use in human medicine and/or veterinarian medicine.
  • the present invention provides the compounds according to the invention as described herein or a pharmaceutical composition as described herein, for use as a medicament.
  • the present invention also provides the compounds of the present invention, or the pharmaceutical composition of the invention for use in a method for the prevention or treatment of cancer. Also provided is a method for treating and/or preventing cancers, said method comprising administering the compounds of the present invention, or the
  • composition of the invention to a subject in need thereof. Also provided is the use of the compounds of the present invention, or the pharmaceutical composition of the invention for the manufacture of a medicament for treating and/or preventing cancers in a subject. Also provided is the use of the compounds of the present invention, or the
  • Cancers to be prevented or treated are preferably Notch dependent cancers, more preferably, Notch dependent cancers selected from the group consisting of adenoid cystic carcinoma (ACC), T cell-Acute lymphoblastic leukemia (T-ALL), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), Mantle cell lymphoma (MCL), breast cancer, pancreatic cancer, prostate cancer, melanoma, brain tumors, tumor angiogenesis, liver cancer and colorectal cancer.
  • the compounds of the present invention can be also used in the treatment of cancers where Notch dependent cancers are resistant to g-secretase inhibitor treatment.
  • Notch signalling dependent human tumors resistant to g-secretase inhibitor treatment can be determined by the levels of NICD, Notch target genes as well as by mutation status of Notch receptor and other components of the Notch pathway.
  • the present invention provides a method of treatment of a disease associated with an up-regulated Notch signaling pathway activity, said method comprising administering the compounds of the present invention, or the pharmaceutical composition of the invention to a subject in need thereof.
  • the daily dose of compounds of the present invention will necessarily be varied depending upon the host treated, the particular route of administration, and the severity and kind of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.
  • a therapeutically effective dose can be estimated initially from cell culture assays, animal models, or microdosing of human subjects. “Treatment” as used herein, refers to both therapeutic treatment and prophylactic or preventative measures.
  • Subjects in need of treatment include those already with the disorder, such as cancer, as well as those in which the disorder, such as cancer, is to be prevented.
  • the mammal, preferably human, to be treated herein may have been diagnosed as having the disorder, such as cancer, or may be predisposed or susceptible to the disorder, such as cancer.
  • “Prevention” as used herein comprise prophylactic treatments.
  • the pharmaceutical combination of the invention is administered to a subject suspected of having, or at risk for developing cancer.
  • the pharmaceutical combination is administered to a subject such as a patient already suffering from cancer, in an amount sufficient to cure or at least partially arrest the symptoms of the disease. Amounts effective for this use will depend on the severity and course of the disease, previous therapy, the subject's health status and response to the drugs, and the judgment of the treating physician.
  • the term“therapeutically effective amount” refers to an amount of a drug effective to treat a disease or disorder in a mammal.
  • the therapeutically effective amount of the drug may reduce the number of tumor or cancer cells, reduce the tumor size; inhibit (i.e., slow to some extent and preferably stop) cancer cells infiltration into peripheral organs;
  • the compounds of the present invention may prevent growth and/or kill existing cancer cells, it may be cytostatic and/or cytotoxic.
  • “therapeutically effective amount” is used herein to mean an amount sufficient to prevent, or preferably reduce by at least about 30 percent, preferably by at least 50 percent, preferably by at least 70 percent, preferably by at least 80 percent, preferably by at least 90%, a clinically significant change in the growth or progression or mitotic activity of a target cellular mass, group of cancer cells, or other feature of pathology.
  • the compounds of the present invention may be used against cell proliferate diseases in combination (for example either at the same time, or almost at the same time, or one after the other) with conventional treatments such as standard radiotherapy and/or standard chemotherapy.
  • the standard radiotherapy and chemotherapy can be also the concomitant chemo-radiotherapy.
  • the standard radiotherapy and/or chemotherapy can be performed before, simultaneously or after the administration of a therapeutically effective amount of the compound of the present invention, or pharmaceutical compositions containing thereof.
  • the term“concomitant chemo-radiotherapy” is used when these two treatments
  • chemotherapy and radiotherapy are given either at the same time, or almost at the same time, for instance one after the other, or on the same day, etc.
  • standard radiotherapy refers to the use of ionizing radiation as part of cancer treatment to control malignant cells.
  • the ionizing radiation is g-irradiation. It is also common to combine radiotherapy with surgery, chemotherapy, hormone therapy, or combinations thereof. Most common cancer types can be usually treated with radiotherapy.
  • the precise treatment intent (curative, adjuvant, neoadjuvant or palliative) will depend on the tumor type, location, and stage, as well as the general health of the subject in need thereof.
  • standard chemotherapy generally refers to a treatment of a cancer using specific chemotherapeutic/chemical agents.
  • a chemotherapeutic agent refers to a pharmaceutical agent generally used for treating cancer.
  • the chemotherapeutic agents for treating cancer include, for example, Altretamine, Bleomycin, Busulphan, Capecitabine, Carboplatin, Carmustine, Chlorambucil, Cisplatin, Cladribine, Crisantaspase, Cyclophosphamid,
  • Cytarabine dacarbazine, Daunorubicin , Doxorubicin, Epirubicin, Etoposide, Fludarabine, Fluorouracil, Gemcitabine, Idarubicin, Ifosfamide, Irinotecan, Lomustine, Melphalan, Mercaptopurine, Methotrexate, Mitomycin, Mitoxantrone, Oxaliplatin, Pentostatin,
  • chemotherapeutic agent When a chemotherapeutic agent is used in combination with a compound according to the present invention, then this may be used in the form of a medicament containing a chemotherapeutic agent.
  • the two agents for simultaneous administration, or they may be used in the form of separate dosage forms, each containing one of the agents, and in the latter case the individual dosage forms may be used e.g. sequentially, i.e. one dosage form with the compound of the invention , followed by a dosage form containing the chemotherapeutic agent (or vice versa).
  • This embodiment of two separate dosage forms may be conceived and provided in the form of a kit.
  • the compounds of the present invention may be used against cell proliferate diseases, such as cancers, in combination with conventional removal of a tumor bulk, by for example segmental resection (biopsy or gross resection).
  • the term“removal of a tumor bulk” refers to any removal, ablation or resection of a tumor bulk from a subject.
  • the removal can be chemical, radiation or surgical.
  • Preferably said removal is surgical, such as ablation or resection.
  • Resection can be“segmental resection” (or segmentectomy), a surgical procedure to remove part of an organ or gland from a subject. It may also be used to remove a tumor and normal tissue around it.
  • Debulking agent may be also used to remove tumor bulk.
  • the term“debulking agent” includes any molecule (e.g. chemical, biological) or any external/environmental agent (e.g. g-irradiation) or traditional surgery that would allow killing cancer cells from the tumor bulk (e.g.
  • “pharmaceutically acceptable carrier” means a carrier or excipient that is useful in preparing a pharmaceutical composition that is generally safe, and possesses acceptable toxicities. Acceptable carriers include those that are acceptable for veterinary use as well as human pharmaceutical use.
  • pharmaceutically acceptable carrier includes both one and more than one such carrier.
  • pharmaceutical composition of the present invention further comprises one or more additional active agents selected among the non limiting group comprising
  • chemotherapeutic agents for treating cancer may be selected among the group comprising, for example, Altretamine, Bleomycin, Busulphan, Capecitabine, Carboplatin, Carmustine, Chlorambucil, Cisplatin, Cladribine, Crisantaspase,
  • Cyclophosphamid Cytarabine, dacarbazine, Daunorubicin , Doxorubicin, Epirubicin, Etoposide, Fludarabine, Fluorouracil, Gemcitabine, Idarubicin, Ifosfamide, Irinotecan, Lomustine, Melphalan, Mercaptopurine, Methotrexate, Mitomycin, Mitoxantrone,
  • Tioguanine/Thioguanine Tioguanine/Thioguanine, Thiotepa, Topotecan, Treosulfan, Vinblastine, Vincristine,
  • the compounds of the invention that can be used in the treatment and/or prevention of cancers can be incorporated into a variety of formulations and medicaments for therapeutic administration. More particularly, one or more compound(s) as provided herein can be formulated into pharmaceutical compositions by combination with appropriate,
  • pharmaceutically acceptable carriers can be formulated into preparations in solid, semi- solid, liquid or gaseous forms, such as tablets, capsules, pills, powders, granules, dragees, gels, slurries, ointments, solutions, suppositories, injections, inhalants and aerosols.
  • administration of the compounds can be achieved in various ways, including oral, buccal, rectal, parenteral, intraperitoneal, intradermal, transdermal, intracranial and/or intratracheal administration.
  • the compound can be administered in a local rather than systemic manner, in a depot or sustained release formulation.
  • the compounds can be formulated with common excipients, diluents or carriers, and compressed into tablets, or formulated as elixirs or solutions for convenient oral administration, or administered by the intramuscular or intravenous routes.
  • the compounds can be administered transdermally, and can be formulated as sustained release dosage forms and the like.
  • the compounds can be administered alone, in combination with each other, or they can be used in combination with other known compounds. Suitable formulations for use in the present invention are found in Remington's Pharmaceutical Sciences (Mack Publishing Company (1985) Philadelphia, PA, 17th ed.), which is incorporated herein by reference.
  • Suitable formulations for use in the present invention are found in Remington's Pharmaceutical Sciences (Mack Publishing Company (1985) Philadelphia, PA, 17th ed.), which is incorporated herein by reference.
  • for a brief review of methods for drug delivery see, Langer, Science (1990) 249:1527-1533, which is incorporated herein by reference.
  • suitable unit doses for the compounds of the present invention can, for example, preferably contain between 0.1 mg to about 1000 mg, between 1 mg to about 500 mg, and between 1 mg to about 300 mg of the active compound. In another example, the unit dose is between 1 mg to about 100 mg.
  • Such unit doses can be administered more than once a day, for example, 2, 3, 4, 5 or 6 times a day, but preferably 1 or 2 times per day, so that the total dosage for a 70 kg human adult is in the range of 0.001 to about 15 mg per kg weight of subject per
  • a preferred dosage is 0.01 to about 1.5 mg per kg weight of subject per administration, and such therapy can extend for a number of weeks or months, and in some cases, years. It will be understood, however, that the specific dose level for any particular patient will depend on a variety of factors including the activity of the specific compound employed; the age, body weight, general health, sex and diet of the individual being treated; the time and route of administration; the rate of excretion; other drugs that have previously been administered; and the severity of the particular disease undergoing therapy, as is well understood by those of skill in the area.
  • a typical dosage can be one 1 mg to about 100 mg tablet or 1 mg to about 300 mg taken once a day, or, multiple times per day, or one time-release capsule or tablet taken once a day and containing a proportionally higher content of active ingredient.
  • the time-release effect can be obtained by capsule materials that dissolve at different pH values, by capsules that release slowly by osmotic pressure, or by any other known means of controlled release. It can be necessary to use dosages outside these ranges in some cases as will be apparent to those skilled in the art.
  • a further object of the present invention is a kit comprising a container and a package insert, wherein the container comprises at least one dose of a medicament comprising a compound of formula (I) and optionally one or more pharmaceutically acceptable diluents, excipients or carrier, and the package insert comprises instructions for treating a subject for cancer using the medicament.
  • the kit can further comprise one or more doses of a chemotherapeutic agent.
  • the kit may also comprise reagents and/or instructions for use.
  • the kit comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, etc.
  • the containers may be formed from a variety of materials such as glass or plastic.
  • the container holds the pharmaceutical composition that is effective for treating the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
  • the label or package insert indicates that the composition is used for treating the condition of choice, such as cancer.
  • the present invention provides the use of the compounds of the invention for inhibiting in vitro or in vivo the Notch signalling pathway in cells. Usually, said cells are cancer cells.
  • the present invention provides a method of treating a subject for Notch dependent cancer, comprising i) determining in cancer cells obtained from a biological sample of said subject whether the cancer is Notch signalling pathway dependent,
  • the present disclosure consists in an in vitro g-secretase complex activity assays as described herein.
  • This method of treating may further comprise administering at least one conventional cancer treatment.
  • the conventional cancer treatment is administered before, simultaneously or after the administration of the therapeutically effective amount of compounds of the invention, or the pharmaceutical composition of the invention.
  • the conventional cancer treatment consists in radiotherapy and/or chemotherapy.
  • the present invention provides the use of the compounds of the invention in a method for provoking apoptosis in a cell, either in vitro or in vivo, by inducing G0/G1 cell cycle arrest.
  • the present invention provides the use of the compounds of the invention in diagnosing, predicting, and/or monitoring of Notch dependent cancer in a subject.
  • EtOH/H2O/AcOH 2:2:1 (0.1 M). The reaction was sonicated until completion (monitored by TLC, with EtOAc/hexanes or EtOAc/cyclohexane as eluent and stained with KMnO 4 ). The obtained brown slurry was filtered through filter paper, rinsed with EtOAc and the organic solvents were evaporated. EtOAc was added followed by careful addition of a saturated aqueous solution of NaHCO 3 . Layers were separated and the aqueous layer was extracted three times with EtOAc. The combined organic layers were dried over MgSO 4 or Na 2 SO 4 , filtered-off and the solvent was evaporated.
  • the starting material was prepared as follows: Step 1: 2-([1,1'-Biphenyl]-4-yloxy)-5-nitropyridine Following the General procedure A, 2-([1,1'-biphenyl]-4-yloxy)-5-nitropyridine was obtained in 99 % yield without purification (4.65 mmol, 1.36 g) from [1,1’-biphenyl]-4-ol (4.70 mmol, 800 mg) and 2-chloro-5-nitropyridine (4.70 mmol, 745 mg).
  • 6-([1,1'-biphenyl]-4-yloxy)-N-methylpyridin-3-amine was obtained in 86 % yield (3.98 mmol, 1.10 g) from 6-([1,1'-biphenyl]-4-yloxy)pyridin-3- amine (4.61 mmol, 1.21 g).
  • the starting material was prepared as follows: Step 1: 5-Nitro-2-((6-phenylpyridin-3-yl)oxy)pyridine Following the General procedure A, 5-nitro-2-((6-phenylpyridin-3-yl)oxy)pyridine was obtained in 93 % yield (2.63 mmol, 0.77 g) from 6-phenylpyridin-3-ol (2.92 mmol, 0.51 g) and 2-chloro-5-nitropyridine (2.84 mmol, 0.45 g).
  • the starting material was prepared as follows:
  • Example 7 4-([1,1'-Biphenyl]-4-yloxy)aniline Following the General procedure B, 4-([1,1'-biphenyl]-4-yloxy)aniline was obtained in 33 % yield (2.4 mmol, 0.62 g) from 4-(4-nitrophenoxy)-1,1'-biphenyl (7.1 mmol, 2.08 g).
  • Step 1 4-(4-Nitrophenoxy)-1,1'-biphenyl Following the General procedure A, 4-(4-nitrophenoxy)-1,1'-biphenyl was obtained in 61 % yield (7.1 mmol, 2.08 g) from [1,1’-biphenyl]-4-ol (11.8 mmol, 2.00 g) and 4-fluoro- nitrobenzene (11.5 mmol, 1.63 g).
  • the starting material was prepared as follows: Step 1: 6-([1,1'-Biphenyl]-4-yloxy)-2-methyl-3-nitropyridine Following the General procedure A, 6-([1,1'-biphenyl]-4-yloxy)-2-methyl-3-nitropyridine was obtained in 89 % yield (5.3 mmol, 1.63 g) from [1,1’-biphenyl]-4-ol (5.9 mmol, 1.00 g) and 6- chloro-2-methyl-3-nitropyridine (5.8 mmol, 1.00 g).
  • Example 9 6-([1,1'-Biphenyl]-4-yloxy)-4-methylpyridin-3-amine Following the General procedure B, 6-([1,1'-biphenyl]-4-yloxy)-4-methylpyridin-3-amine was obtained in 74 % yield (1.5 mmol, 410 mg) from 6-([1,1'-biphenyl]-4-yloxy)-4-methyl-3- nitropyridine (2.0 mmol, 600 mg).
  • the starting material was prepared as follows: Step 1: 6-([1,1'-Biphenyl]-4-yloxy)-4-methyl-3-nitropyridine Following the General procedure A, 6-([1,1'-biphenyl]-4-yloxy)-4-methyl-3-nitropyridine was obtained in 38 % yield (2.3 mmol, 0.71 g) from [1,1’-biphenyl]-4-ol (5.9 mmol, 1.00 g) and 6- chloro-4-methyl-3-nitropyridine (5.8 mmol, 1.00 g).
  • Step 1 2-(4-Bromophenoxy)-5-nitropyridine
  • 2-(4-bromophenoxy)-5-nitropyridine was obtained in 89 % yield (37.2 mmol, 10.97 g) from 4-bromophenol (42.8 mmol, 7.40 g) and 2-chloro-5- nitropyridine (41.6 mmol, 6.60 g).
  • Example 11 6-(4-(Thiazol-5-yl)phenoxy)pyridin-3-amine Following the General procedure B, 6-(4-(thiazol-5-yl)phenoxy)pyridin-3-amine was obtained in 46 % yield (1.8 mmol, 0.48 g) from 5-(4-((5-nitropyridin-2-yl)oxy)phenyl)thiazole (3.8 mmol, 1.15 g).
  • the starting material was prepared as follows: Step 1: 5-Nitro-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pyridine
  • Step 2 5-(4-((5-Nitropyridin-2-yl)oxy)phenyl)thiazole
  • a mixture of 5-nitro-2-(4-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)phenoxy)pyridine (9.2 mmol, 3.50 g)
  • 5-bromothiazole (7.4 mmol, 1.25 g)
  • Cs 2 CO 3 (15.0 mmol, 4.90 g)
  • PdCl 2 (PPh 3 ) 2 (10 % mol) in dioxane/H 2 O 4:1 (0.05-0.1 M) was converted to 5-(4-((5-nitropyridin-2-yl)oxy)phenyl)thiazole in 52 % yield (3.8 mmol, 1.15 g).
  • Step 2 2,2'-Dimethyl-4-(4-nitrophenoxy)-1,1'-biphenyl
  • a mixture of o-tolylboronic acid (30.9 mmol, 4.20 g), 1- bromo-2-methyl-4-(4-nitrophenoxy)benzene (27.1 mmol, 8.34 g), K 2 CO 3 (55.0 mmol, 7.60 g) and Pd(PPh 3 ) 4 (10 % mol) in dioxane/H 2 O 4:1 (0.05-0.1 M) was converted to 2,2'-dimethyl-4- (4-nitrophenoxy)-1,1'-biphenyl in 92 % yield (24.9 mmol, 7.96 g).
  • Example 13 4-((2,2'-Dimethyl-[1,1'-biphenyl]-4-yl)oxy)-N-methylaniline
  • 4-((2,2'-dimethyl-[1,1'-biphenyl]-4-yl)oxy)-N- methylaniline was obtained in 86 % yield (8.9 mmol, 2.70 g) from 4-((2,2'-dimethyl-[1,1'- biphenyl]-4-yl)oxy)aniline (10.4 mmol, 3.00 g).
  • Step 2 2-((2,2'-Dimethyl-[1,1'-biphenyl]-4-yl)oxy)-5-nitropyridine
  • a mixture of o-tolylboronic acid (1.9 mmol, 264 mg), 2- (4-bromo-3-methylphenoxy)-5-nitropyridine (1.3 mmol, 400 mg), K 2 CO 3 (2.6 mmol, 358 mg) and Pd(PPh 3 ) 4 (10 % mol) in dioxane/H 2 O 4:1 (0.05-0.1 M) was converted to 2-((2,2'- dimethyl-[1,1'-biphenyl]-4-yl)oxy)-5-nitropyridine in 95 % yield (1.2 mmol, 392 mg).
  • Step 3 6-((2,2'-Dimethyl-[1,1'-biphenyl]-4-yl)oxy)pyridin-3-amine
  • 6-((2,2'-dimethyl-[1,1'-biphenyl]-4-yl)oxy)pyridin-3- amine was obtained in 37 % yield (0.5 mmol, 132 mg) from 2-((2,2'-dimethyl-[1,1'-biphenyl]- 4-yl)oxy)-5-nitropyridine (1.2 mmol, 392 mg).
  • Example 15 3-Fluoro-4-(4-(pyridin-4-yl)phenoxy)aniline Following the General procedure B, 3-fluoro-4-(4-(pyridin-4-yl)phenoxy)aniline was obtained in 71 % yield (211 mg, 0.752 mmol) from 4-(4-(2-fluoro-4-nitrophenoxy)phenyl)pyridine (330mg, 1.06 mmol).
  • Example 16 6-(4-(Thiazol-2-yl)phenoxy)pyridin-3-amine Following the General procedure B, 6-(4-(thiazol-2-yl)phenoxy)pyridin-3-amine was obtained in 21 % yield (15 mg, 0.057 mmol) from 2-(4-((5-nitropyridin-2-yl)oxy)phenyl)thiazole (100 mg, 0.300 mmol).
  • the starting material was prepared as follows: Step 1: 2-(4-((5-Nitropyridin-2-yl)oxy)phenyl)thiazole Following the General procedure A, 2-(4-((5-nitropyridin-2-yl)oxy)phenyl)thiazole was obtained in 61 % yield (206 mg, 0.688 mmol) from 4-(thiazol-2-yl)phenol (0.23 g, 1.30 mmol) and 2-chloro-5-nitropyridine (0.18 g, 1.10 mmol).
  • the starting material was prepared as follows: Step 1: (4'-((5-Nitropyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)methanol Following the General procedure E, (4'-((5-nitropyridin-2-yl)oxy)-[1,1'-biphenyl]-3- yl)methanol was obtained in 65 % yield (281 mg, 0.872 mmol) from 2-(4-bromophenoxy)-5- nitropyridine (400 mg, 1.36 mmol; Example 10:Step 1) and (3- (hydroxymethyl)phenyl)boronic acid (240 mg, 1.60 mmol).
  • Example 18 6-((3'-(Aminomethyl)-[1,1'-biphenyl]-4-yl)oxy)pyridin-3-amine 2-((4'-((5-Aminopyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)methyl)isoindoline-1,3-dione (51 mg, 0.121 mmol) was suspended in methanol (1 mL, 0.1M) (poor solubility at RT) under N 2 . Hydrazine hydrate (15 mg, 0.30 mmol) was added. The yellow solution was refluxed overnight. When allowing to RT, a white solid precipitated.The reaction mixture was filtered and the filtrate was concentrated.
  • the starting material was prepared as follows: Step 1: 2-((4'-((5-Nitropyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)methyl)isoindoline-1,3- dione To a 25-mL round-bottom flask, (4'-((5-nitropyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)methanol (0.117 g, 0.363 mmol), triphenylphosphine (0.115 g, 0.438 mmol) and phthalimide (0.068 g, 0.46 mmol) were added under N 2 , followed by THF (2 mL).
  • Step 2 2-((4'-((5-Aminopyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)methyl)isoindoline-1,3- dione 2-((4'-((5-Nitropyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)methyl)isoindoline-1,3-dione (158 mg, 0.350 mmol) was suspended in EtOAc (3mL) under N 2 .
  • the starting material was prepared as follows: Step 1: 2-(4'-((5-Nitropyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)acetonitrile Following the General procedure E 2-(4'-((5-nitropyridin-2-yl)oxy)-[1,1'-biphenyl]-3- yl)acetonitrile was obtained in 99 % yield (432 mg, 1.7 mmol) from 2-(4-bromophenoxy)-5- nitropyridine (500 mg, 1.69 mmol; Example 10:Step 1) and 2-(3-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)phenyl)acetonitrile (536 mg, 2.20 mmol).
  • the crude product was purified with the Biotage Isolera Four (KP-sil 25 g column, cyclohexane/EtOAc, EtOAc 0 to 100 %, 18 CV), yielding 2-(4'-((5- nitropyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)acetamide as a yellow gum (30 mg, 0.100 mmol, 57 %).
  • 6-((2-(4-nitrophenoxy)-[1,1'-biphenyl]-4-yl)oxy)pyridin- 3-amine was obtained in 32 % yield (50 mg, 0.13 mmol) from 5-nitro-2-((2-(4-nitrophenoxy)- [1,1'-biphenyl]-4-yl)oxy)pyridine (166 mg, 0.387mmol). Then 6-((2-(4-nitrophenoxy)-[1,1'- biphenyl]-4-yl)oxy)pyridin-3-amine (50 mg, 0.130 mmol) was suspended in MeOH (1.5 mL, 0.08M). Pd/C (10 %, 6.7 mg) was added resulting in a black suspension.
  • Step 2 6,6'-([1,1'-Biphenyl]-2,4-diylbis(oxy))bis(3-nitropyridine)
  • phenylboronic acid 120 mg, 0.96 mmol
  • 6,6'- ((4-bromo-1,3-phenylene)bis(oxy))bis(3-nitropyridine) 320 mg, 0.74 mmol
  • potassium carbonate 210 mg, 1.50 mmol
  • water 1 mL
  • 2-propanol (6 mL) under N 2 .
  • the crude product was purified with the Biotage Isolera Four (KP-sil 50 g column, cyclohexane/EtOAc, EtOAc 0-25 %, 22 CV) yielding 6,6'- ([1,1'-biphenyl]-2,4-diylbis(oxy))bis(3-nitropyridine) as a colorless oil (90 mg, 28%).
  • phenylboronic acid 63 mg, 0.51 mmol
  • 1- bromo-4-methoxy-2-(2-(4-nitrophenoxy)ethyl)benzene 150 mg, 0.43 mmol
  • potassium carbonate 154 mg, 1.11 mmol
  • water 1 mL
  • 2-propanol 4 mL
  • the crude product was purified with the Biotage Isolera Four (KP-sil 50 g column, cyclohexane/EtOAc, EtOAc 0-30 %, 13 CV) yielding 4- methoxy-2-(2-(4-nitrophenoxy)ethyl)-1,1'-biphenyl as a colorless oil (120 mg, 81 %).
  • 6-(4-(pyridin-2-yl)phenoxy)pyridin-3-amine was obtained in 67 % yield (0.23 mmol, 60 mg) from 5-nitro-2-(4-(pyridin-2-yl)phenoxy)pyridine (100 mg, 0.341 mmol).
  • 6-(4-(pyridin-3-yl)phenoxy)pyridin-3-amine was obtained in 52 % yield (1.25 mmol, 330 mg) from the 5-nitro-2-(4-(pyridin-3- yl)phenoxy)pyridine (710 mg, 2.42 mmol).
  • Example 26 6-(4-(Pyridin-4-yl)phenoxy)pyridin-3-amine Following the General procedure B, 6-(4-(pyridin-4-yl)phenoxy)pyridin-3-amine was obtained in 57 % yield (0.40 mmol, 100 mg) from the 5-nitro-2-(4-(pyridin-4- yl)phenoxy)pyridine (19 mg, 0.672 mmol).
  • the starting material was prepared as follows: Step 1: 5-Nitro-2-(4-(pyridin-4-yl)phenoxy)pyridine
  • 6-(4-bromophenoxy)-2-methyl-3-nitropyridine was obtained in 93 % yield (26.9 mmol, 8.31 g) from 6-chloro-2-methyl-3-nitropyridine (29 mmol, 5.00 g) and 4-bromophenol (32 mmol, 5.50 g).
  • Step 2 2-((4'-Fluoro-[1,1'-biphenyl]-4-yl)oxy)-4-methyl-5-nitropyridine
  • 2-((4'-fluoro-[1,1'-biphenyl]-4-yl)oxy)-4-methyl-5- nitropyridine was obtained in 82 % yield (1.13 mmol, 0.30 g) from 2-(4-bromophenoxy)-4- methyl-5-nitropyridine (1.13 mmol, 0.350 mg) and (4-fluorophenyl)boronic acid (1.70 mmol, 0.238 mg).
  • the starting material was prepared as follows: Step 1: 6-Phenylpyridin-3-ol Following the General procedure D, a mixture of phenylboronic acid (11.49 mmol, 1.40 g), 6- bromopyridin-3-ol (5.75 mmol, 1.00 g), Na 2 CO 3 (11.49 mmol, 1.22 g), and Pd(PPh 3 ) 4 (0.287 mmol, 332 mg) in a 3:1 mixture of DME/H 2 O (0.32 M) was converted to 6-phenylpyridin-3- ol in 61 % yield (3.50 mmol, 600 mg).
  • Step 2 2-Methyl-3-nitro-6-((6-phenylpyridin-3-yl)oxy)pyridine
  • 2-methyl-3-nitro-6-((6-phenylpyridin-3-yl)oxy)pyridine was obtained in 95 % yield (1.22 mmol, 374 mg) from 6-chloro-2-methyl-3-nitropyridine (1.27 mmol, 220 mg).
  • Example 31 4-Methyl-6-((6-phenylpyridin-3-yl)oxy)pyridin-3-amine Following the General procedure B, 4-methyl-6-((6-phenylpyridin-3-yl)oxy)pyridin-3-amine was obtained in 78 % yield (0.30 mmol, 84 mg) from 4-methyl-5-nitro-2-((6-phenylpyridin-3- yl)oxy)pyridine (0.39 mmol, 120 mg).
  • Step 1 4-Methyl-5-nitro-2-((6-phenylpyridin-3-yl)oxy)pyridine
  • Step 1 4-Methyl-5-nitro-2-((6-phenylpyridin-3-yl)oxy)pyridine
  • Step 1 4-Methyl-5-nitro-2-((6-phenylpyridin-3-yl)oxy)pyridine
  • 6-phenylpyridin-3-ol 0.56 mmol, 164 mg
  • 2-chloro-4-methyl-5-nitropyridine 0.869 mmol, 150 mg.
  • Example 32 2-Methyl-6-(4-(thiazol-5-yl)phenoxy)pyridin-3-amine Following the General procedure B, 2-methyl-6-(4-(thiazol-5-yl)phenoxy)pyridin-3-amine was obtained in 64 % yield (0.42 mmol, 120 mg) from 5-(4-((6-methyl-5-nitropyridin-2- yl)oxy)phenyl)thiazole (0.66 mmol, 206 mg).
  • the starting material was prepared as follows: Step 1: 5-(4-((6-Methyl-5-nitropyridin-2-yl)oxy)phenyl)thiazole Following the General procedure D, a mixture of 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)thiazole (4.89 mmol, 1.03 g), 6-(4-bromophenoxy)-2-methyl-3-nitropyridine (3.26 mmol, 1.01 g; expl.28, Step 1), Na 2 CO 3 (8.15 mmol, 864 mg), and Pd(PPh 3 ) 4 (0.163 mmol, 188 mg, 5% mol) in a 4:1 mixture of dioxane/H2O (0.06 M) was converted to 5-(4-((6-methyl-5- nitropyridin-2-yl)oxy)phenyl)thiazole in 20 % yield (0.67 mmol, 209 mg).
  • Example 33 4-Methyl-6-(4-(thiazol-5-yl)phenoxy)pyridin-3-amine Following the General procedure B, 4-methyl-6-(4-(thiazol-5-yl)phenoxy)pyridin-3-amine was obtained in 33 % yield (0.424 mmol, 0.120 g) from 5-(4-((4-methyl-5-nitropyridin-2- yl)oxy)phenyl)thiazole (1.02 mmol, 0.320 g).
  • the starting material was prepared as follows: Step 1: 5-(4-((4-Methyl-5-nitropyridin-2-yl)oxy)phenyl)thiazole Following the General procedure E, 5-(4-((4-methyl-5-nitropyridin-2-yl)oxy)phenyl)thiazole was obtained in 40 % yield (1.02 mmol, 0.320 g) from 5-(4,4,5,5-tetramethyl-1,3-dioxolan-2- yl)thiazole (3.78 mmol, 0.799 mg) and 2-(4-bromophenoxy)-4-methyl-5-nitropyridine (2.52 mmol, 0.780 g; expl.29, Step 1).
  • N-methyl-6-(4-(thiazol-5-yl)phenoxy)pyridin-3-amine was obtained in 59 % yield (0.18 mmol, 50 mg) from 6-(4-(thiazol-5-yl)phenoxy)pyridin-3- amine (0.30 mmol, 80 mg; expl.11).
  • Example 35 2-Methyl-6-(4-(thiazol-2-yl)phenoxy)pyridin-3-amine Following the General procedure B, 2-methyl-6-(4-(thiazol-2-yl)phenoxy)pyridin-3-amine was obtained in 68 % yield (0.434 mmol, 123 mg) from 2-(4-((6-methyl-5-nitropyridin-2- yl)oxy)phenyl)thiazole (0.638 mmol, 200 mg).
  • the starting material was prepared as follows: Step 1: 2-(4-((6-Methyl-5-nitropyridin-2-yl)oxy)phenyl)thiazole Following the General procedure A, 2-(4-((6-methyl-5-nitropyridin-2-yl)oxy)phenyl)thiazole was obtained in 51 % yield (1.44 mmol, 0.450 g) from 4-(2-thiazolyl)phenol (2.82 mmol, 500 mg) and 6-chloro-2-methyl-3-nitropyridine (3.10 mmol, 536 mg).
  • Example 36 4-Methyl-6-(4-(thiazol-2-yl)phenoxy)pyridin-3-amine Following the General procedure F, 4-methyl-6-(4-(thiazol-2-yl)phenoxy)pyridin-3-amine was obtained in 94 % yield (1.16 mmol, 330 mg) from 2-(4-((4-methyl-5-nitropyridin-2- yl)oxy)phenyl)thiazole (1.24 mmol, 390 mg).
  • the starting material was prepared as follows: Step 1: 2-(4-((4-Methyl-5-nitropyridin-2-yl)oxy)phenyl)thiazole Following the General procedure A, 2-(4-((4-methyl-5-nitropyridin-2-yl)oxy)phenyl)thiazole was obtained in 72 % yield (1.24 mmol, 390 mg) from 4-(thiazol-2-yl)phenol (1.91 mmol, 339 mg) and 2-chloro-4-methyl-5-nitropyridine (1.74 mmol, 300 mg).
  • 6-(4-bromo-3-methylphenoxy)-2-methyl-3-nitropyridine was obtained in 94 % yield (5.46 mmol, 1.76 g) from 6-chloro-2-methyl-3-nitropyridine (5.79 mmol, 1.00 g) and 4-bromo-3-methylphenol (6.37 mmol, 1.19 g).
  • N-methyl-6-(4-(thiazol-2-yl)phenoxy)pyridin-3-amine was obtained in 86 % yield (0.32 mmol, 90 mg) from 6-(4-(thiazol-2-yl)phenoxy)pyridin-3- amine (0.371 mmol, 100 mg; expl.16).
  • Example 41 N,4-Dimethyl-6-(4-(thiazol-5-yl)phenoxy)pyridin-3-amine Following the General procedure C, N,4-dimethyl-6-(4-(thiazol-5-yl)phenoxy)pyridin-3- amine was obtained in 51 % yield (0.091 mmol, 0.027 g) from 4-methyl-6-(4-(thiazol-5- yl)phenoxy)pyridin-3-amine (0.18 mmol, 0.050 g; expl.33).
  • Example 42 N,2-Dimethyl-6-(4-(thiazol-5-yl)phenoxy)pyridin-3-amine Following the General procedure C, N,2-dimethyl-6-(4-(thiazol-5-yl)phenoxy)pyridin-3- amine was obtained in 55 % (0.098 mmol, 29 mg) from 2-methyl-6-(4-(thiazol-5- yl)phenoxy)pyridin-3-amine (0.18 mmol, 50 mg; expl.32).
  • Example 44 N,2-Dimethyl-6-(4-(thiazol-2-yl)phenoxy)pyridin-3-amine Following the General procedure C, N,2-dimethyl-6-(4-(thiazol-2-yl)phenoxy)pyridin-3- amine was obtained in 93 % yield (0.404 mmol, 0.120 g) from 2-methyl-6-(4-(thiazol-2- yl)phenoxy)pyridin-3-amine (0.434 mmol, 0.123 g; expl.35).
  • Example 45 N,2-Dimethyl-6-((6-phenylpyridin-3-yl)oxy)pyridin-3-amine Following the General procedure C, N,2-dimethyl-6-((6-phenylpyridin-3-yl)oxy)pyridin-3- amine was obtained in 80 % yield (0.23 mmol, 67 mg) from 2-methyl-6-((6-phenylpyridin-3- yl)oxy)pyridin-3-amine (0.29 mmol, 80 mg; expl.30).
  • the starting material was prepared as follows: Step 1: 2-(4-(6-Methoxypyridin-3-yl)phenoxy)-4-methyl-5-nitropyridine Following the General procedure E, 2-(4-(6-methoxypyridin-3-yl)phenoxy)-4-methyl-5- nitropyridine was obtained in 55 % yield (0.892 mmol, 0.300 g) from 2-(4-bromophenoxy)-4- methyl-5-nitropyridine (1.62 mmol, 0.500 g; expl.29, Step 1) and (6-methoxypyridin-3- yl)boronic acid (1.95 mmol, 0.298 g).
  • Example 47 6-(4-(2-Methoxypyridin-4-yl)phenoxy)-4-methylpyridin-3-amine Following the General procedure B, 6-(4-(2-methoxypyridin-4-yl)phenoxy)-4-methylpyridin- 3-amine was obtained in 20 % yield (0.091 mmol, 28 mg) from 2-(4-(2-methoxypyridin-4- yl)phenoxy)-4-methyl-5-nitropyridine (0.446 mmol, 0.150 g).
  • Step 2 4-Methyl-5-nitro-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)phenoxy)pyridine
  • 4-methyl-5-nitro-2-(4-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)phenoxy)pyridine was obtained in 95 % yield (3.09 mmol, 1.10 g) from 2- (4-bromophenoxy)-4-methyl-5-nitropyridine (3.23 mmol, 1.0 g; expl.29, Step 1) and bis(pinacolato)diborane (4.79 mmol, 1.22 g).
  • Step 4 2-(4-(1H-Imidazol-4-yl)phenoxy)-4-methyl-5-nitropyridine
  • HCl in dioxane 0.19 mL, 4 molar, 0.75 mmol
  • the reaction mixture was concentrated to dryness and the residue was suspended in the saturated solution of NaHCO 3 and extracted with CHCl 3 (3x). The combined organic layers were dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to get crude.
  • Example 49 6-(4-(2H-Tetrazol-5-yl)phenoxy)-4-methylpyridin-3-amine
  • 2-(4-(2H-tetrazol-5-yl)phenoxy)-4-methyl-5-nitropyridine (0.14 mmol, 42 mg) was dissolved in EtOH (1.4 mL, 0.10 molar) and flushed with nitrogen.
  • Pd/C 0.014 mmol, 15 mg was added, a hydrogen balloon was attached and the mixture evacuated/backfilled (3x). The mixture was then left stirring for 5 h. Upon full conversion, the mixture was
  • reaction mixture Upon full conversion by TLC, the reaction mixture was allowed to cool to RT, concentrated to a minimal amount of solvent, and loaded directly on Biotage C18 column (30 g cartridge, 5-95 % MeOH/H 2 O + 0.1% HCOOH) to afford 2-(4- (2H-tetrazol-5-yl)phenoxy)-4-methyl-5-nitropyridine (0.15 mmol, 45 mg) in 24 % yield.
  • Example 50 6-(4-(1H-Pyrazol-4-yl)phenoxy)-4-methylpyridin-3-amine
  • a solution of 4-methyl-6-(4-(1-trityl-1H-pyrazol-4-yl)phenoxy)pyridin-3-amine (0.08 mmol, 0.04 g)
  • DCM 0.4 mL
  • HCl 0.2 mL, 0.8 mmol
  • the mixture was stirred at RT overnight.
  • the mixture was diluted in H 2 O and the two layers separated.
  • the aqueous layer was washed with DCM.
  • Step 3 4-Methyl-6-(4-(1-trityl-1H-pyrazol-4-yl)phenoxy)pyridin-3-amine
  • Step 3 6,6'-((4'-Fluoro-[1,1'-biphenyl]-2,4-diyl)bis(oxy))bis(3-nitropyridine)
  • Example 52 6-((2,2'-Dimethyl-[1,1'-biphenyl]-4-yl)oxy)-4-methylpyridin-3-amine collowing the General procedure B, 6-((2,2'-dimethyl-[1,1'-biphenyl]-4-yl)oxy)-4- methylpyridin-3-amine was obtained in 61 % yield (0.31 mmol, 94 mg) from 2-((2,2'- dimethyl-[1,1'-biphenyl]-4-yl)oxy)-4-methyl-5-nitropyridine (0.508 mmol, 170 mg)
  • the starting material was prepared as follows: Step 1: 2,2'-Dimethyl-[1,1'-biphenyl]-4-ol
  • 6-((6-(4-fluorophenyl)pyridin-3-yl)oxy)-2-methyl-3- nitropyridine was obtained in 100 % yield (3.00 mmol, 900 mg) from 6-(4- fluorophenyl)pyridin-3-ol (3.00 mmol, 600 mg) and 6-chloro-2-methyl-3-nitropyridine (3.00 mmol, 500 mg).
  • 6-((6-(4-fluorophenyl)pyridin-3-yl)oxy)-N,2- dimethylpyridin-3-amine was obtained in 70 % yield with purification (0.810 mmol, 0.250 g) from 6-((6-(4-fluorophenyl)pyridin-3-yl)oxy)-2-methylpyridin-3-amine (1.155 mmol, 0.341 g) and paraformaldehyde (1.617 mmol, 1.40 eq.).
  • 6-((6-(4-fluorophenyl)pyridin-3-yl)oxy)-N,4- dimethylpyridin-3-amine was obtained in 69 % yield after purification (0.786 mmol, 0.243 g) from 6-((6-(4-fluorophenyl)pyridin-3-yl)oxy)-4-methylpyridin-3-amine (1.14 mmol, 0.337 g) and paraformaldehyde (1.60 mmol, 1.40 eq.).
  • the starting material was prepared as follows: Step 1: tert-butyl((4'-fluoro-[1,1'-biphenyl]-4-yl)(4-nitrophenyl)methoxy)dimethylsilane
  • NOTCH positive/driven human T cell acute lymphoblastic leukemia cell line RPMI 8402 was treated with selected compounds and downregulation of NOTCH target genes was measured. Materials and Methods Cell culture
  • RNA extraction One million human NOTCH positive T-ALL cell line RPMI8402 were treated with NOTCH targeting compounds at 1 ⁇ M concentration for 24 hours. Following treatment cells were harvested and washed with 1x PBS. Total RNA and total protein lysates were extracted as described below. RNA extraction
  • RNA pellet was dried off of excess of ethanol and resuspended in 40 ml DPEC water.
  • RNA extracted from the cell was used to synthesize cDNA by reverse transcription reaction. Reverse transcription was performed according to one of the two following protocols. In first protocol, SuperScriptTM RT (Invitrogen) was used for reverse transcription reaction. RNA concentration was measured using NanoDrop®ND-1000 spectrophotometer (Witec AG) and 500 ng of total RNA was mixed with a 10mM mix of dNTPs and 100 ng of random primers. The reaction mix was incubated at 65°C for 5 minutes and quickly incubated on ice for 1 minute. Following incubation on ice, 5x first strand buffer and 0.1M DTT were added and mix was incubated for 2 minutes at 25°C.
  • SuperScriptTM RT Invitrogen
  • RNA concentration was measured using NanoDrop®ND-1000 spectrophotometer (Witec AG) and 500 ng of total RNA was mixed with a 10mM mix of dNTPs and 100 ng of random primers. The reaction mix was incubated at 65°C
  • RNA concentration was measured using NanoDrop®ND-1000 spectrophotometer (Witec AG) and 1 mg of total RNA was mixed with 4 mL 5X PrimeScript RT Master Mix in a total reaction volume of 20 mL. The reaction mix was incubated at 37°C for 15 minutes followed by heat inactivation at 85°C for 5 seconds.
  • Alamarblue® and PrestoBlue proliferation assays were performed to determine the growth kinetics of Notch inhibitor treated cells.
  • Alamar blue® and PrestoBlue consists of a cell permeable substrate resazurin. In metabolically active and proliferating cells, resazurin is converted to resorufin due to an intrinsic reducing power of live cells and produces a red fluorescence. Therefore production of resorufin serves as an indicator of the viability of the cell population.
  • Proliferation assays were performed by seeding 5000 cells/well in a 96 well plate. Cells were treated with DMSO or compounds for 72 hours using concentration ranges of 0.01-10 ⁇ M. Each concentration was tested in 4 replicates.
  • Example 27 Compounds exhibiting high potency against NOTCH driven human cancers
  • NOTCH positive/driven human T cell acute lymphoblastic leukemia cell line RPMI 8402 was treated with selected compounds.
  • figure 1 and table 1 4-([1,1'-Biphenyl]-4-yloxy)aniline , 6-([1,1'- Biphenyl]-4-yloxy)-N-methylpyridin-3-amine,
  • Table 1 Anti-proliferative effect of compounds on NOTCH positive human leukemic cells. Cells were treated with compounds (concentration range 0.01-10 ⁇ M) for 72 hours. Anti- proliferative effect was measured using Alamar blue assay (See Material and methods for details). IC 50 values were calculated using Graph prism software.
  • Example 28 Downregulation of mRNA transcripts of NOTCH target genes
  • NOTCH positive human leukemic cell lines were treated with compounds for 24 hours at a concentration of 1 ⁇ M.
  • the effect on NOTCH signalling was investigated by quantifying the levels of mRNA transcripts of NOTCH target genes by quantitative PCR. An increase in potency of newly synthesized compounds was calculated as percentage improvement over 6-(4-tert-butylphenoxy)pyridin-3-amine activity.
  • compounds exhibit enhanced potency in downregulating NOTCH target genes such as HES1, cMYC and DTX1.
  • Table 2 Human leukemic cells RPMI8402 were treated with compounds at 1mM concentration for 24 hours at 37C. Total RNA was extracted, cDNA synthesized and RNA expression of respective genes was quantified using quantitative PCR (qPCR). The activity of 6-(4-tert-butylphenoxy)pyridin-3-amine to downregulate NOTCH target genes was set to 100% and corresponding increase in activity of various compounds was calculated using 6-(4- tert-butylphenoxy)pyridin-3-amine activity as a reference point. ND: not determined.
  • Example 29 Downregulation of NOTCH target genes at protein level
  • NOTCH positive leukemic cell lines were treated with selected -compounds for 24 hours at a concentration of 1 ⁇ M.
  • Total protein lysates were analysed by western blot analysis using N1-ICD (cleaved and active NOTCH1 Intracellular Domain), cMYC and ACTIN specific antibodies.
  • NOTCH positive/driven human T cell acute lymphoblastic leukemia cell line RPMI 8402 was treated with selected compounds.
  • the compounds shown in figure 1 and table 3 exhibit 1.5x to 24x higher anti- proliferative potency than 6-(4-tert-butylphenoxy)pyridin-3-amine.
  • NOTCH positive leukemic cell lines were treated with selected compounds for 24 hours at a concentration of 1 ⁇ M.
  • Total protein lysates were analysed by Jess western blot analysis using N1-ICD (cleaved and active NOTCH1 Intracellular Domain), cMYC and GAPDH specific antibodies.
  • N1-ICD cleaved and active NOTCH1 Intracellular Domain
  • cMYC cMYC
  • GAPDH specific antibodies specific antibodies.
  • the compounds shown in table 4 demonstrate a stronger downregulation of cMYC and N1-ICD (both direct target genes of NOTCH signalling in human leukemic cells) when compared with 6-(4-tert-butylphenoxy)pyridin-3-amine (described in WO2013/093885).
  • Table 4 Human leukemic cells RPMI8402 were treated with compounds at 1 ⁇ M concentration for 24 hours at 37°C. Total protein lysate were analysed by Jess western blot.
  • Example 32 Downregulation of mRNA transcripts of NOTCH target genes To further determine anti-NOTCH activity and potency of compounds (compared to 6-(4-tert- butylphenoxy)pyridin-3-amine), NOTCH positive human leukemic cell lines were treated with compounds for 24 hours at a concentration of 1 ⁇ M. The effect on NOTCH signalling was investigated by quantifying the levels of mRNA transcripts of NOTCH target genes by quantitative PCR. As show in table 5, in comparison to 6-(4-tert-butylphenoxy)pyridin-3- amine, the listed compounds exhibit enhanced potency in downregulating NOTCH target genes such as cMYC, DTX1 and HES1.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to new inhibitors of Notch signalling pathway and its use in the treatment and/or prevention of cancers.

Description

Inhibitors of Notch signalling pathway and use thereof in treatment of cancers FIELD OF THE INVENTION
The present invention relates to new inhibitors of Notch signalling pathway and its use in the treatment and/or prevention of cancers. BACKGROUND OF THE INVENTION
The Notch signalling pathway represents a critical component in the molecular circuits that control cell fate during development, cell survival and cell proliferation (Shih IeM, Wang TL in Cancer Res 2007;67(5):1879–82). Aberrant activation of this pathway contributes to tumorigenesis. The Notch family members are being revealed as oncogenes in an ever- increasing number of cancers. The role of Notch in human cancer has been highlighted recently by the presence of activating mutations and amplification of Notch genes in human cancer and by the demonstration that genes/proteins in the Notch signalling pathway could be potential therapeutic targets. It has become clear that one of the major therapeutic targets in the Notch pathway are the Notch receptors, in which g-secretase inhibitors prevent the generation of the oncogenic (intracellular) domain of Notch molecules and suppress the Notch activity. Though significant progress has been made in dissecting the complex workings of this signalling pathway, there are very limited options available for developing novel Notch inhibitors. However, the pioneering class of Notch inhibitors is already in clinical trials for few cancer types, such as g-secretase inhibitors AL101 from Ayala Pharma (formerly BMS 906024), LY3039478 from Eli Lilly and Nirogacestat from Springworks Therapeutics, a synthetic small molecule, inhibits the Notch signalling pathway, which may result in induction of growth arrest in tumor cells in which the Notch signalling pathway is
overactivated. One of the drawbacks of use of g-secretase inhibitors to block Notch signaling, as currently under investigation, is their wide range of additional targets such as amyloid precursor protein. Due to their ability to block Notch signalling via all four receptors g-secretase inhibitors are known to cause goblet cell metaplasia in the intestine. In addition, some of the hematological malignancies and solid tumors harbor mutations in the Notch receptors (such as chromosomal translocations) resulting in constitutive expression of dominant active form of NICD independent of cleavage by g-secretase complex. Therefore these tumors will fail to respond to g-secretase inhibitors treatment. WO2013/093885 discloses several Notch inhibiting compounds among them 6-(4-tert- butylphenoxy)pyridin-3-amine as particular preferred compound. Notch inhibition measured varies significantly among the disclosed compounds. Therefore, there is still a need to identify and develop further specific and selective inhibitors of Notch signaling pathway with improved properties useful for treating and/or preventing cancers. SUMMARY OF THE INVENTION The present invention provides compounds of formula (I)
Figure imgf000003_0001
pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof,
wherein X is selected from CH2, CF2, CHF, CO, CHOH, CHO(C1-C3) alkyl, NH, N(C1-C3 alkyl), S, SO and O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl;
wherein R1 is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3- C 12 cycloalkyl, C3-C12 heterocyclyl; and C1-C6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1- C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3- C12 cycloalkyl, C3-C12 heterocyclyl, C(O)R12 , C1-C6 alkyl C(O)R12;
wherein R3 is selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, C3- C12 heterocyclyl and C1-C6 alkoxy;
wherein R4 , R5 and R6 are each independently selected from H, halogen, CN, C1-C6 alkoxy, C1-C6-S-alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl and C3-C12 heterocyclyl; wherein R7 is absent when Y1 is N or is selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl and C1-C6 alkoxy when Y1 is C;
wherein R8 is absent when Y3 is N or is selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl and C1-C6 alkoxy when Y3 is C;
wherein R9 is absent when Y2 is N or is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; and C1-C6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3- C12 heterocyclyl;
wherein R12 is selected from H, NH2, NHC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl and C3-C12 heterocyclyl;
with the proviso that the compound of formula (I) is not 6-([1,1’-Biphenyl]-4-yloxy)- pyridine-3-amine, 4-([1,1’-Biphenyl]-4-yloxy)-aniline, 6-([1,1’-Biphenyl]-4-yloxy)-2- methylpyridin-3-amine and 6-([1,1’-Biphenyl]-4-yloxy)-4-methylpyridin-3-amine. The present invention also provides compounds of formula (I)
Figure imgf000005_0001
pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof,
wherein X is selected from CH2, CF2, CHF, CO, CHOH, CHO(C1-C3) alkyl, NH, N(C1-C3 alkyl), S, SO and O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl;
wherein R1 is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3- C12 cycloalkyl, C3-C12 heterocyclyl; and C1-C6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1- C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3- C1 cycloalkyl, C -C heterocyclyl, C(O)R12 , C -C alkyl C(O)R12
2 3 12 1 6 ;
wherein R3 is selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, C3- C12 heterocyclyl and C1-C6 alkoxy;
wherein R4 , R5 and R6 are each independently selected from H, halogen, CN, C1-C6 alkoxy, C1-C6-S-alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl and C3-C12 heterocyclyl; wherein R7 is absent when Y1 is N or is selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl and C1-C6 alkoxy when Y1 is C;
wherein R8 is absent when Y3 is N or is selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl and C1-C6 alkoxy when Y3 is C; wherein R9 is absent when Y2 is N or is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; and C1-C6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3- C12 heterocyclyl;
wherein R12 is selected from H, NH2, NHC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl and C3-C12 heterocyclyl, for use in a method for the prevention or treatment of cancer, preferably for use in a method for the prevention or treatment of a Notch dependent cancer. The present invention also provides a pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically acceptable carrier, and a kit comprising a compound of formula (I), optionally with reagents and/or instructions. The present invention also provides the use of compounds of formula (I), for inhibiting in vitro or in vitro the Notch signalling pathway in cells. It has been surprisingly found by the inventors of the present application that compounds which differ with respect to their chemical structure substantially from the compounds specifically disclosed in WO2013/093885 show unrivalled biological properties in Notch inhibition like high potency against NOTCH driven human cancers and high potency in downregulating NOTCH target genes.
DESCRIPTION OF THE FIGURES
Figure 1 shows anti-proliferative effect of compounds on NOTCH positive and NOTCH dependent human leukemic cell lines (RPMI8402). Cells were treated with compounds for 72 hours and effect on proliferation was quantified using Alamar blue readout.
Figure 2 shows effect of 6-([1,1'-Biphenyl]-4-yloxy)-N-methylpyridin-3-amine on N1-ICD and cMYC (NOTCH target gene) in human leukemic cells. NOTCH positive human leukemic RPMI8402 cells were treated with 1 µM of 6-(4-tert-butylphenoxy)pyridin-3-amine and 6- ([1,1'-Biphenyl]-4-yloxy)-N-methylpyridin-3-amine for 24 hours. Following treatment, total protein lysates were extracted and protein expression analysed by western blot. Data shows that 6-([1,1'-Biphenyl]-4-yloxy)-N-methylpyridin-3-amine has enhanced potency in downregulating NOTCH pathway in human cancer cells compared with 6-(4-tert- butylphenoxy)pyridin-3-amine.
Figure 3 shows effect of 6-((4'-Fluoro-[1,1'-biphenyl]-4-yl)oxy)pyridin-3-amine, 6-([1,1'- Biphenyl]-4-yloxy)-4-methylpyridin-3-amine, 6-([1,1'-Biphenyl]-4-yloxy)-2-methylpyridin-3- amine and N-Methyl-6-((6-phenylpyridin-3-yl)oxy)pyridin-3-amine on N1-ICD and cMYC (NOTCH target gene) in human leukemic cells. NOTCH positive human leukemic RPMI8402 cells were treated with 1 µM of 6-(4-tert-butylphenoxy)pyridin-3-amine and 6-((4'-Fluoro- [1,1'-biphenyl]-4-yl)oxy)pyridin-3-amine, 6-([1,1'-Biphenyl]-4-yloxy)-4-methylpyridin-3- amine, 6-([1,1'-Biphenyl]-4-yloxy)-2-methylpyridin-3-amine and N-Methyl-6-((6- phenylpyridin-3-yl)oxy)pyridin-3-amine for 24 hours. Following treatment, total protein lysates were extracted and protein expression analysed by western blot. Data shows that 6- ((4'-Fluoro-[1,1'-biphenyl]-4-yl)oxy)pyridin-3-amine, 6-([1,1'-Biphenyl]-4-yloxy)-4- methylpyridin-3-amine, 6-([1,1'-Biphenyl]-4-yloxy)-2-methylpyridin-3-amine and N-Methyl- 6-((6-phenylpyridin-3-yl)oxy)pyridin-3-amine has enhanced potency in downregulating NOTCH pathway in human cancer cells compared with 6-(4-tert-butylphenoxy)pyridin-3- amine. DETAILED DESCRIPTION OF THE INVENTION
All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. The publications and applications discussed herein are provided solely for their disclosure prior to the filing date of the present application. In addition, the materials, methods, and examples are illustrative only and are not intended to be limiting. In the case of conflict, the present specification, including definitions, will control. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in art to which the subject matter herein belongs. As used herein, the following definitions are supplied in order to facilitate the understanding of the present invention. As used herein, the term“comprise/comprising” is generally used in the sense of
include/including, that is to say permitting the presence of one or more features or
components. The terms“comprise” and“comprising” also encompass the more restricted terms“consist” and“consisting”. As used herein, the singular form“a”,“an” and“the” include plural references unless the context clearly dictates otherwise. As used herein the terms“subject” is well-recognized in the art, and, refers to a mammal, including dog, cat, rat, mouse, monkey, cow, horse, goat, sheep, pig, camel, and, most preferably, a human. In some embodiments, the subject is a subject in need of treatment or a subject with a disease or disorder, such as cancer. However, in other embodiments, the subject can be a normal subject or a subject who has already undergone a treatment against cancer. The term does not denote a particular age or sex. Thus, adult, children and newborn subjects, whether male or female, are intended to be covered. The terms“cancer”,“cancer cells”,“cell proliferative diseases” and“cell proliferative disorders” as used herein refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. According to the present invention, cancer refers preferably to solid tumors, such as salivary, liver, brain, breast, prostate, colorectum, kidney, lung, sarcoma, or melanoma and liquid tumors, affecting the blood, such as leukemia. More preferably according to the present invention, cancers are Notch dependent cancers selected from the group comprising adenoid cystic carcinoma (ACC), T cell-Acute
lymphoblastic leukemia (T-ALL), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), Mantle cell lymphoma, breast cancer, pancreatic cancer, prostate cancer, melanoma, brain tumors, tumor angiogenesis, liver cancer and colorectal cancer. Even more preferably, the Notch dependent cancer is resistant to g–secretase inhibitor treatment.
Examples of g–secretase inhibitor treatment comprise 1) Gamma secretase inhibitor
RO4929097 and Cediranib Maleate in treating patients with advanced solid tumors
(NCT01131234), 2) Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia (NCT01088763), 3) Study of MK-0752 in combination with Tamoxifen or Letrozole to treat early stage breast cancer (NCT00756717), 4) GDC-0449 and RO4929097 in treating patients with Advances or metastatic sarcoma (NCT01154452) 5) RO4929097 and Erlotinib
Hydrochloride in treating patients with stage IV or recurrent Non-Small Cell Lung Cancer (NCT01193881), 6) Bicalutamide and RO4929097 in treating patients with previously treated prostate cancer (NCT01200810), 7) RO4929097 in treating patients with recurrent invasive Gliomas (NCT01269411), 8) A Notch signaling pathway inhibitor for patients with T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL) (NCT00100152) and 9) RO4929097 in treating patients with metastatic colorectal cancer (NCT01116687). The term "alkyl" as used herein refers to a saturated straight or branched chain group of carbon atoms derived from an alkane by the removal of one hydrogen atom. C1-C3 alkyl comprises for example methyl, ethyl, n-propyl, i-propyl and comprises preferably non- branched C1-C3 alkyl. C1-C4 alkyl comprises for example methyl, ethyl, n-propyl, i-propyl, n- butyl, i-butyl, tert-butyl and comprises preferably non-branched C1-C4 alkyl. C1-C6 alkyl comprises for example methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl, and n-hexyl and comprises preferably non-branched C1-C6 alkyl. C1-C10 alkyl comprises for example methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl, n-hexyl, n- heptyl, n- octyl, n-nonyl or n-decyl and comprises preferably non-branched C1-C10 alkyl. The term“C0 alkyl“as used herein refers to a covalent bond. Thus e.g. the term“C0 alkylOC0 alkyl aryl” refers to Oaryl. The term“C0-C3 alkylOC0-C3 alkyl aryl” as used herein refers to Oaryl as defined herein when both C0-C3 alkyl groups are C0 alkyl. The term refers to OC0-C3 alkyl aryl when the first C0-C3 alkyl group is C0 alkyl. The term refers to C0-C3 alkylOaryl when the second C0-C3 alkyl group is C0 alkyl. Preferably C0-C3 alkylOC0-C3 alkyl aryl is C0-C3 alkylOaryl, more preferably Oaryl or C1-C3 alkylOaryl. The term“C0-C3 alkylOC0-C3 alkyl heteroaryl” as used herein refers to Oheteroaryl as defined herein when both C0-C3 alkyl groups are C0 alkyl. The term refers to OC0-C3 alkyl heteroaryl when the first C0-C3 alkyl group is C0 alkyl. The term refers to C0-C3 alkylOheteroaryl when the second C0-C3 alkyl group is C0 alkyl. Preferably C0-C3 alkylOC0-C3 alkyl heteroaryl is C0-C3 alkylOheteroaryl, more preferably Oheteroaryl or C1-C3 alkylOheteroaryl, most preferably Oheteroaryl. The aryl and the heteroaryl of C0-C3 alkylOC0-C3 alkyl aryl and C0-C3 alkylOC0-C3 alkyl heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl, preferably are optionally substituted by NH2. The term "heteroalkyl" as used herein refers to an alkyl radical as defined herein wherein one, two, three or four hydrogen atoms have been replaced with a substituent independently selected from the group consisting of ORa, C(O)ORa, NRbRc, C(O)NRbRc, S(O)nRd (where n is an integer from 0 to 2) and halogen, with the understanding that the point of attachment of the heteroalkyl radical is through a carbon atom, wherein Ra is H, C1-C3 alkylcarbonyl, C1-C3 alkyl, or C3-7 cycloalkyl; Rb and Rc are each independently H, C1-C3 alkylcarbonyl, C1-C3 alkyl, C3-7 cycloalkyl or NRbRc is guanidinyl; and when n is 0, Rd is H, C1-C3 alkyl or C3-7 cycloalkyl, and when n is 1 or 2, Rd is C1-C3 alkyl or C3-7 cycloalkyl. Preferably. the term "heteroalkyl" or“heteroalkanediyl” as used herein refers to an alkyl radical or an alkanediyl radical as defined herein wherein one, two, three or four hydrogen atoms have been replaced with a substituent independently selected from the group consisting of OH, NH2, guanidinyl and halogen, more preferably wherein one or two hydrogen atoms have been replaced with a substituent independently selected from the group consisting of OH, NH2 and halogen.
Representative examples include, but are not limited to, 2-hydroxyethyl, 2-hydroxypropyl, 3- hydroxypropyl, 2-hydroxy-1-hydroxymethylethyl, 2-hydroxy-1-methylethyl, 2,3- dihydroxypropyl, 1-hydroxymethylethyl, 3-hydroxybutyl, 2,3-dihydroxybutyl, 1-hydroxy-2- methylpropyl, 3-hydroxy-1-(2-hydroxyethyl)-propyl, 2-hydroxy-1-methylpropyl, 1,1,1- trifluoroethyl, 1,1,1-trifluoromethyl, 2,2,3,3-tetrafluoropropyl. The term " C3-12 cycloalkyl " and“C3-7 cycloalkyl” as used herein refers to a monovalent saturated monocyclic or bicyclic hydrocarbon group, preferably a monovalent saturated monocyclic goup of 3-12 or 3-7 carbons, respectively derived from a cycloalkane by the removal of a single hydrogen atom.“C3-7 cycloalkyl” includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. The term "C3-12 cycloalkyl " and“C3-7 cycloalkyl” as used herein also includes cycloalkyl groups that comprise a C1-3 alkyl radical. Examples of such "C3-7 cycloalkyl" groups comprise cyclopropylmethyl, 2-cyclopropylethyl,
cyclobutylmethyl, 2-cyclobutylethyl, cyclopentylmethyl, 2-cyclopentylethyl. Cycloalkyl groups of this invention can be optionally substituted. The term "aryloxy" or“Oaryl” which are used interchangeably herein refers to a radical -OR where R is an aryl as defined herein, e. g. phenoxy. The term "C1-C6 alkoxy" or“OC1-C6 alkyl” which are used interchangeably herein refers to a radical -OR where R is a C1-C6 alkyl as defined herein. Examples are methoxy, ethoxy, propoxy, butoxy. The term "aryl" as used herein refers to a mono- or bicyclic carbocyclic ring system having one or two aromatic rings, and is preferably a monocyclic carbocyclic ring system. The aryl group can also be fused to a cyclohexane, cyclohexene, cyclopentane, or cyclopentene ring or to a cyclohexane, cyclohexene, cyclopentane, or cyclopentene ring comprising a carbonyl group. The aryl groups of this invention can be optionally substituted as further described below. A preferred aryl group and optionally substituted aryl group, respectively of this invention is a phenyl group or substituted phenyl group. Substituents can be e.g. NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C(O)R12 , C1-C6 alkyl C(O)R12. The term "heteroaryl" as used herein refers to substituted and unsubstituted aromatic 5-, or 6- membered monocyclic groups and 9- or 10-membered bicyclic groups, preferably a substituted and unsubstituted aromatic 5-, or 6- membered monocyclic group, which have at least one heteroatom (O, S or N) in at least one of the ring(s). Each ring of the heteroaryl group containing a heteroatom can contain one or two oxygen or sulfur atoms and/or from one to four nitrogen atoms provided that the total number of heteroatoms in each ring is four or less and each ring has at least one carbon atom. The fused rings completing the bicyclic group may contain only carbon atoms and may be saturated, partially saturated, or unsaturated. Heteroaryl groups must include at least one fully aromatic ring but the other fused ring or rings may be aromatic or non-aromatic. The heteroaryl group may be attached at any available nitrogen or carbon atom of any ring. Heteroaryl groups of this invention can be optionally substituted as further described below. Usually, a heteroaryl group and optionally substituted heteroaryl group, respectively of this invention is selected from the group consisting of substituted and/or unsubstituted aromatic 5-, or 6- membered monocyclic groups, which have at least one heteroatom (O, S or N), preferably one or two heteroatoms selected from S and N in the ring, more preferably one S and one N in the ring, or one or two N in the ring. A preferred heteroaryl group is an optionally substituted heteroaryl group, selected from the group consisting of an optionally substituted pyridinyl group, an optionally substituted pyrimidinyl group, an optionally substituted di- or triazine group, an optionally substituted thiazole group, an optionally substituted oxazole group, and an optionally substituted imidazole group. An even more preferred heteroaryl group is an optionally substituted pyridinyl group, an optionally substituted pyrimidinyl group, an optionally substituted imidazole group or an optionally substituted thiazole group. Most preferably an optionally substituted pyridinyl group, an optionally substituted imidazole group or an optionally substituted thiazole group, is used as heteroaryl group in the present invention. Optional substituents can be e.g. NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3- C12 cycloalkyl, C3-C12 heterocyclyl, C(O)R12 , C1-C6 alkyl C(O)R12 , or NH2, OC1-C6 alkyl, C1- C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl. The term "heterocyclyl" as used herein means a saturated, monocyclic ring with 3 to 12, preferably with 3 to 7, more preferably 5 to 6 ring atoms which contains up to 3, preferably 1 or 2 heteroatoms selected independently from nitrogen, oxygen or sulfur, and wherein the remaining ring atoms being carbon atoms. Examples of such saturated heterocycles include [1,3]dioxanyl, [1,3]dioxolanyl, pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl, oxazolidinyl, thiazolidinyl, azepanyl and the like. Preferably such heterocyclyl groups are unsubstituted. The terms "halo" or "halogen" as used herein refers to F, Cl, Br, or I and is preferably F, Cl, or Br, more preferably F. The term”optionally substituted” or“substituted” means that the referenced group is substituted with one or more additional group(s), preferably with one additional group, individually and independently selected from the listed groups. The compound 6-([1,1’-Biphenyl]-4-yloxy)-pyridine-3-amine which is excluded from the compounds of formula (I) in some aspects or embodiments of the present invention has the following chemical structure:
Figure imgf000012_0001
The compound 4-([1,1’-Biphenyl]-4-yloxy)-aniline which is excluded from the compounds of formula (I) in some aspects or embodiments of the present invention has the following chemical structure:
Figure imgf000012_0002
The compound 6-([1,1’-Biphenyl]-4-yloxy)-2-methylpyridin-3-amine which is excluded from the compounds of formula (I) in some aspects or embodiments of the present invention has the following chemical structure:
Figure imgf000013_0001
The compound 6-([1,1’-Biphenyl]-4-yloxy)-4-methylpyridin-3-amine which is excluded from the compounds of formula (I) in some aspects or embodiments of the present invention has the following chemical structure:
Figure imgf000013_0002
The compound 4-(4’-Methoxy-biphenyl-4-yloxy)phenylamine which is excluded from the compounds of formula (I) in some aspects or embodiments of the present invention has the following chemical structure:
Figure imgf000013_0003
The compound 4-(4’-Chloro-biphenyl-4-yloxy)phenylamine which is excluded from the compounds of formula (I) in some aspects or embodiments of the present invention has the following chemical structure:
Figure imgf000013_0004
The compound 4-(4’-tert-Butyl-biphenyl-4-yloxy)phenylamine which is excluded from the compounds of formula (I) in some aspects or embodiments of the present invention has the following chemical structure:
Figure imgf000013_0005
The compound 4-(4-(thiazol-2-yl)phenoxy)aniline which is excluded from the compounds of formula (I) in some aspects or embodiments of the present invention has the following chemical structure:
Figure imgf000014_0001
The compound 4-(4-(1H-imidazol-2-yl)phenoxy)aniline which is excluded from the compounds of formula (I) in some aspects or embodiments of the present invention has the following chemical structure:
Figure imgf000014_0002
The compound 4-(4-(oxazol-2-yl)phenoxy)aniline which is excluded from the compounds of formula (I) in some aspects or embodiments of the present invention has the following chemical structure:
Figure imgf000014_0003
The compound 4-(4-(1H-pyrrol-1-yl)phenoxy)aniline which is excluded from the compounds of formula (I) in some aspects or embodiments of the present invention has the following chemical structure:
Figure imgf000014_0004
Thus, in a first aspect the present invention provides a compound of formula (I)
Figure imgf000015_0001
pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof,
wherein X is selected from CH2, CF2, CHF, CO, CHOH, CHO(C1-C3) alkyl, NH, N(C1-C3 alkyl), S, SO and O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl;
wherein R1 is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3- C12 cycloalkyl, C3-C12 heterocyclyl; and C1-C6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1- C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3- C12 cycloalkyl, C3-C12 heterocyclyl, C(O)R12 , C1-C6 alkyl C(O)R12;
wherein R3 is selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, C3- C12 heterocyclyl and C1-C6 alkoxy;
wherein R4 , R5 and R6 are each independently selected from H, halogen, CN, C1-C6 alkoxy, C1-C6-S-alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl and C3-C12 heterocyclyl; wherein R7 is absent when Y1 is N or is selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl and C1-C6 alkoxy when Y1 is C;
wherein R8 is absent when Y3 is N or is selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl and C1-C6 alkoxy when Y3 is C; wherein R9 is absent when Y2 is N or is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkyl aryl wherein the arylis optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; and C1-C6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl areoptionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3- C12 heterocyclyl;
wherein R12 is selected from H, NH2, NHC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl and C3-C12 heterocyclyl;
with the proviso that the compound of formula (I) is not 6-([1,1’-Biphenyl]-4-yloxy)- pyridine-3-amine, 4-([1,1’-Biphenyl]-4-yloxy)-aniline, 6-([1,1’-Biphenyl]-4-yloxy)-2- methylpyridin-3-amine and 6-([1,1’-Biphenyl]-4-yloxy)-4-methylpyridin-3-amine, preferably with the proviso that the compound of formula (I) is not 6-([1,1’-Biphenyl]-4-yloxy)- pyridine-3-amine, 4-([1,1’-Biphenyl]-4-yloxy)-aniline, 6-([1,1’-Biphenyl]-4-yloxy)-2- methylpyridin-3-amine, 6-([1,1’-Biphenyl]-4-yloxy)-4-methylpyridin-3-amine, 4-(4’- Methoxy-biphenyl-4-yloxy)phenylamine, 4-(4’-Chloro-biphenyl-4-yloxy)phenylamine, and 4- (4’-tert-Butyl-biphenyl-4-yloxy)phenylamine, more preferably with the proviso that the compound of formula (I) is not 6-([1,1’-Biphenyl]-4-yloxy)-pyridine-3-amine, 4-([1,1’- Biphenyl]-4-yloxy)-aniline, 6-([1,1’-Biphenyl]-4-yloxy)-2-methylpyridin-3-amine, 6-([1,1’- Biphenyl]-4-yloxy)-4-methylpyridin-3-amine, 4-(4’-Methoxy-biphenyl-4-yloxy)phenylamine, 4-(4’-Chloro-biphenyl-4-yloxy)phenylamine, 4-(4’-tert-Butyl-biphenyl-4-yloxy)phenylamine, 4-(4-(thiazol-2-yl)phenoxy)aniline, 4-(4-(1H-imidazol-2-yl)phenoxy)aniline, 4-(4-(oxazol-2- yl)phenoxy)aniline and 4-(4-(1H-pyrrol-1-yl)phenoxy)aniline. The Notch signalling pathway is evolutionarily conserved and the basic molecular players in this pathway are ligands (Delta and Jagged), Notch receptors, and the transcription factors (Shih IeM, Wang TL in Cancer Res 2007;67(5):1879–82). Notch is a transmembrane heterodimeric receptor and there are four distinct members (Notch1, Notch2, Notch3 and Notch4) in humans and rodents. In a physiologic condition, binding of the Notch ligand to its receptor initiates Notch signalling by releasing the intracellular domain of the Notch receptor (Notch-ICD) through a cascade of proteolytic cleavages by both a-secretase (also called tumor necrosis factor-a–converting enzyme) and g-secretase. The released intracellular Notch-ICD then translocates into the nucleus where it modulates gene expression primarily by binding to a ubiquitous transcription factor, CBF1, suppressor of hairless, Lag-1 (CSL). This binding recruits transcription activators to the CSL complex and converts it from a
transcriptional repressor into an activator, which turns on several downstream effectors. The physiologic functions of Notch signalling are multifaceted, including maintenance of stem cells, specification of cell fate, and regulation of differentiation in development as well as in oncogenesis. In cancers, molecular genetic alterations, such as chromosomal translocation, point mutations, and chromosomal amplification at the Notch receptor loci, are the known mechanisms for constitutive activation of Notch pathway. Despite the different mechanisms, they all result in increased levels of intracellular Notch-IC. The oncogenic potential of Notch was first discovered in human T-cell acute lymphoblastic leukemia (T-ALL), adenoid cystic carcinoma (ACC), breast cancer and chronic lymphocytic leukemia (CLL). While Notch1 signalling is essential for normal development of T-cell progenitors, constitutive activation of Notch1 signalling due to molecular genetic alterations is associated with T-ALL. For example, interstitial deletions of the extracellular portion of human Notch1 due to chromosomal translocation are associated with ~1% of T-ALL cases and activating point mutations of Notch1 are present in about 50% of T-ALL cases. Formation of T-cell leukemia/lymphoma was observed in a Notch-ICD transgenic mouse model, which indicates a causal role of Notch activation in T-ALL development. In non–small cell lung cancer, chromosomal translocation has been identified in a subset of tumors, and the translocation is thought to elevate Notch3 transcription in tumors. In ovarian cancer, Notch3 gene amplification was found to occur in about 19% of tumors, and overexpression of Notch3 was found in more than half of the ovarian serous carcinomas. Similarly, Notch signalling activation has been shown in the development of breast cancer. In animal models, constitutively active Notch4 expression causes mammary tumors in mice and Notch1-activating mutations contribute to the development of T-ALL. A recent study further shows that overexpression of activated Notch1 and Notch3 in transgenic mice blocks mammary gland development and induces mouse breast tumors. Notch signalling activation has also been implicated in lung and bone metastasis of breast cancer cells. Overexpression of Notch3 is sufficient to induce choroid plexus tumor formation in a mouse model, suggesting a role of Notch3 in the development of certain types of brain tumors. The present invention also encompasses chemical modifications of the compounds of the present invention to prolong their circulating lifetimes. Non-limiting examples of methods for transiently, or reversibly, pegylating drugs, including polypeptide-based drugs, are provided in U.S. Pat. Nos.4,935,465 (issued in Jun.19, 1990) and 6,342,244 (issued Jan.29, 2002); and in U.S. published applications number US2006/0074024. One skilled in the art would typically find more details about PEG-based reagents in, for example, published applications WO2005047366, US2005171328, and those listed on the NEKTAR PEG Reagent Catalog® 2005-2006 (Nektar Therapeutics, San Carlos, Calif.). The invention also relates to salts, hydrates or solvates of the compounds of formula (I).
Preferably, these salts, hydrates and/or solvates are pharmaceutically acceptable. According to the present invention, pharmaceutically acceptable salts are produced from acidic inorganic or organic compounds, or alkaline inorganic or organic compounds. As used herein, the phrase “pharmaceutically acceptable salt” refers to a salt that retains the biological effectiveness of the free acids and bases of a specified compound and that is not biologically or otherwise undesirable. The invention also relates to stereoisomers of the compounds of formula (I).“Stereoisomer” or“stereoisomers” refer to compounds that differ in the chirality of one or more stereocentres. Stereoisomers include enantiomers and diastereomers. A compound of formula (I) may exist in stereoisomeric form if they possess one or more asymmetric centres or a double bond with asymmetric substitution and, therefore, can be produced as individual stereoisomers or as mixtures. Unless otherwise indicated, the description is intended to include individual stereoisomers as well as mixtures. The methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art (see discussion in Chapter 4 of Advanced Organic Chemistry, 4th ed., J. March, John Wiley and Sons, New York, 1992). A skilled person will know that, if the compounds of the present invention contain charged group, a suitable counterion will be derived from an organic or inorganic acid. Such counterions include halide (such as chloride, bromide, fluoride, iodide), sulfate, phosphate, acetate, succinate, citrate, lactate, maleate, fumarate, palmitate, cholate, glutamate, glutarate, tartrate, stearate, salicylate, methanesulfonate, benzenesulfonate, sorbate, picrate, benzoate, cinnamate, and the like. If the polar moiety is a negatively charged group, a suitable counterion will be selected from sodium, ammonium, barium, calcium, copper, iron, lithium, potassium and zinc, and the like. In a further aspect the present invention provides a pharmaceutical composition comprising the compounds of the present invention, pharmaceutically acceptable salts, hydrates, or stereoisomers thereof, and a pharmaceutically acceptable carrier. Thus in a further aspect the present invention provides a pharmaceutical composition comprising a compound of formula (I)
Figure imgf000019_0001
pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof,
wherein X is selected from CH2, CF2, CHF, CO, CHOH, CHO(C1-C3) alkyl, NH, N(C1-C3 alkyl), S, SO and O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl;
wherein R1 is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3- C12 cycloalkyl, C3-C12 heterocyclyl; and C1-C6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1- C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3- C12 cycloalkyl, C3-C12 heterocyclyl, C(O)R12 , C1-C6 alkyl C(O)R12;
wherein R3 is selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, C3- C12 heterocyclyl and C1-C6 alkoxy;
wherein R4 , R5 and R6 are each independently selected from H, halogen, CN, C1-C6 alkoxy, C1-C6-S-alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl and C3-C12 heterocyclyl; wherein R7 is absent when Y1 is N or is selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl and C1-C6 alkoxy when Y1 is C;
wherein R8 is absent when Y3 is N or is selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl and C1-C6 alkoxy when Y3 is C;
wherein R9 is absent when Y2 is N or is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkyl aryl wherein the arylis optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; and C1-C6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl areoptionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3- C12 heterocyclyl;
wherein R12 is selected from H, NH2, NHC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl and C3-C12 heterocyclyl; and a pharmaceutically acceptable carrier. Preferably the compound of formula (I) comprised by the pharmaceutical composition is not 4-([1,1’-Biphenyl]-4-yloxy)-aniline, more preferably is not 6-([1,1’- Biphenyl]-4-yloxy)-pyridine-3-amine, 4-([1,1’-Biphenyl]-4-yloxy)-aniline, 6-([1,1’- Biphenyl]-4-yloxy)-2-methylpyridin-3-amine and 6-([1,1’-Biphenyl]-4-yloxy)-4- methylpyridin-3-amine. Even more preferably the compound of formula (I) comprised by the pharmaceutical composition is not 6-([1,1’-Biphenyl]-4-yloxy)-pyridine-3-amine, 4-([1,1’- Biphenyl]-4-yloxy)-aniline, 6-([1,1’-Biphenyl]-4-yloxy)-2-methylpyridin-3-amine, 6-([1,1’- Biphenyl]-4-yloxy)-4-methylpyridin-3-amine, 4-(4’-Methoxy-biphenyl-4-yloxy)phenylamine, 4-(4’-Chloro-biphenyl-4-yloxy)phenylamine, and 4-(4’-tert-Butyl-biphenyl-4- yloxy)phenylamine. In particular the compound of formula (I) comprised by the
pharmaceutical composition is not 6-([1,1’-Biphenyl]-4-yloxy)-pyridine-3-amine, 4-([1,1’- Biphenyl]-4-yloxy)-aniline, 6-([1,1’-Biphenyl]-4-yloxy)-2-methylpyridin-3-amine, 6-([1,1’- Biphenyl]-4-yloxy)-4-methylpyridin-3-amine, 4-(4’-Methoxy-biphenyl-4-yloxy)phenylamine, 4-(4’-Chloro-biphenyl-4-yloxy)phenylamine, 4-(4’-tert-Butyl-biphenyl-4-yloxy)phenylamine, 4-(4-(thiazol-2-yl)phenoxy)aniline, 4-(4-(1H-imidazol-2-yl)phenoxy)aniline, 4-(4-(oxazol-2- yl)phenoxy)aniline and 4-(4-(1H-pyrrol-1-yl)phenoxy)aniline. In a further aspect the present invention provides a compound of formula (I)
Figure imgf000021_0001
pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof,
wherein X is selected from CH2, CF2, CHF, CO, CHOH, CHO(C1-C3) alkyl, NH, N(C1-C3 alkyl), S, SO and O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl;
wherein R1 is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3- C12 cycloalkyl, C3-C12 heterocyclyl; and C1-C6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1- C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3- C12 cycloalkyl, C3-C12 heterocyclyl, C(O)R12 , C1-C6 alkyl C(O)R12; wherein R3 is selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, C3- C12 heterocyclyl and C1-C6 alkoxy;
wherein R4 , R5 and R6 are each independently selected from H, halogen, CN, C1-C6 alkoxy, C1-C6-S-alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl and C3-C12 heterocyclyl; wherein R7 is absent when Y1 is N or is selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl and C1-C6 alkoxy when Y1 is C;
wherein R8 is absent when Y3 is N or is selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl and C1-C6 alkoxy when Y3 is C;
wherein R9 is absent when Y2 is N or is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkyl aryl wherein the arylis optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; and C1-C6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl areoptionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3- C12 heterocyclyl;
wherein R12 is selected from H, NH2, NHC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl and C3-C12 heterocyclyl, for use in a method for the prevention or treatment of cancer. Preferably the compound of formula (I) for use in a method for the prevention or treatment of cancer is not 4-([1,1’-Biphenyl]-4-yloxy)-aniline, more preferably is not 6-([1,1’-Biphenyl]-4-yloxy)-pyridine-3-amine, 4-([1,1’-Biphenyl]-4-yloxy)- aniline, 6-([1,1’-Biphenyl]-4-yloxy)-2-methylpyridin-3-amine and 6-([1,1’-Biphenyl]-4- yloxy)-4-methylpyridin-3-amine. Even more preferably the compound of formula (I) for use in a method for the prevention or treatment of cancer is not 6-([1,1’-Biphenyl]-4-yloxy)- pyridine-3-amine, 4-([1,1’-Biphenyl]-4-yloxy)-aniline, 6-([1,1’-Biphenyl]-4-yloxy)-2- methylpyridin-3-amine, 6-([1,1’-Biphenyl]-4-yloxy)-4-methylpyridin-3-amine, 4-(4’- Methoxy-biphenyl-4-yloxy)phenylamine, 4-(4’-Chloro-biphenyl-4-yloxy)phenylamine, and 4- (4’-tert-Butyl-biphenyl-4-yloxy)phenylamine. In particular the compound of formula (I) for use in a method for the prevention or treatment of cancer is not 6-([1,1’-Biphenyl]-4-yloxy)- pyridine-3-amine, 4-([1,1’-Biphenyl]-4-yloxy)-aniline, 6-([1,1’-Biphenyl]-4-yloxy)-2- methylpyridin-3-amine, 6-([1,1’-Biphenyl]-4-yloxy)-4-methylpyridin-3-amine, 4-(4’- Methoxy-biphenyl-4-yloxy)phenylamine, 4-(4’-Chloro-biphenyl-4-yloxy)phenylamine, 4-(4’- tert-Butyl-biphenyl-4-yloxy)phenylamine, 4-(4-(thiazol-2-yl)phenoxy)aniline, 4-(4-(1H- imidazol-2-yl)phenoxy)aniline, 4-(4-(oxazol-2-yl)phenoxy)aniline and 4-(4-(1H-pyrrol-1- yl)phenoxy)aniline. When R1 is C0-C3 alkylOC0-C3 alkyl aryl or C0-C3 alkylOC0-C3 alkyl heteroaryl, the optional substitutions of the aryl and the heteroaryl group are preferably in para position.
When R2 is aryl or heteroaryl, the optional substitutions are preferably in ortho or meta position, provided that the substitutents are not halogen, OC1-C6 alkyl or methyl and are in para position when the substituents are halogen, OC1-C6 alkyl or methyl.
When R9 is C0-C3 alkylOC0-C3 alkyl aryl or C0-C3 alkylOC0-C3 alkyl heteroaryl the optional substitutions of the aryl and the heteroaryl group are preferably in para position. In one embodiment X is selected from CH2, CF2, CHF, NH, N(C1-C3 alkyl), S, SO and O. In a further embodiment X is selected from CO, CHOH, CHO(C1-C3) alkyl, S, SO and O. In a preferred embodiment X is selected from CH2, NH, and O. In a more preferred embodiment X is selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, NH, and O. In an even more preferred embodiment X is selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, and O. In a particular preferred embodiment X is selected from CH2, CO, CHOH, CHOCH3, and O. In a more particular preferred embodiment X is selected from CH2 and O. In an even more particular preferred embodiment X is O. In one embodiment R1 is selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, preferably is optionally substituted by NH2; and C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl, preferably is optionally substituted by NH2. In a further embodiment R1 is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy and C1-C6 heteroalkyl. In a preferred embodiment R1 is selected from H, halogen and C1-C4 alkyl, C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, preferably is optionally substituted by NH2; and C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl, preferably is optionally substituted by NH2. In a further preferred embodiment R1 is selected from H, halogen, C1-C6 alkyl and C1-C6 heteroalkyl. In a more preferred embodiment R1 is selected from H, C1-C6 alkyl, C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, preferably is optionally substituted NH2; C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, preferably is optionally substituted by NH2. In an even more preferred embodiment R1 is selected from H, C1-C4 alkyl and C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, preferably is optionally substituted by NH2; C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl, preferably is optionally substituted by NH2. In a further more preferred embodiment R1 is selected from H, halogen and C1-C4 alkyl. In an even more preferred embodiment R1 is selected from H, methyl, C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, preferably is optionally substituted by NH2; and C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl, preferably is optionally substituted by NH2. In a further even more preferred embodiment R1 is selected from C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl, preferably is optionally substituted by NH2; C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl, preferably is optionally substituted by NH2; and C1-C6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl, preferably is optionally substituted by NH2. In a further even more preferred embodiment R1 is selected from C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl, preferably is optionally substituted by NH2; and C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3- C12 cycloalkyl, C3-C12 heterocyclyl, preferably is optionally substituted by NH2. In a further even more preferred embodiment R1 is selected from H and methyl. In one embodiment R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl is substituted by a substituent selected from NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C(O)R12 and C1-C6 alkyl C(O)R12. In a further embodiment R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6
heteroalkyl, halogen, CN, C(O)R12 , C1-C6 alkyl C(O)R12.
In a preferred embodiment R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3- C12 cycloalkyl, C3-C12 heterocyclyl, C(O)R12 and C1-C6 alkyl C(O)R12. In a more preferred embodiment R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C(O)R12 , C1-C6 alkyl C(O)R12. In a further more preferred embodiment R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl. In a particular preferred embodiment R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by C1-C6 alkyl, halogen, C1-C6 heteroalkyl, C(O)R12 , C1-C6 alkyl C(O)R12. In a further particular preferred embodiment R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by C1-C6 alkyl, halogen. In a further particular preferred embodiment R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, halogen, CN. In a further particular preferred embodiment R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by C(O)R12 , C1-C6 alkyl C(O)R12. Among the particular preferred embodiments the embodiment wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by C1-C6 alkyl, halogen, C1-C6 heteroalkyl, C(O)R12 , C1-C6 alkyl C(O)R12 is preferred. In an even more particular preferred embodiment R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, C1-C6 alkyl C(O)R12.
In an even more particular preferred embodiment R2 is selected from phenyl, pyridyl, imidazole and thiazole each optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C(O)R12 , C1-C6 alkyl C(O)R12. In a further even more particular preferred embodiment R2 is selected from phenyl, thiazole, pyridyl, imidazole and thiazole each optionally substituted by NH2, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C(O)R12 , C1-C6 alkyl C(O)R12. In a further even more particular preferred embodiment R2 is selected from phenyl, pyridyl, imidazole and thiazole each optionally substituted by NH2, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C(O)R12 , C1-C6 alkyl C(O)R12. In a further even more particular preferred embodiment R2 is selected from phenyl, pyridyl, imidazole and thiazole each optionally substituted by C1-C6 alkyl, halogen, C1-C6 heteroalkyl, C(O)R12 , C1-C6 alkyl C(O)R12. In a further even more particular preferred embodiment R2 is selected from phenyl, pyridyl, imidazole and thiazole each optionally substituted by C1-C6 alkyl, halogen. In a further even more particular preferred embodiment R2 is selected from phenyl, pyridyl, imidazole and thiazole each optionally substituted by NH2, halogen, CN. In a further even more particular preferred embodiment R2 is selected from phenyl, pyridyl, imidazole and thiazole each optionally substituted by C(O)R12 , C1-C6 alkyl C(O)R12. Among the even more particular preferred embodiments the embodiment wherein R2 is selected from phenyl, pyridyl, imidazole and thiazole each optionally substituted by C1-C6 alkyl, halogen, C1-C6 heteroalkyl, C(O)R12 , C1-C6 alkyl C(O)R12 is preferred. In a further even more particular preferred embodiment R2 is selected from phenyl, pyridyl, imidazole and thiazole each optionally substituted by C1-C6 alkyl, halogen. In a further even more particular preferred embodiment R2 is selected from phenyl, pyridyl, imidazole and thiazole each optionally substituted by C(O)R12 , C1-C6 alkyl C(O)R12. In a most particular preferred embodiment R2 is selected from phenyl, pyridyl, imidazole and thiazole each optionally substituted by OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, C1-C6 alkyl C(O)R12.
In a preferred embodiment R2 is selected from aryl and heteroaryl wherein the heteroaryl is an optionally substituted aromatic 5-, or 6- membered monocyclic group.
In a further preferred embodiment R2 is selected from aryl and heteroaryl, with the proviso that the heteroaryl is not unsubstituted thiazole, oxazole, imidazole and pyrrole.
In a further more preferred embodiment R2 is selected from aryl and heteroaryl, with the proviso that the heteroaryl is not thiazole, oxazole, imidazole and pyrrole. In one embodiment R3 is selected from H, halogen, C1-C6 alkyl, and C3-C12 cycloalkyl. In a preferred embodiment R3 is selected from H, halogen, C1-C4 alkyl, and C3-C7 cycloalkyl. In a more preferred embodiment R3 is selected from H, halogen and C1-C4 alkyl. In an even more preferred embodiment R3 is H. In one embodiment R4 , R5 and R6 are each independently selected from H, halogen, CN, C1- C6 alkyl and C1-C6 heteroalkyl. In a preferred embodiment R4 , R5 and R6 are each
independently selected from H, halogen, CN, C1-C4 alkyl and C1-C4 heteroalkyl. In an even more preferred embodiment R4 , R5 and R6 are each independently selected from H, halogen, and C1-C4 alkyl. In a particular preferred embodiment R4 , R5 and R6 are each independently selected from H, halogen, and methyl. In an more particular preferred embodiment R4 is selected from H and halogen and/or R5 and/or R6 are selected from H and C1-C6 alkyl, in particular from H and C1-C4 alkyl, more particular from H and methyl. In one embodiment R7 is absent when Y1 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y1 is C. In a preferred embodiment R7 is absent when Y1 is N or is selected from H, halogen, C1-C4 alkyl and C3-C7 cycloalkyl when Y1 is C. In a more preferred embodiment R7 is absent when Y1 is N or is selected from H, halogen and C1-C4 alkyl, preferably selected from H, halogen, and methyl when Y1 is C. In an even more preferred embodiment R7 is absent when Y1 is N or is selected from H, halogen, and methyl when Y1 is C. In a particular preferred embodiment R7 is absent when Y1 is N or is selected from H and halogen when Y1 is C. In a more particular preferred embodiment R7 is absent.
In one embodiment R8 is absent when Y3 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y3 is C. In a preferred embodiment R8 is absent when Y3 is N or is selected from H, halogen, C1-C4 alkyl and C3-C7 cycloalkyl when Y3 is C. In a more preferred embodiment R8 is absent when Y3 is N or is selected from H, halogen and C1-C4 alkyl preferably selected from H, halogen, and methyl when Y3 is C. In an even more preferred embodiment R8 is absent when Y3 is N or is selected from H, halogen, and methyl when Y3 is C. In a particular preferred embodiment R8 is absent when Y3 is N or is selected from H and halogen when Y3 is C. In a particular preferred embodiment R8 is H.
In one embodiment R9 is absent when Y2 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y2 is C. In a preferred embodiment R9 is absent when Y2 is N or is selected from H, halogen, C1-C4 alkyl and C3-C7 cycloalkyl when Y2 is C. In a more preferred embodiment R9 is absent when Y2 is N or is selected from H and C1-C4 alkyl preferably selected from H, halogen, and methyl when Y2 is C. In an even more preferred embodiment R9 is absent when Y2 is N or is selected from H, halogen, and methyl when Y2 is C. In a particular preferred embodiment R9 is absent when Y2 is N or is selected from H and halogen, preferably H, when Y2 is C. In one embodiment R7 is absent when Y1 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y1 is C, preferably selected from H, halogen, and methyl when Y1 is C, R8 is absent when Y3 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl, preferably selected from H, halogen, and methyl when Y3 is C, and R9 is absent when Y2 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl, preferably selected from H, halogen, and methyl when Y2 is C. In a preferred embodiment R7 is absent when Y1 is N or is selected from H and halogen when Y1 is C, R8 is absent when Y3 is N or is H when Y3 is C, and R9 is absent when Y2 is N or is selected from H and methyl when Y2 is C. In one embodiment at least one of R10 and R11 is C1-C6 alkyl, preferably C1-C4 alkyl, more preferably methyl. In a preferred embodiment R10 and R11 are independently selected from H and methyl. In a more preferred embodiment R10 is H and R11 is selected from H and C1-C4 alkyl. In an even more preferred embodiment R10 is H and R11 is H or methyl. In a particular preferred embodiment R10 is H and R11 is C1-C6 alkyl. In a more particular preferred embodiment R10 is H and R11 is C1-C4 alkyl. In an even more particular preferred embodiment R10 is H and R11 is methyl. In one embodiment R12 is selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl, and C1-C6 heteroalkyl. In a preferred embodiment R12 is selected from NH2, C1-C6 alkyl, and C1-C6 heteroalkyl. In a more preferred embodiment R12 is NH2. In one embodiment Y1 is N. In a preferred embodiment Y1 and Y2 are each independently selected from N and C and Y3 is C. In a more preferred embodiment Y1 is selected from N and C and Y2 and Y3 are selected from N and C with the proviso that one of Y2and Y3 is C. In a particular preferred embodiment Y1 is N and R7 is absent, Y2 is selected from N and C and Y3 is C. In a more particular preferred embodiment Y1 is N and R7 is absent. In one embodiment at least one of the substituents selected from R1 , R3, R4 , R5, R6, R7, R8, and R9 is not H. In a further embodiment at least one of the substituents selected from R1 , R3, R8, and R9 is not H. Preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
wherein X is selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, NH, and O, preferably selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, and O; wherein Y1 , Y2 , and Y3 are each independently selected from N and C, preferably Y1 and Y2 are each independently selected from N and C and Y3 is C, more preferably Y1 is N and R7 is absent, Y2 is selected from N and C and Y3 is C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl;
wherein R1 is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy; C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3- C12 cycloalkyl, C3-C12 heterocyclyl; and C1-C6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1- C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3- C12 cycloalkyl, C3-C12 heterocyclyl, C(O)R12 , C1-C6 alkyl C(O)R12;
wherein R3 is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl;
wherein R4 , R5 and R6 are each independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl;
wherein R7 is absent when Y1 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y1 is C;
wherein R8 is absent when Y3 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y3 is C;
wherein R9 is absent when Y2 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y2 is C; and
wherein R12 is selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl, and C1-C6 heteroalkyl. Further preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
wherein X is selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, NH, and O, preferably selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, and O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C, preferably Y1 and Y2 are each independently selected from N and C and Y3 is C, more preferably Y1 is N and R7 is absent, Y2 is selected from N and C and Y3 is C; wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl;
wherein R1 is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy; C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3- C12 cycloalkyl, C3-C12 heterocyclyl; and C1-C6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1- C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3- C12 cycloalkyl C3-C12 heterocyclyl, C(O)R12 , C1-C6 alkyl C(O)R12;
wherein R3 is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl;
wherein R4 , R5 and R6 are each independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl;
wherein R7 is absent when Y1 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y1 is C;
wherein R8 is absent when Y3 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y3 is C;
wherein R9 is absent when Y2 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y2 is C; and
wherein R12 is selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl, and C1-C6 heteroalkyl; with the proviso that when R1 is selected from C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; and C1-C6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl, R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, halogen, CN, preferably wherein the aryl and the heteroaryl are not substituted. More preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
wherein X is selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, NH, and O, preferably selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, and O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C, preferably Y1 and Y2 are each independently selected from N and C and Y3 is C, more preferably Y1 is N and R7 is absent, Y2 is selected from N and C and Y3 is C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl;
wherein R1 is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy and C1-C6 heteroalkyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3- C12 cycloalkyl, C3-C12 heterocyclyl, C(O)R12 , C1-C6 alkyl C(O)R12;
wherein R3 is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl;
wherein R4 , R5 and R6 are each independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl;
wherein R7 is absent when Y1 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y1 is C;
wherein R8 is absent when Y3 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y3 is C;
wherein R9 is absent when Y2 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y2 is C; and
wherein R12 is selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl, and C1-C6 heteroalkyl. Further more preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
wherein X is selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, NH, and O, preferably selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, and O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C, preferably Y1 and Y2 are each independently selected from N and C and Y3 is C, more preferably Y1 is N and R7 is absent, Y2 is selected from N and C and Y3 is C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl; wherein R1 is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy and C1-C6 heteroalkyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3- C12 cycloalkyl, C3-C12 heterocyclyl, C(O)R12 , C1-C6 alkyl C(O)R12;
wherein R3 is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl;
wherein R4 , R5 and R6 are each independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl;
wherein R7 is absent when Y1 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y1 is C;
wherein R8 is absent when Y3 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y3 is C; and
wherein R9 is absent when Y2 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y2 is C; and
wherein R12 is selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl, and C1-C6 heteroalkyl, with the proviso that when R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are substituted by C1-C6 alkyl, halogen, C1-C6 heteroalkyl, C(O)R12 , C1-C6 alkyl C(O)R12 , R1 is selected from H, halogen, C1-C6 alkyl and C1-C6 heteroalkyl, preferably is H or methyl. Further more preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
wherein X is selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, NH, and O, preferably selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, and O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C, preferably Y1 and Y2 are each independently selected from N and C and Y3 is C, more preferably Y1 is N and R7 is absent, Y2 is selected from N and C and Y3 is C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl;
wherein R1 is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy and C1-C6 heteroalkyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C(O)R12 , C1-C6 alkyl C(O)R12; wherein R3 is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl;
wherein R4 , R5 and R6 are each independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl;
wherein R7 is absent when Y1 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y1 is C;
wherein R8 is absent when Y3 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y3 is C; and
wherein R9 is absent when Y2 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y2 is C; and
wherein R12 is selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl, and C1-C6 heteroalkyl. Further more preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those ,
wherein X is selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, NH, and O, preferably selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, and O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C, preferably Y1 and Y2 are each independently selected from N and C and Y3 is C, more preferably Y1 is N and R7 is absent, Y2 is selected from N and C and Y3 is C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl;
wherein R1 is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy; C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3- C12 cycloalkyl, C3-C12 heterocyclyl; and C1-C6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1- C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl, preferably wherein R1 is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy; C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; and C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, halogen, CN;
wherein R3 is selected from H, halogen and C1-C4 alkyl;
wherein R4 , R5 and R6 are each independently selected from H, halogen, and C1-C4 alkyl; wherein R7 is absent when Y1 is N or is selected from H, halogen and C1-C4 alkyl when Y1 is C;
wherein R8 is absent when Y3 is N or is selected from H, halogen and C1-C4 alkyl when Y3 is C; and
wherein R9 is absent when Y2 is N or is selected from H, halogen and C1-C4 alkyl when Y2 is C. Even more preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
wherein X is selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, NH, and O, preferably selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, and O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C, preferably Y1 and Y2 are each independently selected from N and C and Y3 is C, more preferably Y1 is N and R7 is absent, Y2 is selected from N and C and Y3 is C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl;
wherein R1 is selected from H, halogen, C1-C4 alkyl and C1-C4 heteroalkyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C(O)R12 , C1-C6 alkyl C(O)R12;
wherein R3 is selected from H, halogen, C1-C4 alkyl and C3-C7 cycloalkyl;
wherein R4 , R5 and R6 are each independently selected from H, halogen, CN, C1-C4 alkyl and C1-C4 heteroalkyl;
wherein R7 is absent when Y1 is N or is selected from H, halogen, C1-C4 alkyl and C3-C7 cycloalkyl when Y1 is C;
wherein R8 is absent when Y3 is N or is selected from H, halogen, C1-C4 alkyl and C3-C7 cycloalkyl when Y3 is C;
wherein R9 is absent when Y2 is N or is selected from H, halogen, C1-C4 alkyl and C3-C7 cycloalkyl when Y2 is C; and wherein R12 is selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl, and C1-C6 heteroalkyl. Particular preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
wherein X is selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, NH, and O, preferably selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, and O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C, preferably Y1 and Y2 are each independently selected from N and C and Y3 is C, more preferably Y1 is N and R7 is absent, Y2 is selected from N and C and Y3 is C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl, preferably independently selected from H and methyl, more preferably R10 is H and R11 is H or methyl;
wherein R1 is selected from H, halogen and C1-C4 alkyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by C1-C6 alkyl, C1-C6 heteroalkyl, halogen, C(O)R12 , C1-C6 alkyl C(O)R12;
wherein R3 is selected from H, halogen and C1-C4 alkyl;
wherein R4 , R5 and R6 are each independently selected from H, halogen and C1-C4 alkyl; wherein R7 is absent when Y1 is N or is selected from H, halogen and C1-C4 alkyl when Y1 is C;
wherein R8 is absent when Y3 is N or is selected from H, halogen and C1-C4 alkyl when Y3 is C;
wherein R9 is absent when Y2 is N or is selected from H, halogen and C1-C4 alkyl when Y2 is C; and
wherein R12 is selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl, and C1-C6 heteroalkyl. Further particular preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
wherein X is selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, NH, and O, preferably selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, and O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C, preferably Y1 and Y2 are each independently selected from N and C and Y3 is C, more preferably Y1 is N and R7 is absent, Y2 is selected from N and C and Y3 is C; wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl, preferably independently selected from H and methyl, preferably R10 is H and R11 is H or methyl;
wherein R1 is selected from H, halogen and C1-C4 alkyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by C1-C6 heteroalkyl;
wherein R3 is selected from H, halogen and C1-C4 alkyl;
wherein R4 , R5 and R6 are each independently selected from H, halogen and C1-C4 alkyl; wherein R7 is absent when Y1 is N or is selected from H, halogen and C1-C4 alkyl when Y1 is C;
wherein R8 is absent when Y3 is N or is selected from H, halogen and C1-C4 alkyl when Y3 is C;
wherein R9 is absent when Y2 is N or is selected from H, halogen and C1-C4 alkyl when Y2 is C; and
wherein R12 is selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl, and C1-C6 heteroalkyl. Further particular preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
wherein X is selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, NH, and O, preferably selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, and O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C, preferably Y1 and Y2 are each independently selected from N and C and Y3 is C, more preferably Y1 is N and R7 is absent, Y2 is selected from N and C and Y3 is C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl, preferably independently selected from H and methyl, preferably R10 is H and R11 is H or methyl;
wherein R1 is selected from H, halogen and C1-C4 alkyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by C1-C6 alkyl, halogen;
wherein R3 is selected from H, halogen and C1-C4 alkyl;
wherein R4 , R5 and R6 are each independently selected from H, halogen and C1-C4 alkyl; wherein R7 is absent when Y1 is N or is selected from H, halogen and C1-C4 alkyl when Y1 is C; wherein R8 is absent when Y3 is N or is selected from H, halogen and C1-C4 alkyl when Y3 is C;
wherein R9 is absent when Y2 is N or is selected from H, halogen and C1-C4 alkyl when Y2 is C; and
wherein R12 is selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl, and C1-C6 heteroalkyl. Further particular preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
wherein X is selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, NH, and O, preferably selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, and O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C, preferably Y1 and Y2 are each independently selected from N and C and Y3 is C, more preferably Y1 is N and R7 is absent, Y2 is selected from N and C and Y3 is C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl, preferably independently selected from H and methyl, preferably R10 is H and R11 is H or methyl;
wherein R1 is selected from H, halogen and C1-C4 alkyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by C(O)R12 , C1-C6 alkyl C(O)R12;
wherein R3 is selected from H, halogen and C1-C4 alkyl;
wherein R4 , R5 and R6 are each independently selected from H, halogen and C1-C4 alkyl; wherein R7 is absent when Y1 is N or is selected from H, halogen and C1-C4 alkyl when Y1 is C;
wherein R8 is absent when Y3 is N or is selected from H, halogen and C1-C4 alkyl when Y3 is C;
wherein R9 is absent when Y2 is N or is selected from H, halogen and C1-C4 alkyl when Y2 is C; and
wherein R12 is selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl, and C1-C6 heteroalkyl. Further particular preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
wherein X is selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, NH, and O, preferably selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, and O; wherein Y1 , Y2 , and Y3 are each independently selected from N and C, preferably Y1 and Y2 are each independently selected from N and C and Y3 is C, more preferably Y1 is N and R7 is absent, Y2 is selected from N and C and Y3 is C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl, preferably independently selected from H and methyl, preferably R10 is H and R11 is H or methyl;
wherein R1 is selected from C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl, preferably is optionally substituted by NH2; C0-C3 alkylOC0- C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1- C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl, preferably is optionally substituted by NH2; and C1-C6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl, preferably is optionally substituted by NH2, wherein R1 is preferably selected from C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl, preferably is optionally substituted by NH2; and C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3- C12 cycloalkyl, C3-C12 heterocyclyl, preferably is optionally substituted by NH2;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, halogen, C1-C6 alkyl, CN, preferably optionally substituted by halogen, C1-C6 alkyl;
wherein R3 is selected from H, halogen and C1-C4 alkyl;
wherein R4 , R5 and R6 are each independently selected from H, halogen, and C1-C4 alkyl; wherein R7 is absent when Y1 is N or is selected from H, halogen and C1-C4 alkyl when Y1 is C;
wherein R8 is absent when Y3 is N or is selected from H, halogen and C1-C4 alkyl when Y3 is C; and
wherein R9 is absent when Y2 is N or is selected from H, halogen and C1-C4 alkyl when Y2 is C. Preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those, wherein X is selected from CH2, NH and O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C, preferably Y1 and Y2 are each independently selected from N and C and Y3 is C, more preferably Y1 is N and R7 is absent, Y2 is selected from N and C and Y3 is C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl;
wherein R1 is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy; C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3- C12 cycloalkyl, C3-C12 heterocyclyl; and C1-C6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1- C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3- C12 cycloalkyl, C3-C12 heterocyclyl, C(O)R12 , C1-C6 alkyl C(O)R12;
wherein R3 is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl;
wherein R4 , R5 and R6 are each independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl;
wherein R7 is absent when Y1 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y1 is C;
wherein R8 is absent when Y3 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y3 is C;
wherein R9 is absent when Y2 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y2 is C; and
wherein R12 is selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl, and C1-C6 heteroalkyl. Further preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
wherein X is selected from CH2, NH and O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C, preferably Y1 and Y2 are each independently selected from N and C and Y3 is C, more preferably Y1 is N and R7 is absent, Y2 is selected from N and C and Y3 is C; wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl;
wherein R1 is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy; C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3- C12 cycloalkyl, C3-C12 heterocyclyl; and C1-C6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1- C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3- C12 cycloalkyl C3-C12 heterocyclyl, C(O)R12 , C1-C6 alkyl C(O)R12;
wherein R3 is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl;
wherein R4 , R5 and R6 are each independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl;
wherein R7 is absent when Y1 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y1 is C;
wherein R8 is absent when Y3 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y3 is C;
wherein R9 is absent when Y2 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y2 is C; and
wherein R12 is selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl, and C1-C6 heteroalkyl; with the proviso that when R1 is selected from C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; and C1-C6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl, R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, halogen, CN, preferably wherein the aryl and the heteroaryl are not substituted. More preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
wherein X is selected from CH2, NH and O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C, preferably Y1 and Y2 are each independently selected from N and C and Y3 is C, more preferably Y1 is N and R7 is absent, Y2 is selected from N and C and Y3 is C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl;
wherein R1 is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy and C1-C6 heteroalkyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3- C12 cycloalkyl, C3-C12 heterocyclyl, C(O)R12 , C1-C6 alkyl C(O)R12;
wherein R3 is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl;
wherein R4 , R5 and R6 are each independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl;
wherein R7 is absent when Y1 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y1 is C;
wherein R8 is absent when Y3 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y3 is C;
wherein R9 is absent when Y2 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y2 is C; and
wherein R12 is selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl, and C1-C6 heteroalkyl. Further more preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
wherein X is selected from CH2, NH and O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C, preferably Y1 and Y2 are each independently selected from N and C and Y3 is C, more preferably Y1 is N and R7 is absent, Y2 is selected from N and C and Y3 is C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl;
wherein R1 is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy and C1-C6 heteroalkyl; wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3- C12 cycloalkyl, C3-C12 heterocyclyl, C(O)R12 , C1-C6 alkyl C(O)R12;
wherein R3 is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl;
wherein R4 , R5 and R6 are each independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl;
wherein R7 is absent when Y1 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y1 is C;
wherein R8 is absent when Y3 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y3 is C; and
wherein R9 is absent when Y2 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y2 is C; and
wherein R12 is selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl, and C1-C6 heteroalkyl, with the proviso that when R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are substituted by C1-C6 alkyl, halogen, C1-C6 heteroalkyl, C(O)R12 , C1-C6 alkyl C(O)R12 , R1 is selected from H, halogen, C1-C6 alkyl and C1-C6 heteroalkyl, preferably is H or methyl. Further more preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
wherein X is selected from CH2, NH and O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C, preferably Y1 and Y2 are each independently selected from N and C and Y3 is C, more preferably Y1 is N and R7 is absent, Y2 is selected from N and C and Y3 is C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl;
wherein R1 is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy and C1-C6 heteroalkyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C(O)R12 , C1-C6 alkyl C(O)R12;
wherein R3 is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl;
wherein R4 , R5 and R6 are each independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl; wherein R7 is absent when Y1 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y1 is C;
wherein R8 is absent when Y3 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y3 is C; and
wherein R9 is absent when Y2 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y2 is C; and
wherein R12 is selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl, and C1-C6 heteroalkyl. Further more preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those ,
wherein X is selected from CH2, NH and O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C, preferably Y1 and Y2 are each independently selected from N and C and Y3 is C, more preferably Y1 is N and R7 is absent, Y2 is selected from N and C and Y3 is C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl;
wherein R1 is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy; C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3- C12 cycloalkyl, C3-C12 heterocyclyl; and C1-C6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1- C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl, preferably wherein R1 is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy; C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; and C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, halogen, CN;
wherein R3 is selected from H, halogen and C1-C4 alkyl;
wherein R4 , R5 and R6 are each independently selected from H, halogen, and C1-C4 alkyl; wherein R7 is absent when Y1 is N or is selected from H, halogen and C1-C4 alkyl when Y1 is C;
wherein R8 is absent when Y3 is N or is selected from H, halogen and C1-C4 alkyl when Y3 is C; and
wherein R9 is absent when Y2 is N or is selected from H, halogen and C1-C4 alkyl when Y2 is C. Even more preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
wherein X is selected from CH2, NH and O, and is preferably O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C, preferably Y1 and Y2 are each independently selected from N and C and Y3 is C, more preferably Y1 is N and R7 is absent, Y2 is selected from N and C and Y3 is C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl;
wherein R1 is selected from H, halogen, C1-C4 alkyl and C1-C4 heteroalkyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C(O)R12 , C1-C6 alkyl C(O)R12;
wherein R3 is selected from H, halogen, C1-C4 alkyl and C3-C7 cycloalkyl;
wherein R4 , R5 and R6 are each independently selected from H, halogen, CN, C1-C4 alkyl and C1-C4 heteroalkyl;
wherein R7 is absent when Y1 is N or is selected from H, halogen, C1-C4 alkyl and C3-C7 cycloalkyl when Y1 is C;
wherein R8 is absent when Y3 is N or is selected from H, halogen, C1-C4 alkyl and C3-C7 cycloalkyl when Y3 is C;
wherein R9 is absent when Y2 is N or is selected from H, halogen, C1-C4 alkyl and C3-C7 cycloalkyl when Y2 is C; and
wherein R12 is selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl, and C1-C6 heteroalkyl. Particular preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
wherein X is selected from CH2, NH and O, and is preferably O; wherein Y1 , Y2 , and Y3 are each independently selected from N and C, preferably Y1 and Y2 are each independently selected from N and C and Y3 is C, more preferably Y1 is N and R7 is absent, Y2 is selected from N and C and Y3 is C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl, preferably independently selected from H and methyl, more preferably R10 is H and R11 is H or methyl;
wherein R1 is selected from H, halogen and C1-C4 alkyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by C1-C6 alkyl, C1-C6 heteroalkyl, halogen, C(O)R12 , C1-C6 alkyl C(O)R12;
wherein R3 is selected from H, halogen and C1-C4 alkyl;
wherein R4 , R5 and R6 are each independently selected from H, halogen and C1-C4 alkyl; wherein R7 is absent when Y1 is N or is selected from H, halogen and C1-C4 alkyl when Y1 is C;
wherein R8 is absent when Y3 is N or is selected from H, halogen and C1-C4 alkyl when Y3 is C;
wherein R9 is absent when Y2 is N or is selected from H, halogen and C1-C4 alkyl when Y2 is C; and
wherein R12 is selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl, and C1-C6 heteroalkyl. Further particular preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
wherein X is selected from CH2, NH and O, and is preferably O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C, preferably Y1 and Y2 are each independently selected from N and C and Y3 is C, more preferably Y1 is N and R7 is absent, Y2 is selected from N and C and Y3 is C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl, preferably independently selected from H and methyl, preferably R10 is H and R11 is H or methyl;
wherein R1 is selected from H, halogen and C1-C4 alkyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by C1-C6 heteroalkyl;
wherein R3 is selected from H, halogen and C1-C4 alkyl;
wherein R4 , R5 and R6 are each independently selected from H, halogen and C1-C4 alkyl; wherein R7 is absent when Y1 is N or is selected from H, halogen and C1-C4 alkyl when Y1 is C;
wherein R8 is absent when Y3 is N or is selected from H, halogen and C1-C4 alkyl when Y3 is C;
wherein R9 is absent when Y2 is N or is selected from H, halogen and C1-C4 alkyl when Y2 is C; and
wherein R12 is selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl, and C1-C6 heteroalkyl. Further particular preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
wherein X is selected from CH2, NH and O, and is preferably O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C, preferably Y1 and Y2 are each independently selected from N and C and Y3 is C, more preferably Y1 is N and R7 is absent, Y2 is selected from N and C and Y3 is C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl, preferably independently selected from H and methyl, preferably R10 is H and R11 is H or methyl;
wherein R1 is selected from H, halogen and C1-C4 alkyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by C1-C6 alkyl, halogen;
wherein R3 is selected from H, halogen and C1-C4 alkyl;
wherein R4 , R5 and R6 are each independently selected from H, halogen and C1-C4 alkyl; wherein R7 is absent when Y1 is N or is selected from H, halogen and C1-C4 alkyl when Y1 is C;
wherein R8 is absent when Y3 is N or is selected from H, halogen and C1-C4 alkyl when Y3 is C;
wherein R9 is absent when Y2 is N or is selected from H, halogen and C1-C4 alkyl when Y2 is C; and
wherein R12 is selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl, and C1-C6 heteroalkyl. Further particular preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
wherein X is selected from CH2, NH and O, and is preferably O; wherein Y1 , Y2 , and Y3 are each independently selected from N and C, preferably Y1 and Y2 are each independently selected from N and C and Y3 is C, more preferably Y1 is N and R7 is absent, Y2 is selected from N and C and Y3 is C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl, preferably independently selected from H and methyl, preferably R10 is H and R11 is H or methyl;
wherein R1 is selected from H, halogen and C1-C4 alkyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by C(O)R12 , C1-C6 alkyl C(O)R12;
wherein R3 is selected from H, halogen and C1-C4 alkyl;
wherein R4 , R5 and R6 are each independently selected from H, halogen and C1-C4 alkyl; wherein R7 is absent when Y1 is N or is selected from H, halogen and C1-C4 alkyl when Y1 is C;
wherein R8 is absent when Y3 is N or is selected from H, halogen and C1-C4 alkyl when Y3 is C;
wherein R9 is absent when Y2 is N or is selected from H, halogen and C1-C4 alkyl when Y2 is C; and
wherein R12 is selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl, and C1-C6 heteroalkyl. Further particular preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
wherein X is selected from CH2, NH and O, and is preferably O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C, preferably Y1 and Y2 are each independently selected from N and C and Y3 is C, more preferably Y1 is N and R7 is absent, Y2 is selected from N and C and Y3 is C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl, preferably independently selected from H and methyl, preferably R10 is H and R11 is H or methyl;
wherein R1 is selected from C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl, preferably is optionally substituted by NH2; C0-C3 alkylOC0- C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1- C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl, preferably is optionally substituted by NH2; and C1-C6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl, preferably is optionally substituted by NH2, wherein R1 is preferably selected from C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl, preferably is optionally substituted by NH2; and C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3- C12 cycloalkyl, C3-C12 heterocyclyl, preferably is optionally substituted by NH2;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, halogen, C1-C6 alkyl, CN, preferably optionally substituted by halogen, C1-C6 alkyl;
wherein R3 is selected from H, halogen and C1-C4 alkyl;
wherein R4 , R5 and R6 are each independently selected from H, halogen, and C1-C4 alkyl; wherein R7 is absent when Y1 is N or is selected from H, halogen and C1-C4 alkyl when Y1 is C;
wherein R8 is absent when Y3 is N or is selected from H, halogen and C1-C4 alkyl when Y3 is C; and
wherein R9 is absent when Y2 is N or is selected from H, halogen and C1-C4 alkyl when Y2 is C. Further particular preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
wherein X is selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, NH, and O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl;
wherein R1 is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy and C1-C6 heteroalkyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3- C12 cycloalkyl, C3-C12 heterocyclyl, C(O)R12 , C1-C6 alkyl C(O)R12;
wherein R3 is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl;
wherein R4 , R5 and R6 are each independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl; wherein R7 is absent when Y1 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y1 is C;
wherein R8 is absent when Y3 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y3 is C;
wherein R9 is absent when Y2 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y2 is C; and
wherein R12 is selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl, and C1-C6 heteroalkyl. More particular preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
wherein X is selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, NH, and O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl;
wherein R1 is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3- C12 cycloalkyl, C3-C12 heterocyclyl; and C1-C6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1- C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3- C12 cycloalkyl, C3-C12 heterocyclyl, C(O)R12 , C1-C6 alkyl C(O)R12;
wherein R3 is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl;
wherein R4 , R5 and R6 are each independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl;
wherein R7 is absent when Y1 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y1 is C;
wherein R8 is absent when Y3 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y3 is C;
wherein R9 is absent when Y2 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y2 is C; and wherein R12 is selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl, and C1-C6 heteroalkyl. Further more particular preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
wherein X is selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, NH, and O;
wherein Y1 is N and R7 is absent, Y2 is selected from N and C and Y3 is C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl;
wherein R1 is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3- C12 cycloalkyl, C3-C12 heterocyclyl; and C1-C6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1- C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3- C12 cycloalkyl, C3-C12 heterocyclyl, C(O)R12 , C1-C6 alkyl C(O)R12;
wherein R3 is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl;
wherein R4 , R5 and R6 are each independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl;
wherein R8 is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl;
wherein R9 is absent when Y2 is N or is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl when Y2 is C; and
wherein R12 is selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl, and C1-C6 heteroalkyl. Further more particular preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
wherein X is selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, NH, and O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl; wherein R1 is selected from H, C1-C6 alkyl, C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2; C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, C1-C6 alkyl C(O)R12;
wherein R3 is H;
wherein R4 is selected from H and halogen;
wherein R5 and R6 are each independently selected from H and C1-C6 alkyl;
wherein R7 is absent when Y1 is N or is H when Y1 is C;
wherein R8 is absent when Y3 is N or is H when Y3 is C;
wherein R9 is absent when Y2 is N or is H when Y2 is C; and
wherein R12 is NH2. Further more particular preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
wherein X is selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, NH, and O;
wherein Y1 is N and R7 is absent, Y2 is selected from N and C and Y3 is C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl;
wherein R1 is selected from H, C1-C6 alkyl, C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2; C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, C1-C6 alkyl C(O)R12;
wherein R3 is H;
wherein R4 is selected from H and halogen;
wherein R5 and R6 are each independently selected from H and C1-C6 alkyl;
wherein R8 is H;
wherein R9 is absent when Y2 is N or is H when Y2 is C; and
wherein R12 is NH2. Further more particular preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
wherein X is selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, NH, and O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl;
wherein R1 is selected from H and C1-C6 alkyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, C1-C6 alkyl C(O)R12;
wherein R3 is H;
wherein R4 is selected from H and halogen;
wherein R5 and R6 are each independently selected from H and C1-C6 alkyl;
wherein R7 is absent when Y1 is N or is H when Y1 is C;
wherein R8 is absent when Y3 is N or is H when Y3 is C;
wherein R9 is absent when Y2 is N or is H when Y2 is C; and
wherein R12 is NH2. Further more particular preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
wherein X is selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, NH, and O;
wherein Y1 is N and R7 is absent, Y2 is selected from N and C and Y3 is C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl;
wherein R1 is selected from H and C1-C6 alkyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, C1-C6 alkyl C(O)R12;
wherein R3 is H;
wherein R4 is selected from H and halogen;
wherein R5 and R6 are each independently selected from H and C1-C6 alkyl;
wherein R8 is H;
wherein R9 is absent when Y2 is N or is H when Y2 is C; and wherein R12 is NH2. Further more particular preferred compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are those,
wherein X is selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, NH, and O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl;
wherein R1 is selected from C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; and C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, halogen, C1-C6 alkyl, CN;
wherein R3 is selected from H, halogen and C1-C4 alkyl;
wherein R4 , R5 and R6 are each independently selected from H, halogen, and C1-C4 alkyl; wherein R7 is absent when Y1 is N or is selected from H, halogen and C1-C4 alkyl when Y1 is C;
wherein R8 is absent when Y3 is N or is selected from H, halogen and C1-C4 alkyl when Y3 is C; and
wherein R9 is absent when Y2 is N or is selected from H, halogen and C1-C4 alkyl when Y2 is C. Even more particular preferred compounds of the compound of formula (I) are selected from the group consisting of
Figure imgf000053_0001
Figure imgf000054_0001
Figure imgf000055_0001
Figure imgf000056_0001
Figure imgf000057_0001
Further even more particular preferred compounds of the compound of formula (I) are selected from the group consisting of
Figure imgf000057_0002
Figure imgf000058_0001
Figure imgf000059_0001
Figure imgf000060_0001
Figure imgf000061_0001
Further even more particular preferred compounds of the compound of formula (I) are selected from the group consisting of
Figure imgf000061_0002
Figure imgf000062_0001
Figure imgf000063_0001
Figure imgf000064_0001
Figure imgf000065_0001
Further even more particular preferred compounds of the compound of formula (I) are selected from the group consisting of
Figure imgf000066_0001
Figure imgf000067_0001
Figure imgf000068_0001
Figure imgf000069_0001
Figure imgf000070_0002
Further even more particular preferred compounds of the compound of formula (I) are selected from the group consisting of
Figure imgf000070_0001
Figure imgf000071_0001
Figure imgf000072_0001
Figure imgf000073_0001
Figure imgf000074_0002
Further even more particular preferred compounds of the compound of formula (I) are selected from the group consisting of
Figure imgf000074_0001
Figure imgf000075_0001
Figure imgf000076_0002
Most particular preferred compounds of the compound of formula (I) are selected from the group consisting of
Figure imgf000076_0001
More particular preferred compounds of formula (I), pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are selected from the group consisting of
Figure imgf000077_0001
Figure imgf000078_0002
Further more particular preferred compounds of formula (I), pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof are selected from the group consisting of
Figure imgf000078_0001
Figure imgf000079_0001
Further more particular preferred compounds of the compound of formula (I) for use, and the pharmaceutical composition comprising a compound of formula (I) are selected from the group consisting of
Figure imgf000079_0002
Figure imgf000080_0001
Figure imgf000081_0002
Further more particular preferred compounds of the compound of formula (I) for use, and the pharmaceutical composition comprising a compound of formula (I) are selected from the group consisting of
Figure imgf000081_0001
Figure imgf000082_0002
Preparation of the compounds
The compounds of the invention may be prepared by the exemplary processes described in the following reaction schemes or by the processes described in the examples. Exemplary reagents and procedures for these reactions appear hereinafter. Starting materials can be purchased or readily prepared by one of ordinary skilled in the art. Scheme 1: X = NH, N(C1-C3-alkyl), S and O
Figure imgf000082_0001
The syntheses of the di-arylamino, di-arylether and di-arylthioether analogs is depicted in Scheme 1: The respective amino-aryl moiety of formula (II) (X=NH, eventually
monoalkylated) is reacted with the halogenated nitro-aryl precurser of formula (III) in a polar solvent in presence of a base at elevated temperatures. Preferably the solvent is a mixture of DMSO and an alcohol like tBuOH. As a base an alcoholate like tBuOK can be used. Reaction temperatures are between room temperature and 150 °C, preferably between 60 and 110 °C. The respective hydroxy- or mercapto-aryl moiety of formula (II) (X=O, S) is reacted with the halogenated nitro-aryl precurser of formula (III) in a polar solvent in presence of a base. A preferred reaction condition is carbonate as base in DMF at room temperature. Finally, the nitro function of formula (IV) can be reduced to the respective amine of formula (V) under Béchamp conditions or via catalytic hydrogenation. Preferred Béchamp conditions are Fe powder in a mixture of EtOH, H2O and AcOH under sonication. Catalytic hydrogenation can be performed in presence of Pd/C in a polar solvent like an alcohol. Alternatively, target compounds of formula (VIII) (Y3=N) can be obtained via substitution of the halogene of formula (VI) by the X-containing aryl moiety of formula (VII), eventually in presence of a protection group (PG). Preferred conditions are phosphate as a base in an unpolar aromatic solvent at 100 to 150 °C under ferrocenyl catalysis [see: Advanced Synthesis & Catalysis 353 (2011), 3403]. Scheme 2:
Figure imgf000083_0001
Scheme 2 depicts the reductive alkylation of amino-derivatives of formula (V): A preferred method is stirring the amine of formula (V) and the respective aldehyde in a polar solvent like an alcohol in presence of a weak acid like acetic acid. Then a reducing reagent like NaBH3CN is added. Basic work-up finally yields compounds of formula (IX). Alternatively, the amine of formula (V) and the aldehyde are mixed in an unpolar solvent like dichloromethane in presence of a base like triethylamine. Then a reducing reagent like NaBH(OAc)3 is added. Aqueous work-up finally yields compounds of formula (IX). The N-methylated derivatives of formula (IX; R=H) are obtained from compounds of formula (V) and paraformaldehyde in MeOH with MeONa as a base followed by reduction with NaBH4 and aqueous work-up. Scheme 3: X = CH2, CF2, CHF, CHOH, CHOAlk, CO
Figure imgf000084_0001
Scheme 3 illustrates the syntheses of carbon-bridged analogs (X = CH2, CF2, CHF, CHOH, CHOAlk, CO): The halogen-aryl moiety of formula (X) is decarboxylatively coupled to the aryl-acetate of formula (XI), catalyzed by a transition metal complex, yielding the nitro derivative of formula (XII). Preferred conditions are XPhos/Pd2(allyl)2Cl2 as the catalyst in a unpolar solvent at elevated temperatures. The methylene bridge (X=CH2) of formula (XII) can be oxidized to the respective di-aryl-ketone of formula (XIV). Preferred conditions are oxygen as the reagent in a mixture of acetic acid and DMSO at elevated temperature, catalyzed by FeCl .
2(H2O)4 [analogously to: Angew. Chem. Int. Ed.51 (2012), 2745].
Reduction of the carbonyl group of formula (XIV) leads to the benzylic alcohol of formula (XVII). A preferred reducing reagent could be sodium borohydride. Alternatively, the benzylic alcohol of formula (XVII) can be obtained via cross coupling of a boronate of formula (XV) with an aryl-aldehyde of formula (XVI). Alkylation of the compound of formula (XVII) with an alkyl-iodide in presence of a strong base (e.g. NaH) in an aprotic polar solvent yields the alkoxy-derivative of formula (XVIII) [analogously to: Example 2 in US 5965740]. The mono-fluoro derivative of formula (XIX) can be obtained either by oxidative fluorination of the compound of formula (XII) or hydroxy-substitution in a compound of formula (XVII). The oxidative fluorination can be done under conditions as Jacobsen salene complex, iodosylbenzene, base, tris(hydrogen fluoride) in a polar solvent at elevated temperatures [J. Am. Chem.Soc.136 (2014), 6842]. Substitution of the benzylic hydroxy group by fluoride can be achieved by applying conditions like activation with trichloroacetimidate, 1,8-diazabicyclo[5.4.0]undec-7-ene in dichloromethane in presence of bis(1,5-cyclooctadiene)rhodium(I) tetrafluoroborate followed by triethylamine tris(hydrogen fluoride) in a mixture of F3C-C6H5 and tetrahydrofurane at slightly elevated temperatures [Tetrahedron 71 (2015), 5932]. The keto-derivative of formula (XIV) can be converted to the difluoromethylen derivative of formula (XX) with [bis(2-methoxyethyl)amino]-sulfur trifluoride at elevated temperatures [analogously to: US2015246938; Step 2, Preparation of Compound 76; page 55]. Finally, the nitro-groups of compounds of formula (XII), (XIV) and (XVII)-(XX) can be reduced to the respective amino derivatives as described in Scheme 1. Stereoisomers
Compounds of the present invention can exist as stereoisomers wherein asymmetric or chiral centers are present. These compounds are designated by the symbols"R"or"S", depending on the configuration of substituents around the chiral carbon atom. The present invention contemplates various stereoisomers and mixtures thereof. Stereoisomers include enantiomers and diastereomers, and mixtures of enantiomers or diastereomers. Individual stereoisomers of compounds of the present invention can be prepared synthetically from commercially available starting materials which contain asymmetric or chiral centers or by preparation of racemic mixtures followed by resolution well-known to those of ordinary skill in the art. These methods of resolution are exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and liberation of the optically pure product from the auxiliary, (2) salt formation employing an optically active resolving agent, or (3) direct separation of the mixture of optical enantiomers on chiral chromatographic columns.
Geometric isomers can also exist in the compounds of the present invention. The present invention contemplates the various geometric isomers and mixtures thereof resulting from the arrangement of substituents around a carbon-carbon double bond or arrangement of substituents around a carbocyclic ring.
Compounds of the present invention can also exist as racemates which is given the descriptor “rac”. The term racemate, as used herein, means an equimolar mixture of a pair of enantiomers. A racemate is usually formed when synthesis results in the generation of a stereocenter. As used herein, the term racemic mixture means racemate. Compounds of the present invention can also exist as diastereomeric meso forms which is given the descriptor “rel”. The term diastereomeric meso form as used herein means achiral forms with a pseudostereogenic C-atom, which is given the descriptor“r”or“s”, respectively. Salts
The compounds of the present invention may be used in the form of pharmaceutically- acceptable salts derived from inorganic or organic acids. By "pharmaceutically-acceptable salt"is meant those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically-acceptable salts are well-known in the art. The salts may be prepared in situ during the final isolation and purification of the compounds of the invention or separately by reacting a free base function with a suitable acid. Representative acid addition salts include, but are not limited to trifluoroacetic acid (TFA), acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate (isethionate), lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, phosphate, glutamate, bicarbonate, p-toluenesulfonate and undecanoate. Also, the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl and diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides ; arylalkyl halides like benzyl and phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained. Examples of acids which may be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, hydrobromic acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, succinic acid and citric acid. Basic addition salts can be prepared in situ during the final isolation and purification of compounds of this invention by reacting a carboxylic acid-containing moiety with a suitable base such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation or with ammonia or an organic primary, secondary or tertiary amine. Pharmaceutically- acceptable basic addition salts include, but are not limited to, cations based on alkali metals or alkaline earth metals such as lithium, sodium, potassium, calcium, magnesium and aluminum salts and the like and nontoxic quaternary ammonia and amine cations including ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine and the like. Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, piperazine and the like. Solvates/hydrates
It should be appreciated that solvates and hydrates of the compound according to formula (I) are also within the scope of the present application. Methods of solvation are generally known in the art.A further embodiment of the present invention may also include compounds, which are identical to the compounds of formula (I) except that one or more atoms are replaced by an atom having an atomic mass number or mass different from the atomic mass number or mass usually found in nature, e.g. compounds enriched in 2H (D), 3H, 13C,
Figure imgf000087_0001
etc. These isotopic analogs and their pharmaceutical salts and formulations are considered useful agents in therapy and/or diagnosis, for example, but not limited to, where a fine-tuning of in vivo half-life time could lead to an optimized dosage regimen. Pharmaceutical compositions
In a further aspect the present invention provides a pharmaceutical composition comprising a compound of formula (I) according to the invention and a pharmaceutically acceptable diluent, excipient or carrier. In one embodiment the pharmaceutical composition further comprises another pharmaceutical active agent. In one embodiment, the invention provides a pharmaceutical composition comprising a compound of formula (I) according to the invention and a pharmaceutically acceptable diluent, excipient or carrier, wherein said compound of formula (I) is present in a
therapeutically effective amount. Formulations and modes of administration:
The compounds of the present invention may, in accordance with the invention, be administered in single or divided doses by oral, parenteral, inhalatory, rectal or topical administration including cutaneous, ophthalmic, mucosal scalp, sublingual, buccal and intranasal routes of administration; further, the compounds provided by the invention may be formulated to be used for the treatment of leukocyte populations ex vivo and in vitro.
When the compounds of the present invention are to be administered e.g. by the oral route, they may be administered as medicaments in the form of pharmaceutical compositions which contain them in association with a pharmaceutically acceptable diluent, excipient or carrier material. Thus the present invention also provides a pharmaceutical composition comprising the compounds according to the invention as described supra and one or more
pharmaceutically acceptable diluent, excipient or carrier. The pharmaceutical compositions can be prepared in a conventional manner and finished dosage forms can be solid dosage forms, for example, tablets, dragees, capsules, and the like, or liquid dosage forms, for example solutions, suspensions, emulsions and the like. Pharmaceutically acceptable diluent, excipient or carrier include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. The use of such media and agents for pharmaceutically active substances is known in the art. In one embodiment, the invention provides a pharmaceutical composition comprising a compound of formula (I) according to the invention and at least one pharmaceutically acceptable diluent, excipient or carrier, wherein the composition is a tablet or a capsule, preferably a tablet. Dosing regimen
An exemplary treatment regime entails administration once daily, twice daily, three times daily, every second day, twice per week, once per week. The composition of the invention is usually administered on multiple occasions. Intervals between single dosages can be, for example, less than a day, daily, every second day, twice per week, or weekly. The
composition of the invention may be given as a continous uninterrupted treatment. In an exemplary treatment regime the compound of formula (I) according to the invention can be administered from 0.1– 100 mg per day. Therapeutic use
The compounds according to the invention as described supra have preventive and therapeutic utility in human and veterinary diseases. Thus, in a further aspect the present invention provides the use of the compounds as described herein and the use of the pharmaceutical composition described herein for preventive and/or therapeutic purposes. In one embodiment of the present invention, the compounds according to the invention as described herein or the pharmaceutical composition as described herein may be used as a medicament, preferably for use in human medicine and/or veterinarian medicine. Accordingly the present invention provides the compounds according to the invention as described herein or a pharmaceutical composition as described herein, for use as a medicament. In a further aspect the present invention also provides the compounds of the present invention, or the pharmaceutical composition of the invention for use in a method for the prevention or treatment of cancer. Also provided is a method for treating and/or preventing cancers, said method comprising administering the compounds of the present invention, or the
pharmaceutical composition of the invention to a subject in need thereof. Also provided is the use of the compounds of the present invention, or the pharmaceutical composition of the invention for the manufacture of a medicament for treating and/or preventing cancers in a subject. Also provided is the use of the compounds of the present invention, or the
pharmaceutical composition of the invention for treating and/or preventing cancers in a subject. Cancers to be prevented or treated are preferably Notch dependent cancers, more preferably, Notch dependent cancers selected from the group consisting of adenoid cystic carcinoma (ACC), T cell-Acute lymphoblastic leukemia (T-ALL), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), Mantle cell lymphoma (MCL), breast cancer, pancreatic cancer, prostate cancer, melanoma, brain tumors, tumor angiogenesis, liver cancer and colorectal cancer. Preferably, the compounds of the present invention can be also used in the treatment of cancers where Notch dependent cancers are resistant to g-secretase inhibitor treatment. Notch signalling dependent human tumors resistant to g-secretase inhibitor treatment can be determined by the levels of NICD, Notch target genes as well as by mutation status of Notch receptor and other components of the Notch pathway. In a further aspect the present invention provides a method of treatment of a disease associated with an up-regulated Notch signaling pathway activity, said method comprising administering the compounds of the present invention, or the pharmaceutical composition of the invention to a subject in need thereof. The daily dose of compounds of the present invention will necessarily be varied depending upon the host treated, the particular route of administration, and the severity and kind of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient. Further, it is noted that the clinician or treating physician will know how and when to start, interrupt, adjust, or terminate therapy in conjunction with individual patient response. For any compound used in the methods of the present invention, a therapeutically effective dose can be estimated initially from cell culture assays, animal models, or microdosing of human subjects. “Treatment” as used herein, refers to both therapeutic treatment and prophylactic or preventative measures. Subjects in need of treatment include those already with the disorder, such as cancer, as well as those in which the disorder, such as cancer, is to be prevented. Hence, the mammal, preferably human, to be treated herein may have been diagnosed as having the disorder, such as cancer, or may be predisposed or susceptible to the disorder, such as cancer. “Prevention” as used herein comprise prophylactic treatments. In preventive applications, the pharmaceutical combination of the invention is administered to a subject suspected of having, or at risk for developing cancer. In therapeutic applications, the pharmaceutical combination is administered to a subject such as a patient already suffering from cancer, in an amount sufficient to cure or at least partially arrest the symptoms of the disease. Amounts effective for this use will depend on the severity and course of the disease, previous therapy, the subject's health status and response to the drugs, and the judgment of the treating physician. The term“therapeutically effective amount” refers to an amount of a drug effective to treat a disease or disorder in a mammal. In the case of cancer, the therapeutically effective amount of the drug may reduce the number of tumor or cancer cells, reduce the tumor size; inhibit (i.e., slow to some extent and preferably stop) cancer cells infiltration into peripheral organs;
inhibit (i.e., slow to some extent and preferably stop) tumor metastasis; inhibit, to some extent, tumor growth; and/or relieve to some extent one or more of the symptoms associated with the cancer. To the extent the compounds of the present invention may prevent growth and/or kill existing cancer cells, it may be cytostatic and/or cytotoxic. The phrase
“therapeutically effective amount” is used herein to mean an amount sufficient to prevent, or preferably reduce by at least about 30 percent, preferably by at least 50 percent, preferably by at least 70 percent, preferably by at least 80 percent, preferably by at least 90%, a clinically significant change in the growth or progression or mitotic activity of a target cellular mass, group of cancer cells, or other feature of pathology. In one embodiment the compounds of the present invention may be used against cell proliferate diseases in combination (for example either at the same time, or almost at the same time, or one after the other) with conventional treatments such as standard radiotherapy and/or standard chemotherapy. The standard radiotherapy and chemotherapy can be also the concomitant chemo-radiotherapy. The standard radiotherapy and/or chemotherapy can be performed before, simultaneously or after the administration of a therapeutically effective amount of the compound of the present invention, or pharmaceutical compositions containing thereof. The term“concomitant chemo-radiotherapy” is used when these two treatments
(chemotherapy and radiotherapy) are given either at the same time, or almost at the same time, for instance one after the other, or on the same day, etc. The term“standard radiotherapy” refers to the use of ionizing radiation as part of cancer treatment to control malignant cells. Preferably the ionizing radiation is g-irradiation. It is also common to combine radiotherapy with surgery, chemotherapy, hormone therapy, or combinations thereof. Most common cancer types can be usually treated with radiotherapy. The precise treatment intent (curative, adjuvant, neoadjuvant or palliative) will depend on the tumor type, location, and stage, as well as the general health of the subject in need thereof. The term“standard chemotherapy”generally refers to a treatment of a cancer using specific chemotherapeutic/chemical agents. A chemotherapeutic agent refers to a pharmaceutical agent generally used for treating cancer. The chemotherapeutic agents for treating cancer include, for example, Altretamine, Bleomycin, Busulphan, Capecitabine, Carboplatin, Carmustine, Chlorambucil, Cisplatin, Cladribine, Crisantaspase, Cyclophosphamid,
Cytarabine, Dacarbazine, Daunorubicin , Doxorubicin, Epirubicin, Etoposide, Fludarabine, Fluorouracil, Gemcitabine, Idarubicin, Ifosfamide, Irinotecan, Lomustine, Melphalan, Mercaptopurine, Methotrexate, Mitomycin, Mitoxantrone, Oxaliplatin, Pentostatin,
Procarbazine, Streptozocin, Taco, Temozolomide, Tioguanine/Thioguanine, Thiotepa, Topotecan, Treosulfan, Vinblastine, Vincristine, Vindesine or Vinorelbine. When a chemotherapeutic agent is used in combination with a compound according to the present invention, then this may be used in the form of a medicament containing a
combination of these two agents, for simultaneous administration, or they may be used in the form of separate dosage forms, each containing one of the agents, and in the latter case the individual dosage forms may be used e.g. sequentially, i.e. one dosage form with the compound of the invention , followed by a dosage form containing the chemotherapeutic agent (or vice versa). This embodiment of two separate dosage forms may be conceived and provided in the form of a kit. Also optionally the compounds of the present invention may be used against cell proliferate diseases, such as cancers, in combination with conventional removal of a tumor bulk, by for example segmental resection (biopsy or gross resection). The term“removal of a tumor bulk” refers to any removal, ablation or resection of a tumor bulk from a subject. The removal can be chemical, radiation or surgical. Preferably said removal is surgical, such as ablation or resection. Resection can be“segmental resection” (or segmentectomy), a surgical procedure to remove part of an organ or gland from a subject. It may also be used to remove a tumor and normal tissue around it. Debulking agent may be also used to remove tumor bulk. The term“debulking agent” includes any molecule (e.g. chemical, biological) or any external/environmental agent (e.g. g-irradiation) or traditional surgery that would allow killing cancer cells from the tumor bulk (e.g. FL10 and FL1- cells as mentioned above). As to the appropriate carriers, reference may be made to the standard literature describing these, e.g. to chapter 25.2 of Vol.5 of“Comprehensive Medicinal Chemistry”, Pergamon Press 1990, and to“Lexikon der Hilfsstoffe für Pharmazie, Kosmetik und angrenzende Gebiete”, by H.P. Fiedler, Editio Cantor, 2002. The term“pharmaceutically acceptable carrier” means a carrier or excipient that is useful in preparing a pharmaceutical composition that is generally safe, and possesses acceptable toxicities. Acceptable carriers include those that are acceptable for veterinary use as well as human pharmaceutical use. A
“pharmaceutically acceptable carrier” as used in the specification and claims includes both one and more than one such carrier. Optionally, the pharmaceutical composition of the present invention further comprises one or more additional active agents selected among the non limiting group comprising
chemotherapeutic agents for treating cancer. Such chemotherapeutic agents may be selected among the group comprising, for example, Altretamine, Bleomycin, Busulphan, Capecitabine, Carboplatin, Carmustine, Chlorambucil, Cisplatin, Cladribine, Crisantaspase,
Cyclophosphamid, Cytarabine, Dacarbazine, Daunorubicin , Doxorubicin, Epirubicin, Etoposide, Fludarabine, Fluorouracil, Gemcitabine, Idarubicin, Ifosfamide, Irinotecan, Lomustine, Melphalan, Mercaptopurine, Methotrexate, Mitomycin, Mitoxantrone,
Oxaliplatin, Pentostatin, Procarbazine, Streptozocin, Taco, Temozolomide, ,
Tioguanine/Thioguanine, Thiotepa, Topotecan, Treosulfan, Vinblastine, Vincristine,
Vindesine and Vinorelbine. The compounds of the invention that can be used in the treatment and/or prevention of cancers can be incorporated into a variety of formulations and medicaments for therapeutic administration. More particularly, one or more compound(s) as provided herein can be formulated into pharmaceutical compositions by combination with appropriate,
pharmaceutically acceptable carriers, and can be formulated into preparations in solid, semi- solid, liquid or gaseous forms, such as tablets, capsules, pills, powders, granules, dragees, gels, slurries, ointments, solutions, suppositories, injections, inhalants and aerosols. As such, administration of the compounds can be achieved in various ways, including oral, buccal, rectal, parenteral, intraperitoneal, intradermal, transdermal, intracranial and/or intratracheal administration. Moreover, the compound can be administered in a local rather than systemic manner, in a depot or sustained release formulation. The compounds can be formulated with common excipients, diluents or carriers, and compressed into tablets, or formulated as elixirs or solutions for convenient oral administration, or administered by the intramuscular or intravenous routes. The compounds can be administered transdermally, and can be formulated as sustained release dosage forms and the like. The compounds can be administered alone, in combination with each other, or they can be used in combination with other known compounds. Suitable formulations for use in the present invention are found in Remington's Pharmaceutical Sciences (Mack Publishing Company (1985) Philadelphia, PA, 17th ed.), which is incorporated herein by reference. Moreover, for a brief review of methods for drug delivery, see, Langer, Science (1990) 249:1527-1533, which is incorporated herein by reference. The amount of a compound as provided herein that can be combined with a carrier material to produce a single dosage form will vary depending upon the disease treated, the subject in need thereof, and the particular mode of administration. However, as a general guide, suitable unit doses for the compounds of the present invention can, for example, preferably contain between 0.1 mg to about 1000 mg, between 1 mg to about 500 mg, and between 1 mg to about 300 mg of the active compound. In another example, the unit dose is between 1 mg to about 100 mg. Such unit doses can be administered more than once a day, for example, 2, 3, 4, 5 or 6 times a day, but preferably 1 or 2 times per day, so that the total dosage for a 70 kg human adult is in the range of 0.001 to about 15 mg per kg weight of subject per
administration. A preferred dosage is 0.01 to about 1.5 mg per kg weight of subject per administration, and such therapy can extend for a number of weeks or months, and in some cases, years. It will be understood, however, that the specific dose level for any particular patient will depend on a variety of factors including the activity of the specific compound employed; the age, body weight, general health, sex and diet of the individual being treated; the time and route of administration; the rate of excretion; other drugs that have previously been administered; and the severity of the particular disease undergoing therapy, as is well understood by those of skill in the area. A typical dosage can be one 1 mg to about 100 mg tablet or 1 mg to about 300 mg taken once a day, or, multiple times per day, or one time- release capsule or tablet taken once a day and containing a proportionally higher content of active ingredient. The time-release effect can be obtained by capsule materials that dissolve at different pH values, by capsules that release slowly by osmotic pressure, or by any other known means of controlled release. It can be necessary to use dosages outside these ranges in some cases as will be apparent to those skilled in the art. A further object of the present invention is a kit comprising a container and a package insert, wherein the container comprises at least one dose of a medicament comprising a compound of formula (I) and optionally one or more pharmaceutically acceptable diluents, excipients or carrier, and the package insert comprises instructions for treating a subject for cancer using the medicament. The kit can further comprise one or more doses of a chemotherapeutic agent. Optionally, the kit may also comprise reagents and/or instructions for use. Generally, the kit comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, etc. The containers may be formed from a variety of materials such as glass or plastic. The container holds the pharmaceutical composition that is effective for treating the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). The label or package insert indicates that the composition is used for treating the condition of choice, such as cancer. In a further object the present invention provides the use of the compounds of the invention for inhibiting in vitro or in vivo the Notch signalling pathway in cells. Usually, said cells are cancer cells. In a further object the present invention provides a method of treating a subject for Notch dependent cancer, comprising i) determining in cancer cells obtained from a biological sample of said subject whether the cancer is Notch signalling pathway dependent,
ii) and treating said subject based upon whether the cancer is Notch dependent cancer by administering a therapeutically effective amount of the compounds of the invention, or a pharmaceutical composition of the invention. Usually, the Notch signalling pathway dependency in cancer cells is determined by any method known in the art. As an example, this method can consist in an in vitro g-secretase complex activity assays as described herein. This method of treating may further comprise administering at least one conventional cancer treatment. The conventional cancer treatment is administered before, simultaneously or after the administration of the therapeutically effective amount of compounds of the invention, or the pharmaceutical composition of the invention. Usually, the conventional cancer treatment consists in radiotherapy and/or chemotherapy. In a further object the present invention provides the use of the compounds of the invention in a method for provoking apoptosis in a cell, either in vitro or in vivo, by inducing G0/G1 cell cycle arrest. In a further object the present invention provides the use of the compounds of the invention in diagnosing, predicting, and/or monitoring of Notch dependent cancer in a subject. Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications without departing from the spirit or essential characteristics thereof. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations or any two or more of said steps or features. The present disclosure is therefore to be considered as in all aspects illustrated and not restrictive, the scope of the invention being indicated by the appended Claims, and all changes which come within the meaning and range of equivalency are intended to be embraced therein. Various references are cited throughout this Specification, each of which is incorporated herein by reference in its entirety. The foregoing description will be more fully understood with reference to the following Examples. Such Examples, are, however, exemplary of methods of practicing the present invention and are not intended to limit the scope of the invention.
EXAMPLES CHEMICAL SYNTHESIS OF COMPOUNDS Abbreviations
AcOH acetic acid
brine saturated aqueous NaCl solution CV column volumes
DCM dichloromethane
DME 1,2-dimethoxyethane
DMF dimethylformamide
DMSO-d6 deuterated dimethyl sulfoxide equiv equivalent(s)
EtOAc ethyl acetate
Et2O diethyl ether
EtOH ethanol
expl. example
Fe iron
h hour(s)
M molar concentration
MeOH methanol
MgSO4 magnesium sulfate
min minute(s)
mL milliliter(s)
Mw molecular weight
NaHCO3 sodium bicarbonate
Na2SO4 sodium sulfate
Pd/C palladium on carbon
pTSA p-toluenesulfonic acid
RT room temperature
tBuOH tert.-butanol
tBuOK potassium tert.-butylate
TEA triethylamine
THF tetrahydrofurane TLC thin layer chromatography (Rf: retention factor)
The following general procedure were used for the synthesis of the compounds reported: General procedure A: Aromatic nucleophilic substitution with substituted phenol (refers to Scheme 1)
Figure imgf000098_0001
To the desired aryl alcohol A (1.1 equiv) and the corresponding 4-halo-nitroaryl B (1.0 equiv) in DMF (0.5 M), was added K2CO3 (1.2 equiv). The reaction was stirred at RT. After completion (monitored by TLC with EtOAc/hexanes or EtOAc/cyclohexane as eluent and stained with KMnO4), usually observed after 14 h, the reaction mixture was poured into a mixture of Et2O and a satured aqueous solution of NaHCO3. The layers were separated and the aqueous phase extracted twice with Et2O. The combined organic layers were washed with a saturated aqueous solution of NaHCO3, dried over Na2SO4 or MgSO4, filtered-off and concentrated under reduced pressure. The crude product was purified by combi flash column chromatography using EtOAc/hexanes or EtOAc/cyclohexane as the eluent, to afford the corresponding nitro compound C. General procedure B: Nitro-aromatic reduction (refers to Scheme 1)
Figure imgf000098_0002
To the nitro compound C (1.0 equiv) were added Fe powder (5.0 equiv) and
EtOH/H2O/AcOH 2:2:1 (0.1 M). The reaction was sonicated until completion (monitored by TLC, with EtOAc/hexanes or EtOAc/cyclohexane as eluent and stained with KMnO4). The obtained brown slurry was filtered through filter paper, rinsed with EtOAc and the organic solvents were evaporated. EtOAc was added followed by careful addition of a saturated aqueous solution of NaHCO3. Layers were separated and the aqueous layer was extracted three times with EtOAc. The combined organic layers were dried over MgSO4 or Na2SO4, filtered-off and the solvent was evaporated. The crude product was purified by combi flash column chromatography using EtOAc/hexanes or EtOAc/cyclohexane as the eluent, to afford the corresponding title compound D. General procedure C: Aminoaryl methylation (refers to Scheme 2)
Figure imgf000099_0001
To a freshly prepared solution of sodium methoxide (Na 5.0 equiv, MeOH 0.1M) under inert atmosphere, the aminoaryl derivative D (1.0 equiv) was added. The reaction was stirred at RT (1 h). Then, para-formaldehyde (1.4 equiv) was added followed, after 16 h, by NaBH4 (2.0 equiv). The mixture was stirred until completion (monitored by TLC). MeOH was evaporated and EtOAc followed by saturated aqueous NaHCO3 were added. The layers were separated and the organic layer was washed with brine, dried over MgSO4 or Na2SO4, filtered and evaporated under vacuum. The crude residue was purified by column chromatography using EtOAc/hexanes or EtOAc/cyclohexane as the eluent, to afford the target compound E. General procedure D: Suzuki coupling
Figure imgf000099_0002
To a suspension of the desired boronic acid F (1.2 equiv), the desired bromoaryl G (1.0 equiv) and the accurate base (2.0-2.5 equiv) in dioxane/H2O 4:1 (0.05-0.1 M), the palladium catalyst (10 % mol) was added. The reaction mixture was stirred at reflux. After 16 h, EtOAc and H2O were added. The layers were separated and the aqueous layer was extracted with EtOAc (2x). The combined organic layers were washed with brine, dried over MgSO4 or Na2SO4, filtered through a pad of celite and concentrated under reduced pressure. The residue was purified by column chromatography using EtOAc/hexanes or EtOAc/cyclohexane as the eluent, to afford the target compound C. N.B.: This procedure was also applied to Suzuki couplings between F as a bromoaryl derivative and G as aryl boronic acid/ester. General procedure E: Suzuki coupling
Figure imgf000100_0001
To a suspension of the desired boronic acid F (1.2 equiv), the desired bromoaryl G (1.0 equiv) and K2CO3 (2.0-2.5 equiv) in dioxane:H2O 4:1 (0.05-0.1 M),
tetrakis(triphenylphosphine)palladium(0) (10 % mol) was added. The reaction mixture was stirred at reflux. After 16 h, EtOAc and H2O were added. The layers were separated and the aqueous layer was extracted with EtOAc (2x). The combined organic layers were washed with brine, dried over MgSO4 or Na2SO4, filtered through a pad of celite and concentrated under reduced pressure. The residue was purified by column chromatography using
EtOAc/hexanes or EtOAc/cyclohexane as the eluent, to afford the target compound C. General procedure F: Nitro-aromatic reduction (refers to Scheme 1)
Figure imgf000100_0002
To a solution of the nitro compound C (1.0 equiv), at RT, in a 3:1 mixture of acetone/H2O was added NH4Cl (5 equiv). To this stirring solution Zn (5.0 equiv) was added in portions. The reaction mixture was stirred for 1 h (monitored by TLC, with EtOAc/hexanes or
EtOAc/cyclohexane as eluent and stained with KMnO4) and then concentrated under reduced pressure. The residue was suspended in EtOAc and filtered through a pad of celite which was washed with EtOAc. The filtrate was washed washed with NaHCO3 (2x), dried over MgSO4 or Na2SO4, filtered-off and the solvent was evaporated to afford the corresponding title compound D. General procedure G: Aminoaryl methylation (refers to Scheme 2)
Figure imgf000101_0001
To a solution of the aminoaryl derivative D (1.0 equiv), in DCE (0.25M), at RT, was added para-formaldehyde (1.1 equiv). The mixture was stirred for 5 min before NaBH(OAc)3 ( 1.5 equiv) was added followed by AcOH (1 equiv) addition. The reaction was stirred at RT overnight. The reaction mixture was quenched by adding 1M NaOH and diluted with H2O and CH2Cl2. The two layers were separated and the aqueous layer was extracted with CH2Cl2 (2x). The combined organic layers were washed with brine, dried over MgSO4 or Na2SO4, filtered and evaporated under vacuum. The crude residue was purified by column chromatography using EtOAc/hexanes or EtOAc/cyclohexane as the eluent, to afford the target compound E.
Example 1: 6-([1,1'-Biphenyl]-4-yloxy)pyridin-3-amine
Figure imgf000101_0002
Following the General procedure B, 6-([1,1'-biphenyl]-4-yloxy)pyridin-3-amine was obtained in 97 % yield (1.66 mmol, 434 mg) from 2-([1,1'-biphenyl]-4-yloxy)-5-nitropyridine (1.71 mmol, 500 mg).
C17H14N2O; Mw = 262.31 g.mol-1; 1H NMR (400 MHz, CDCl3) d 7.75 (dd, J = 3.0, 0.6 Hz, 1 H), 7.61-7.52 (m, 4 H), 7.47-7.39 (m, 2 H), 7.36-7.29 (m, 1 H), 7.17-7.06 (m, 3 H), 6.82 (dd, J = 8.6, 0.6 Hz, 1 H); 13C NMR (101 MHz, CDCl3) d 156.60, 155.34, 140.87, 138.96, 136.84, 134.28, 128.85, 128.45, 127.11, 127.09, 127.01, 120.20, 112.77, 77.48, 77.16, 76.84.
The starting material was prepared as follows: Step 1: 2-([1,1'-Biphenyl]-4-yloxy)-5-nitropyridine
Figure imgf000102_0001
Following the General procedure A, 2-([1,1'-biphenyl]-4-yloxy)-5-nitropyridine was obtained in 99 % yield without purification (4.65 mmol, 1.36 g) from [1,1’-biphenyl]-4-ol (4.70 mmol, 800 mg) and 2-chloro-5-nitropyridine (4.70 mmol, 745 mg).
C17H12N2O3; Mw = 292.29 g.mol-1; 1H NMR (400 MHz, CDCl3) d 9.08 (d, J = 2.8 Hz, 1 H), 8.50 (dd, J = 9.1, 2.8 Hz, 1 H), 7.67 (d, J = 8.8 Hz, 2 H), 7.60 (dd, J = 8.3, 1.2 Hz, 2 H), 7.46 (dd, J = 8.2, 6.8 Hz, 2 H), 7.40-7.33 (m, 1 H), 7.26-7.20 (m, 2 H), 7.08 (dd, J = 9.1, 0.5 Hz, 1 H). Example 2: 6-([1,1'-Biphenyl]-4-yloxy)-N-methylpyridin-3-amine
Figure imgf000102_0002
Following the General procedure C, 6-([1,1'-biphenyl]-4-yloxy)-N-methylpyridin-3-amine was obtained in 86 % yield (3.98 mmol, 1.10 g) from 6-([1,1'-biphenyl]-4-yloxy)pyridin-3- amine (4.61 mmol, 1.21 g).
C18H16N2O; Mw = 276.34 g.mol-1; 1H NMR (400 MHz, CDCl3) d 7.69 (d, J = 3.0 Hz, 1H), 7.59-7.53 (m, 4H), 7.42 (t, J = 7.6 Hz, 2H), 7.35-7.29 (m, 1H), 7.15-7.09 (m, 2H), 7.05 (dd, J = 8.7, 3.1 Hz, 1H), 6.86 (d, J = 8.7 Hz, 1H), 2.86 (s, 3H). Example 3: 6-((6-Phenylpyridin-3-yl)oxy)pyridin-3-amine
Figure imgf000103_0001
Following the General procedure B, 6-((6-phenylpyridin-3-yl)oxy)pyridin-3-amine was obtained in 93 % yield (2.43 mmol, 0.64 g) from 5-nitro-2-((6-phenylpyridin-3- yl)oxy)pyridine (2.63 mmol, 0.77 g).
C16H13N3O; Mw = 263.30 g.mol-1; Solid; 11H NMR (400 MHz, CDCl3) d 8.53 (d, J = 2.7 Hz, 1 H), 7.96 (d, J = 7.3 Hz, 2 H), 7.71 (dd, J = 7.9, 5.9 Hz, 2 H), 7.51 (dd, J = 8.6, 2.7 Hz, 1 H), 7.46 (t, J = 7.5 Hz, 2 H), 7.39 (t, J = 7.3 Hz, 1 H), 7.13 (dd, J = 8.6, 2.9 Hz, 1 H), 6.86 (d, J = 8.6 Hz, 1 H), 3.63 (s, 2 H). The starting material was prepared as follows: Step 1: 5-Nitro-2-((6-phenylpyridin-3-yl)oxy)pyridine
Figure imgf000103_0002
Following the General procedure A, 5-nitro-2-((6-phenylpyridin-3-yl)oxy)pyridine was obtained in 93 % yield (2.63 mmol, 0.77 g) from 6-phenylpyridin-3-ol (2.92 mmol, 0.51 g) and 2-chloro-5-nitropyridine (2.84 mmol, 0.45 g).
H11N3O3; Mw = 293.28 g.mol- C1 1 6; Solid; 1H NMR (400 MHz, CDCl ) d 9.04 (d, J = 2.7 Hz, 1 H), 8.59 (d, J = 2.6 Hz, 1 H), 8.54 (dd, J = 9.0, 2.8 Hz, 1 H), 8.04-7.97 (m, 2 H), 7.83 (d, J = 8.6 Hz, 1 H), 7.62 (dd, J = 8.6, 2.8 Hz, 1 H), 7.52-7.47 (m, 2H), 7.45 (dd, J = 4.9, 3.6 Hz, 1 H), 7.16 (d, J = 9.0 Hz, 1 H).
Example 4: 3-Fluoro-4-(4-(pyridin-2-yl)phenoxy)aniline
Figure imgf000103_0003
Following the General procedure B, 3-fluoro-4-(4-(pyridin-2-yl)phenoxy)aniline was obtained in 42 % yield (1.8 mmol, 0.51 g) from 2-(4-(2-fluoro-4-nitrophenoxy)phenyl)pyridine (4.38 mmol, 1.36 g).
C17H13FN2O; Mw = 280.30 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.63 (d, J= 5.0 Hz, 1H), 7.90 (d, J= 8.5 Hz, 2H), 7.75 (s, 1H), 7.66 (d, J= 8.0 Hz, 1H), 7.28 (m, 1H), 7.02-6.94 (m, 2H), 6.90 (t, J= 8.8 Hz, 1H), 6.46 (dd, J= 12.0, 2.7 Hz, 1H), 6.39 (ddd, J= 8.6, 2.7, 1.3 Hz, 1H).
The starting material was prepared as follows:
Step 1: 2-(4-(2-Fluoro-4-nitrophenoxy)phenyl)pyridine
Figure imgf000104_0001
Following the General procedure A, 2-(4-(2-fluoro-4-nitrophenoxy)phenyl)pyridine was obtained in 30 % yield (4.38 mmol, 1.36 g) from 4-(pyridin-2-yl)phenol (14.6 mmol, 2.50 g) and 1,2-difluoro-4-nitrobenzene (14.3 mmol, 2.28 g).
CI7H11FN2O3; MW = 310.28 g.mol-1; 1H NMR (400 MHz, CDC13) d 8.71 (ddd, 7= 4.9, 1.8,
0.9 Hz, 1H), 8.12 (dd, J= 10.2, 2.6 Hz, 1H), 8.10-8.04 (m, 2H), 8.01 (ddd, J= 9.0, 2.6, 1.5
Hz, 1H), 7.84-7.76 (m, 1H), 7.76-7.71 (m, 1H), 7.29 (s, 1H), 7.23-7.16 (m, 2H), 7.06 (dd, J = 9.1, 7.9 Hz, 1H).
Example 5: 3-Fluoro-4-(4-(pyridin-3-yl)phenoxy)aniline
Figure imgf000104_0002
Following the General procedure B, 3-fluoro-4-(4-(pyridin-3-yl)phenoxy)aniline was obtained in 63 % yield (11.1 mmol, 3.1 g) from 3-(4-(2-fluoro-4-nitrophenoxy)phenyl)pyridine (17.7 mmol, 5.48 g).
C17H13FN2O; Mw = 280.30 g.mol-1; 1H NMR (400 MHz, CDC13) d 8.82 (d, J= 2.4 Hz, 1H), 8.57 (dd, J= 5.0, 1.5 Hz, 1H), 7.95 (s, 1H), 7.52-7.47 (m, 2H), 7.45 (s, 1H), 7.06-7.00 (m, 2H), 6.97 (t, J = 8.7 Hz, 1H), 6.54 (dd, J = 12.0, 2.7 Hz, 1H), 6.46 (ddd, J = 8.6, 2.7, 1.2 Hz, 1H). The starting material was prepared as follows: Step 1: 3-(4-(2-Fluoro-4-nitrophenoxy)phenyl)pyridine
Figure imgf000105_0001
Following the General procedure A, 3-(4-(2-fluoro-4-nitrophenoxy)phenyl)pyridine was obtained in 79 % yield (17.7 mmol, 5.48 g) from 4-(pyridin-3-yl)phenol (22.4 mmol, 3.84 g) and 1,2-difluoro-4-nitrobenzene (22.0 mmol, 3.50 g).
CI7H11FN2O3; Mw = 310.28 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.88 (s, 1H), 8.64 (d, J = 5.0 Hz, 1H), 8.13 (dd, J = 10.2, 2.7 Hz, 1H), 8.09-7.98 (m, 2H), 7.69-7.61 (m, 2H), 7.55-7.48 (m, 1H), 7.23-7.17 (m, 2H), 7.11 (dd, J = 9.0, 7.8 Hz, 1H). Example 6: 4-([1,1'-Biphenyl]-4-yloxy)-3-fluoro-N-methylaniline
Figure imgf000105_0002
Following the General procedure C, 4-([1,1'-biphenyl]-4-yloxy)-3-fluoro-N-methylaniline was obtained in 77 % yield (3.2 mmol, 0.93 g) from 4-([1,1'-biphenyl]-4-yloxy)-3-fluoroaniline (4.1 mmol, 1.15 g).
C19H16FNO; Mw = 293.34 g.mol-1; 11H NMR (400 MHz, CDCl3) d 7.57-7.52 (m, 2H), 7.52- 7.47 (m, 2H), 7.41 (t, J = 7.6 Hz, 2H), 7.31 (t, J = 7.4 Hz, 1H), 7.03-6.95 (m, 3H), 6.46 (dd, J = 12.7, 2.7 Hz, 1H), 6.39 (dd, J = 8.7, 1.7 Hz, 1H), 4.04 (s, 1H), 2.85 (s, 3H). The starting material was prepared as follows: Step 1: 1-(4-Bromophenoxy)-2-fluoro-4-nitrobenzene
Figure imgf000105_0003
Following the General procedure A, 1-(4-bromophenoxy)-2-fluoro-4-nitrobenzene was obtained in 96 % yield (12.0 mmol, 3.73 g) from 4-bromophenol (12.8 mmol, 2.21 g) and 1,2- difluoro-4-nitrobenzene (12.5 mmol, 1.99 g).
C12H7BrFNO3; Mw = 312.09 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.10 (dd, J = 10.2, 2.7 Hz, 1H), 8.01 (ddd, J = 9.1, 2.7, 1.6 Hz, 1H), 7.57-7.51 (m, 2H), 7.05-7.00 (m, 1H), 7.00-6.94 (m, 2H). Step 2: 4-(2-Fluoro-4-nitrophenoxy)-1,1'-biphenyl
Figure imgf000106_0001
Following the General procedure E, a mixture of phenylboronic acid (12.1 mmol, 1.48 g), 1- (4-bromophenoxy)-2-fluoro-4-nitrobenzene (9.9 mmol, 3.10 g), K2CO3 (21.5 mmol, 2.97 g) and Pd(PPh3)4 (10 % mol) in dioxane/H2O 4:1 (0.05-0.1 M) was converted to 4-(2-fluoro-4- nitrophenoxy)-1,1'-biphenyl in 56 % yield (5.6 mmol, 1.72 g).
C18H12FNO3; Mw = 309.30 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.11 (dd, J = 10.2, 2.6 Hz, 1H), 8.01 (ddd, J = 9.1, 2.6, 1.5 Hz, 1H), 7.67-7.62 (m, 2H), 7.61-7.56 (m, 2H), 7.46 (t, J = 7.5 Hz, 2H), 7.37 (t, J = 7.3 Hz, 1H), 7.19-7.14 (m, 2H), 7.06 (dd, J = 9.0, 8.0 Hz, 1H). Step 3: 4-([1,1'-Biphenyl]-4-yloxy)-3-fluoroaniline
Figure imgf000106_0002
Following the General procedure B, 4-([1,1'-biphenyl]-4-yloxy)-3-fluoroaniline was obtained in 85 % yield (4.7 mmol, 1.31 g) from 4-(2-fluoro-4-nitrophenoxy)-1,1'-biphenyl (5.5 mmol, 1.70 g).
C18H14FNO; Mw = 279.31 g.mol-1; 1H NMR (400 MHz, CDCl3) d 7.58-7.52 (m, 2H), 7.52- 7.48 (m, 2H), 7.41 (t, J = 7.6 Hz, 2H), 7.31 (t, J = 7.4 Hz, 1H), 7.01-6.93 (m, 3H), 6.53 (dd, J = 12.0, 2.7 Hz, 1H), 6.48-6.42 (m, 1H), 3.70 (br s, 2H). Example 7: 4-([1,1'-Biphenyl]-4-yloxy)aniline
Figure imgf000107_0001
Following the General procedure B, 4-([1,1'-biphenyl]-4-yloxy)aniline was obtained in 33 % yield (2.4 mmol, 0.62 g) from 4-(4-nitrophenoxy)-1,1'-biphenyl (7.1 mmol, 2.08 g).
C18H15NO; Mw = 261.32 g.mol-1; 1H NMR (400 MHz, CDCl3) d 7.57-7.53 (m, 2H), 7.53-7.47 (m, 2H), 7.45-7.39 (m, 2H), 7.34-7.28 (m, 1H), 7.03-6.97 (m, 2H), 6.95-6.89 (m, 2H), 6.74- 6.66 (m, 2H), 3.61 (br s, 2H). The starting material was prepared as follows:
Step 1: 4-(4-Nitrophenoxy)-1,1'-biphenyl
Figure imgf000107_0002
Following the General procedure A, 4-(4-nitrophenoxy)-1,1'-biphenyl was obtained in 61 % yield (7.1 mmol, 2.08 g) from [1,1’-biphenyl]-4-ol (11.8 mmol, 2.00 g) and 4-fluoro- nitrobenzene (11.5 mmol, 1.63 g).
C18H13NO3; Mw = 291.31 g.mol-1; 11H NMR (400 MHz, CDCl3) d 8.26-8.20 (m, 2H), 7.69- 7.63 (m, 2H), 7.62-7.57 (m, 2H), 7.50-7.43 (m, 2H), 7.41-7.34 (m, 1H), 7.19-7.14 (m, 2H), 7.11-7.05 (m, 2H). Example 8: 6-([1,1'-Biphenyl]-4-yloxy)-2-methylpyridin-3-amine
Figure imgf000107_0003
Following the General procedure B, 6-([1,1'-biphenyl]-4-yloxy)-2-methylpyridin-3-amine was obtained in 90 % yield (4.7 mmol, 1.31 g) from 6-([1,1'-biphenyl]-4-yloxy)-2-methyl-3- nitropyridine (5.3 mmol, 1.61 g). C18H16N2O; Mw = 276.34 g.mol-1; 1HNMR (400 MHz, CDCl3) d 7.59-7.52 (m, 4H), 7.42 (t, J = 7.6 Hz, 2H), 7.32 (ddd, J = 7.4, 3.9, 1.2 Hz, 1H), 7.10 (d, J = 8.7 Hz, 2H), 7.02 (d, J = 8.4 Hz, 1H), 6.63 (d, J = 8.4 Hz, 1H), 3.49 (s, 2H), 2.37 (s, 3H).
The starting material was prepared as follows: Step 1: 6-([1,1'-Biphenyl]-4-yloxy)-2-methyl-3-nitropyridine
Figure imgf000108_0001
Following the General procedure A, 6-([1,1'-biphenyl]-4-yloxy)-2-methyl-3-nitropyridine was obtained in 89 % yield (5.3 mmol, 1.63 g) from [1,1’-biphenyl]-4-ol (5.9 mmol, 1.00 g) and 6- chloro-2-methyl-3-nitropyridine (5.8 mmol, 1.00 g).
C18H14N2O3; Mw = 306.32 g.mol-1; 1HNMR (400 MHz, CDCl3) d 8.38 (d, J = 8.9 Hz, 1H), 7.63 (dd, J = 16.5, 7.9 Hz, 4H), 7.46 (t, J = 7.6 Hz, 2H), 7.37 (dd, J = 8.3, 6.4 Hz, 1H), 7.24 (d, J = 8.7 Hz, 2H), 6.84 (d, J = 8.9 Hz, 1H), 2.78 (s, 3H). Example 9: 6-([1,1'-Biphenyl]-4-yloxy)-4-methylpyridin-3-amine
Figure imgf000108_0002
Following the General procedure B, 6-([1,1'-biphenyl]-4-yloxy)-4-methylpyridin-3-amine was obtained in 74 % yield (1.5 mmol, 410 mg) from 6-([1,1'-biphenyl]-4-yloxy)-4-methyl-3- nitropyridine (2.0 mmol, 600 mg).
C18H16N2O; Mw = 276.34 g.mol-1; 1HNMR (400 MHz, CDCl3) d 7.69 (s, 1H), 7.61-7.52 (m, 4H), 7.42 (t, J = 7.6 Hz, 2H), 7.33 (dt, J = 9.2, 4.3 Hz, 1H), 7.12 (d, J = 8.7 Hz, 2H), 6.72 (s, 1H), 3.03 (s, 2H), 2.21 (d, J = 0.5 Hz, 3H).
The starting material was prepared as follows: Step 1: 6-([1,1'-Biphenyl]-4-yloxy)-4-methyl-3-nitropyridine
Figure imgf000109_0001
Following the General procedure A, 6-([1,1'-biphenyl]-4-yloxy)-4-methyl-3-nitropyridine was obtained in 38 % yield (2.3 mmol, 0.71 g) from [1,1’-biphenyl]-4-ol (5.9 mmol, 1.00 g) and 6- chloro-4-methyl-3-nitropyridine (5.8 mmol, 1.00 g).
C18H14N2O3; Mw = 306.32 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.92 (s, 1H), 7.69-7.63 (m, 2H), 7.63-7.57 (m, 2H), 7.49-7.42 (m, 2H), 7.40-7.34 (m, 1H), 7.25-7.20 (m, 2H), 6.88 (d, J = 0.9 Hz, 1H), 2.69 (d, J = 0.8 Hz, 3H). Example 10: 6-((4'-Fluoro-[1,1'-biphenyl]-4-yl)oxy)pyridin-3-amine
Figure imgf000109_0002
Following the General procedure B, 6-((4'-fluoro-[1,1'-biphenyl]-4-yl)oxy)pyridin-3-amine was obtained in 58 % yield (3.9 mmol, 1.10 g) from 2-((4'-fluoro-[1,1'-biphenyl]-4-yl)oxy)-5- nitropyridine (6.8 mmol, 2.10 g).
C17H13FN2O; Mw = 280.30 g.mol-1; 1H NMR (400 MHz, CDCl3) d 7.75 (d, J = 3.0 Hz, 1H),7.51 (m, 4H), 7.16-7.07 (m, 5H), 6.82 (d, J = 8.6 Hz, 1H).19F NMR (376 MHz, Chloroform- d) d 116.54.
The starting materials were prepared as followed: Step 1: 2-(4-Bromophenoxy)-5-nitropyridine
Figure imgf000109_0003
Following the General procedure A, 2-(4-bromophenoxy)-5-nitropyridine was obtained in 89 % yield (37.2 mmol, 10.97 g) from 4-bromophenol (42.8 mmol, 7.40 g) and 2-chloro-5- nitropyridine (41.6 mmol, 6.60 g). C11H7BrN2O3; Mw = 295.09 g.mol-1; 1H NMR (400 MHz, CDCl3) d 9.03 (d, J = 2.6 Hz, 1H), 8.49 (dd, J = 9.0, 2.8 Hz, 1H), 7.57 (d, J = 8.8 Hz, 2H), 7.06 (m, 3H). Step 2: 2-((4'-Fluoro-[1,1'-biphenyl]-4-yl)oxy)-5-nitropyridine
Figure imgf000110_0001
Following the General procedure E, a mixture of 4-fluorophenylboronic acid (8.9 mmol, 1.25 g), 2-(4-bromophenoxy)-5-nitropyridine (7.8 mmol, 2.30 g), K2CO3 (19.5 mmol, 2.70 g) and Pd(PPh3)4 (10 % mol) in dioxane/H2O 4:1 (0.05-0.1 M) was converted to 2-((4'-fluoro-[1,1'- biphenyl]-4-yl)oxy)-5-nitropyridine in 87 % yield (6.8 mmol, 2.10 g).
C17H11FN2O3; Mw = 310.28 g.mol-1; 1H NMR (400 MHz, CDCl3) d 9.07 (d, J = 2.7 Hz, 1H), 8.50 (dd, J = 9.0, 2.7 Hz, 1H), 7.62 (d, J = 8.5 Hz, 2H), 7.55 (dd, J = 8.5, 5.4 Hz, 2H), 7.23 (d, J = 8.6 Hz, 2H), 7.14 (t, J = 8.6 Hz, 2H), 7.09 (d, J = 9.0 Hz, 1H). Example 11: 6-(4-(Thiazol-5-yl)phenoxy)pyridin-3-amine
Figure imgf000110_0002
Following the General procedure B, 6-(4-(thiazol-5-yl)phenoxy)pyridin-3-amine was obtained in 46 % yield (1.8 mmol, 0.48 g) from 5-(4-((5-nitropyridin-2-yl)oxy)phenyl)thiazole (3.8 mmol, 1.15 g).
C14H11N3OS; Mw = 269.32 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.67 (s, 1H), 7.95 (s, 1H), 7.67 (d, J = 3.0 Hz, 1H), 7.49 (d, J = 8.7 Hz, 2H), 7.05 (m, 3H), 6.76 (d, J = 8.6 Hz, 1H).
The starting material was prepared as follows: Step 1: 5-Nitro-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pyridine
Figure imgf000110_0003
To a suspension of 2-(4-bromophenoxy)-5-nitropyridine (20.6 mmol, 6.08 g), CH3COOK (61.1 mmol, 6.00 g) and bis(pinacolato)diboron (30.5 mmol, 7.75 g) in dioxane (0.1 M, 150 mL) under inert atmosphere, Pd(dppf)Cl2CH2Cl2 (5 % mol) was added. The red mixture was stirred 16 h at 105 °C. The reaction mixture was filtered through a pad of celite. Water was added to the filtrate and the mixture was extracted with EtOAc (2x). The organic layer was washed with sat. aq. NaHCO3, brine, dried over Na2SO4, filtered-off and concentrated. The crude product was purified by combi flash column chromatography using EtOAc/cyclohexane (1 % to 20 %) as the eluent, to afford 5-nitro-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)phenoxy)pyridine (15.6 mmol, 5.93 g, 76 % yield).
C17H19BN2O5; Mw = 342.16 g.mol-1; 1H NMR (400 MHz, CDCl3) d 9.04 (d, J = 2.5 Hz, 1H), 8.47 (dd, J = 9.1, 2.8 Hz, 1H), 7.94-7.88 (m, 2H), 7.20-7.13 (m, 2H), 7.06-7.01 (m, 1H), 1.35 (s, 12H). Step 2: 5-(4-((5-Nitropyridin-2-yl)oxy)phenyl)thiazole
Figure imgf000111_0001
Following the General procedure D, a mixture of 5-nitro-2-(4-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)phenoxy)pyridine (9.2 mmol, 3.50 g), 5-bromothiazole (7.4 mmol, 1.25 g), Cs2CO3 (15.0 mmol, 4.90 g) and PdCl2(PPh3)2 (10 % mol) in dioxane/H2O 4:1 (0.05-0.1 M) was converted to 5-(4-((5-nitropyridin-2-yl)oxy)phenyl)thiazole in 52 % yield (3.8 mmol, 1.15 g).
C14H9N3O3S; Mw = 299.30 g.mol-1; 1H NMR (400 MHz, CDCl3) d 9.05 (d, J = 2.6 Hz, 1H), 8.78 (s, 1H), 8.51 (dd, J = 9.1, 2.8 Hz, 1H), 8.08 (s, 1H), 7.67 (d, J = 8.2 Hz, 2H), 7.23 (d, J = 8.4 Hz, 2H), 7.10 (d, J = 9.0 Hz, 1H). Example 12: 4-((2,2'-Dimethyl-[1,1'-biphenyl]-4-yl)oxy)aniline
Figure imgf000111_0002
Following the General procedure B, 4-((2,2'-dimethyl-[1,1'-biphenyl]-4-yl)oxy)aniline was obtained in 88 % yield (21.9 mmol, 6.33 g) from 2,2'-dimethyl-4-(4-nitrophenoxy)-1,1'- biphenyl (24.9 mmol, 7.96 g).
C20H19NO; Mw = 289.38 g.mol-1; 1H NMR (400 MHz, CDCl3) d 7.26-7.24 (m, 2H), 7.23-7.18 (m, 1H), 7.10 (d, J = 6.8 Hz, 1H), 7.00 (d, J = 8.3 Hz, 1H), 6.96-6.91 (m, 2H), 6.84 (d, J = 2.5 Hz, 1H), 6.77 (dd, J = 8.4, 2.6 Hz, 1H), 6.75-6.71 (m, 2H), 2.07 (s, 3H), 2.00 (s, 3H).
The starting material was prepared as follows: Step 1: 1-Bromo-2-methyl-4-(4-nitrophenoxy)benzene
Figure imgf000112_0001
Following the General procedure A, 1-bromo-2-methyl-4-(4-nitrophenoxy)benzene was obtained in 91 % yield (27.1 mmol, 8.34 g) from 4-bromo-3-methyl-phenol (31.5 mmol, 6.01 g) and 4-fluoro-nitrobenzene (29.9 mmol, 4.22 g).
C13H10BrNO3; Mw = 308.13 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.24-8.18 (m, 2H), 7.57 (d, J = 8.6 Hz, 1H), 7.05-6.96 (m, 3H), 6.80 (dd, J = 8.6, 2.9 Hz, 1H), 2.41 (s, 3H). Step 2: 2,2'-Dimethyl-4-(4-nitrophenoxy)-1,1'-biphenyl
Figure imgf000112_0002
Following the General procedure E, a mixture of o-tolylboronic acid (30.9 mmol, 4.20 g), 1- bromo-2-methyl-4-(4-nitrophenoxy)benzene (27.1 mmol, 8.34 g), K2CO3 (55.0 mmol, 7.60 g) and Pd(PPh3)4 (10 % mol) in dioxane/H2O 4:1 (0.05-0.1 M) was converted to 2,2'-dimethyl-4- (4-nitrophenoxy)-1,1'-biphenyl in 92 % yield (24.9 mmol, 7.96 g).
C20H17NO3; Mw = 319.36 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.26-8.21 (m, 2H), 7.31- 7.27 (m, 2H), 7.24 (d, J = 4.8 Hz, 1H), 7.14 (dd, J = 14.2, 7.6 Hz, 2H), 7.11-7.04 (m, 2H), 7.00 (d, J = 2.5 Hz, 1H), 6.95 (dd, J = 8.2, 2.2 Hz, 1H), 2.09 (s, 3H), 2.07 (s, 3H). Example 13: 4-((2,2'-Dimethyl-[1,1'-biphenyl]-4-yl)oxy)-N-methylaniline
Figure imgf000113_0001
Following the General procedure C, 4-((2,2'-dimethyl-[1,1'-biphenyl]-4-yl)oxy)-N- methylaniline was obtained in 86 % yield (8.9 mmol, 2.70 g) from 4-((2,2'-dimethyl-[1,1'- biphenyl]-4-yl)oxy)aniline (10.4 mmol, 3.00 g).
C21H21NO; Mw = 303.41 g.mol-1; 1H NMR (400 MHz, CDCl3) d 7.26-7.23 (m, 2H), 7.20 (ddd, J = 9.0, 5.8, 3.7 Hz, 1H), 7.10 (d, J = 6.8 Hz, 1H), 7.04-6.95 (m, 3H), 6.84 (s, 1H), 6.77 (dd, J = 8.2, 2.1 Hz, 1H), 6.64 (d, J = 7.9 Hz, 2H), 3.78 (s, 1H), 2.86 (s, 3H), 2.07 (s, 3H), 2.00 (s, 3H). Example 14: 6-((2,2'-Dimethyl-[1,1'-biphenyl]-4-yl)oxy)-N-methylpyridin-3-amine
Figure imgf000113_0002
Following the General procedure C, 6-((2,2'-dimethyl-[1,1'-biphenyl]-4-yl)oxy)-N- methylpyridin-3-amine was obtained in 78 % yield (0.2 mmol, 53 mg) from 6-((2,2'-dimethyl- [1,1'-biphenyl]-4-yl)oxy)pyridin-3-amine (0.2 mmol, 65 mg).
C20H20N2O; Mw = 304.39 g.mol-1; 1H NMR (400 MHz, CDCl3) d 7.72 (d, J = 3.0 Hz, 1H), 7.26-7.24 (m, 2H), 7.21 (m, 1H), 7.11 (d, J = 6.8 Hz, 1H), 7.08-7.02 (m, 2H), 6.95 (d, J = 2.5 Hz, 1H), 6.89 (dd, J = 8.2, 2.6 Hz, 1H), 6.86 (d, J = 8.7 Hz, 1H), 2.87 (s, 3H), 2.08 (s, 3H), 2.02 (s, 3H). The starting material was prepared as follows: Step 1: 2-(4-Bromo-3-methylphenoxy)-5-nitropyridine
Figure imgf000113_0003
Following the General procedure A, 2-(4-bromo-3-methylphenoxy)-5-nitropyridine was obtained in 98 % yield (6.2 mmol, 1.93 g) from 4-bromo-3-methyl-phenol (6.8 mmol, 1.28 g) and 2-chloro-5-nitropyridine (6.4 mmol, 1.01 g).
C12H9BrN2O3; Mw = 309.12 g.mol-1; 1H NMR (400 MHz, CDCl3) d 9.04 (d, J = 2.7 Hz, 1H), 8.49 (dd, J = 9.0, 2.9 Hz, 1H), 7.59 (d, J = 8.6 Hz, 1H), 7.10-7.01 (m, 2H), 6.88 (dd, J = 8.6, 2.8 Hz, 1H), 2.42 (s, 3H). Step 2: 2-((2,2'-Dimethyl-[1,1'-biphenyl]-4-yl)oxy)-5-nitropyridine
Figure imgf000114_0001
Following the General procedure E, a mixture of o-tolylboronic acid (1.9 mmol, 264 mg), 2- (4-bromo-3-methylphenoxy)-5-nitropyridine (1.3 mmol, 400 mg), K2CO3 (2.6 mmol, 358 mg) and Pd(PPh3)4 (10 % mol) in dioxane/H2O 4:1 (0.05-0.1 M) was converted to 2-((2,2'- dimethyl-[1,1'-biphenyl]-4-yl)oxy)-5-nitropyridine in 95 % yield (1.2 mmol, 392 mg).
C19H16N2O3; Mw = 320.35 g.mol-1; 1H NMR (400 MHz, CDCl3) d 9.11 (d, J = 2.8 Hz, 1H), 8.49 (dd, J = 9.1, 2.8 Hz, 1H), 7.35-7.31 (m, 1H), 7.29 (m, 1H), 7.25-7.22 (m, 1H), 7.18 (d, J = 8.2 Hz, 1H), 7.15 (dt, J = 7.0, 1.2 Hz, 1H), 7.09-7.00 (m, 3H), 2.10 (s, 3H), 2.09 (s, 3H). Step 3: 6-((2,2'-Dimethyl-[1,1'-biphenyl]-4-yl)oxy)pyridin-3-amine
Figure imgf000114_0002
Following the General procedure B, 6-((2,2'-dimethyl-[1,1'-biphenyl]-4-yl)oxy)pyridin-3- amine was obtained in 37 % yield (0.5 mmol, 132 mg) from 2-((2,2'-dimethyl-[1,1'-biphenyl]- 4-yl)oxy)-5-nitropyridine (1.2 mmol, 392 mg).
C19H18N2O; Mw = 290.37 g.mol-1; 11H NMR (400 MHz, CDCl3) d 7.79 (d, J = 2.8 Hz, 1H), 7.25 (s, 2H), 7.23-7.18 (m, 1H), 7.12 (t, J = 6.2 Hz, 2H), 7.06 (d, J = 8.2 Hz, 1H), 6.96 (d, J = 1.9 Hz, 1H), 6.90 (dd, J = 8.3, 2.3 Hz, 1H), 6.82 (d, J = 8.6 Hz, 1H), 2.85 (s, 2H), 2.08 (s, 3H), 2.02 (s, 3H). Example 15: 3-Fluoro-4-(4-(pyridin-4-yl)phenoxy)aniline
Figure imgf000115_0001
Following the General procedure B, 3-fluoro-4-(4-(pyridin-4-yl)phenoxy)aniline was obtained in 71 % yield (211 mg, 0.752 mmol) from 4-(4-(2-fluoro-4-nitrophenoxy)phenyl)pyridine (330mg, 1.06 mmol).
C17H13FN2O; Mw = 280.30 g.mol-1; 11H NMR (400 MHz, DMSO-d6) d 8.59 (dd, J = 4.5, 1.6 Hz, 2H), 7.80-7.74 (m, 2H), 7.65 (dd, J = 4.5, 1.6 Hz, 2H), 7.01-6.93 (m, 3H), 6.51 (dd, J = 13.3, 2.5 Hz, 1H), 6.44-6.39 (m, 1H), 5.39 (s, 2H). The starting material was prepared as follows: Step 1: 4-(4-(2-Fluoro-4-nitrophenoxy)phenyl)pyridine
Figure imgf000115_0002
Following the General procedure E, 4-(4-(2-fluoro-4-nitrophenoxy)phenyl)pyridine was obtained in 75 % yield (300 mg, 0.967 mmol) from 1-(4-bromophenoxy)-2-fluoro-4- nitrobenzene (400 mg, 1.28 mmol; Example 6: Step 1).
C17H11FN2O3; Mw = 310.28 g.mol-1; 11H NMR (400 MHz, CDCl3) d 8.68 (d, J = 6.1 Hz, 2H), 8.13 (dd, J = 10.2, 2.7 Hz, 1H), 8.04 (ddd, J = 9.0, 2.6, 1.5 Hz, 1H), 7.70 (d, J = 8.8 Hz, 2H), 7.49 (d, J = 6.2 Hz, 2H), 7.19 (d, J = 8.8 Hz, 2H), 7.10 (dd, J = 9.0, 7.9 Hz, 1H). Example 16: 6-(4-(Thiazol-2-yl)phenoxy)pyridin-3-amine
Figure imgf000115_0003
Following the General procedure B, 6-(4-(thiazol-2-yl)phenoxy)pyridin-3-amine was obtained in 21 % yield (15 mg, 0.057 mmol) from 2-(4-((5-nitropyridin-2-yl)oxy)phenyl)thiazole (100 mg, 0.300 mmol). C14H11N3OS; Mw = 269.32 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.00-7.95 (m, 2H), 7.85 (d, J = 3.3 Hz, 1H), 7.77 (d, J = 3.0 Hz, 1H), 7.31 (d, J = 3.3 Hz, 1H), 7.16-7.11 (m, 3H), 6.84 (d, J = 8.5 Hz, 1H). The starting material was prepared as follows: Step 1: 2-(4-((5-Nitropyridin-2-yl)oxy)phenyl)thiazole
Figure imgf000116_0001
Following the General procedure A, 2-(4-((5-nitropyridin-2-yl)oxy)phenyl)thiazole was obtained in 61 % yield (206 mg, 0.688 mmol) from 4-(thiazol-2-yl)phenol (0.23 g, 1.30 mmol) and 2-chloro-5-nitropyridine (0.18 g, 1.10 mmol).
C14H9N3SO3; Mw = 299.30 g.mol-1; 11H NMR (400 MHz, CDCl3) d 9.06 (d, J = 2.8 Hz, 1H), 8.51 (dd, J = 9.0, 2.8 Hz, 1H), 8.10–8.04 (m, 2H), 7.88 (d, J = 3.3 Hz, 1H), 7.36 (d, J = 3.3 Hz, 1H), 7.29-7.23 (m, 2H), 7.10 (d, J = 9.0 Hz, 1H).
Example 17: (4'-((5-Aminopyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)methanol
Figure imgf000116_0002
Following the General procedure B, (4'-((5-aminopyridin-2-yl)oxy)-[1,1'-biphenyl]-3- yl)methanol was obtained in 44 % yield (20 mg, 0.044 mmol) from (4'-((5-nitropyridin-2- yl)oxy)-[1,1'-biphenyl]-3-yl)methanol (50 mg, 0.16 mmol).
C18H16N2O2; Mw = 292.34 g.mol-1; 11H NMR (400 MHz, CDCl3) d 7.75 (d, J = 2.9 Hz, 1H), 7.57 (dd, J = 6.5, 2.1 Hz, 3H), 7.50 (d, J = 7.7 Hz, 1H), 7.42 (t, J = 7.6 Hz, 1H), 7.33 (d, J = 7.6 Hz, 1H), 7.18-7.06 (m, 3H), 6.82 (d, J = 8.6 Hz, 1H), 4.76 (s, 2H), 3.49 (s, 2H). The starting material was prepared as follows: Step 1: (4'-((5-Nitropyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)methanol
Figure imgf000117_0001
Following the General procedure E, (4'-((5-nitropyridin-2-yl)oxy)-[1,1'-biphenyl]-3- yl)methanol was obtained in 65 % yield (281 mg, 0.872 mmol) from 2-(4-bromophenoxy)-5- nitropyridine (400 mg, 1.36 mmol; Example 10:Step 1) and (3- (hydroxymethyl)phenyl)boronic acid (240 mg, 1.60 mmol).
C18H14N2O4; Mw = 322.32 g.mol-1; 1H NMR (400 MHz, DMSO-d6) d 9.07 (dd, J = 2.8, 0.6 Hz, 1H), 8.50 (dd, J = 9.1, 2.8 Hz, 1H), 7.71-7.65 (m, 2H), 7.62 (td, J = 1.8, 0.7 Hz, 1H), 7.54 (dt, J = 7.6, 1.6 Hz, 1H), 7.46 (t, J = 7.5 Hz, 1H), 7.37 (dt, J = 7.6, 1.4 Hz, 1H), 7.26-7.22 (m, 2H), 7.08 (dd, J = 9.1, 0.6 Hz, 1H), 4.79 (d, J = 5.9 Hz, 2H), 1.72 (t, J = 5.9 Hz, 1H). Example 18: 6-((3'-(Aminomethyl)-[1,1'-biphenyl]-4-yl)oxy)pyridin-3-amine
Figure imgf000117_0002
2-((4'-((5-Aminopyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)methyl)isoindoline-1,3-dione (51 mg, 0.121 mmol) was suspended in methanol (1 mL, 0.1M) (poor solubility at RT) under N2. Hydrazine hydrate (15 mg, 0.30 mmol) was added. The yellow solution was refluxed overnight. When allowing to RT, a white solid precipitated.The reaction mixture was filtered and the filtrate was concentrated. The crude residue was purified with the Biotage Isolera Four (KP-sil 25 g column, DCM/MeOH, MeOH 1-15 %; 28 CV), yielding 6-((3'- (aminomethyl)-[1,1'-biphenyl]-4-yl)oxy)pyridin-3-amine as a pale yellow solid (20 mg, 0.07 mmol, 57 %).
C18H17N3O; Mw = 291.35 g.mol-1 ; 11H NMR (400 MHz, DMSO-d6) d 7.66 (d, J = 1.8 Hz, 1H), 7.65–7.61 (m, 2H), 7.57 (d, J = 2.9 Hz, 1H), 7.52 (dt, J = 7.7, 1.5 Hz, 1H), 7.41 (t, J = 7.6 Hz, 1H), 7.33 (d, J = 7.7 Hz, 1H), 7.10 (dd, J = 8.6, 3.0 Hz, 1H), 7.06–7.02 (m, 2H), 6.81 (d, J = 8.6 Hz, 1H), 5.13 (s, 2H), 3.88 (s, 2H). The starting material was prepared as follows: Step 1: 2-((4'-((5-Nitropyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)methyl)isoindoline-1,3- dione
Figure imgf000118_0001
To a 25-mL round-bottom flask, (4'-((5-nitropyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)methanol (0.117 g, 0.363 mmol), triphenylphosphine (0.115 g, 0.438 mmol) and phthalimide (0.068 g, 0.46 mmol) were added under N2, followed by THF (2 mL). Diisopropyl azodicarboxylate (0.075 mL, 0.39 mmol) was added dropwise at 0 °C. The yellow solution was stirred at RT (2 d). The mixture was concentrated and the crude was purified with the Biotage Isolera Four (KP-sil 25 g column, cyclohexane/EtOAc, EtOAc 0-40 %, 15 CV), yielding 2-((4'-((5- nitropyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)methyl)isoindoline-1,3-dione (158 mg, 0.350 mmol, 96 %) as a yellow foam.
C26H17N3O5; Mw = 451.44 g.mol-1; 11H NMR (400 MHz, CDCl3) d 9.07 (dd, J = 2.8, 0.6 Hz, 1H), 8.49 (dd, J = 9.0, 2.8 Hz, 1H), 7.87-7.84 (m, 2H), 7.72 (dd, J = 5.5, 3.0 Hz, 2H), 7.66 (d, J = 1.8 Hz, 1H), 7.66-7.62 (m, 2H), 7.50 (dt, J = 7.3, 1.7 Hz, 1H), 7.47-7.43 (m, 1H), 7.40 (t, J = 7.5 Hz, 1H), 7.24-7.20 (m, 2H), 7.07 (dd, J = 9.0, 0.6 Hz, 1H), 4.92 (s, 2H). TLC
(cyclohexane/EtOAc 7:3) Rf = 0.42. Step 2: 2-((4'-((5-Aminopyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)methyl)isoindoline-1,3- dione
Figure imgf000118_0002
2-((4'-((5-Nitropyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)methyl)isoindoline-1,3-dione (158 mg, 0.350 mmol) was suspended in EtOAc (3mL) under N2. Pd/C (10%, 16 mg) was added resulting in a black suspension which was stirred overnight under a H2 atmosphere (1 atm). The reaction mixture was filtered through celite and the filtrate concentrated, giving 170 mg of crude product as a yellow oil. The crude product was purified with the Biotage Isolera Four (KP-sil 25 g column, cyclohexane/EtOAc, EtOAc 12-100 %, 18 CV), yielding 2-((4'-((5- aminopyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)methyl)isoindoline-1,3-dione as a yellow gum (100 mg, 0.200 mmol, 67 %).
C26H19N3O3; Mw = 421.46 g.mol-1; 11H NMR (400 MHz, CDCl3) d 7.85 (dd, J = 5.4, 3.1 Hz, 2H), 7.75 (dd, J = 3.0, 0.7 Hz, 1H), 7.71 (dd, J = 5.5, 3.0 Hz, 2H), 7.63 (s, 1H), 7.56-7.52 (m, 2H), 7.47 (dt, J = 7.0, 1.8 Hz, 1H), 7.43-7.34 (m, 2H), 7.14-7.09 (m, 3H), 6.81 (dd, J = 8.7, 0.6 Hz, 1H), 4.90 (s, 2H). Example 19: 2-(4'-((5-Aminopyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)acetamide
Figure imgf000119_0001
Following the General procedure B, 2-(4'-((5-aminopyridin-2-yl)oxy)-[1,1'-biphenyl]-3- yl)acetamide was obtained in 89 % yield (17 mg, 0.053 mmol) from 2-(4'-((5-nitropyridin-2- yl)oxy)-[1,1'-biphenyl]-3-yl)acetamide (21 mg, 0.060 mmol).
C19H17N3O2; Mw = 319.36 g.mol-1; 11H NMR(400 MHz, CDCl3) d 7.74 (d, J = 2.9 Hz, 1H), 7.56 (d, J = 8.6 Hz, 2H), 7.53-7.46 (m, 2H), 7.42 (t, J = 7.6 Hz, 1H), 7.24 (s, 1H), 7.17-7.06 (m, 3H), 6.82 (d, J = 8.6 Hz, 1H), 5.37 (d, J = 24.0 Hz, 2H), 3.66 (s, 2H). The starting material was prepared as follows: Step 1: 2-(4'-((5-Nitropyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)acetonitrile
Figure imgf000119_0002
Following the General procedure E 2-(4'-((5-nitropyridin-2-yl)oxy)-[1,1'-biphenyl]-3- yl)acetonitrile was obtained in 99 % yield (432 mg, 1.7 mmol) from 2-(4-bromophenoxy)-5- nitropyridine (500 mg, 1.69 mmol; Example 10:Step 1) and 2-(3-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)phenyl)acetonitrile (536 mg, 2.20 mmol).
C19H13N3O3; Mw = 331.33 g.mol-1; 11H NMR (400 MHz, CDCl3) d 9.07 (d,J = 2.7 Hz, 1H), 8.51 (dd,J = 9.1, 2.8 Hz, 1H), 7.69-7.63 (m, 2H), 7.57 (d, J = 6.7 Hz, 2H), 7.47 (t,J = 8.0 Hz, 1H), 7.33 (d,J = 7.9 Hz, 1H), 7.28-7.24 (d, 2H), 7.10 (d,J = 9.0 Hz, 1H), 3.84 (s, 2H). Step 2: 2-(4'-((5-Nitropyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)acetamide
Figure imgf000119_0003
H2SO4 (500 ul; 9.0 mmol) was slowly added, at 0°C, to 2-(4'-((5-nitropyridin-2-yl)oxy)-[1,1'- biphenyl]-3-yl)acetonitrile (50 mg, 0.18 mmol). The mixture was stirred at RT overnight. The solution was poured into ice water and neutralized with 2M aqueous solution of NaOH. Then a 2M aqueous solution of HCl was used to get a solution at pH = 6. The aqueous layer was washed 3 times with EtOAc. The crude product was purified with the Biotage Isolera Four (KP-sil 25 g column, cyclohexane/EtOAc, EtOAc 0 to 100 %, 18 CV), yielding 2-(4'-((5- nitropyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)acetamide as a yellow gum (30 mg, 0.100 mmol, 57 %).
C19H15N3O4; Mw = 349.35 g.mol-1; 1H NMR (400 MHz, CDCl3) d 9.07 (d, J = 2.8 Hz, 1H), 8.51 (dd, J = 9.1, 2.8 Hz, 1H), 7.66 (d, J = 8.6 Hz, 2H), 7.57-7.51 (m, 2H), 7.46 (t, J = 7.7 Hz, 1H), 7.30 (d, 1H), 7.24 (d, 2H), 7.09 (d, J = 9.0 Hz, 1H), 5.43-5.32 (m, 2H), 3.67 (s, 2H) Example 20: 6-((2-(4-Aminophenoxy)-[1,1'-biphenyl]-4-yl)oxy)pyridin-3-amine
Figure imgf000120_0001
Following the General procedure B, 6-((2-(4-nitrophenoxy)-[1,1'-biphenyl]-4-yl)oxy)pyridin- 3-amine was obtained in 32 % yield (50 mg, 0.13 mmol) from 5-nitro-2-((2-(4-nitrophenoxy)- [1,1'-biphenyl]-4-yl)oxy)pyridine (166 mg, 0.387mmol). Then 6-((2-(4-nitrophenoxy)-[1,1'- biphenyl]-4-yl)oxy)pyridin-3-amine (50 mg, 0.130 mmol) was suspended in MeOH (1.5 mL, 0.08M). Pd/C (10 %, 6.7 mg) was added resulting in a black suspension. The mixture was stirred overnight under H2 atmosphere (1 atm). The reaction mixture was filtered through celite pad. The filtrate was concentrated. The crude product was purified with the Biotage Isolera Four (KP-sil 10 g column, cyclohexane/EtOAc, EtOAc 50-100 %, 22 CV), yielding 6- ((2-(4-aminophenoxy)-[1,1'-biphenyl]-4-yl)oxy)pyridin-3-amine as an orange solid (40 mg, 0.110 mmol, 86 %).
C23H19N3O2; Mw = 369.42 g.mol-1; 1H NMR (400 MHz, CDCl3) d 7.72 (d, J = 2.9 Hz, 1H), 7.57 (d, J = 7.1 Hz, 2H), 7.40-7.34 (m, 4H), 7.07 (dd, J = 8.6, 3.0 Hz, 1H), 6.84 (d, J = 8.8 Hz, 2H), 6.80-6.74 (m, 2H), 6.64-6.60 (m, 3H). The starting material was prepared as follows: Step 1: 4-Methoxy-[1,1'-biphenyl]-2-ol
Figure imgf000121_0001
To a 500-mL round-bottom flask phenylboronic acid (310 mg, 2.50 mmol), 2-bromo-5- methoxyphenol (0.41 g, 2.00 mmol), potassium carbonate (0.66 g, 4.70 mmol), water (4 mL) and 2-propanol (16 mL) were added under N2. Bis(triphenylphosphine)palladium(II) chloride (140 mg, 0.20 mmol) was then added and the yellow suspension was stirred at RT for 20 min before being heated to reflux (16 h). The mixture was filtered through a pad of celite and the filtrate was concentrated under vacuum. Water and EtOAc were added to the residue. The layers were separated and the aqueous layer was washed with EtOAc (twice). All the organic layers were combined, dried (Na2SO4), filtered and concentrated under vacuum. The crude product was purified with the Biotage Isolera Four (KP-sil 50 g column, hexane/EtOAc, EtOAc 2-20 %, 16 CV) yielding 4-methoxy-[1,1'-biphenyl]-2-ol as a brown oil (0.87 g, 84 %).
C13H12O2; Mw = 200.24 g.mol-1; 1H NMR (400 MHz, CDCl3) d 7.51-7.41 (m, 4H), 7.38 (d, J = 7.1 Hz, 1H), 7.19-7.12 (m, 1H), 6.57 (d, J = 7.1 Hz, 2H), 5.25 (s, 1H), 3.83 (s, 3H). Step 2: 4-Methoxy-2-(4-nitrophenoxy)-1,1'-biphenyl
Figure imgf000121_0002
Following the General procedure A, 4-methoxy-2-(4-nitrophenoxy)-1,1'-biphenyl was obtained in 66 % yield (0.255 g, 0.794 mmol) from 4-methoxy-[1,1'-biphenyl]-2-ol (0.244 g, 1.20 mmol) and 1-fluoro-4-nitrobenzene (0.200 g, 1.40 mmol).
C19H15NO4; Mw = 321.33 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.11-8.05 (m, 2H), 7.43 (d, J = 8.6 Hz, 1H), 7.41-7.37 (m, 2H), 7.29 (t, J = 7.4 Hz, 2H), 7.24-7.20 (m, 1H), 6.92 (dd, J = 8.6, 2.6 Hz, 1H), 6.90-6.85 (m, 2H), 6.68 (d, J = 2.6 Hz, 1H), 3.84 (s, 3H).
TLC (cyclohexane/EtOAc 9:1) Rf = 0.39. Step 3: 2-(4-Nitrophenoxy)-[1,1'-biphenyl]-4-ol
Figure imgf000122_0001
In a 100-mL round-bottom flask, 4-methoxy-2-(4-nitrophenoxy)-1,1'-biphenyl (255 mg, 0.794 mmol) was dissolved in CH2Cl2 (10 mL, 0.06M) under N2. The brown solution was cooled down to 0 °C. A CH2Cl2 solution of BBr3 (0.5 M, 2.38 mL, 1.19 mmol) was added dropwise during 1 h with a syringe pump. The solution was allowed to reach RT and then stirred for 4 h. The mixture was quenched at 0 °C with water, then neutralized with a 6M aqueous solution of NaOH. The layers were separated and the aqueous layer was washed with CH2Cl2 (twice), the combined organic layers were washed with brine, dried (Na2SO4), filtered and
concentrated. The crude product was purified with the Biotage Isolera Four (KP-sil 25 g column, cyclohexane/EtOAc, EtOAc 0-15 %, 22 CV) yielding 139 mg of 2-(4-nitrophenoxy)- [1,1'-biphenyl]-4-ol as a yellow solid (51 %).
C18H13NO4; Mw = 307.31 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.12-8.06 (m, 2H), 7.41- 7.35 (m, 3H), 7.29 (t, J = 7.5 Hz, 2H), 7.25-7.22 (m, 1H), 6.91-6.86 (m, 2H), 6.84 (dd, J = 8.4, 2.5 Hz, 1H), 6.64 (d, J = 2.5 Hz, 1H), 4.94 (s, 1H). Step 4: 5-Nitro-2-((2-(4-nitrophenoxy)-[1,1'-biphenyl]-4-yl)oxy)pyridine
Figure imgf000122_0002
Following the General procedure A, 5-nitro-2-((2-(4-nitrophenoxy)-[1,1'-biphenyl]-4- yl)oxy)pyridine was obtained in 86 % yield (166 mg, 0.387 mmol) from 2-(4-nitrophenoxy)- [1,1'-biphenyl]-4-ol (139 mg, 0.452 mmol) and 2-chloro-5-nitropyridine (72 mg, 0.452 mmol).
C23H15N3O6; Mw = 429.39 g.mol-1; 1H NMR (400 MHz, CDCl3) d 9.07 (d, J = 2.8 Hz, 1H), 8.52 (dd, J = 9.0, 2.8 Hz, 1H), 8.14-8.09 (m, 2H), 7.58 (d, J = 8.5 Hz, 1H), 7.49-7.44 (m, 2H), 7.38-7.28 (m, 3H), 7.19 (dd, J = 8.5, 2.4 Hz, 1H), 7.11 (d, J = 9.0 Hz, 1H), 7.00 (d, J = 2.4 Hz, 1H), 6.97-6.93 (m, 2H).
Example 21: 6,6'-([1,1'-Biphenyl]-2,4-diylbis(oxy))bis(pyridin-3-amine)
Figure imgf000123_0001
Following the General procedure B, 6,6'-([1,1'-biphenyl]-2,4-diylbis(oxy))bis(pyridin-3- amine) was obtained in 13 % yield (10 mg, 0.021 mmol) from 6,6'-([1,1'-biphenyl]-2,4- diylbis(oxy))bis(3-nitropyridine) (90 mg, 0.31 mmol).
C22H18N4O2; Mw = 370.41 g.mol-1; 1H NMR (400 MHz, CDCl3) d 7.75 (d, J = 2.9 Hz, 1H), 7.66 (d, J = 2.9 Hz, 1H), 7.53-7.48 (m, 2H), 7.38 (d, J = 8.5 Hz, 1H), 7.32 (t, J = 7.4 Hz, 3H), 7.09 (dd, J = 8.7, 2.9 Hz, 1H), 7.01-6.96 (m, 1H), 6.92 (dd, J = 8.4, 2.3 Hz, 1H), 6.82-6.78 (m, 2H), 6.62 (d, J = 8.7 Hz, 1H). The starting material was prepared as follows: Step 1: 6,6'-((4-Bromo-1,3-phenylene)bis(oxy))bis(3-nitropyridine)
Figure imgf000123_0002
Following the General procedure A, 6,6'-((4-bromo-1,3-phenylene)bis(oxy))bis(3- nitropyridine) was obtained in 97 % yield (320 mg, 0.74 mmol) from 4-bromoresorcinol (150 mg, 0.78 mmol) and 2-chloro-5-nitropyridine (260 mg, 1.60 mmol).
C16H9BrN4O6; Mw = 433.17 g.mol-1; 1H NMR (400 MHz, CDCl3) d 9.05 (dd, J = 2.8, 0.6 Hz, 1H), 9.02 (dd, J = 2.8, 0.6 Hz, 1H), 8.52 (ddd, J = 9.0, 8.3, 2.8 Hz, 2H), 7.73 (d, J = 8.7 Hz, 1H), 7.18-7.05 (m, 4H). Step 2: 6,6'-([1,1'-Biphenyl]-2,4-diylbis(oxy))bis(3-nitropyridine)
Figure imgf000124_0001
To a 250-mL round-bottom flask was added phenylboronic acid (120 mg, 0.96 mmol), 6,6'- ((4-bromo-1,3-phenylene)bis(oxy))bis(3-nitropyridine) (320 mg, 0.74 mmol), potassium carbonate (210 mg, 1.50 mmol), water (1 mL) and 2-propanol (6 mL) under N2.
Bis(triphenylphosphine)palladium(II) chloride (51 mg, 0.071 mmol) was then added and the yellow suspension was stirred at RT for 5 min before being heated to reflux (16 h). The mixture was filtered through a pad of celite and the filtrate was concentrated under vacuum. Water and EtOAc were added to the residue. The layers were separated and the aqueous layer was washed with EtOAc (twice). All the organic layers were combined, dried (Na2SO4), filtered and concentrated under vacuum. The crude product was purified with the Biotage Isolera Four (KP-sil 50 g column, cyclohexane/EtOAc, EtOAc 0-25 %, 22 CV) yielding 6,6'- ([1,1'-biphenyl]-2,4-diylbis(oxy))bis(3-nitropyridine) as a colorless oil (90 mg, 28%).
C22H14N4O6; Mw = 430.38 g.mol-1; 1H NMR (400 MHz, CDCl3) d 9.09 (dd, J = 2.8, 0.6 Hz, 1H), 8.92 (dd, J = 2.8, 0.6 Hz, 1H), 8.52 (dd, J = 9.0, 2.8 Hz, 1H), 8.34 (dd, J = 9.0, 2.8 Hz, 1H), 7.56 (d, J = 8.4 Hz, 1H), 7.45-7.40 (m, 2H), 7.35-7.27 (m, 3H), 7.23 (dd, J = 8.5, 2.4 Hz, 1H), 7.16-7.10 (m, 2H), 6.90 (dd, J = 9.0, 0.6 Hz, 1H). Example 22: 6-((2-(2-(4-Aminophenoxy)ethyl)-[1,1'-biphenyl]-4-yl)oxy)pyridin-3-amine
Figure imgf000124_0002
Following the General procedure B, 6-((2-(2-(4-aminophenoxy)ethyl)-[1,1'-biphenyl]-4- yl)oxy)pyridin-3-amine was obtained in 12 % yield (5 mg, 0.012 mmol) from 5-nitro-2-((2- (2-(4-nitrophenoxy)ethyl)-[1,1'-biphenyl]-4-yl)oxy)pyridine (48 mg, 0.10 mmol). C25H23N3O2; Mw = 397.48 g.mol-1; 1H NMR (400 MHz, CDCl3) d 7.75 (d, J = 3.0 Hz, 1H), 7.42-7.38 (m, 2H), 7.37-7.31 (m, 3H), 7.20 (d, J = 8.3 Hz, 1H), 7.13-7.07 (m, 2H), 6.96 (dd, J = 8.3, 2.5 Hz, 1H), 6.82 (d, J = 8.6 Hz, 1H), 6.59-6.51 (m, 4H), 3.92 (t, J = 7.4 Hz, 2H), 3.01 (t, J = 7.4 Hz, 2H). The starting material was prepared as follows: Step 1: 2-(2-Bromo-5-methoxyphenyl)acetic acid
Figure imgf000125_0001
In a 250-mL round-bottom flask, 2-(3-methoxyphenyl)acetic acid (1.50 g, 9.00 mmol) was dissolved in CH2Cl2 (25 mL, 0.36M). N-Bromsuccinimid (1.80 g, 9.90 mmol) was added portionwise at 0 °C and under N2. The colorless solution was stirred at RT for 3 h. Water was added to the mixture and the layers were separated. The aqueous layer was washed with CH2Cl2. All the organic layers were combined and washed with brine, dried (Na2SO4), filtered and concentrated yielding 2-(2-bromo-5-methoxyphenyl)acetic acid as an orange solid (2.22 g, 100 %).
C9H9BrO3; Mw = 245.07 g.mol-1; 1H NMR (400 MHz, CDCl3) d 7.46 (d, J = 8.8 Hz, 1H), 6.86 (d, J = 3.0 Hz, 1H), 6.73 (dd, J = 8.8, 3.0 Hz, 1H), 3.81 (s, 2H), 3.79 (s, 3H). Step 2: 2-(2-Bromo-5-methoxyphenyl)ethan-1-ol
Figure imgf000125_0002
In a 250-mL round-bottom flask, 2-(2-bromo-5-methoxyphenyl)acetic acid (2.22 g, 9.06 mmol) was dissolved in in dry THF (16 mL, 0.55M). The yellow solution was cooled down to 0 °C and a 2.4M THF solution of LiAlH4 (2.30 ml, 5.5 mmol) was added dropwise. The yellow solution was stirred at RT (2 h). The reaction mixture was quenched at 0 °C with 1M NaOH (10 mL). THF was evaporated, CH2Cl2 and water were added. The cloudy mixture was stirred for 1 h. The layers were separated and the aqueous layer was washed with CH2Cl2. All the organic layers were combined and washed with 1M HCl, brine, dried (Na2SO4), filtered and concentrated, yielding 2-(2-bromo-5-methoxyphenyl)ethan-1-ol as a pale yellow oil (1.35 g, 65 %).
C9H11BrO2; Mw = 231.09 g.mol-1; 1H NMR (400 MHz, CDCl3) d 7.43 (d, J = 8.8 Hz, 1H), 6.83 (d, J = 3.0 Hz, 1H), 6.67 (dd, J = 8.8, 3.1 Hz, 1H), 3.88 (t, J = 6.6 Hz, 2H), 3.78 (s, 3H), 2.99 (t, J = 6.6 Hz, 2H). Step 3: 1-Bromo-4-methoxy-2-(2-(4-nitrophenoxy)ethyl)benzene
Figure imgf000126_0001
In a 25-mL round-bottom flask, 2-(2-bromo-5-methoxyphenyl)ethan-1-ol (190 mg, 0.82 mmol) was dissolved in dry DMF (3 mL, 0.3M). NaH (60 %, 42 mg, 1.00 mmol) was added portionwise resulting in a dark yellow suspension. The solution was stirred at RT (15 min), then 1-fluoro-4-nitrobenzene (110 mg, 0.78 mmol) was added. The dark green suspension was stirred overnight at RT. Water was added to quench the mixture, followed by EtOAc. The layers are separated. The aqueous layer was washed with EtOAc. All organic layers were combined, washed with brine, dried (Na2SO4), filtered and concentrated. The crude product was purified with the Biotage Isolera Four (KP-sil 25 g column, cyclohexane/EtOAc, EtOAc 0-20 %, 16 CV) yielding 1-bromo-4-methoxy-2-(2-(4-nitrophenoxy)ethyl)benzene as a yellow solid (150 mg, 60 %).
C15H14BrNO4; Mw = 352.18 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.22-8.16 (m, 2H), 7.45 (d, J = 8.8 Hz, 1H), 6.98-6.93 (m, 2H), 6.88 (d, J = 3.0 Hz, 1H), 6.70 (dd, J = 8.8, 3.0 Hz, 1H), 4.28 (t, J = 7.0 Hz, 2H), 3.79 (s, 3H), 3.23 (t, J = 7.0 Hz, 2H). TLC (cyclohexane/EtOAc 9:1) Rf = 0.28. Step 4: 4-Methoxy-2-(2-(4-nitrophenoxy)ethyl)-1,1'-biphenyl
Figure imgf000126_0002
To a 250-mL round-bottom flask was added phenylboronic acid (63 mg, 0.51 mmol), 1- bromo-4-methoxy-2-(2-(4-nitrophenoxy)ethyl)benzene (150 mg, 0.43 mmol), potassium carbonate (154 mg, 1.11 mmol), water (1 mL) and 2-propanol (4 mL) under N2.
Bis(triphenylphosphine)palladium(II) chloride (39 mg, 0.054 mmol) was then added and the yellow suspension was stirred at RT for 5 min before being heated to reflux (16 h). The mixture was filtered through a pad of celite and the filtrate was concentrated under vacuum. Water and EtOAc were added to the residue. The layers were separated and the aqueous layer was washed with EtOAc (twice). All the organic layers were combined, dried (Na2SO4), filtered and concentrated under vacuum. The crude product was purified with the Biotage Isolera Four (KP-sil 50 g column, cyclohexane/EtOAc, EtOAc 0-30 %, 13 CV) yielding 4- methoxy-2-(2-(4-nitrophenoxy)ethyl)-1,1'-biphenyl as a colorless oil (120 mg, 81 %).
C21H19NO4; Mw = 349.39 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.12-8.06 (m, 2H), 7.47- 7.38 (m, 3H), 7.34-7.30 (m, 2H), 7.19 (d, J = 8.4 Hz, 1H), 6.92 (d, J= 2.6 Hz, 1H), 6.86 (dd, J = 8.4, 2.7 Hz, 1H), 6.70-6.64 (m, 2H), 4.06 (t, J = 7.4 Hz, 2H), 3.85 (s, 3H), 3.09 (t, J = 7.4 Hz, 2H). Step 5: 2-(2-(4-Nitrophenoxy)ethyl)-[1,1'-biphenyl]-4-ol
Figure imgf000127_0001
In a 100-mL round-bottom flask, 4-methoxy-2-(2-(4-nitrophenoxy)ethyl)-1,1'-biphenyl (115 mg, 0.329 mmol) was dissolved in CH2Cl2 (4 mL, 0.9M) under N2. The brown solution was cooled down to 0 °C. A CH2Cl2 solution of BBr3 (0.5 M, 1.0 mL, 0.50 mmol) was added dropwise during 30 min with a syringe pump. The solution was allowed to reach RT and then stirred for 2.3 h. The mixture was quenched at 0 °C with water, then neutralized with a 6M aqueous solution of NaOH. The layers were separated and the aqueous layer was re-extracted with CH2Cl2 (twice). The combined organic layers were washed with brine, dried (Na2SO4), filtered and concentrated. The crude product was purified with the Biotage Isolera Four (KP- sil 25 g column, cyclohexane/EtOAc, EtOAc 5-40 %, 13 CV), yielding 2-(2-(4- nitrophenoxy)ethyl)-[1,1'-biphenyl]-4-ol as a yellow oil (47 mg, 41 %).
C20H17NO4; Mw = 349.39 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.13-8.07 (m, 2H), 7.47- 7.38 (m, 3H), 7.33-7.28 (m, 2H), 7.13 (d, J = 8.2 Hz, 1H), 6.86 (d, J = 2.7 Hz, 1H), 6.78 (dd, J = 8.3, 2.7 Hz, 1H), 6.70-6.65 (m, 2H), 4.76 (s, 1H), 4.05 (t, J = 7.4 Hz, 2H), 3.07 (t, J = 7.4 Hz, 2H). Step 6: 5-Nitro-2-((2-(2-(4-nitrophenoxy)ethyl)-[1,1'-biphenyl]-4-yl)oxy)pyridine
Figure imgf000128_0001
Following the General procedure A, 5-nitro-2-((2-(2-(4-nitrophenoxy)ethyl)-[1,1'-biphenyl]- 4-yl)oxy)pyridine was obtained in 75 % yield (48 mg, 0.10 mmol) from 2-(2-(4- nitrophenoxy)ethyl)-[1,1'-biphenyl]-4-ol (47 mg, 0.14 mmol) and 2-chloro-5-nitropyridine (27 mg, 0.17 mmol).
C25H19N3O6; Mw = 457.44 g.mol-1; 1H NMR (400 MHz, CDCl3) d 9.08 (dd, J = 2.8, 0.6 Hz, 1H), 8.51 (dd, J = 9.0, 2.8 Hz, 1H), 8.13-8.07 (m, 2H), 7.49-7.43 (m, 3H), 7.40-7.32 (m, 3H), 7.20 (d, J = 2.4 Hz, 1H), 7.15-7.08 (m, 2H), 6.72-6.66 (m, 2H), 4.08 (t, J = 7.2 Hz, 2H), 3.14 (t, J = 7.2 Hz, 2H). Example 23: N-Methyl-6-((6-phenylpyridin-3-yl)oxy)pyridin-3-amine
Figure imgf000128_0002
To a solution of freshly prepared MeONa (4.4 equiv, 2.609 mmol) in MeOH (0.15 M) under inert atmosphere, 6-((6-phenylpyridin-3-yl)oxy)pyridin-3-amine (1.0 equiv, 0.588 mmol, 155 mg; Example 3) was added. The so obtained suspension was stirred for 0.5 h and became a solution. A suspension of para-formaldehyde (1.4 equiv, 0.824 mmol, 27 mg) in MeOH (1 ml) was then poured into the previous solution and the mixture was stirred for 14 h. NaBH4 (2.0 equiv, 1.165 mmol, 45 mg) was added to the reaction and the mixture was stirred for 3 h (completion monitored by TLC). The mixture was finally diluted with H2O at 0 °C. The aqueous layer was extracted three times with EtOAc. The combined organic layers were dried over Na2SO4, filtered-off and concentrated. The crude product was purified by combi flash column chromatography using EtOAc/cyclohexane (15 % to 70 %) as the eluent, to afford N- methyl-6-((6-phenylpyridin-3-yl)oxy)pyridin-3-amine (0.436 mmol, 121 mg, 74 % yield). C17H15N3O; Mw = 277.33 g.mol-1; Solid; 1H NMR (400 MHz, CDCl3) d 8.52 (d, J = 2.7 Hz, 1 H), 7.95 (d, J = 7.5 Hz, 2 H), 7.71 (d, J = 8.6 Hz, 1 H), 7.63 (d, J = 3.0 Hz, 1 H), 7.51-7.42 (m, 3 H), 7.38 (t, J = 7.3 Hz, 1 H), 7.05 (dd, J = 8.7, 3.0 Hz, 1 H), 6.89 (d, J = 8.7 Hz, 1 H), 2.86 (s, 3 H). Example 24: 6-(4-(Pyridin-2-yl)phenoxy)pyridin-3-amine
Figure imgf000129_0001
Following the General procedure B, 6-(4-(pyridin-2-yl)phenoxy)pyridin-3-amine was obtained in 67 % yield (0.23 mmol, 60 mg) from 5-nitro-2-(4-(pyridin-2-yl)phenoxy)pyridine (100 mg, 0.341 mmol).
C16H13N3O; Mw = 263.30 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.67 (dd, J = 4.8, 0.8 Hz, 1H), 7.98 (d, J = 8.7 Hz, 2H), 7.76-7.66 (m, 3H), 7.23-7.17 (m, 1H), 7.15 (d, J = 8.8 Hz, 2H), 7.12-7.06 (m, 1H), 6.81 (d, J = 8.6 Hz, 1H), 3.24 (s, 2H). The starting material was prepared as follows: Step 1: 5-Nitro-2-(4-(pyridin-2-yl)phenoxy)pyridine
Figure imgf000129_0002
Following the General procedure A, 5-nitro-2-(4-(pyridin-2-yl)phenoxy)pyridine was obtained in 97 % yield (500 mg, 1.70 mmol) from 4-(pyridin-2-yl)phenol (1.75 mmol, 0.300 g) and 2-chloro-5-nitropyridine (1.75 mmol, 0.278 g). C16H11N3O3; Mw = 293.28 g.mol-1; 1H NMR (300 MHz, CDCl3) d 9.11-9.05 (m, 1H), 8.91- 8.85 (m, 1H), 8.62 (d, J = 4.8 Hz, 1H), 8.52 (dd, J = 9.1, 2.8 Hz, 1H), 7.94-7.85 (m, 1H), 7.67 (d, J = 8.6 Hz, 2H), 7.42-7.36 (m, 1H), 7.29 (d, J = 8.6 Hz, 2H), 7.11 (d, J = 9.0 Hz, 1H). Example 25: 6-(4-(Pyridin-3-yl)phenoxy)pyridin-3-amine
Figure imgf000130_0001
Following the General procedure B, 6-(4-(pyridin-3-yl)phenoxy)pyridin-3-amine was obtained in 52 % yield (1.25 mmol, 330 mg) from the 5-nitro-2-(4-(pyridin-3- yl)phenoxy)pyridine (710 mg, 2.42 mmol).
C16H13N3O; Mw = 263.30 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.85-8.81 (m, 1H), 8.56 (dd, J = 4.8, 1.6 Hz, 1H), 7.84 (ddd, J = 7.9, 2.4, 1.6 Hz, 1H), 7.74 (dd, J = 3.0, 0.6 Hz, 1H), 7.55 (d, J = 8.7 Hz, 2H), 7.34 (ddd, J = 7.9, 4.8, 0.9 Hz, 1H), 7.17 (d, J = 8.7 Hz, 2H), 7.11 (dd, J = 8.6, 3.0 Hz, 1H), 6.83 (dd, J = 8.6, 0.7 Hz, 1H), 3.48 (s, 2H). The starting material was prepared as follows: Step 1: 5-Nitro-2-(4-(pyridin-3-yl)phenoxy)pyridine
Figure imgf000130_0002
Following the General procedure A, 5-nitro-2-(4-(pyridin-3-yl)phenoxy)pyridine was obtained in 40 % yield (270 mg, 0.92 mmol) from 4-(pyridin-3-yl)phenol (2.34 mmol, 0.400 g) and 2-chloro-5-nitropyridine (2.34 mmol, 0.370 g).
C16H11N3O3; Mw = 293.28 g.mol-1; 1H NMR (300 MHz, CDCl3) d 9.07 (dd, J = 2.8, 0.6 Hz, 1H), 8.70 (ddd, J = 4.8, 1.7, 1.1 Hz, 1H), 8.50 (dd, J = 9.1, 2.8 Hz, 1H), 8.10 (d, J = 8.9 Hz, 2H), 7.79-7.74 (m, 2H), 7.28 (d, J = 9.0 Hz, 3H), 7.08 (dd, J = 9.1, 0.6 Hz, 1H). Example 26: 6-(4-(Pyridin-4-yl)phenoxy)pyridin-3-amine
Figure imgf000131_0001
Following the General procedure B, 6-(4-(pyridin-4-yl)phenoxy)pyridin-3-amine was obtained in 57 % yield (0.40 mmol, 100 mg) from the 5-nitro-2-(4-(pyridin-4- yl)phenoxy)pyridine (19 mg, 0.672 mmol).
16H13N3O; Mw = 263.30 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.64 (dd, J = 4.6, 1.6 Hz, 2H), 7.75 (d, J = 3.0 Hz, 1H), 7.66-7.60 (m, 2H), 7.50 (dd, J = 4.6, 1.6 Hz, 2H), 7.20-7.10 (m, 3H), 6.85 (d, J = 8.6 Hz, 1H).
The starting material was prepared as follows: Step 1: 5-Nitro-2-(4-(pyridin-4-yl)phenoxy)pyridine
Figure imgf000131_0002
Following the General procedure E, 5-nitro-2-(4-(pyridin-4-yl)phenoxy)pyridine was obtained in 95 % yield (33 mg, 0.11 mmol) from 2-(4-bromophenoxy)-5-nitropyridine (50 mg, 0.17 mmol; Example 10: Step 1) and pyridin-4-ylboronic acid (25 mg, 0.20 mmol).
C16H11N3O3; Mw = 293.28 g.mol-1; 1H NMR (300 MHz, CDCl3) d 9.06 (d, J = 2.7 Hz, 1H), 8.69 (d, J = 6.2 Hz, 2H), 8.62 (dd, J = 9.1, 2.7 Hz, 1H), 7.70 (d, J = 8.7 Hz, 2H), 7.52 (d, J = 6.2 Hz, 2H), 7.30 (d, J = 8.7 Hz, 2H), 7.11 (d, J = 9.1 Hz, 1H). Example 27: 6-((4'-Fluoro-[1,1'-biphenyl]-4-yl)oxy)-N-methylpyridin-3-amine
Figure imgf000131_0003
Following the General procedure C, 6-((4'-fluoro-[1,1'-biphenyl]-4-yl)oxy)-N-methylpyridin- 3-amine was obtained in 73 % yield (0.221 mmol, 85 mg) from 6-((4'-fluoro-[1,1'-biphenyl]- 4-yl)oxy)pyridin-3-amine (0.303 mmol, 65 mg; expl.10). C18H15FN2O; Mw = 294.33 g.mol-1; 1H NMR (400 MHz, CDCl3) d 7.68 (d, J = 3.0 Hz, 1H), 7.53-7.47 (m, 4H), 7.14-7.08 (m, 4H), 7.05 (dd, J = 8.7, 3.0 Hz, 1H), 6.86 (d, J = 8.7 Hz, 1H), 2.86 (s, 3H). Example 28: 6-((4'-Fluoro-[1,1'-biphenyl]-4-yl)oxy)-2-methylpyridin-3-amine
Figure imgf000132_0001
Following the General procedure B, 6-((4'-fluoro-[1,1'-biphenyl]-4-yl)oxy)-2-methylpyridin- 3-amine was obtained in 72 % yield (1.11 mmol, 330 mg) from 6-((4'-fluoro-[1,1'-biphenyl]- 4-yl)oxy)-2-methyl-3-nitropyridine (1.54 mmol, 500 mg).
C18H15FN2O; Mw = 294.33 g.mol-1; 1H NMR (400 MHz, DMSO-d6) d 7.71-7.63 (m, 2H), 7.63-7.56 (m, 2H), 7.32-7.22 (m, 2H), 7.08 (d, J = 8.3 Hz, 1H), 7.02-6.96 (m, 2H), 6.67 (d, J = 8.3 Hz, 1H), 4.90 (s, 2H), 2.18 (s, 3H).
The starting materials were prepared as followed: Step 1: 6-(4-Bromophenoxy)-2-methyl-3-nitropyridine
Figure imgf000132_0002
Following the General procedure A, 6-(4-bromophenoxy)-2-methyl-3-nitropyridine was obtained in 93 % yield (26.9 mmol, 8.31 g) from 6-chloro-2-methyl-3-nitropyridine (29 mmol, 5.00 g) and 4-bromophenol (32 mmol, 5.50 g).
C 1H
12H9BrN2O3; Mw = 309.12 g.mol-1; NMR (400 MHz, CDCl3) d 8.38 (d, J = 8.9 Hz, 1H), 7.72-7.42 (m, 2H), 7.15-6.99 (m, 2H), 6.84 (d, J = 8.9 Hz, 1H), 2.73 (s, 3H). Step 2: 6-((4'-Fluoro-[1,1'-biphenyl]-4-yl)oxy)-2-methyl-3-nitropyridine
Figure imgf000132_0003
Following the General procedure E, a mixture of (4-fluorophenyl)boronic acid (4.85 mmol, 679 mg), 6-(4-bromophenoxy)-2-methyl-3-nitropyridine (3.23 mmol, 1.00 g), K2CO3 (8.09 mmol, 1.12 g), and Pd(PPh3)4 (0.162 mmol, 187 mg, 5% mol) in 4:1 mixture of dioxane/H2O (0.1 M) was converted to 6-((4'-fluoro-[1,1'-biphenyl]-4-yl)oxy)-2-methyl-3-nitropyridine in 90 % yield (2.94 mmol, 900 mg).
C18H13FN2O3; Mw = 324.31 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.38 (d, J = 8.9 Hz, 1H), 7.62-7.58 (m, 2H), 7.58-7.53 (m, 2H), 7.25-7.21 (m, 2H), 7.19-7.11 (m, 2H), 6.84 (dd, J = 8.9, 0.7 Hz, 1H), 2.77 (s, 3H). Example 29: 6-((4'-Fluoro-[1,1'-biphenyl]-4-yl)oxy)-4-methylpyridin-3-amine
Figure imgf000133_0001
Following the General procedure B, 6-((4'-fluoro-[1,1'-biphenyl]-4-yl)oxy)-4-methylpyridin- 3-amine was obtained in 86 % yield (476 mmol, 0.140 g) from 2-((4'-fluoro-[1,1'-biphenyl]-4- yl)oxy)-4-methyl-5-nitropyridine (555 mmol, 0.180 g).
C18H15FN2O; Mw = 294.33 g.mol-1; 1H NMR (400 MHz, CDCl3) d 7.69 (s, 1H), 7.54-7.46 (m, 4H), 7.14-7.06 (m, 4H), 6.72 (s, 1H), 2.20 (s, 3H), 2.07 (s, 2H).
The starting materials were prepared as followed: Step1: 2-(4-Bromophenoxy)-4-methyl-5-nitropyridine
Figure imgf000133_0002
Following the General procedure A, 2-(4-bromophenoxy)-4-methyl-5-nitropyridine was obtained in 40 % yield (11 mmol, 3.50 g) from 4-bromophenol (31.9 mmol, 5.51 g) and 2- chloro-4-methyl-5-nitropyridine (29 mmol, 5.00 g).
C12H9BrN2O3; Mw= 309.12 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.86 (s, 1H), 7.55 (d, J =8.9 Hz, 2H), 7.04 (d, J = 8.9 Hz, 2H), 6.86 (d, J = 1.0 Hz, 1H), 2.68 (app d, J = 1.0 Hz, 3H).
Step 2: 2-((4'-Fluoro-[1,1'-biphenyl]-4-yl)oxy)-4-methyl-5-nitropyridine Following the General procedure E, 2-((4'-fluoro-[1,1'-biphenyl]-4-yl)oxy)-4-methyl-5- nitropyridine was obtained in 82 % yield (1.13 mmol, 0.30 g) from 2-(4-bromophenoxy)-4- methyl-5-nitropyridine (1.13 mmol, 0.350 mg) and (4-fluorophenyl)boronic acid (1.70 mmol, 0.238 mg).
C18H13FN2O3; Mw = 324.31 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.91 (s, 1H), 7.63-7.58 (m, 2H), 7.57-7.52 (m, 2H), 7.23-7.19 (m, 2H), 7.17-7.11 (m, 2H), 6.89 (d, J = 0.9 Hz, 1H), 2.69 (s, 3H). Example 30: 2-Methyl-6-((6-phenylpyridin-3-yl)oxy)pyridin-3-amine
Figure imgf000134_0001
Following the General procedure B, 2-methyl-6-((6-phenylpyridin-3-yl)oxy)pyridin-3-amine was obtained in 89 % yield (1.08 mmol, 300 mg) from 2-methyl-3-nitro-6-((6-phenylpyridin- 3-yl)oxy)pyridine (1.22 mmol, 374 mg).
C17H15N3O; Mw = 277.33 g.mol-1; 1H NMR (400 MHz, DMSO-d6) d 8.40 (d, J = 2.5 Hz, 1H), 8.15-7.98 (m, 2H), 7.94 (d, J = 8.7 Hz, 1H), 7.55-7.45(m, 3H), 7.44-7.37 (m, 1H), 7.10 (d, J = 8.4 Hz, 1H), 6.75 (d, J = 8.4 Hz, 1H), 4.93 (s, 2H), 2.17 (s, 3H). The starting material was prepared as follows: Step 1: 6-Phenylpyridin-3-ol
Figure imgf000134_0002
Following the General procedure D, a mixture of phenylboronic acid (11.49 mmol, 1.40 g), 6- bromopyridin-3-ol (5.75 mmol, 1.00 g), Na2CO3 (11.49 mmol, 1.22 g), and Pd(PPh3)4 (0.287 mmol, 332 mg) in a 3:1 mixture of DME/H2O (0.32 M) was converted to 6-phenylpyridin-3- ol in 61 % yield (3.50 mmol, 600 mg). C11H9NO; Mw = 171.20 g.mol-1; 1H NMR (400 MHz, DMSO-d6) d 9.19 (s, 1H), 7.40-7.34 (m, 1H), 7.15-7.09 (m, 2H), 6.95 (dd, J = 8.6, 0.7 Hz, 1H), 6.65-6.57 (m, 2H), 6.54-6.49 (m, 1H), 6.40 (dd, J = 8.6, 2.9 Hz, 1H). Step 2: 2-Methyl-3-nitro-6-((6-phenylpyridin-3-yl)oxy)pyridine
Figure imgf000135_0001
Following the General procedure A, 2-methyl-3-nitro-6-((6-phenylpyridin-3-yl)oxy)pyridine was obtained in 95 % yield (1.22 mmol, 374 mg) from 6-chloro-2-methyl-3-nitropyridine (1.27 mmol, 220 mg).
C17H13N3O3; Mw = 307.31 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.60 (dd, J = 2.8, 0.7 Hz, 1H), 8.42 (d, J = 8.9 Hz, 1H), 8.09-7.93 (m, 2H), 7.82 (dd, J = 8.7, 0.7 Hz, 1H), 7.62 (dd, J = 8.7, 2.8 Hz, 1H), 7.56-7.40 (m, 3H), 6.96 (d, J = 8.9 Hz, 1H), 2.73 (s, 3H). Example 31: 4-Methyl-6-((6-phenylpyridin-3-yl)oxy)pyridin-3-amine
Figure imgf000135_0002
Following the General procedure B, 4-methyl-6-((6-phenylpyridin-3-yl)oxy)pyridin-3-amine was obtained in 78 % yield (0.30 mmol, 84 mg) from 4-methyl-5-nitro-2-((6-phenylpyridin-3- yl)oxy)pyridine (0.39 mmol, 120 mg).
C17H15N3O; Mw = 277.33 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.51 (dd, J = 2.8, 0.7 Hz, 1H), 7.98-7.90 (m, 2H), 7.71 (dd, J = 8.6, 0.7 Hz, 1H), 7.64 (s, 1H), 7.50-7.42 (m, 3H), 7.41- 7.35 (m, 1H), 6.77 (s, 1H), 3.49 (s, 2H), 2.22 (s, 3H). The starting material was prepared as follows: Step 1: 4-Methyl-5-nitro-2-((6-phenylpyridin-3-yl)oxy)pyridine
Figure imgf000135_0003
Following the General procedure A, 4-methyl-5-nitro-2-((6-phenylpyridin-3-yl)oxy)pyridine was obtained in 76 % yield (0.664 mmol, 204 mg) 6-phenylpyridin-3-ol (0.956 mmol, 164 mg) and 2-chloro-4-methyl-5-nitropyridine (0.869 mmol, 150 mg).
C17H13N3O3; Mw = 307.31 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.87 (s, 1H), 8.57 (d, J = 2.7 Hz, 1H), 8.02-7.97 (m, 2H), 7.82 (d, J = 8.6 Hz, 1H), 7.60 (dd, J = 8.6, 2.7 Hz, 1H), 7.52- 7.39 (m, 3H), 6.97 (s, 1H), 2.71 (s, 3H). Example 32: 2-Methyl-6-(4-(thiazol-5-yl)phenoxy)pyridin-3-amine
Figure imgf000136_0001
Following the General procedure B, 2-methyl-6-(4-(thiazol-5-yl)phenoxy)pyridin-3-amine was obtained in 64 % yield (0.42 mmol, 120 mg) from 5-(4-((6-methyl-5-nitropyridin-2- yl)oxy)phenyl)thiazole (0.66 mmol, 206 mg).
C15H13N3OS; Mw = 283.35 g.mol-1; 1H NMR (400 MHz, DMSO-d6) d 9.04 (d, J = 0.7 Hz, 1H), 8.22 (d, J = 0.7 Hz, 1H), 7.63 (d, J = 8.8 Hz, 2H), 7.08 (d, J = 8.3 Hz, 1H), 6.99 (d, J = 8.7 Hz, 2H), 6.68 (d, J = 8.4 Hz, 1H), 4.92 (s, 2H), 2.17 (s, 3H). The starting material was prepared as follows: Step 1: 5-(4-((6-Methyl-5-nitropyridin-2-yl)oxy)phenyl)thiazole
Figure imgf000136_0002
Following the General procedure D, a mixture of 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)thiazole (4.89 mmol, 1.03 g), 6-(4-bromophenoxy)-2-methyl-3-nitropyridine (3.26 mmol, 1.01 g; expl.28, Step 1), Na2CO3 (8.15 mmol, 864 mg), and Pd(PPh3)4 (0.163 mmol, 188 mg, 5% mol) in a 4:1 mixture of dioxane/H2O (0.06 M) was converted to 5-(4-((6-methyl-5- nitropyridin-2-yl)oxy)phenyl)thiazole in 20 % yield (0.67 mmol, 209 mg).
C15H11N3O3S; Mw = 313.33 g.mol-1; 1H NMR (400 MHz, DMSO-d6) d 9.10 (app d, J = 0.7 Hz, 1H), 8.52 (d, J = 8.9 Hz, 1H), 8.33 (s, 1H), 7.91-7.71 (m, 2H), 7.40-7.21 (m, 2H), 7.11 (d, J = 8.9 Hz, 1H), 2.60 (s, 3H). Example 33: 4-Methyl-6-(4-(thiazol-5-yl)phenoxy)pyridin-3-amine
Figure imgf000137_0001
Following the General procedure B, 4-methyl-6-(4-(thiazol-5-yl)phenoxy)pyridin-3-amine was obtained in 33 % yield (0.424 mmol, 0.120 g) from 5-(4-((4-methyl-5-nitropyridin-2- yl)oxy)phenyl)thiazole (1.02 mmol, 0.320 g).
C15H13N3OS; Mw = 283.35 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.72 (s, 1H), 8.00 (s, 1H), 7.67 (s, 1H), 7.54 (d, J = 8.7 Hz, 2H), 7.09 (d, J = 8.7 Hz, 2H), 6.73 (s, 1H), 2.21 (s, 3H), 2.04 (s, 2H). The starting material was prepared as follows: Step 1: 5-(4-((4-Methyl-5-nitropyridin-2-yl)oxy)phenyl)thiazole
Figure imgf000137_0002
Following the General procedure E, 5-(4-((4-methyl-5-nitropyridin-2-yl)oxy)phenyl)thiazole was obtained in 40 % yield (1.02 mmol, 0.320 g) from 5-(4,4,5,5-tetramethyl-1,3-dioxolan-2- yl)thiazole (3.78 mmol, 0.799 mg) and 2-(4-bromophenoxy)-4-methyl-5-nitropyridine (2.52 mmol, 0.780 g; expl.29, Step 1).
C15H11N3O3S; Mw = 313.33 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.89 (s, 1H), 8.78 (s, 1H), 8.07 (s, 1H), 7.65 (d, J = 8.7 Hz, 2H), 7.21 (d, J = 8.7 Hz, 2H), 6.90 (s, 1H), 2.69 (s, 3H). Example 34: N-Methyl-6-(4-(thiazol-5-yl)phenoxy)pyridin-3-amine
Figure imgf000137_0003
Following the General procedure C, N-methyl-6-(4-(thiazol-5-yl)phenoxy)pyridin-3-amine was obtained in 59 % yield (0.18 mmol, 50 mg) from 6-(4-(thiazol-5-yl)phenoxy)pyridin-3- amine (0.30 mmol, 80 mg; expl.11). C15H13N3OS; Mw = 283.35 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.72 (s, 1H), 8.00 (s, 1H), 7.67 (d, J = 3.0 Hz, 1H), 7.57-7.51 (m, 2H), 7.13-7.07 (m, 2H), 7.05 (dd, J = 8.7, 3.1 Hz, 1H), 6.86 (d, J = 8.7 Hz, 1H), 2.86 (s, 3H). Example 35: 2-Methyl-6-(4-(thiazol-2-yl)phenoxy)pyridin-3-amine
Figure imgf000138_0001
Following the General procedure B, 2-methyl-6-(4-(thiazol-2-yl)phenoxy)pyridin-3-amine was obtained in 68 % yield (0.434 mmol, 123 mg) from 2-(4-((6-methyl-5-nitropyridin-2- yl)oxy)phenyl)thiazole (0.638 mmol, 200 mg).
C15H13N3OS; Mw = 283.35 g.mol-1; 1H NMR (400 MHz, CDCl3) d 7.85 (d, J = 8.8 Hz, 2H), 7.76 (d, J =3.3 Hz, 1H), 7.22 (d, J =3.3 Hz, 1H), 7.01 (d, J =8.8 Hz, 2H), 6.97 (d, J = 8.4 Hz, 1H), 6.59 (d, J = 8.4 Hz, 1H), 2.30 (s, 3H). The starting material was prepared as follows: Step 1: 2-(4-((6-Methyl-5-nitropyridin-2-yl)oxy)phenyl)thiazole
Figure imgf000138_0002
Following the General procedure A, 2-(4-((6-methyl-5-nitropyridin-2-yl)oxy)phenyl)thiazole was obtained in 51 % yield (1.44 mmol, 0.450 g) from 4-(2-thiazolyl)phenol (2.82 mmol, 500 mg) and 6-chloro-2-methyl-3-nitropyridine (3.10 mmol, 536 mg).
C15H11N3O3S; Mw = 313.33 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.39 (d, J = 8.9 Hz, 1H), 8.04 (d, J =8.5 Hz, 2H), 7.88 (s, 1H), 7.36 (s, 1H), 7.25 (d, J = 8.2 Hz, 2H), 6.87 (d, J = 8.9 Hz, 1H), 2.74 (s, 3H). Example 36: 4-Methyl-6-(4-(thiazol-2-yl)phenoxy)pyridin-3-amine
Figure imgf000138_0003
Following the General procedure F, 4-methyl-6-(4-(thiazol-2-yl)phenoxy)pyridin-3-amine was obtained in 94 % yield (1.16 mmol, 330 mg) from 2-(4-((4-methyl-5-nitropyridin-2- yl)oxy)phenyl)thiazole (1.24 mmol, 390 mg).
C15H13N3OS; Mw = 283.35 g.mol-1; 1H NMR (400 MHz, CDCl3) d 7.95-7.90 (m, 2H), 7.83 (d, J = 3.3 Hz, 1H), 7.69 (s, 1H), 7.28 (d, J = 3.3 Hz, 1H), 7.12-7.07 (m, 2H), 6.73 (s, 1H), 2.21 (s, 3H). The starting material was prepared as follows: Step 1: 2-(4-((4-Methyl-5-nitropyridin-2-yl)oxy)phenyl)thiazole
Figure imgf000139_0001
Following the General procedure A, 2-(4-((4-methyl-5-nitropyridin-2-yl)oxy)phenyl)thiazole was obtained in 72 % yield (1.24 mmol, 390 mg) from 4-(thiazol-2-yl)phenol (1.91 mmol, 339 mg) and 2-chloro-4-methyl-5-nitropyridine (1.74 mmol, 300 mg).
C15H11N3O3S; Mw = 313.33 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.89 (s, 1H), 8.09-7.99 (m, 2H), 7.87 (d, J = 3.3 Hz, 1H), 7.34 (d, J = 3.3 Hz, 1H), 7.25-7.20 (m, 2H), 6.90-6.87 (m, 1H), 2.68 (s 3H).
Example 37: 6-((2,2'-Dimethyl-[1,1'-biphenyl]-4-yl)oxy)-2-methylpyridin-3-amine
Figure imgf000139_0002
Following the General procedure B, 6-((2,2'-dimethyl-[1,1'-biphenyl]-4-yl)oxy)-2- methylpyridin-3-amine was obtained in 80 % yield (0.60 mmol, 183 mg) from 6-((2,2'- dimethyl-[1,1'-biphenyl]-4-yl)oxy)-2-methyl-3-nitropyridine (0.75 mmol, 250 mg).
C20H20N2O; Mw = 304.39 g.mol-1; 1H NMR (400 MHz, methanol-d4) d 7.29-7.16 (m, 4H), 7.06-7.03 (m, 1H), 7.01 (d, J = 8.3 Hz, 1H), 6.88 (d, J = 2.6 Hz, 1H), 6.80 (dd, J = 8.3, 2.6 Hz, 1H), 6.63 (dd, J = 8.5, 0.7 Hz, 1H), 2.33 (s, 3H), 2.05 (s, 3H), 1.99 (s, 3H). The starting material was prepared as follows: Step 1: 6-(4-Bromo-3-methylphenoxy)-2-methyl-3-nitropyridine
Figure imgf000140_0001
Following the General procedure A, 6-(4-bromo-3-methylphenoxy)-2-methyl-3-nitropyridine was obtained in 94 % yield (5.46 mmol, 1.76 g) from 6-chloro-2-methyl-3-nitropyridine (5.79 mmol, 1.00 g) and 4-bromo-3-methylphenol (6.37 mmol, 1.19 g).
C13H11BrN2O3; Mw = 323.15 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.36 (d, J = 8.9 Hz, 1H), 7.56 (d, J = 8.6 Hz, 1H), 7.05 (d, J = 2.6 Hz, 1H), 6.88 (dd, J = 8.6, 2.6 Hz, 1H), 6.80 (d, J = 8.9 Hz, 1H), 2.74 (s, 3H), 2.42 (s, 3H). Step 2: 6-((2,2'-Dimethyl-[1,1'-biphenyl]-4-yl)oxy)-2-methyl-3-nitropyridine
Figure imgf000140_0002
Following the General procedure D, a mixture of o-tolylboronic acid (3.71 mmol, 505 mg), 6- (4-bromo-3-methylphenoxy)-2-methyl-3-nitropyridine (2.48 mmol, 800 mg), Na2CO3 (4.95 mmol, 525 mg), and Pd(PPh3)4 (0.124 mmol, 143 mg, 5 % mol) in a 3:1 mixture of DME/H2O (0.43 M) was converted to 6-((2,2'-dimethyl-[1,1'-biphenyl]-4-yl)oxy)-2-methyl-3- nitropyridine in 90 % yield (2.24 mmol, 750 mg).
C20H18N2O3; Mw = 334.38 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.38 (d, J = 8.9 Hz, 1H), 7.33-7.21 (m, 3H), 7.19-7.09 (m, 2H), 7.07 (d, J = 2.5 Hz, 1H), 7.02 (dd, J = 8.2, 2.5 Hz, 1H), 6.81 (d, J = 8.9 Hz, 1H), 2.81 (s, 3H), 2.10 (s, 3H), 2.08 (s, 3H). Example 38: N-Methyl-6-(4-(thiazol-2-yl)phenoxy)pyridin-3-amine
Figure imgf000140_0003
Following the General procedure C, N-methyl-6-(4-(thiazol-2-yl)phenoxy)pyridin-3-amine was obtained in 86 % yield (0.32 mmol, 90 mg) from 6-(4-(thiazol-2-yl)phenoxy)pyridin-3- amine (0.371 mmol, 100 mg; expl.16). C15H13N3OS; Mw=283.35 g.mol-1; 1H NMR (400 MHz, CDCl3) d 7.96-7.90 (m, 2H), 7.83 (d, J = 3.3 Hz, 1H), 7.68 (dd, J = 3.1, 0.6 Hz, 1H), 7.28 (d, J = 3.3 Hz, 1H), 7.13-7.07 (m, 2H), 7.03 (dd, J = 8.7, 3.1 Hz, 1H), 6.86 (dd, J = 8.7, 0.6 Hz, 1H), 2.87 (s, 3H). Example 39: 6-((4'-Fluoro-[1,1'-biphenyl]-4-yl)oxy)-N,4-dimethylpyridin-3-amine
Figure imgf000141_0001
Following the General procedure C, 6-((4'-fluoro-[1,1'-biphenyl]-4-yl)oxy)-N,4- dimethylpyridin-3-amine was obtained in 45 % yield (0.15 mmol, 0.047 g) from 6-((4'-fluoro- [1,1'-biphenyl]-4-yl)oxy)-4-methylpyridin-3-amine (0.34 mmol, 100 mg; expl.29).
C19H17FN2O; Mw=308.35 g.mol-1; 1H NMR (400 MHz, CDCl3) d 7.55 (s, 1H), 7.45-7.35 (m, 4H), 7.10 (t, J = 8.3 Hz, 4H), 6.73 (s, 1H), 3.36 (s, 1H), 2.91 (s, 3H), 2.17 (s, 3H). Example 40: 6-((4'-Fluoro-[1,1'-biphenyl]-4-yl)oxy)-N,2-dimethylpyridin-3-amine
Figure imgf000141_0002
Following the General procedure C, 6-((4'-fluoro-[1,1'-biphenyl]-4-yl)oxy)-N,2- dimethylpyridin-3-amine was obtained in 72 % yield (0.19 mmol, 0.060 g) from 6-((4'-fluoro- [1,1'-biphenyl]-4-yl)oxy)-2-methylpyridin-3-amine (0.27 mmol, 80 mg; expl.28).
C19H17FN2O; Mw=308.35 g.mol-1; 1H NMR (400 MHz, CDCl3) d 7.55-7.45 (m, 4H), 7.19- 7.00 (m, 5H), 6.74 (d, J = 8.6 Hz, 1H), 2.92 (s, 3H), 2.42 (s, 3H), 1.65-1.48 (bs, 1H). Example 41: N,4-Dimethyl-6-(4-(thiazol-5-yl)phenoxy)pyridin-3-amine
Figure imgf000141_0003
Following the General procedure C, N,4-dimethyl-6-(4-(thiazol-5-yl)phenoxy)pyridin-3- amine was obtained in 51 % yield (0.091 mmol, 0.027 g) from 4-methyl-6-(4-(thiazol-5- yl)phenoxy)pyridin-3-amine (0.18 mmol, 0.050 g; expl.33). C16H15N3OS; Mw = 297.38 g.mol-1; 1H NMR (400 MHz, DMSO-d6) d 9.03 (d, J = 0.7 Hz, 1H), 8.22 (d, J = 0.7 Hz, 1H), 7.63 (d, J = 8.7 Hz, 2H), 7.00-6.95 (m, 3H), 6.79 (d, J = 8.5 Hz, 1H), 5.20 (q, J = 5.0 Hz, 1H), 2.73 (d, J = 4.9 Hz, 3H), 2.21 (s, 3H). Example 42: N,2-Dimethyl-6-(4-(thiazol-5-yl)phenoxy)pyridin-3-amine
Figure imgf000142_0001
Following the General procedure C, N,2-dimethyl-6-(4-(thiazol-5-yl)phenoxy)pyridin-3- amine was obtained in 55 % (0.098 mmol, 29 mg) from 2-methyl-6-(4-(thiazol-5- yl)phenoxy)pyridin-3-amine (0.18 mmol, 50 mg; expl.32).
C16H15N3OS; Mw = 297.38 g.mol-1; 11H NMR (400 MHz, DMSO-d6) d 9.03 (d, J = 0.7 Hz, 1H), 8.22 (d, J = 0.7 Hz, 1H), 7.78-7.50 (m, 2H), 7.05 - 6.90 (m, 3H), 6.79 (d, J = 8.5 Hz, 1H), 5.20 (q, J = 5.0 Hz, 1H), 2.73 (d, J = 4.9 Hz, 3H), 2.21 (s, 3H). Example 43: 6-((2,2'-Dimethyl-[1,1'-biphenyl]-4-yl)oxy)-N,2-dimethylpyridin-3-amine
Figure imgf000142_0002
Following the General procedure C, 6-((2,2'-dimethyl-[1,1'-biphenyl]-4-yl)oxy)-N,2- dimethylpyridin-3-amine was obtained in 82 % yield (0.22 mmol, 69 mg) from 6-((2,2'- dimethyl-[1,1'-biphenyl]-4-yl)oxy)-2-methylpyridin-3-amine (0.26 mmol, 80 mg; expl.37). C21H22N2O; Mw = 318.42 g.mol-1; 1H NMR (400 MHz, CDCl3) d 7.26-7.18 (m, 3H), 7.10 (d, J = 6.8 Hz, 1H), 7.03 (dd, J = 8.4, 3.3 Hz, 2H), 6.92 (d, J = 2.5 Hz, 1H), 6.85 (dd, J = 8.3, 2.5 Hz, 1H), 6.74 (d, J = 8.5 Hz, 1H), 2.91 (s, 3H), 2.40 (s, 3H), 2.07 (s, 3H), 2.01 (s, 3H), 1.70- 1.48 (bs, 1H). Example 44: N,2-Dimethyl-6-(4-(thiazol-2-yl)phenoxy)pyridin-3-amine
Figure imgf000142_0003
Following the General procedure C, N,2-dimethyl-6-(4-(thiazol-2-yl)phenoxy)pyridin-3- amine was obtained in 93 % yield (0.404 mmol, 0.120 g) from 2-methyl-6-(4-(thiazol-2- yl)phenoxy)pyridin-3-amine (0.434 mmol, 0.123 g; expl.35).
C16H15N3OS; Mw= 297.38 g.mol-1; 1H NMR (400 MHz, CDCl3) d 7.89 (d, J = 8.9 Hz, 2H), 7.80 (d, J =8.9 Hz, 2H), 7.25 (d, J =3.3 Hz, 1H), 7.04 (d, J =8.9 Hz, 2H), 6.94 (d, J = 8.5 Hz, 1H), 6.74 (d, J = 8.5 Hz, 1H), 2.88 (s, 3H), 2.32 (s, 3H). Example 45: N,2-Dimethyl-6-((6-phenylpyridin-3-yl)oxy)pyridin-3-amine
Figure imgf000143_0001
Following the General procedure C, N,2-dimethyl-6-((6-phenylpyridin-3-yl)oxy)pyridin-3- amine was obtained in 80 % yield (0.23 mmol, 67 mg) from 2-methyl-6-((6-phenylpyridin-3- yl)oxy)pyridin-3-amine (0.29 mmol, 80 mg; expl.30).
C18H17N3O; Mw = 291.35 g.mol-1; 1H NMR (400 MHz, DMSO-d6) d 8.40 (d, J = 2.8 Hz, 1H), 8.03 (app d, J = 8.2, 2H), 7.93 (d, J = 8.7 Hz, 1H), 7.51-7.44 (m, 3H), 7.43-7.37 (m, 1H), 6.98 (d, J = 8.2 Hz, 1H), 6.86 (d, J = 8.4 Hz, 1H), 5.21 (q, J = 5.0 Hz, 1H), 2.73 (d, J = 4.9 Hz, 3H), 2.20 (s, 3H). Example 46: 6-(4-(6-Methoxypyridin-3-yl)phenoxy)-4-methylpyridin-3-amine
Figure imgf000143_0002
Following the General procedure B, 6-(4-(6-methoxypyridin-3-yl)phenoxy)-4-methylpyridin- 3-amine was obtained in 55 % yield (0.490 mmol, 165 mg) from 2-(4-(6-methoxypyridin-3- yl)phenoxy)-4-methyl-5-nitropyridine (0.892 mmol, 0.300 g).
C18H17N3O2; Mw= 307.35 g.mol-1; d 1H NMR (400 MHz, CDCl3) d 8.21 (d, J = 5.4 Hz, 1H), 7.71 (s, 1H), 7.62 (d, J = 8.8 Hz, 2H), 7.16 (d, J = 8.8 Hz, 2H), 7.12 (dd, J = 5.4, 1.5 Hz, 1H), 6.97-6.94 (m, 3H), 6.77 (s, 1H), 4.01 (s, 3H), 2.24 (s, 3H). The starting material was prepared as follows: Step 1: 2-(4-(6-Methoxypyridin-3-yl)phenoxy)-4-methyl-5-nitropyridine
Figure imgf000144_0001
Following the General procedure E, 2-(4-(6-methoxypyridin-3-yl)phenoxy)-4-methyl-5- nitropyridine was obtained in 55 % yield (0.892 mmol, 0.300 g) from 2-(4-bromophenoxy)-4- methyl-5-nitropyridine (1.62 mmol, 0.500 g; expl.29, Step 1) and (6-methoxypyridin-3- yl)boronic acid (1.95 mmol, 0.298 g).
C18H15N3O4; Mw= 337.33g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.91 (s, 1H), 8.40 (d, J = 2.1 Hz, 1H), 7.79 (dd, J = 8.6, 2.6 Hz, 1H), 7.59 (d, J = 8.7 Hz, 2H), 7.23 (d, J = 8.6 Hz, 2H), 6.90 (s, 1H), 6.86-6.81 (m, 1H), 3.99 (s, 3H), 2.69 (s, 3H). Example 47: 6-(4-(2-Methoxypyridin-4-yl)phenoxy)-4-methylpyridin-3-amine
Figure imgf000144_0002
Following the General procedure B, 6-(4-(2-methoxypyridin-4-yl)phenoxy)-4-methylpyridin- 3-amine was obtained in 20 % yield (0.091 mmol, 28 mg) from 2-(4-(2-methoxypyridin-4- yl)phenoxy)-4-methyl-5-nitropyridine (0.446 mmol, 0.150 g).
C18H17N3O2; Mw= 307.35 g.mol-1; d 1H NMR (400 MHz, CDCl3) d 8.38 (d, J = 2.0 Hz, 1H), 7.78 (dd, J = 8.6, 2.6 Hz, 1H), 7.70 (s, 1H), 7.53-7.48 (m, 2H), 7.17-7.12 (m, 2H), 6.85-6.80 (m, 1H), 6.75 (s, 1H), 4.00 (s, 3H), 2.23 (m, 3H), 1.61 (s, 2H). The starting material was prepared as follows: Step 1: 2-(4-(2-Methoxypyridin-4-yl)phenoxy)-4-methyl-5-nitropyridine
Figure imgf000144_0003
Following the General procedure E, 2-(4-(2-methoxypyridin-4-yl)phenoxy)-4-methyl-5- nitropyridine was obtained in 28 % yield (0.446 mmol, 0.150 g) from 2-(4-bromophenoxy)-4- methyl-5-nitropyridine (1.62 mmol, 0.500 g; expl.29, Step 1) and (2-methoxypyridin-4- yl)boronic acid (1.95 mmol, 0.298 g). C18H15N3O4; Mw= 337.33g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.91 (s, 1H), 8.40 (dd, J = 2.6, 0.7 Hz, 1H), 7.79 (dd, J = 8.6, 2.6 Hz, 1H), 7.61-7.55 (m, 2H), 7.25-7.20 (m, 2H), 6.90 (d, J = 1.0 Hz, 1H), 6.83 (dd, J = 8.6, 0.7 Hz, 1H), 3.99 (s, 3H), 2.69 (d, J = 0.8 Hz, 3H). Example 48: 6-(4-(1H-Imidazol-4-yl)phenoxy)-4-methylpyridin-3-amine
Figure imgf000145_0001
Following the General procedure B, 6-(4-(1H-imidazol-4-yl)phenoxy)-4-methylpyridin-3- amine was obtained in 61 % yield (86 µmol, 23 mg) from 2-(4-(1H-imidazol-4-yl)phenoxy)- 4-methyl-5-nitropyridine (0.10 mmol, 0.040 g).
C15H14N4O; Mw 266.30; 1H NMR (400 MHz, methanol-d4) d 7.72 (d, J = 1.2 Hz, 1H), 7.71- 7.64 (m, 2H), 7.62 (s, 1H), 7.37 (d, J = 1.2 Hz, 1H), 7.02-6.92 (m, 2H), 6.77-6.64 (m, 1H), 3.35 (s, 1H), 2.20 (s, 3H). The starting material was prepared as follows: Step 1: 4-Bromo-1-trityl-1H-imidazole
Figure imgf000145_0002
To a solution of 4-bromo-1H-imidazole (10.00 mmol, 2.00 g) in CHCl3 (20 mL) was added TEA (40.00 mmol, 4.00 g, 6.0 mL) and the mixture was cooled to 0°C. To this was added a solution of trityl-Cl (10.00 mol, 4.00 g) in 20 ml of CHCl3 and the mixture was stirred at RT for 2 h. The reaction mixture was diluted with 1M HCl and extracted with CHCl3(3x). The combined organic layers were washed with brine, dried with Na2SO4, filtered, and concentrated under reduced pressure to get 4-bromo-1-trityl-1H-imidazole (4.40 g). This was used without any further purification.
C22H17BrN2; Mw = 389.30 g.mol-1; 1H NMR (400 MHz, CDCl3) d 7.39-7.30 (m, 10H), 7.16- 7.08 (m, 6H), 6.80 (d, J = 1.6 Hz, 1H). Step 2: 4-Methyl-5-nitro-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)phenoxy)pyridine
Figure imgf000145_0003
Following the General procedure E, 4-methyl-5-nitro-2-(4-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)phenoxy)pyridine was obtained in 95 % yield (3.09 mmol, 1.10 g) from 2- (4-bromophenoxy)-4-methyl-5-nitropyridine (3.23 mmol, 1.0 g; expl.29, Step 1) and bis(pinacolato)diborane (4.79 mmol, 1.22 g).
C18H21BN2O5; Mw= 356.19 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.88 (s, 1H), 7.90 (d, J = 8.5 Hz, 2H), 7.14 (d, J = 8.5 Hz, 2H), 6.82 (s, 1H), 2.66 (s, 3H), 1.35 (s, 12H). Step 3: 4-Methyl-5-nitro-2-(4-(1-trityl-1H-imidazol-4-yl)phenoxy)pyridine
Figure imgf000146_0001
Following the General procedure E, 4-methyl-5-nitro-2-(4-(1-trityl-1H-imidazol-4- yl)phenoxy)pyridine was obtained in 51% yield (0.15 mmol, 81 mg) from 4-methyl-5-nitro-2- (4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pyridine (0.3 mmol, 0.1 g) and 4- bromo-1-trityl-1H-imidazole (0.4 mmol, 0.2 g).
C34H26N4O3; Mw = 538.61;11H NMR (400 MHz, CDCl3) d 8.89 (s, 1H), 7.82-7.76 (m, 2H), 7.53-7.48 (m, 1H), 7.45-7.27 (m, 9H), 7.24-7.18 (m, 6H), 7.13-7.07 (m, 3H), 6.80 (d, J = 1.0 Hz, 1H), 2.65 (d, J = 0.8 Hz, 3H).
Step 4: 2-(4-(1H-Imidazol-4-yl)phenoxy)-4-methyl-5-nitropyridine
Figure imgf000146_0002
To a solution of 4-methyl-5-nitro-2-(4-(1-trityl-1H-imidazol-4-yl)phenoxy)pyridine (0.15 mmol, 0.081 g) in DCM (10 mL) was added HCl in dioxane (0.19 mL, 4 molar, 0.75 mmol) and stirred at RT overnight. The reaction mixture was concentrated to dryness and the residue was suspended in the saturated solution of NaHCO3 and extracted with CHCl3(3x). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to get crude. This was purified using Biotage, 25 g silica column, DCM and MeOH as eluent to get 2-(4-(1H-imidazol-4-yl)phenoxy)-4-methyl-5-nitropyridine (0.1 mmol, 0.04 g). C15H12N4O3; Mw = 296.29; 1H NMR (400 MHz, CDCl3) d 8.91 (s, 1H), 7.82 (d, J = 8.4 Hz, 2H), 7.73 (s, 1H), 7.34 (d, J = 1.1 Hz, 1H), 7.23-7.09 (m, 2H), 6.90-6.79 (m, 1H), 2.67 (d, J = 0.8 Hz, 3H). Example 49: 6-(4-(2H-Tetrazol-5-yl)phenoxy)-4-methylpyridin-3-amine
Figure imgf000147_0001
In a flask, 2-(4-(2H-tetrazol-5-yl)phenoxy)-4-methyl-5-nitropyridine (0.14 mmol, 42 mg) was dissolved in EtOH (1.4 mL, 0.10 molar) and flushed with nitrogen. Pd/C (0.014 mmol, 15 mg) was added, a hydrogen balloon was attached and the mixture evacuated/backfilled (3x). The mixture was then left stirring for 5 h. Upon full conversion, the mixture was
evacuated/backfilled (3x) with nitrogen, filtered through a syringe filter, and concentrated under reduced pressure. The crude material was purified on a Biotage C18 column (25 g, 5-95 % MeOH/H2O + 0.1% HCOOH) to afford 6-(4-(2H-tetrazol-5-yl)phenoxy)-4-methylpyridin- 3-amine (0.097 mmol, 26 mg) in 69 % yield as a pale yellow solid.
C13H12N6O; Mw = 268.28 g.mol-1; 1H NMR (400 MHz, DMSO-d6) d 7.99 (d, J = 8.8 Hz, 2H), 7.58 (s, 1H), 7.12 (d, J = 8.7 Hz, 2H), 6.79 (s, 1H), 2.12 (s, 3H). The starting material was prepared as follows: Step 1: 4-(2H-Tetrazol-5-yl)phenol
Figure imgf000147_0002
A 100 mL round bottomed flask equipped with a Teflon coated magnetic stirring bar, and a Findenser™ cooler, was charged with 4-hydroxybenzonitrile (8.39 mmol, 1.00 g), sodium azide (25.2 mmol, 1.64 g), and triethylamine hydrochloride (25.2 mmol, 3.47 g) and toluene (42.0 mL, 0.20 M). The reaction mixture was heated at 100 °C overnight with vigorous stirring. Then it was cooled to ambient temperature and poured into a separatory funnel and extracted with H2O (3x). The combined aqueous phases were treated dropwise with HCl (conc.) to precipitate the product. The precipitate was collected by vacuum filtration, and dried under vacuum to afford 4-(2H-tetrazol-5-yl)phenol in 88 % yield (7.40 mmol, 1.19 g) as an off-white solid.
C7H6N4O; Mw = 162.15 g.mol-1; 1H NMR (400 MHz, DMSO-d6) d 10.16 (s, 1H), 7.86 (d, J = 8.7 Hz, 2H), 6.95 (d, J = 8.7 Hz, 2H). Step 2: 2-(4-(2H-Tetrazol-5-yl)phenoxy)-4-methyl-5-nitropyridine
Figure imgf000148_0001
To a 100-mL round-bottom flask were added 4-(2H-tetrazol-5-yl)phenol (0.62 mmol, 100 mg), 2-chloro-4-methyl-5-nitropyridine (1.85 mmol, 319 mg), and anhydrous K2CO3 (1.85 mmol, 256 mg). DMF (2.1 mL, 0.30 molar) was added and the resulting brown suspension was heated to 60 °C overnight. Upon full conversion by TLC, the reaction mixture was allowed to cool to RT, concentrated to a minimal amount of solvent, and loaded directly on Biotage C18 column (30 g cartridge, 5-95 % MeOH/H2O + 0.1% HCOOH) to afford 2-(4- (2H-tetrazol-5-yl)phenoxy)-4-methyl-5-nitropyridine (0.15 mmol, 45 mg) in 24 % yield. C13H10N6O3; Mw = 298.26 g.mol-1; 1H NMR (400 MHz, DMSO-d6) d 8.87 (s, 1H), 8.22-7.99 (m, 2H), 7.52-7.36 (m, 2H), 7.30 (s, 1H), 2.63 (s, 3H). Example 50: 6-(4-(1H-Pyrazol-4-yl)phenoxy)-4-methylpyridin-3-amine
Figure imgf000148_0002
To a solution of 4-methyl-6-(4-(1-trityl-1H-pyrazol-4-yl)phenoxy)pyridin-3-amine (0.08 mmol, 0.04 g), in DCM (0.4 mL), was added a 4M solution of HCl (0.2 mL, 0.8 mmol) in dioxane. The mixture was stirred at RT overnight. The mixture was diluted in H2O and the two layers separated. The aqueous layer was washed with DCM. The aqueous layer was basified to pH=8 with saturated aqueous solution of NaHCO3. The aqueous layer was extracted with EtOAc (3x). The combined organic layers were dried over MgSO4, filtered and concentrated under reduce pressure.6-(4-(1H-pyrazol-4-yl)phenoxy)-4-methylpyridin-3- amine was obtained as a light green solid in 90 % yield (0.072 mmol, 19 mg).
C H
15H14N4O; Mw = 266.30 g.mol-1; 1 NMR (400 MHz, methanol-d4) d 7.91 (s, 2H), 7.61 (s, 1H), 7.58-7.52 (m, 2H), 7.00-6.92 (m, 2H), 6.72-6.67 (m, 1H), 2.20 (app d, J = 0.8 Hz, 3H). The starting material was prepared as follows: Step 1: 4-Bromo-1-trityl-1H-pyrazole
Figure imgf000148_0003
4-Bromo-1H-pyrazole (3.40 mmol, 500 mg) was dissolved in DMF (4.00 mL, 0.85 molar), set under N2, and cooled to 0 °C. To the solution were added tBuOK (4.08 mmol, 458 mg, 1.20 eq.) and trityl-Cl (3.74 mmol, 1.04 g, 1.10 eq.) and the mixture was left stirring at RT overnight. The reaction mixture was diluted with H2O, and the aqueous layer was extracted with EtOAc (3x). The combined organic layers were washed with brine, dried with Na2SO4, filtered, and concentrated under reduced pressure. The crude material was purified by column chromatography using cyclohexane:EtOAc as eluent to afford 4-bromo-1-trityl-1H-pyrazole (2.638 mmol, 1.027 g) in 77 % yield as a white solid.
C22H17BrN2; Mw = 389.30 g.mol-1; 1H NMR (400 MHz, DMSO-d6) d 7.76 (d, J = 0.7 Hz, 1H), 7.51 (d, J = 0.7 Hz, 1H), 7.43-7.31 (m, 9H), 7.11-6.99 (m, 6H). Step 2: 4-Methyl-5-nitro-2-(4-(1-trityl-1H-pyrazol-4-yl)phenoxy)pyridine
Figure imgf000149_0001
Following the General procedure D, a mixture of 4-methyl-5-nitro-2-(4-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)phenoxy)pyridine (0.85 mmol, 302 mg; expl.48, Step2), 4-bromo-1- trityl-1H-pyrazole (0.77 mmol, 300 mg), K2CO3 (1.54 mmol, 213 mg), and Pd(PPh3)4 (0.08 mmol, 89 mg, 10 % mol) in a 3:1 mixture of DME/H2O (0.13 M) was converted to 4-methyl- 5-nitro-2-(4-(1-trityl-1H-pyrazol-4-yl)phenoxy)pyridine (0.41 mmol, 223 mg) in 54 % yield. C34H26N4O3; Mw = 538.61 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.87 (s, 1H), 7.93 (d, J = 0.8 Hz, 1H), 7.60 (d, J = 0.9 Hz, 1H), 7.52-7.46 (m, 2H), 7.40-7.27 (m, 9H), 7.22-7.16 (m, 6H), 7.13-7.07 (m, 2H), 6.82 (d, J = 1.0 Hz, 1H), 2.66 (s, 3H).
Step 3: 4-Methyl-6-(4-(1-trityl-1H-pyrazol-4-yl)phenoxy)pyridin-3-amine
Figure imgf000149_0002
Following the General procedure B, 4-methyl-6-(4-(1-trityl-1H-pyrazol-4- yl)phenoxy)pyridin-3-amine (0.08 mmol, 0.04 g) was prepared in 42 % yield from 4-methyl- 5-nitro-2-(4-(1-trityl-1H-pyrazol-4-yl)phenoxy)pyridine (0.20 mmol, 0.10 g). C34H28N4O; Mw = 508.61 g.mol-1; 1H NMR (400 MHz, CDCl3) d 7.89 (d, J = 0.8 Hz, 1H), 7.64 (s, 1H), 7.55 (d, J = 0.8 Hz, 1H), 7.41-7.37 (m, 2H), 7.40-7.27 (m, 9H), 7.22-7.17 (m, 6H), 7.01 (d, J = 8.7 Hz, 2H), 6.65 (t, J = 0.7 Hz, 1H), 3.42 (s, 2H), 2.18 (app d, J = 0.8 Hz, 3H).
Example 51: 6,6'-((4'-Fluoro-[1,1'-biphenyl]-2,4-diyl)bis(oxy))bis(pyridin-3-amine)
Figure imgf000150_0001
Following the General procedure B, 6,6'-((4'-fluoro-[1,1'-biphenyl]-2,4- diyl)bis(oxy))bis(pyridin-3-amine) (0.05 mmol, 0.02 g), was prepared from 6,6'-((4'-fluoro- [1,1'-biphenyl]-2,4-diyl)bis(oxy))bis(3-nitropyridine) (0.156 mmol, 0.070 g) in 32 % yield after purification.
C22H17FN4O2; Mw = 388.39 g.mol-1; 1H NMR (400 MHz, CDCl3) d 7.73 (dd, J = 3.1, 0.7 Hz, 1H), 7.64 (dd, J = 3.0, 0.7 Hz, 1H), 7.49-7.44 (m, 2H), 7.34 (d, J = 8.5 Hz, 1H), 7.08 (dd, J = 8.6, 3.0 Hz, 1H), 7.03 - 6.95 (m, 3H), 6.91 (dd, J = 8.6, 2.4 Hz, 1H), 6.81-6.77 (m, 2H), 6.61 (dd, J = 8.6, 0.7 Hz, 1H), 3.53 (s, 4H).19F NMR (377 MHz, CDCl3) d -115.99. The starting material was prepared as follows: Step 1: 4'-Fluoro-2-methoxy-[1,1'-biphenyl]-4-ol
Figure imgf000150_0002
Following the General procedure D, a mixture of 4-bromo-3-methoxyphenol (9.9 mmol, 2.0 g), (4-fluorophenyl)boronic acid (11 mmol, 1.5 g), K2CO3 (20 mmol, 2.7 g), and Pd(PPh3)2Cl2 (0.985 mmol, 0.691 g) in a 3:1 mixture of 2-propanol/H2O (0.1 M) was converted to 4'- fluoro-2-methoxy-[1,1'-biphenyl]-4-ol (5.45 mmol, 1.19 g) in 55 % yield.
C13H11FO2; Mw= 218.22 g.mol-1; 1H NMR (400 MHz, CDCl3) d 7.48-7.40 (m, 2H), 7.14 (d, J = 8.2 Hz, 1H), 7.10-7.01 (m, 2H), 6.51 (d, J = 2.4 Hz, 1H), 6.47 (dd, J = 8.2, 2.4 Hz, 1H), 3.79 (s, 3H). Step 2: 4'-Fluoro-[1,1'-biphenyl]-2,4-diol
Figure imgf000151_0001
4'-Fluoro-2-methoxy-[1,1'-biphenyl]-4-ol (916 µmol, 200 mg) was dissolved in DCM (9.16 mL, 0.1M), set under N2, and cooled to -78 °C. BBr3 (1.83 mmol, 1.83 mL, 1M in DCM) was added dropwise. After 30 min at that temperature, the mixture was left to reach RT slowly overnight. Still a small amount of starting material was observed, nevertheless the reaction mixture was quenched by slow addition of water. The aqueous layer was neutralized/basified with 15% NaOH and extracted with DCM (3x). The combined organic layers were dried with Na2SO4, filtered, and concentrated under reduced pressure. The crude material was purified by flash column chromatography using EtOAc:cyclohexane to afford 4'-fluoro-[1,1'- biphenyl]-2,4-diol (0.74 mmol, 152 mg) in 81 % yield as a white solid.
C12H9FO2; Mw = 204.20 g.mol-1; 1H NMR (400 MHz, CDCl3) d 7.48-7.33 (m, 2H), 7.18-7.07 (m, 2H), 7.09-7.05 (m, 1H), 6.65-6.35 (m, 2H), 5.07 (s, 1H), 4.81 (s, 1H).
Step 3: 6,6'-((4'-Fluoro-[1,1'-biphenyl]-2,4-diyl)bis(oxy))bis(3-nitropyridine)
Figure imgf000151_0002
Following the General procedure A, 6,6'-((4'-fluoro-[1,1'-biphenyl]-2,4-diyl)bis(oxy))bis(3- nitropyridine) was obtained in 63 % yield (0.44 mmol, 195 mg) from 4'-fluoro-[1,1'- biphenyl]-2,4-diol (0.69 mmol, 140 mg) and 2-chloro-5-nitropyridine (1.51 mmol, 239 mg). C22H13FN4O6; Mw = 448.37 g.mol-1; 1H NMR (400 MHz, CDCl3) d 9.09 (dd, J = 2.8, 0.6 Hz, 1H), 8.93 (dd, J = 2.8, 0.6 Hz, 1H), 8.52 (dd, J = 9.0, 2.8 Hz, 1H), 8.37 (dd, J = 9.0, 2.8 Hz, 1H), 7.53 (d, J = 8.5 Hz, 1H), 7.44-7.36 (m, 2H), 7.23 (dd, J = 8.4, 2.4 Hz, 1H), 7.13 (dd, J = 9.1, 0.6 Hz, 1H), 7.10 (d, J = 2.3 Hz, 1H), 7.04-6.98 (m, 2H), 6.91 (dd, J = 9.0, 0.6 Hz, 1H). Example 52: 6-((2,2'-Dimethyl-[1,1'-biphenyl]-4-yl)oxy)-4-methylpyridin-3-amine
Figure imgf000152_0001
collowing the General procedure B, 6-((2,2'-dimethyl-[1,1'-biphenyl]-4-yl)oxy)-4- methylpyridin-3-amine was obtained in 61 % yield (0.31 mmol, 94 mg) from 2-((2,2'- dimethyl-[1,1'-biphenyl]-4-yl)oxy)-4-methyl-5-nitropyridine (0.508 mmol, 170 mg)
C20H20N2O; Mw = 304.39 g.mol-1; 1H NMR (400 MHz, CDCl3) d 7.71 (s, 1H), 7.25-7.23 (m, 2H), 7.23-7.18 (m, 1H), 7.13-7.09 (m, 1H), 7.05 (d, J = 8.3 Hz, 1H), 6.94 (d, J = 2.6 Hz, 1H), 6.88 (dd, J = 8.3, 2.5 Hz, 1H), 6.73-6.71 (m, 1H), 2.21 (s, 3H), 2.08 (s, 3H), 2.02 (s, 3H).
The starting material was prepared as follows: Step 1: 2,2'-Dimethyl-[1,1'-biphenyl]-4-ol
Figure imgf000152_0002
Following the General procedure D, 2,2'-dimethyl-[1,1'-biphenyl]-4-ol was obtained in 85 % yield (4.54 mmol, 0.900 g) from 4-bromo-3-methylphenol (5.3 mmol, 1.0 g) and o- tolylboronic acid (6.95 mmol, 0.944 g).
C14H14O; Mw= 198.26 g.mol-1; 1H NMR (400 MHz, CDCl3) d 7.28-7.18 (m, 3H), 7.11-7.07 (m, 1H), 6.97 (d, J = 8.2 Hz, 1H), 6.77 (d, J = 2.4 Hz, 1H), 6.71 (dd, J = 8.2, 2.6 Hz, 1H), 5.21 (app d, 1H), 2.06 (s, 3H), 2.01 (s, 3H). Step 2: 2-((2,2'-Dimethyl-[1,1'-biphenyl]-4-yl)oxy)-4-methyl-5-nitropyridine
Figure imgf000152_0003
Following the General procedure A, 2-((2,2'-dimethyl-[1,1'-biphenyl]-4-yl)oxy)-4-methyl-5- nitropyridine was obtained in 61 % yield (0.526 mmol, 176 mg) from 2-chloro-4-methyl-5- nitropyridine (0.869 mmol, 150 mg) and 2,2'-dimethyl-[1,1'-biphenyl]-4-ol (0.956 mmol, 190 mg). C20H18N2O3; Mw = 334.37 g.mol-1; 1H NMR (400 MHz, CDCl3) d 7.30-7.27 (m, 3H), 7.25- 7.21 (m, 1H), 7.19-7.13 (m, 2H), 7.05 (d, J = 2.5 Hz, 1H), 7.00 (dd, J = 8.2, 2.4 Hz, 1H), 6.86 (s, 1H), 2.69 (s, 3H), 2.10 (s, 3H), 2.08 (s, 3H).
Example 53: 6-((6-(4-Fluorophenyl)pyridin-3-yl)oxy)-2-methylpyridin-3-amine
Figure imgf000153_0001
Following the General procedure B, 6-((6-(4-fluorophenyl)pyridin-3-yl)oxy)-2- methylpyridin-3-amine was obtained in 89 % yield (2.80 mmol, 732 mg) from 6-((6-(4- fluorophenyl)pyridin-3-yl)oxy)-2-methyl-3-nitropyridine (2.80 mmol, 910 mg).
C17H14FN3O; Mw = 295.31 g.mol-1; 11H NMR (400 MHz, CDCl3) d 8.49 (dd, J = 2.8, 0.7 Hz, 1H), 7.98-7.88 (m, 2H), 7.64 (dd, J = 8.4, 0.7 Hz, 1H), 7.45 (dd, J = 8.7, 2.8 Hz, 1H), 7.19- 7.08 (m, 2H), 7.04 (d, J = 8.4 Hz, 1H), 6.68 (dd, J = 8.4, 0.7 Hz, 1H), 3.50 (s, 2H), 2.33 (s, 3H). The starting material was prepared as follows: Step 1: 2-Bromo-5-(methoxymethoxy)pyridine
Figure imgf000153_0002
To a solution of 6-bromopyridin-3-ol (29 mmol, 5.0 g), in dry DMF (29 mL), under N2, at 0° C, was added portionwise NaH (29 mmol, 1.1 g, 60% wt). The mixture was stirred at 0 °C for 1 h. Methyl chloromethyl ether (29 mmol, 2.3 g, 2.2 mL,) was then slowly added. The mixture was stirred at 0 °C for 1 h and then allowed to warm to RT over the weekend. The reaction mixture was cooled to 0 °C and saturated NaHCO3 solution was added. The mixture was warmed to RT and diluted with H2O. The mixture was extracted with AcOEt (3x). The combined organic layers were washed with H2O (3x) and brine. The mixture was dried over MgSO4, filtered and concentrated under reduced pressure. The product, 2-bromo-5- (methoxymethoxy)pyridine (29 mmol, 6.3 g), was isolated as a colorless oil in quantitative yield.
C7H8BrNO2; Mw = 218.05 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.15 (dd, J = 3.1, 0.6 Hz, 1H), 7.35 (dd, J = 8.7, 0.6 Hz, 1H), 7.27-7.20 (m, 1H), 5.15 (s, 2H), 3.46 (s, 3H). Step 2: 2-(4-Fluorophenyl)-5-(methoxymethoxy)pyridine
Figure imgf000154_0001
Following the General procedure D, a mixture of (4-fluorophenyl)boronic acid (32.0 mmol, 4.4 g), 2-bromo-5-(methoxymethoxy)pyridine (29.0 mmol, 6.3 g), K2CO3 (58.0 mmol, 8.0 g), and Pd(PPh3)2Cl2 (2.9 mmol, 2.0 g) in 4:1 mixture of 2-propanol/H2O (0.1 M) was converted to 2-(4-fluorophenyl)-5-(methoxymethoxy)pyridine in 56 % yield (16.20 mmol, 3.79 g).
C13H12FNO2; Mw = 233.24 g.mol--1; 1H NMR (400 MHz, CDCl3) d 8.46 (dd, J = 2.9, 0.7 Hz, 1H), 7.97-7.83 (m, 2H), 7.60 (dd, J = 8.7, 0.7 Hz, 1H), 7.43 (dd, J = 8.7, 2.9 Hz, 1H), 7.13 (dd, J = 8.9, 8.5 Hz, 2H), 5.23 (s, 2H), 3.51 (s, 3H). Step 3: 6-(4-Fluorophenyl)pyridin-3-ol
Figure imgf000154_0002
To a solution of 2-(4-fluorophenyl)-5-(methoxymethoxy)pyridine (16.20 mmol, 3.79 g), in dioxane (20 mL), at RT was added a 4M HCl (146 mmol, 36.6 mL) dioxane solution. The mixture was heated at 80 °C overnight. The reaction mixture was cooled to RT and
concentrated under reduced pressure. The residue was dissolved in H2O and extracted with DCM (3x). The aqueous layer was neutralized to pH=6-7 with solid Na2CO3. The precipitated white solid was filtered off, washed with hexane and dried under vacuo for 2 h, to afford 6-(4- fluorophenyl)pyridin-3-ol (15.0 mmol, 2.83g) in 92 % yield.
C11H8FNO; Mw = 189.19 g.mol-1; 11H NMR (400 MHz, DMSO-d6) d 10.04 (s, 1H), 8.20 (dd, J = 2.9, 0.7 Hz, 1H), 8.09-7.93 (m, 2H), 7.78 (dd, J = 8.7, 0.7 Hz, 1H), 7.33-7.15 (m, 3H). Step 4: 6-((6-(4-Fluorophenyl)pyridin-3-yl)oxy)-2-methyl-3-nitropyridine
Figure imgf000154_0003
Following the General procedure A, 6-((6-(4-fluorophenyl)pyridin-3-yl)oxy)-2-methyl-3- nitropyridine was obtained in 100 % yield (3.00 mmol, 900 mg) from 6-(4- fluorophenyl)pyridin-3-ol (3.00 mmol, 600 mg) and 6-chloro-2-methyl-3-nitropyridine (3.00 mmol, 500 mg).
C17H12FN3O3; Mw = 325.29 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.58 (dd, J = 2.7, 0.7 Hz, 1H), 8.42 (d, J = 8.9 Hz, 1H), 8.03-7.96 (m, 2H), 7.76 (dd, J = 8.7, 0.7 Hz, 1H), 7.60 (dd, J = 8.7, 2.7 Hz, 1H), 7.20-7.14 (m, 2H), 6.96 (dd, J = 8.9, 0.7 Hz, 1H), 2.72 (s, 3H). Example 54: 6-((6-(4-Fluorophenyl)pyridin-3-yl)oxy)-N,2-dimethylpyridin-3-amine
Figure imgf000155_0001
Following the General procedure C, 6-((6-(4-fluorophenyl)pyridin-3-yl)oxy)-N,2- dimethylpyridin-3-amine was obtained in 70 % yield with purification (0.810 mmol, 0.250 g) from 6-((6-(4-fluorophenyl)pyridin-3-yl)oxy)-2-methylpyridin-3-amine (1.155 mmol, 0.341 g) and paraformaldehyde (1.617 mmol, 1.40 eq.).
C18H16FN3O; MW = 309.34 g.mol-1 ; 1H NMR (400 MHz, DMSO-d6) d 8.38 (d, J = 2.7 Hz, 1H), 8.08 (dd, J = 8.9, 5.6 Hz, 2H), 7.93 (d, J = 8.7 Hz, 1H), 7.46 (dd, J = 8.7, 2.9 Hz, 1H), 7.30 (t, J = 8.9 Hz, 2H), 6.98 (d, J = 8.5 Hz, 1H), 6.86 (d, J = 8.5 Hz, 1H), 5.21 (q, J = 5.0 Hz, 1H), 2.73 (d, J = 5.0 Hz, 3H), 2.20 (s, 3H). Example 55: 6-((6-(4-Fluorophenyl)pyridin-3-yl)oxy)-4-methylpyridin-3-amine
Figure imgf000155_0002
Following the General procedure B, 6-((6-(4-fluorophenyl)pyridin-3-yl)oxy)-4- methylpyridin-3-amine was obtained in 96 % yield (2.58 mmol, 763 mg) from 2-((6-(4- fluorophenyl)pyridin-3-yl)oxy)-4-methyl-5-nitropyridine (2.70 mmol, 900 mg).
C17H14FN3O; Mw = 295.31 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.48 (dd, J = 2.8, 0.6 Hz, 1H), 7.95-7.89 (m, 2H),7.66 (dd, J = 8.1, 0.6 Hz, 1H), 7.64 (s, 1H), 7.47 (dd, J = 8.7, 2.8 Hz, 1H), 7.19 (app t, J = 8.7 Hz, 2H), 6.77 (s, 1H), 3.48 (s, 2H), 2.22 (s, 3H). The starting material was prepared as follows: Step 1: 2-((6-(4-Fluorophenyl)pyridin-3-yl)oxy)-4-methyl-5-nitropyridine
Figure imgf000156_0001
Following the General procedure A, 2-((6-(4-fluorophenyl)pyridin-3-yl)oxy)-4-methyl-5- nitropyridin was obtained in 90 % yield (2.70 mmol, 900 mg) from 6-(4- fluorophenyl)pyridin-3-ol (3.00 mmol, 600 mg; expl.53, Step 3) and 2-chloro-4-methyl-5- nitropyridine (5.00 mmol, 800 mg).
C17H12FN3O3; Mw = 325.29 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.86 (s, 1H), 8.55 (dd, J = 2.8, 0.6 Hz, 1H), 8.01-7.95 (m, 2H), 7.76 (dd, J = 8.7, 0.6 Hz, 1H), 7.60 (dd, J = 8.6, 2.8 Hz, 1H), 7.17 (app t, J = 8.8 Hz, 2H), 6.97 (s, 1H), 2.72 (s, 3H). Example 56: 6-((6-(4-Fluorophenyl)pyridin-3-yl)oxy)-N,4-dimethylpyridin-3-amine
Figure imgf000156_0002
Following the General procedure C, 6-((6-(4-fluorophenyl)pyridin-3-yl)oxy)-N,4- dimethylpyridin-3-amine was obtained in 69 % yield after purification (0.786 mmol, 0.243 g) from 6-((6-(4-fluorophenyl)pyridin-3-yl)oxy)-4-methylpyridin-3-amine (1.14 mmol, 0.337 g) and paraformaldehyde (1.60 mmol, 1.40 eq.).
C18H16FN3O; MW = 309.34 g.mol-1 ; 1H NMR (400 MHz, DMSO-d6) d 8.41 (d, J = 2.8 Hz, 1H), 8.11-8.03 (m, 2H), 7.94 (d, J = 8.7 Hz, 1H), 7.52 (dd, J = 8.7, 2.8 Hz, 1H), 7.36-7.24 (m, 3H), 6.87 (s, 1H), 5.14 (q, J = 4.9 Hz, 1H), 2.74 (d, J = 4.9 Hz, 3H), 2.15 (s, 3H). Example 57: (4-Aminophenyl)(4'-fluoro-[1,1'-biphenyl]-4-yl)methanol
Figure imgf000156_0003
Following the General procedure F, (4-aminophenyl)(4'-fluoro-[1,1'-biphenyl]-4-yl)methanol was obtained in 98 % yield with purification (1.55 mmol, 0.445 g) from (4'-fluoro-[1,1'- biphenyl]-4-yl)(4-nitrophenyl)methanol (1.52 mmol, 0.500 g).
C19H16FNO; Mw = 293.33 g.mol-1; 1H NMR (400 MHz, CDCl3) d 7.56-7.48 (m, 4H), 7.47- 7.41 (m, 2H), 7.22-7.15 (m, 2H), 7.13-7.07 (m, 2H), 6.71-6.60 (m, 2H), 5.80 (s, 1H). The starting material was prepared as follows: Step 1: (4'-Fluoro-[1,1'-biphenyl]-4-yl)boronic acid
Figure imgf000157_0001
To a solution of 4-bromo-4'-fluoro-1,1'-biphenyl (1.99 mmol, 0.500 g), in dry THF (19.9 ml), at -78 °C, under inert atmosphere, tert-butyllithium (2.390 mmol, 1.4 ml) was added dropwise. The reaction mixture was stirred at -78 °C for 20 min before trimethyl borate (1.99 mmol, 0.222 ml) was added dropwise. After stirring for 1 h the reaction mixture was brought to RT and quenched with 1N HCl and stirred for 30 min. The reaction mixture was concentrated under vacuo and the observed precipitate was filtered off and air dried to get (4'-fluoro-[1,1'- biphenyl]-4-yl)boronic acid (1.852 mmol, 0.400 g) in 93 % yield as a white powder.
The NMR spectra was identical to the previously reported one (Neya, et al., WO 2003 022842). Step 2: (4'-Fluoro-[1,1'-biphenyl]-4-yl)(4-nitrophenyl)methanol
Figure imgf000157_0002
To a solution of chloro(1,5-cyclooctadiene)rhodium(I) dimer (0.093 mmol, 0.046 g) in dry dioxane (12.3 ml), at RT, under inert atmosphere, was added potassium hydroxide (1.852 mmol, 1.234 ml) and the mixture stirred for 3 min. To this solution (4'-fluoro-[1,1'-biphenyl]- 4-yl)boronic acid (1.852 mmol, 0.400 g) was added followed by 4-nitrobenzaldehyde (3.760 mmol, 0.560 g). The mixture was stirred for 14 h at RT and then quenched by addition of brine. The mixture was extracted with EtOAc (3x). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography (Biotage KP-Sil 50 g, hexane/EtOAc, 0-20%) to afford (4'-fluoro-[1,1'- biphenyl]-4-yl)(4-nitrophenyl)methanol (1.46 mmol, 0.473 g) in 79 % yield as a white solid. C19H14FNO3; Mw = 323.32 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.25-8.16 (m, 2H), 7.65- 7.59 (m, 2H), 7.56-7.48 (m, 4H), 7.44-7.39 (m, 2H), 7.17-7.06 (m, 2H), 5.97 (s, 1H), 2.41 (s, 1H).19F NMR (377 MHz, CDCl3) d -115.19. Example 58: 4-((4'-Fluoro-[1,1'-biphenyl]-4-yl)(methoxy)methyl)aniline
Figure imgf000158_0001
Following the General procedure F, 4-((4'-fluoro-[1,1'-biphenyl]-4-yl)(methoxy)methyl)- aniline was obtained in 78 % yield with purification (1.30 mmol, 0.400 g) from 4-fluoro-4'- (methoxy(4-nitrophenyl)methyl)-1,1'-biphenyl (1.78 mmol, 0.600 g).
C20H18FNO; Mw = 307.37 g.mol-1; 1H NMR (300 MHz, Chloroform-d) d 7.59-7.44 (m, 4H), 7.45-7.33 (m, 2H), 7.22-7.00 (m, 4H), 6.76-6.55 (m, 2H), 5.19 (s, 1H), 3.38 (s, 3H). The starting material was prepared as follows: Step 1: 4-Fluoro-4'-(methoxy(4-nitrophenyl)methyl)-1,1'-biphenyl
Figure imgf000158_0002
To a solution of (4'-fluoro-[1,1'-biphenyl]-4-yl)(4-nitrophenyl)methanol (0.464 mmol, 0.15 g; expl.57, Step 2), in acetone (4.64 ml), was added Cs2CO3 (1.392 mmol, 0.453 g) followed by iodomethane (0.696 mmol, 0.044 ml). The reaction mixture was refluxed for 4 h in a sealed tube at 60 °C. The cooled reaction mixture was directly loaded on silica and the residue purified by flash chromatograpy (Biotage KP-Sil 25 g, hexane/EtOAc, 0-20%) to afford 4- fluoro-4'-(methoxy(4-nitrophenyl)methyl)-1,1'-biphenyl (0.406 mmol, 0.137 g) in 88 % yield. C20H16FNO3; Mw = 337.34 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.22-8.17 (m, 2H), 7.61- 7.48 (m, 6H), 7.41-7.36 (m, 2H), 7.15-7.07 (m, 2H), 5.36 (s, 1H), 3.43 (s, 3H). Example 59: 4-((4'-Fluoro-[1,1'-biphenyl]-4-yl)methyl)aniline
Figure imgf000158_0003
Following the General procedure F, 4-((4'-fluoro-[1,1'-biphenyl]-4-yl)methyl)aniline was obtained in 60 % yield with purification (1.30 mmol, 0.154 g) from 4-fluoro-4'-(fluoro(4- nitrophenyl)methyl)-1,1'-biphenyl (0.92 mmol, 0.300 g). C19H16FN; Mw = 277.34 g.mol-1; 1H NMR (400 MHz, CDCl3) d 7.56-7.50 (m, 2H), 7.49-7.44 (m, 2H), 7.27-7.24 (m, 2H), 7.16-7.09 (m, 2H), 7.06-7.01 (m, 2H), 6.71-6.66 (m, 2H), 3.94 (s, 2H). The starting material was prepared as follows: Step 1: 4-Fluoro-4'-(fluoro(4-nitrophenyl)methyl)-1,1'-biphenyl
Figure imgf000159_0001
To a solution of (4'-fluoro-[1,1'-biphenyl]-4-yl)(4-nitrophenyl)methanol (1.54 mmol, 0.500 g; expl.57, Step 2), in dry DCM (7.73 ml), under inert atmosphere, at -78 °C, was added dropwise diethylamino-sulfur-trifluoride (1.85 mmol, 0.245 ml). The reaction mixture was stirred at the same temperature for 2 h then brought to RT. The reaction was then quenched using saturated NaHCO3 solution. The two layers were separated, and the aqueous layer was extracted with DCM (3x). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to afford 4-fluoro-4'-(fluoro(4-nitrophenyl)methyl)-1,1'- biphenyl (1.38 mmol, 0.450 g) in 89 % yield as yellow solid.
C19H13F2NO2; Mw = 325.31 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.29-8.22 (m, 2H), 7.59- 7.49 (m, 6H), 7.42-7.36 (m, 2H), 7.17-7.09 (m, 2H), 6.58 (d, J = 47.0 Hz, 1H). Example 60: (4-Aminophenyl)(4'-fluoro-[1,1'-biphenyl]-4-yl)methanone hydrochloride
Figure imgf000159_0002
To the solution of tert-butyl (4-(4'-fluoro-[1,1'-biphenyl]-4-carbonyl)phenyl)carbamate (0.51 mmol, 0.200 g) in DCM (10 ml) was added 3 ml of 4M HCl in dioxane. This was stirred at RT overnight. The reaction mixture was concentrated to dryness and the residue was suspended in Et2O, sonicated for 10 min and filtered off. The residue was washed with Et2O and then air-dried to get (4-aminophenyl)(4'-fluoro-[1,1'-biphenyl]-4-yl)methanone hydrochloride in 58 % yield (0.29 mmol, 0.098 g). C19H14FNO . HCl; Mw = 291.33 g.mol-1; 1H NMR (400 MHz, DMSO-d6) d 9.33 (s), 7.90- 7.74 (m, 8H), 7.72-7.65 (m, 2H), 7.41-7.30 (m, 2H).
The starting material was prepared as follows: Step 1: tert-butyl((4'-fluoro-[1,1'-biphenyl]-4-yl)(4-nitrophenyl)methoxy)dimethylsilane
Figure imgf000160_0001
To a solution of (4'-fluoro-[1,1'-biphenyl]-4-yl)(4-nitrophenyl)methanol (3.09 mmol, 1.00 g; expl.57, Step 2) in DMF (31 ml) at RT was added imidazole (6.09 mmol, 0.421 g) and tert - butyl dimethyl silyl chloride (4.02 mmol, 0.606 g) and the reaction mixture was stirred overnight. The reaction was quenched by the addition of brine and extracted with Et2O (3x). The combined organic layers were washed with water (5x) and the separated organic layer were dried over Na2SO4, filtered and concentrated under reduced pressure to get crude material. This was purified by flash chromatography (Biotage KP-Sil 50 g, hexane/EtOAc, 0- 20%) to afford tert-butyl((4'-fluoro-[1,1'-biphenyl]-4-yl)(4- nitrophenyl)methoxy)dimethylsilane (1.37 mmol, 0.600 g) in 44 % yield as a white solid. C25H28FNO3Si; Mw = 437.58 g.mol-1; 1H NMR (400 MHz, CDCl3) d 8.20-8.17 (m, 2H), 7.61- 7.46 (m, 6H), 7.41-7.36 (m, 2H), 7.15-7.06 (m, 2H), 5.86 (s, 1H), 0.94 (app d, 9H), 0.04 (bs, 3H), 0.01 (bs, 3H). Step 2: 4-(((tert-butyldimethylsilyl)oxy)(4'-fluoro-[1,1'-biphenyl]-4-yl)methyl)aniline
Figure imgf000160_0002
Following the General procedure F, 4-(((tert-butyldimethylsilyl)oxy)(4'-fluoro-[1,1'- biphenyl]-4-yl)methyl)aniline was obtained in 99 % yield (12.50 mmol, 5.10 g) from tert- butyl((4'-fluoro-[1,1'-biphenyl]-4-yl)(4-nitrophenyl)methoxy)dimethylsilane (12.57 mmol, 5.50 g).
C25H30FNOSi; Mw = 407.60 g.mol-1; 1H NMR (400 MHz, CDCl3) d 7.56-7.35 (m, 6H), 7.17- 7.03 (m, 4H), 6.66-6.59 (m, 2H), 5.70 (s, 1H), 0.92 (app d, 9H), 0.01 (s, 3H), -0.03 (s, 3H). Step 3: tert-butyl (4-(((tert-butyldimethylsilyl)oxy)(4'-fluoro-[1,1'-biphenyl]-4- yl)methyl)phenyl)carbamate
Figure imgf000161_0001
To a solution of 4-(((tert-butyldimethylsilyl)oxy)(4'-fluoro-[1,1'-biphenyl]-4- yl)methyl)aniline (14.72 mmol, 6.00 g) in DCM (75 ml) at RT was added DMAP (1.472 mmol, 0.18 g) and triethyl amine (29.4 mmol, 4.1 ml). To this stirred solution a solution of Boc anhydride (10.83 mmol, 5.50 g) in DCM (20 ml) was added. The reaction mixture was stirred at RT overnight. Then it was washed with water and 1N HCl. The organic layer was dried over Na2SO4, filtered and concentrated to get tert-butyl (4-(((tert- butyldimethylsilyl)oxy)(4'-fluoro-[1,1'-biphenyl]-4-yl)methyl)phenyl)carbamate. (12.80 mmol, 6.5 g) in 87 % yield.
C30H38FNO3Si; Mw = 507.71 g.mol-1; 1H NMR (400 MHz, CDCl3) d 7.54-7.48 (m, 2H), 7.48- 7.27 (m, 8H), 7.15-7.04 (m, 2H), 5.75 (d, J = 2.1 Hz, 1H), 1.41 (d, J = 4.9 Hz, 9H), 0.98-0.81 (m, 9H), 0.09 until -0.12 (m, 6H). Step 4: tert-butyl (4-((4'-fluoro-[1,1'-biphenyl]-4-yl)(hydroxy)methyl)phenyl)carbamate
Figure imgf000161_0002
To a solution of tert-butyl (4-(((tert-butyldimethylsilyl)oxy)(4'-fluoro-[1,1'-biphenyl]-4- yl)methyl)phenyl)carbamate (10.83 mmol, 5.50 g), in THF (110 mL), at RT, under inert atmosphere, was added tetrabutylammonium fluoride (16.25 mmol, 8.12 ml). The reaction mixture was stirred at RT for 4 h. Then it was diluted with saturated NH4Cl solution and extracted with Et2O (2x). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography (Biotage KP-Sil 100 g, hexane/EtOAc, 0-80%) to afford tert-butyl (4-((4'-fluoro-[1,1'- biphenyl]-4-yl)(hydroxy)methyl)phenyl)carbamate (6.40 mmol, 2.52 g) in 59 % yield, as a foam.
C24H24FNO3; Mw = 393.45 g.mol-1; 1H NMR (400 MHz, CDCl3) d 7.54-7.46 (m, 4H), 7.41- 7.34 (m, 4H), 7.23-7.18 (m, 2H), 7.14 -7.07 (m, 2H), 5.87 (s, 1H), 2.26 (s, 1H), 1.44 (s, 9H). Step 5: tert-butyl (4-(4'-fluoro-[1,1'-biphenyl]-4-carbonyl)phenyl)carbamate
Figure imgf000162_0001
To a solution of tert-butyl (4-((4'-fluoro-[1,1'-biphenyl]-4- yl)(hydroxy)methyl)phenyl)carbamate (0.762 mmol, 0.300 g), in DCM (80mL), was added MnO2 (4.57 mmol, 0.40 g) and the suspension was stirred at RT for 16 h. The reaction mixture was filtered through a fritted funnel and the filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography (Biotage KP-Sil 25 g, hexane/EtOAc, 0-40%) to afford tert-butyl (4-(4'-fluoro-[1,1'-biphenyl]-4- carbonyl)phenyl)carbamate (0.588 mmol, 0.230 g) in 77 % yield as a yellow solid.
C24H22FNO3; Mw = 391.43 g.mol-1; 1H NMR (400 MHz, CDCl3) d 7.94-7.80 (m, 4H), 7.71- 7.56 (m, 4H), 7.46-7.41 (m, 2H), 7.21-7.13 (m, 2H), 1.48 (s, 9H).
BIOLOGICAL PROPERTIES OF COMPOUNDS Identification of compounds exhibiting high potency against NOTCH driven human cancers
In order determine anti-cancer potency of compounds NOTCH positive/driven human T cell acute lymphoblastic leukemia cell line RPMI 8402 was treated with selected compounds and downregulation of NOTCH target genes was measured. Materials and Methods Cell culture
One million human NOTCH positive T-ALL cell line RPMI8402 were treated with NOTCH targeting compounds at 1 µM concentration for 24 hours. Following treatment cells were harvested and washed with 1x PBS. Total RNA and total protein lysates were extracted as described below. RNA extraction
Total RNA was extracted from cells using TRIzol® extraction kit (Invitrogen). Briefly, 1x106 cells were washed with ice-cold 1xPBS and lysed in 1 ml of TRIzol® solution for 5 minutes at room temperature to dissociate nucleoprotein complexes. Lysed cells were then treated with 200 ^ ml of chloroform and shaked vigorously for 15-30 seconds and incubated at room temperature for 2-3 minutes. The samples were centrifuged at 14000 rpm using Eppendorf table top centrifuge for 10 minutes at 4°C. Following centrifugation, upper aqueous phase was transferred to new eppendorf tubes. To precipitate total RNA 500 ml of isomyl alcohol was added to the separated aqueous phase and incubated at room temperature for 10 minutes. A RNA pellet was obtained by centrifuging the samples at 4°C for 10 minutes. RNA pellet obtained was washed with 1 ml ice cold 75% ethanol and spun down at 14000 rpm at 4°C. RNA pellet was dried off of excess of ethanol and resuspended in 40 ml DPEC water. cDNA synthesis
Total RNA extracted from the cell was used to synthesize cDNA by reverse transcription reaction. Reverse transcription was performed according to one of the two following protocols. In first protocol, SuperScript™ RT (Invitrogen) was used for reverse transcription reaction. RNA concentration was measured using NanoDrop®ND-1000 spectrophotometer (Witec AG) and 500 ng of total RNA was mixed with a 10mM mix of dNTPs and 100 ng of random primers. The reaction mix was incubated at 65°C for 5 minutes and quickly incubated on ice for 1 minute. Following incubation on ice, 5x first strand buffer and 0.1M DTT were added and mix was incubated for 2 minutes at 25°C. To start the reverse transcription reaction, 200U of SuperScrip™ II RT was added to the reaction mix and incubated at 42°C for 50 minutes. The reaction was stopped by incubating the reaction mix at 75°C for 15 minutes. In second protocol, reverse transcription was performed using PrimeScript RT Master Mix (Takara). RNA concentration was measured using NanoDrop®ND-1000 spectrophotometer (Witec AG) and 1 mg of total RNA was mixed with 4 mL 5X PrimeScript RT Master Mix in a total reaction volume of 20 mL. The reaction mix was incubated at 37°C for 15 minutes followed by heat inactivation at 85°C for 5 seconds.
Quantitative Real Time PCR analyses QRT-PCR were carried out using 7900 HT Fast Real-Time PCR system (Applied
Biosystems) or QuantStudio 3 system (ThermoFisher). Briefly, 12.5 ng of template cDNA was used with a primer concentration of 0.5 mM each and 1X SYBR Green dye in a final volume of 10 mL in a 96 well or 384 well plate format. The melting curves and ct values were analyzed with SDS software (Applied Biosystems) or with QuantStudio Design and Analysis software (ThermoFisher).
Western blot analyses
Cells were lysed in RIPA buffer (50mM Tris.Cl, pH 7.5, 150 mM NaCl, 1% nonidet P-40, 0.5% sodium deoxycholate and 0.1% SDS) for 30 minutes at 4°C. Lysed cells were centrifuged to remove the debris at 14000 rpm at 4°C. Supernatant was transferred to a new eppendorf tube. The protein concentration was determined by Bradford assay using spectrophotometer (Ultrospec 3000 pro). Initially for western blotting, 40 mg of protein were denatured in 1x SDS gel loading buffer (100mM Tris.Cl, pH 6.8, 200 mM DTT, 4 % SDS, 0.2 % bromophenol, 20% glycerol) by heating at 99°C for 5 minutes. Denatured protein samples were stored on ice until loading on to the acrylamide gel. The samples were run on 8% or 10% acrylamide gel in Tris-glycine electrophoresis buffer (25mM Tris, 250 mM glycine, 0.1% SDS). Following separation on the acrylamide gel, protein samples were transferred on to PVDF membrane (PEQ lab, catalog number 39-3010) using transfer buffer (39mM glycine, 48 mM Tris base, 0.037 % SDS and 20 % methanol). For immunoblotting, membranes were blocked with 5 % milk and incubated overnight with primary antibodies at 4°C. Membrane were washed with 1x TBST (1x TBS + 0.5 % tween 20) for 5 minutes (3 times) and incubated with HRP-conjugated secondary antibodies for one hour at room temperature. Signal was detected with Super Signal West chemiluminescent substrate (Thermo Scientific, catalog number 34077). Later on western blotting was carried out using Jess (ProteinSimple, biotechne). Samples containing 0.8 mg protein was denatured in loading buffer containing DTT by heating at 95°C for 5 minutes. Samples were run on 12-230 kDa gel matrix, with incubation time for primary and secondary antibodies of 1 hour and 30 minutes, respectively. Data were analysed using Compass for SW (ProteinSimple, biotechne) software.
Alamarblue/PrestoBlue proliferation assay
Alamarblue® and PrestoBlue proliferation assays were performed to determine the growth kinetics of Notch inhibitor treated cells. Alamar blue® and PrestoBlue consists of a cell permeable substrate resazurin. In metabolically active and proliferating cells, resazurin is converted to resorufin due to an intrinsic reducing power of live cells and produces a red fluorescence. Therefore production of resorufin serves as an indicator of the viability of the cell population. Proliferation assays were performed by seeding 5000 cells/well in a 96 well plate. Cells were treated with DMSO or compounds for 72 hours using concentration ranges of 0.01-10 µM. Each concentration was tested in 4 replicates. To determine the growth kinetics, 10 ml of Alamar blue® or PrestoBlue (Invitrogen) was added to each well and incubated for 4 hours. Readout was taken using Tecan F500 (Tecan) multiplate reader or Varioskan LUX (ThermoFisher) multiplate reader.
Example 27: Compounds exhibiting high potency against NOTCH driven human cancers
In order to determine anti-cancer potency of compounds compared to 6-(4-tert- butylphenoxy)pyridin-3-amine (described in WO2013/093885), NOTCH positive/driven human T cell acute lymphoblastic leukemia cell line RPMI 8402 was treated with selected compounds. As shown in figure 1 and table 1, 4-([1,1'-Biphenyl]-4-yloxy)aniline , 6-([1,1'- Biphenyl]-4-yloxy)-N-methylpyridin-3-amine,
4-([1,1'-Biphenyl]-4-yloxy)-3-fluoro-N-methylaniline, 6-((4'-Fluoro-[1,1'-biphenyl]-4- yl)oxy)pyridin-3-amine, 6-([1,1'-Biphenyl]-4-yloxy)-4-methylpyridin-3-amine), 6-([1,1'- Biphenyl]-4-yloxy)-2-methylpyridin-3-amine, N-Methyl-6-((6-phenylpyridin-3- yl)oxy)pyridin-3-amine and 6-((2-(2-(4-Aminophenoxy)ethyl)-[1,1'-biphenyl]-4- yl)oxy)pyridin-3-amine exhibit 1.05x-9x higher anti-proliferative potency than 6-(4-tert- butylphenoxy)pyridin-3-amine.
Figure imgf000166_0001
* Comparative compound described in WO2013/093885
Table 1: Anti-proliferative effect of compounds on NOTCH positive human leukemic cells. Cells were treated with compounds (concentration range 0.01-10 µM) for 72 hours. Anti- proliferative effect was measured using Alamar blue assay (See Material and methods for details). IC50 values were calculated using Graph prism software. Example 28: Downregulation of mRNA transcripts of NOTCH target genes
To further determine anti-NOTCH activity and potency of compounds (compared to 6-(4-tert- butylphenoxy)pyridin-3-amine), NOTCH positive human leukemic cell lines were treated with compounds for 24 hours at a concentration of 1 µM. The effect on NOTCH signalling was investigated by quantifying the levels of mRNA transcripts of NOTCH target genes by quantitative PCR. An increase in potency of newly synthesized compounds was calculated as percentage improvement over 6-(4-tert-butylphenoxy)pyridin-3-amine activity. As show in table 2, compounds exhibit enhanced potency in downregulating NOTCH target genes such as HES1, cMYC and DTX1.
Figure imgf000167_0001
Figure imgf000168_0001
Figure imgf000169_0001
* Comparative compound described in WO2013/093885 Table 2: Human leukemic cells RPMI8402 were treated with compounds at 1mM concentration for 24 hours at 37C. Total RNA was extracted, cDNA synthesized and RNA expression of respective genes was quantified using quantitative PCR (qPCR). The activity of 6-(4-tert-butylphenoxy)pyridin-3-amine to downregulate NOTCH target genes was set to 100% and corresponding increase in activity of various compounds was calculated using 6-(4- tert-butylphenoxy)pyridin-3-amine activity as a reference point. ND: not determined. Example 29: Downregulation of NOTCH target genes at protein level
To further confirm an anti-NOTCH activity and potency of compounds, NOTCH positive leukemic cell lines were treated with selected -compounds for 24 hours at a concentration of 1 µM. Total protein lysates were analysed by western blot analysis using N1-ICD (cleaved and active NOTCH1 Intracellular Domain), cMYC and ACTIN specific antibodies. As shown in figure 2 and 3, compared to 6-(4-tert-butylphenoxy)pyridin-3-amine (described in WO2013/093885), 6-([1,1'-Biphenyl]-4-yloxy)-N-methylpyridin-3-amine, 6-((4'-Fluoro-[1,1'- biphenyl]-4-yl)oxy)pyridin-3-amine, 6-([1,1'-Biphenyl]-4-yloxy)-4-methylpyridin-3-amine, 6- ([1,1'-Biphenyl]-4-yloxy)-2-methylpyridin-3-amine and N-Methyl-6-((6-phenylpyridin-3- yl)oxy)pyridin-3-amine show a stronger downregulation of cMYC and N1-ICD (both direct target genes of NOTCH signalling in human leukemic cells). Example 30: Compounds exhibiting high potency against NOTCH driven human cancers
In order to determine anti-cancer potency of compounds compared to 6-(4-tert- butylphenoxy)pyridin-3-amine (described in WO2013/093885), NOTCH positive/driven human T cell acute lymphoblastic leukemia cell line RPMI 8402 was treated with selected compounds. The compounds shown in figure 1 and table 3, exhibit 1.5x to 24x higher anti- proliferative potency than 6-(4-tert-butylphenoxy)pyridin-3-amine.
Figure imgf000170_0001
* Comparative compound described in WO2013/093885
Table 3: Anti-proliferative effect of compounds on NOTCH positive human leukemic cells. Cells were treated with compounds (concentration range 0.03-100 µM) for 72 hours. Anti- proliferative effect was measured using PrestoBlue assay (See Material and methods for details). IC50 values were calculated using Graph prism software. Example 31: Downregulation of NOTCH target genes at protein level
To further confirm an anti-NOTCH activity and potency of compounds, NOTCH positive leukemic cell lines were treated with selected compounds for 24 hours at a concentration of 1 µM. Total protein lysates were analysed by Jess western blot analysis using N1-ICD (cleaved and active NOTCH1 Intracellular Domain), cMYC and GAPDH specific antibodies. The compounds shown in table 4 demonstrate a stronger downregulation of cMYC and N1-ICD (both direct target genes of NOTCH signalling in human leukemic cells) when compared with 6-(4-tert-butylphenoxy)pyridin-3-amine (described in WO2013/093885).
Figure imgf000171_0001
Figure imgf000172_0001
* Comparative compound described in WO2013/093885
Table 4: Human leukemic cells RPMI8402 were treated with compounds at 1µM concentration for 24 hours at 37°C. Total protein lysate were analysed by Jess western blot. Example 32: Downregulation of mRNA transcripts of NOTCH target genes To further determine anti-NOTCH activity and potency of compounds (compared to 6-(4-tert- butylphenoxy)pyridin-3-amine), NOTCH positive human leukemic cell lines were treated with compounds for 24 hours at a concentration of 1 µM. The effect on NOTCH signalling was investigated by quantifying the levels of mRNA transcripts of NOTCH target genes by quantitative PCR. As show in table 5, in comparison to 6-(4-tert-butylphenoxy)pyridin-3- amine, the listed compounds exhibit enhanced potency in downregulating NOTCH target genes such as cMYC, DTX1 and HES1.
Figure imgf000172_0002
Figure imgf000173_0001
Figure imgf000174_0001
* Comparative compound described in WO2013/093885 Table 5: Human leukemic cells RPMI8402 were treated with compounds at 1mM concentration for 24 hours at 37°C. Total RNA was extracted, cDNA synthesized and RNA expression of respective genes was quantified using quantitative PCR (qPCR).

Claims

Claims 1. A compound of formula (I)
Figure imgf000175_0001
pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof, wherein X is selected from CH2, CF2, CHF, CO, CHOH, CHO(C1-C3) alkyl, NH, N(C1- C3 alkyl), S, SO and O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl;
wherein R1 is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; and C1- C6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C(O)R12 , C1-C6 alkyl C(O)R12; wherein R3 is selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl and C1-C6 alkoxy;
wherein R4 , R5 and R6 are each independently selected from H, halogen, CN, C1-C6 alkoxy, C1-C6-S-alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl and C3-C12 heterocyclyl;
wherein R7 is absent when Y1 is N or is selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl and C1-C6 alkoxy when Y1 is C; wherein R8 is absent when Y3 is N or is selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl and C1-C6 alkoxy when Y3 is C; wherein R9 is absent when Y2 is N or is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; and C1-C6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl;
wherein R12 is selected from H, NH2, NHC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl and C3-C12 heterocyclyl;
with the proviso that the compound of formula (I) is not 6-([1,1’-Biphenyl]-4-yloxy)- pyridine-3-amine, 4-([1,1’-Biphenyl]-4-yloxy)-aniline, 6-([1,1’-Biphenyl]-4-yloxy)-2- methylpyridin-3-amine and 6-([1,1’-Biphenyl]-4-yloxy)-4-methylpyridin-3-amine.
2. The compound of formula (I)
Figure imgf000176_0001
Formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof, wherein X is selected from CH2, CF2, CHF, CO, CHOH, CHO(C1-C3) alkyl, NH, N(C1- C3 alkyl), S, SO and O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl;
wherein R1 is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; and C1- C6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C(O)R12 , C1-C6 alkyl C(O)R12;
wherein R3 is selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl and C1-C6 alkoxy;
wherein R4 , R5 and R6 are each independently selected from H, halogen, CN, C1-C6 alkoxy, C1-C6-S-alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl and C3-C12 heterocyclyl;
wherein R7 is absent when Y1 is N or is selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl and C1-C6 alkoxy when Y1 is C; wherein R8 is absent when Y3 is N or is selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl and C1-C6 alkoxy when Y3 is C; wherein R9 is absent when Y2 is N or is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; and C1-C6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl;
wherein R12 is selected from H, NH2, NHC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl and C3-C12 heterocyclyl,
for use in a method for the prevention or treatment of cancer.
3. A pharmaceutical composition comprising a compound of formula (I)
Figure imgf000178_0001
pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof, wherein X is selected from CH2, CF2, CHF, CO, CHOH, CHO(C1-C3) alkyl, NH, N(C1- C3 alkyl), S, SO and O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl;
wherein R1 is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; and C1- C6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C(O)R12 , C1-C6 alkyl C(O)R12;
wherein R3 is selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl and C1-C6 alkoxy;
wherein R4 , R5 and R6 are each independently selected from H, halogen, CN, C1-C6 alkoxy, C1-C6-S-alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl and C3-C12 heterocyclyl;
wherein R7 is absent when Y1 is N or is selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl and C1-C6 alkoxy when Y1 is C; wherein R8 is absent when Y3 is N or is selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl and C1-C6 alkoxy when Y3 is C; wherein R9 is absent when Y2 is N or is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; and C1-C6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl;
wherein R12 is selected from H, NH2, NHC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl and C3-C12 heterocyclyl, and a pharmaceutically acceptable carrier.
4. The compound of formula (I) according to claim 1, the compound of formula (I) for use according to claim 2, and the pharmaceutical composition comprising a compound of formula (I) according to claim 3, wherein X is selected from CH2, CO, CHOH,
CHO(C1-C3) alkyl, NH, and O.
5. The compound of formula (I) according to claim 1, the compound of formula (I) for use according to claim 2, and the pharmaceutical composition comprising a compound of formula (I) according to claim 3, wherein X is selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, NH, and O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl;
wherein R1 is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; and C1- C6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C(O)R12 , C1-C6 alkyl C(O)R12;
wherein R3 is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl;
wherein R4 , R5 and R6 are each independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl;
wherein R7 is absent when Y1 is N or is selected from H, halogen, C1-C6 alkyl and C3- C12 cycloalkyl when Y1 is C;
wherein R8 is absent when Y3 is N or is selected from H, halogen, C1-C6 alkyl and C3- C12 cycloalkyl when Y3 is C;
wherein R9 is absent when Y2 is N or is selected from H, halogen, C1-C6 alkyl and C3- C12 cycloalkyl when Y2 is C; and
wherein R12 is selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl, and C1-C6 heteroalkyl.
6. The compound of formula (I) according to claim 1, the compound of formula (I) for use according to claim 2, and the pharmaceutical composition comprising a compound of formula (I) according to claim 3,
wherein X is selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, NH, and O;
wherein Y1 is N and R7 is absent, Y2 is selected from N and C and Y3 is C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl; wherein R1 is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; and C1- C6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C(O)R12 , C1-C6 alkyl C(O)R12;
wherein R3 is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl;
wherein R4 , R5 and R6 are each independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl;
wherein R8 is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl;
wherein R9 is absent when Y2 is N or is selected from H, halogen, C1-C6 alkyl and C3- C12 cycloalkyl when Y2 is C; and
wherein R12 is selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl, and C1-C6 heteroalkyl.
7. The compound of formula (I) according to claim 1, the compound of formula (I) for use according to claim 2, and the pharmaceutical composition comprising a compound of formula (I) according to claim 3,
wherein X is selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, NH, and O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl;
wherein R1 is selected from H, C1-C6 alkyl, C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2; C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, C1-C6 alkyl C(O)R12;
wherein R3 is H; wherein R4 is selected from H and halogen;
wherein R5 and R6 are each independently selected from H and C1-C6 alkyl;
wherein R7 is absent when Y1 is N or is H when Y1 is C;
wherein R8 is absent when Y3 is N or is H when Y3 is C;
wherein R9 is absent when Y2 is N or is H when Y2 is C; and
wherein R12 is NH2.
8. The compound of formula (I) according to claim 1, the compound of formula (I) for use according to claim 2, and the pharmaceutical composition comprising a compound of formula (I) according to claim 3,
wherein X is selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, NH, and O;
wherein Y1 is N and R7 is absent, Y2 is selected from N and C and Y3 is C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl;
wherein R1 is selected from H, C1-C6 alkyl, C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2; C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, C1-C6 alkyl C(O)R12;
wherein R3 is H;
wherein R4 is selected from H and halogen;
wherein R5 and R6 are each independently selected from H and C1-C6 alkyl;
wherein R8 is H;
wherein R9 is absent when Y2 is N or is H when Y2 is C; and
wherein R12 is NH2.
9. The compound of formula (I) according to claim 1, the compound of formula (I) for use according to claim 2, and the pharmaceutical composition comprising a compound of formula (I) according to claim 3,
wherein X is selected from CH2, NH and O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl; wherein R1 is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; and C1- C6 alkyl substituted by aryl or heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C(O)R12 , C1-C6 alkyl C(O)R12;
wherein R3 is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl;
wherein R4 , R5 and R6 are each independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl;
wherein R7 is absent when Y1 is N or is selected from H, halogen, C1-C6 alkyl and C3- C12 cycloalkyl when Y1 is C;
wherein R8 is absent when Y3 is N or is selected from H, halogen, C1-C6 alkyl and C3- C12 cycloalkyl when Y3 is C;
wherein R9 is absent when Y2 is N or is selected from H, halogen, C1-C6 alkyl and C3- C12 cycloalkyl when Y2 is C; and
wherein R12 is selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl, and C1-C6 heteroalkyl.
10. The compound of formula (I) according to claim 1, the compound of formula (I) for use according to claim 2, and the pharmaceutical composition comprising a compound of formula (I) according to claim 3,
wherein X is selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, NH, and O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl;
wherein R1 is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy and C1-C6 heteroalkyl; wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C(O)R12 , C1-C6 alkyl C(O)R12;
wherein R3 is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl;
wherein R4 , R5 and R6 are each independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl;
wherein R7 is absent when Y1 is N or is selected from H, halogen, C1-C6 alkyl and C3- C12 cycloalkyl when Y1 is C;
wherein R8 is absent when Y3 is N or is selected from H, halogen, C1-C6 alkyl and C3- C12 cycloalkyl when Y3 is C;
wherein R9 is absent when Y2 is N or is selected from H, halogen, C1-C6 alkyl and C3- C12 cycloalkyl when Y2 is C; and
wherein R12 is selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl, and C1-C6 heteroalkyl.
11. The compound of formula (I) according to claim 1, the compound of formula (I) for use according to claim 2, and the pharmaceutical composition comprising a compound of formula (I) according to claim 3,
wherein X is selected from CH2, NH and O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl;
wherein R1 is selected from H, halogen, C1-C6 alkyl, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C1-C6 alkoxy and C1-C6 heteroalkyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl, C(O)R12 , C1-C6 alkyl C(O)R12;
wherein R3 is selected from H, halogen, C1-C6 alkyl and C3-C12 cycloalkyl;
wherein R4 , R5 and R6 are each independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl;
wherein R7 is absent when Y1 is N or is selected from H, halogen, C1-C6 alkyl and C3- C12 cycloalkyl when Y1 is C;
wherein R8 is absent when Y3 is N or is selected from H, halogen, C1-C6 alkyl and C3- C12 cycloalkyl when Y3 is C;
wherein R9 is absent when Y2 is N or is selected from H, halogen, C1-C6 alkyl and C3- C12 cycloalkyl when Y2 is C; and
wherein R12 is selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl, and C1-C6 heteroalkyl.
12. The compound of formula (I) according to claim 1, the compound of formula (I) for use according to claim 2, and the pharmaceutical composition comprising a compound of formula (I) according to claim 3,
wherein X is selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, NH, and O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl;
wherein R1 is selected from H and C1-C6 alkyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, C1-C6 alkyl C(O)R12;
wherein R3 is H;
wherein R4 is selected from H and halogen;
wherein R5 and R6 are each independently selected from H and C1-C6 alkyl;
wherein R7 is absent when Y1 is N or is H when Y1 is C;
wherein R8 is absent when Y3 is N or is H when Y3 is C;
wherein R9 is absent when Y2 is N or is H when Y2 is C; and
wherein R12 is NH2.
13. The compound of formula (I) according to claim 1, the compound of formula (I) for use according to claim 2, and the pharmaceutical composition comprising a compound of formula (I) according to claim 3,
wherein X is selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, NH, and O;
wherein Y1 is N and R7 is absent, Y2 is selected from N and C and Y3 is C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl;
wherein R1 is selected from H and C1-C6 alkyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, C1-C6 alkyl C(O)R12;
wherein R3 is H; wherein R4 is selected from H and halogen;
wherein R5 and R6 are each independently selected from H and C1-C6 alkyl;
wherein R8 is H;
wherein R9 is absent when Y2 is N or is H when Y2 is C; and
wherein R12 is NH2.
14. The compound of formula (I) according to claim 1, the compound of formula (I) for use according to claim 2, and the pharmaceutical composition comprising a compound of formula (I) according to claim 3,
wherein X is selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, NH, and O;
wherein Y1 , Y2 , and Y3 are each independently selected from N and C;
wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl;
wherein R1 is selected from C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; and C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, halogen, C1-C6 alkyl, CN;
wherein R3 is selected from H, halogen and C1-C4 alkyl;
wherein R4 , R5 and R6 are each independently selected from H, halogen, and C1-C4 alkyl;
wherein R7 is absent when Y1 is N or is selected from H, halogen and C1-C4 alkyl when Y1 is C;
wherein R8 is absent when Y3 is N or is selected from H, halogen and C1-C4 alkyl when Y3 is C; and
wherein R9 is absent when Y2 is N or is selected from H, halogen and C1-C4 alkyl when Y2 is C.
15. The compound of formula (I) according to claim 1, the compound of formula (I) for use according to claim 2, and the pharmaceutical composition comprising a compound of formula (I) according to claim 3,
wherein X is selected from CH2, NH and O, and is preferably O; wherein Y1 , Y2 , and Y3 are each independently selected from N and C; wherein Z is NR10R11 , wherein R10 and R11 are each independently selected from H and C1-C6 alkyl;
wherein R1 is selected from C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl; and C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl;
wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, halogen, C1-C6 alkyl, CN;
wherein R3 is selected from H, halogen and C1-C4 alkyl;
wherein R4 , R5 and R6 are each independently selected from H, halogen, and C1-C4 alkyl;
wherein R7 is absent when Y1 is N or is selected from H, halogen and C1-C4 alkyl when Y1 is C;
wherein R8 is absent when Y3 is N or is selected from H, halogen and C1-C4 alkyl when Y3 is C; and
wherein R9 is absent when Y2 is N or is selected from H, halogen and C1-C4 alkyl when Y2 is C.
16. The compound of formula (I), the compound of formula (I) for use, and the
pharmaceutical composition comprising a compound of formula (I) according to anyone of claims 1 to 15, wherein X is selected from CH2, CO, CHOH, CHO(C1-C3) alkyl, and O.
17. The compound of formula (I), the compound of formula (I) for use, and the
pharmaceutical composition comprising a compound of formula (I) according to anyone of claims 1 to 15, wherein X is CH2 or O.
18. The compound of formula (I), the compound of formula (I) for use, and the
pharmaceutical composition comprising a compound of formula (I) according to anyone of claims 1 to 15, wherein X is O.
19. The compound of formula (I), the compound of formula (I) for use, and the
pharmaceutical composition comprising a compound of formula (I) according to anyone of claims 1 to 6, 9 and 16 to 18, wherein R1 is selected from H, halogen, C1-C6 alkyl, C1- C6 heteroalkyl, C0-C3 alkylOC0-C3 alkyl aryl wherein the aryl is optionally substituted by NH2, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, preferably is optionally substituted by NH2; and C0-C3 alkylOC0-C3 alkyl heteroaryl wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 cycloalkyl, C3-C12 heterocyclyl, preferably is optionally substituted by NH2.
20. The compound of formula (I), the compound of formula (I) for use, and the
pharmaceutical composition comprising a compound of formula (I) according to anyone of claims 1 to 19, wherein R2 is selected from aryl and heteroaryl, wherein the aryl is a phenyl group which is optionally substituted, wherein the optional substitution of the phenyl group is in meta or para position, preferably in para position.
21. The compound of formula (I), the compound of formula (I) for use, and the
pharmaceutical composition comprising a compound of formula (I) according to anyone of claims 1 to 6, 9 to 11 and 16 to 19, wherein R2 is selected from aryl and heteroaryl wherein the aryl and the heteroaryl are optionally substituted by NH2, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C(O)R12 , C1-C6 alkyl C(O)R12.
22. The compound of formula (I), the compound of formula (I) for use, and the
pharmaceutical composition comprising a compound of formula (I) according to anyone of claims 1 to 6, 9 to11 and 16 to 21, wherein R3 is selected from H, halogen and C1-C4 alkyl, preferably is H and/or
wherein R4 , R5 and R6 are each independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl.
23. The compound of formula (I), the compound of formula (I) for use, and the
pharmaceutical composition comprising a compound of formula (I) according to anyone of claims 1 to 5, 7, 9 to 12, and 14 to 22 wherein R7 is absent when Y1 is N or is selected from H, halogen and C1-C4 alkyl, preferably selected from H, halogen, and methyl when Y1 is C; wherein R8 is absent when Y3 is N or is selected from H, halogen and C1-C4 alkyl preferably selected from H, halogen, and methyl when Y3 is C;
wherein R9 is absent when Y2 is N or is selected from H and C1-C4 alkyl preferably selected from H, halogen, and methyl when Y2 is C; and/or
wherein R10 is H; and R11 is selected from H and C1-C4 alkyl, preferably is H or methyl.
24. The compound of formula (I), the compound of formula (I) for use, and the
pharmaceutical composition comprising a compound of formula (I) according to anyone of claims 1 to 4, wherein R12 is selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl, and C1- C6 heteroalkyl.
25. The compound of formula (I), the compound of formula (I) for use, and the
pharmaceutical composition comprising a compound of formula (I) according to anyone of claims 1 to 5, 7, 9 to 12 and 14 to 22, wherein Y1 is N and R7 is absent.
26. The compound of formula (I), the compound of formula (I) for use, and the
pharmaceutical composition comprising a compound of formula (I) according to anyone of claims 1 to 5, 7, 9 to 12 and 14 to 22, wherein Y1 is N and R7 is absent, Y2 is selected from N and C and Y3 is C.
27. The compound of formula (I), the compound of formula (I) for use, and/or the
pharmaceutical composition comprising a compound of formula (I) according to anyone of claims 1 to 26, wherein R2 is selected from aryl and heteroaryl wherein the heteroaryl is an optionally substituted aromatic 5-, or 6- membered monocyclic group.
28. The compound of formula (I) according to anyone of claims 1 to 27, wherein R2 is
selected from aryl and heteroaryl, with the proviso that the heteroaryl is not
unsubstituted thiazole, oxazole, imidazole and pyrrole.
29. The compound of formula (I), the compound of formula (I) for use, and/or the
pharmaceutical composition comprising a compound of formula (I) according to anyone of claims 1 to 28 with the proviso that the compound of formula (I) is not 4-(4’- Methoxy-biphenyl-4-yloxy)phenylamine, 4-(4’-Chloro-biphenyl-4-yloxy)phenylamine, 4-(4’-tert-Butyl-biphenyl-4-yloxy)phenylamine.
30. The compound of formula (I), the compound of formula (I) for use, and/or the pharmaceutical composition comprising a compound of formula (I) according to anyone of claims 1 to 29 with the proviso that the compound of formula (I) is not 4-(4-(thiazol- 2-yl)phenoxy)aniline, 4-(4-(1H-imidazol-2-yl)phenoxy)aniline, 4-(4-(oxazol-2- yl)phenoxy)aniline and 4-(4-(1H-pyrrol-1-yl)phenoxy)aniline.
31. The compound of formula (I) for use and/or the pharmaceutical composition comprising a compound of formula (I) according to anyone of claims 2 to 30, with the proviso that the compound of formula (I) is not 4-([1,1’-Biphenyl]-4-yloxy)-aniline.
32. The compound of formula (I), the compound of formula (I) for use, and/or the
pharmaceutical composition comprising a compound of formula (I) according to anyone of claims 2 to 30 with the proviso that the compound of formula (I) is not 6-([1,1’- Biphenyl]-4-yloxy)-pyridine-3-amine, 4-([1,1’-Biphenyl]-4-yloxy)-aniline, 6-([1,1’- Biphenyl]-4-yloxy)-2-methylpyridin-3-amine and 6-([1,1’-Biphenyl]-4-yloxy)-4- methylpyridin-3-amine.
33. The compound of formula (I) according to claim 1, the compound of formula (I) for use according to claim 2, and/or the pharmaceutical composition comprising a compound of formula (I) according to claim 3, selected from the group consisting of
Figure imgf000190_0001
Figure imgf000191_0001
Figure imgf000192_0001
Figure imgf000193_0001
Figure imgf000194_0001
34. The compound of formula (I)) for use according to claim 2, selected from the group consisting of
Figure imgf000194_0002
Figure imgf000195_0001
Figure imgf000196_0001
Figure imgf000197_0001
Figure imgf000198_0002
35. The compound of formula (I) according to claim 1, the compound of formula (I) for use according to claim 2, and/or the pharmaceutical composition comprising a compound of formula (I) according to claim 3, selected from the group consisting of
Figure imgf000198_0001
Figure imgf000199_0001
36. The compound of formula (I) for use according to anyone of claims 2 to 27, and 29 to 35, wherein the cancer is a Notch dependent cancer.
PCT/EP2020/060153 2019-04-10 2020-04-09 Inhibitors of notch signalling pathway and use thereof in treatment of cancers WO2020208139A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
CN202080043231.4A CN113966324A (en) 2019-04-10 2020-04-09 NOTCH signaling pathway inhibitors and their use in cancer treatment
AU2020271268A AU2020271268A1 (en) 2019-04-10 2020-04-09 Inhibitors of notch signalling pathway and use thereof in treatment of cancers
US17/602,959 US20220169642A1 (en) 2019-04-10 2020-04-09 Compounds for the treatment of oncovirus induced cancer and methods of use thereof
MX2021012359A MX2021012359A (en) 2019-04-10 2020-04-09 Inhibitors of notch signalling pathway and use thereof in treatment of cancers.
BR112021020226A BR112021020226A2 (en) 2019-04-10 2020-04-09 Notch signaling pathway inhibitors and their use in the treatment of cancer
JP2021559902A JP2022529324A (en) 2019-04-10 2020-04-09 Notch signaling pathway inhibitors and their use in the treatment of cancer
EP20717868.2A EP3953335A1 (en) 2019-04-10 2020-04-09 Inhibitors of notch signalling pathway and use thereof in treatment of cancers
SG11202110545TA SG11202110545TA (en) 2019-04-10 2020-04-09 Inhibitors of notch signalling pathway and use thereof in treatment of cancers
KR1020217036445A KR20220021462A (en) 2019-04-10 2020-04-09 Inhibitors of the Notch signaling pathway and their use in the treatment of cancer
CA3134791A CA3134791A1 (en) 2019-04-10 2020-04-09 Inhibitors of notch signalling pathway and use thereof in treatment of cancers
EA202192394A EA202192394A1 (en) 2019-04-10 2020-04-09 NOTCH PATHWAY INHIBITORS AND THEIR USE FOR CANCER TREATMENT
IL287043A IL287043A (en) 2019-04-10 2021-10-06 Inhibitors of notch signalling pathway and use thereof in treatment of cancers
ZA2021/08579A ZA202108579B (en) 2019-04-10 2021-11-03 Inhibitors of notch signalling pathway and use thereof in treatment of cancers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19168508.0 2019-04-10
EP19168508 2019-04-10

Publications (1)

Publication Number Publication Date
WO2020208139A1 true WO2020208139A1 (en) 2020-10-15

Family

ID=66105107

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2020/060153 WO2020208139A1 (en) 2019-04-10 2020-04-09 Inhibitors of notch signalling pathway and use thereof in treatment of cancers

Country Status (16)

Country Link
US (1) US20220169642A1 (en)
EP (1) EP3953335A1 (en)
JP (1) JP2022529324A (en)
KR (1) KR20220021462A (en)
CN (1) CN113966324A (en)
AU (1) AU2020271268A1 (en)
BR (1) BR112021020226A2 (en)
CA (1) CA3134791A1 (en)
EA (1) EA202192394A1 (en)
IL (1) IL287043A (en)
MA (1) MA55596A (en)
MX (1) MX2021012359A (en)
SG (1) SG11202110545TA (en)
TW (1) TW202104166A (en)
WO (1) WO2020208139A1 (en)
ZA (1) ZA202108579B (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4008324A1 (en) 2020-12-07 2022-06-08 Cellestia Biotech AG Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer
WO2022122667A1 (en) 2020-12-07 2022-06-16 Cellestia Biotech Ag Pharmaceutical combinations for treating cancer
WO2022253794A2 (en) 2021-06-02 2022-12-08 Cellestia Biotech Ag Method for treating an autoimmune and inflammatory disease
WO2023079132A1 (en) 2021-11-08 2023-05-11 Cellestia Biotech Ag Pharmaceutical combinations for treating cancer
EP4223292A1 (en) 2022-02-07 2023-08-09 Cellestia Biotech AG Pharmaceutical combinations for treating cancer

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935465A (en) 1984-11-30 1990-06-19 Beecham Group P.L.C. Conjugates of pharmaceutically useful proteins
WO1998041525A1 (en) * 1997-03-19 1998-09-24 Basf Aktiengesellschaft Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors
US5965740A (en) 1995-09-29 1999-10-12 Shionogi & Co., Ltd. Alpha-substituted benzyl heterocyclic derivatives, intermediates for producing the same and pesticides containing the same as active ingredient
US6342244B1 (en) 1999-04-23 2002-01-29 Alza Corporation Releasable linkage and compositions containing same
WO2003022842A1 (en) 2001-09-07 2003-03-20 Fujisawa Pharmaceutical Co., Ltd. Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors
US20030176438A1 (en) * 2001-10-19 2003-09-18 Arienti Kristen L. Substituted benzimidazoles and imidazo-[4,5]-pyridines
WO2005047366A1 (en) 2003-11-06 2005-05-26 Nektar Therapeutics Al, Corporation Method of preparing carboxylic acid functionalized polymers
US20050171328A1 (en) 1996-09-26 2005-08-04 Nektar Therapeutics Al, Corporation Soluble, degradable poly(ethylene glycol) derivatives for conrollable release of bound molecules into solution
WO2006020951A1 (en) * 2004-08-13 2006-02-23 Praecis Pharmaceuticals, Inc. Methods and compositions for modulating sphingosine-1-phosphate (s1p) receptor activity
US20060074024A1 (en) 1994-04-15 2006-04-06 Genentech, Inc. Treatment of congestive heart failure
US20090105266A1 (en) * 2007-04-19 2009-04-23 Ralf Glatthar Organic compounds
WO2013093885A1 (en) 2011-12-21 2013-06-27 Ecole polytechnique fédérale de Lausanne (EPFL) Inhibitors of notch signalling pathway and use thereof in treatment of cancers
US20150246938A1 (en) 2011-09-09 2015-09-03 Shionogi & Co., Ltd. Novel olefin derivative

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935465A (en) 1984-11-30 1990-06-19 Beecham Group P.L.C. Conjugates of pharmaceutically useful proteins
US20060074024A1 (en) 1994-04-15 2006-04-06 Genentech, Inc. Treatment of congestive heart failure
US5965740A (en) 1995-09-29 1999-10-12 Shionogi & Co., Ltd. Alpha-substituted benzyl heterocyclic derivatives, intermediates for producing the same and pesticides containing the same as active ingredient
US20050171328A1 (en) 1996-09-26 2005-08-04 Nektar Therapeutics Al, Corporation Soluble, degradable poly(ethylene glycol) derivatives for conrollable release of bound molecules into solution
WO1998041525A1 (en) * 1997-03-19 1998-09-24 Basf Aktiengesellschaft Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors
US6342244B1 (en) 1999-04-23 2002-01-29 Alza Corporation Releasable linkage and compositions containing same
WO2003022842A1 (en) 2001-09-07 2003-03-20 Fujisawa Pharmaceutical Co., Ltd. Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors
US20030176438A1 (en) * 2001-10-19 2003-09-18 Arienti Kristen L. Substituted benzimidazoles and imidazo-[4,5]-pyridines
WO2005047366A1 (en) 2003-11-06 2005-05-26 Nektar Therapeutics Al, Corporation Method of preparing carboxylic acid functionalized polymers
WO2006020951A1 (en) * 2004-08-13 2006-02-23 Praecis Pharmaceuticals, Inc. Methods and compositions for modulating sphingosine-1-phosphate (s1p) receptor activity
US20090105266A1 (en) * 2007-04-19 2009-04-23 Ralf Glatthar Organic compounds
US20150246938A1 (en) 2011-09-09 2015-09-03 Shionogi & Co., Ltd. Novel olefin derivative
WO2013093885A1 (en) 2011-12-21 2013-06-27 Ecole polytechnique fédérale de Lausanne (EPFL) Inhibitors of notch signalling pathway and use thereof in treatment of cancers

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
"Angew. Chem. Int. Ed.", vol. 51, 2012, pages: 2745
"Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY
ADVANCED SYNTHESIS & CATALYSIS, vol. 353, 2011, pages 3403
H.P. FIEDLEREDITIO CANTOR, LEXIKON DER HILFSSTOFFE FUR PHARMAZIE, KOSMETIK UND ANGRENZENDE GEBIETE, 2002
HAMMAD ISMAIL ET AL: "Synthesis, Characterization, and Pharmacological Evaluation of Selected Aromatic Amines", JOURNAL OF CHEMISTRY, vol. 2015, 1 January 2015 (2015-01-01), US, pages 1 - 9, XP055629656, ISSN: 2090-9063, DOI: 10.1155/2015/465286 *
J. AM. CHEM.SOC., vol. 136, 2014, pages 6842
J. MARCH: "Advanced Organic Chemistry", 1992, JOHN WILEY AND SONS
KHIM S K ET AL: "Discovery of novel and potent aryl diamines as leukotriene A"4 hydrolase inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 18, no. 14, 15 July 2008 (2008-07-15), pages 3895 - 3898, XP022852858, ISSN: 0960-894X, [retrieved on 20080618], DOI: 10.1016/J.BMCL.2008.06.041 *
LANGER, SCIENCE, vol. 249, 1990, pages 1527 - 1533
MEHDI TAGHAVI ET AL: "A quick and green ionic liquid-mediated approach for the synthesis of high-performance, organosoluble and thermally stable polyimides", CHINESE JOURNAL OF POLYMER SCIENCE, vol. 31, no. 4, 9 March 2013 (2013-03-09), CN, pages 679 - 690, XP055629675, ISSN: 0256-7679, DOI: 10.1007/s10118-013-1258-z *
SHIH IEMWANG TL, CANCER RES, vol. 67, no. 5, 2007, pages 1879 - 82
SUN M ET AL: "Design, synthesis, and in vitro antitumor evaluation of novel diaryl ureas derivatives", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 45, no. 6, 1 June 2010 (2010-06-01), pages 2299 - 2306, XP027013897, ISSN: 0223-5234, [retrieved on 20100206] *
TETRAHEDRON, vol. 71, 2015, pages 5932

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4008324A1 (en) 2020-12-07 2022-06-08 Cellestia Biotech AG Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer
WO2022122667A1 (en) 2020-12-07 2022-06-16 Cellestia Biotech Ag Pharmaceutical combinations for treating cancer
WO2022253794A2 (en) 2021-06-02 2022-12-08 Cellestia Biotech Ag Method for treating an autoimmune and inflammatory disease
WO2022253794A3 (en) * 2021-06-02 2023-01-12 Cellestia Biotech Ag Compounds for use in a method for treating an autoimmune and inflammatory disease
WO2023079132A1 (en) 2021-11-08 2023-05-11 Cellestia Biotech Ag Pharmaceutical combinations for treating cancer
EP4223292A1 (en) 2022-02-07 2023-08-09 Cellestia Biotech AG Pharmaceutical combinations for treating cancer

Also Published As

Publication number Publication date
EP3953335A1 (en) 2022-02-16
US20220169642A1 (en) 2022-06-02
ZA202108579B (en) 2024-03-27
SG11202110545TA (en) 2021-10-28
CN113966324A (en) 2022-01-21
KR20220021462A (en) 2022-02-22
AU2020271268A1 (en) 2021-10-28
BR112021020226A2 (en) 2021-12-07
MA55596A (en) 2022-02-16
JP2022529324A (en) 2022-06-21
EA202192394A1 (en) 2022-01-24
CA3134791A1 (en) 2020-10-15
MX2021012359A (en) 2022-01-19
IL287043A (en) 2021-12-01
TW202104166A (en) 2021-02-01

Similar Documents

Publication Publication Date Title
US20220169642A1 (en) Compounds for the treatment of oncovirus induced cancer and methods of use thereof
JP7293560B2 (en) Aromatic vinyl or aromatic ethyl derivative, its production method, intermediate, drug composition and use
CN105481789B (en) Indoleamine-2,3-dioxygenase inhibitor and preparation method thereof
US20210387941A1 (en) Diphenyl-like Compound, Intermediate Thereof, Preparation Method Therefor, Pharmaceutical Composition Thereof And Uses Thereof
CN107176933B (en) Indoleamine-2,3-dioxygenase inhibitor containing nitrogen alkylated and arylated sulfoximine
US10196358B2 (en) KCNQ2-5 channel activator
KR20190103285A (en) Combination Therapy for the Treatment of Cancer
US20220168268A1 (en) Small-molecule inhibitor of pd-1/pd-l1, pharmaceutical composition thereof with pd-l1 antibody, and application of same
US11767297B2 (en) Compounds for inhibiting TNIK and medical uses thereof
DK3046902T3 (en) COMPOSITIONS FOR TREATING HYPERTENSION AND / OR FIBROSE
KR20200015515A (en) Trisubstituted pyrimidine compounds and compositions for treating cancer, retinal disorders and cardiomyopathy
CN103804352B (en) Triazole phenethyl tetrahydroisoquinolicompounds compounds and its preparation method and application
US20220185793A1 (en) Compounds for the treatment of oncovirus induced cancer and methods of use thereof
JP2024516194A (en) Compounds as PD1/PD-L1 inhibitors and methods thereof
US11530186B2 (en) Inhibitors for the β-catenin / T-cell factor protein-protein interaction
JP2021527064A (en) PRC1 inhibitor and treatment method using it
WO2011070299A1 (en) Tri-substituted 9h-beta-carboline (or 9h-pyrido[3,4-b]indole) derivatives, preparation of same and therapeutic use thereof
CN109096178B (en) Phenylethynyl substituted benzenes and heterocycles useful in the treatment of cancer and uses thereof
CN112384502A (en) Cycloalkyl-substituted amide derivatives, preparation method and medical application thereof
US9650382B2 (en) Heteroarylamide derivatives having antiandrogenic properties

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20717868

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3134791

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021559902

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021020226

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2020271268

Country of ref document: AU

Date of ref document: 20200409

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020717868

Country of ref document: EP

Effective date: 20211110

ENP Entry into the national phase

Ref document number: 112021020226

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20211007

WWE Wipo information: entry into national phase

Ref document number: 521430519

Country of ref document: SA